Never miss out on another presentation!

The WCLC 2019 Virtual Meeting includes:

- Abstracts
- Presentation slides
- Audio/video recordings of presentations
- Electronic version of most posters

The WCLC 2019 Virtual Library is included in your Conference registration.

Check your name badge for your Access Code.
Contents

1 Welcome
   Welcome Messages 4
   Conference Summary 8

2 IASLC & WCLC Committees
   International Association for the Study of Lung Cancer (IASLC) 12
   IASLC Board of Directors 2017–2019 13
   International Lung Cancer Foundation 13
   WCLC Committees 14
      International Program Committee 15
      International Abstract Review Committee 17

3 General Conference Information
   Registration 22
   Press and Media 23
   Information for Invited Faculty and Abstract Presenters 24
   Continuing Medical Education (CME) Information 26
   Onsite Services and General Information 29

4 IASLC & Conference Awards
   IASLC Distinguished Awards 36
   Previous IASLC Distinguished Award Winners 38
   IASLC Lectureship Award Winners 39
   IASLC Academy Award Winners 40
   IASLC International Mentorship Award Winners 40
   WCLC 2019 Early Career Award Winners 41
   WCLC 2019 Developing Nation Award Winners 41
   IASLC Patient Advocacy Award Winners 42
   WCLC 2019 STARS Awards 42
   IASLC Nurse and Allied Health Professional Award Winners 42

5 Conference Program
   Program at a Glance 47
   Session Overview
      Saturday, September 7 48
      Sunday, September 8 49
      Monday, September 9 51
      Tuesday, September 10 53
   Program by Track 55

6 Daily Scientific Program
   Friday, September 6 68
   Saturday, September 7 69
   Sunday, September 8 74
   Monday, September 9 91
   Tuesday, September 10 110
Contents

7 Poster Sessions

Posters by Day
- Sunday, September 8 126
- Monday, September 9 148

8 ePosters

- 172

10 Maps & Floor Plans

- Gran Via, Fira de Barcelona 254
- Hall 8.0 (Level 1) 255

11 Exhibit & Sponsor Information

- Conference Sponsors 259
- Exhibit Floor Plan 262
- Exhibitor Listings 263
- Exhibitor Descriptions 264

12 Industry Symposia & Workshops

- Saturday, September 7 279
- Sunday, September 8 280
- Monday, September 9 282
- Tuesday, September 10 284
- Exhibit Showcase Sessions 285
1 | WELCOME
Dear Friends:

As Mayor of Barcelona, I am very pleased to give my warmest welcome to everyone attending the 2019 World Conference on Lung Cancer (WCLC), hosted by the International Association for the Study of Lung Cancer (IASLC).

During these days, around 7,000 delegates from more than 100 countries will meet together to exchange ideas in the field of lung cancer and thoracic oncology. This is a great opportunity for networking and collaborating with experts, scientists and other health professionals, to discuss the latest findings and to improve medical research. This is a great opportunity to positively impact the world.

I thank the IASLC for hosting this conference and for choosing our city.

I highly encourage all the attendees to take the opportunity to visit our city. I invite you to lose yourself in our streets and neighborhoods, to discover our architectural heritage, the cuisine and the urban environment, to mingle with the residents and to enjoy the social and cultural dynamism that defines Barcelona.

I know you will have a fabulous stay with us.

Please accept my best wishes for a very productive and successful conference.

Sincerely,

Ada Colau Ballano

Pl. de Sant Jaume, 1 E-08002 Barcelona
Tel. +34 932 914 700 Fax +34 933 170 139 alcaldia@bcn.cat www.barcelona.cat
Welcome from the WCLC 2019 Conference Presidents

Dear Colleagues from around the World,
Welcome! ¡Bienvenidos! Benvinguts!

The International Association for the Study of Lung Cancer (IASLC) and the Regional Organizing Committee take great pleasure to welcome you to the IASLC 2019 World Conference on Lung Cancer (WCLC 2019) in Barcelona. In 2005 the WCLC took place in Barcelona for the first time, and much has changed in the IASLC and in the WCLC since then. The IASLC now has more than 7,500 members from over 100 countries, and the WCLC has become the premier conference devoted to all aspects of the management of lung cancer and other thoracic malignancies.

The IASLC 2019 WCLC offers a few days of intense scientific activity bringing together more than 7,500 delegates from all fields in the basic and clinical sciences related to thoracic malignancies. We are proud to have received a historic record of 2,408 submitted abstracts organized in oral, mini oral and poster sessions, including 88, 224 and 1,260 presentations, respectively, in addition to 506 e-posters and 395 invited lectures that certainly will contribute to the exchange of new information among participants.

We encourage you to participate actively in the discussions, and also to enjoy the beauties of Barcelona—its museums, architecture, culture, gastronomy—and to feel the lively pulse of a dynamic, modern, cosmopolitan, Mediterranean society that seeks constant innovation while treasuring the past and its centuries long traditions.

To facilitate discussions and networking opportunities we are using an online tool introduced last year that will allow delegates to ask questions and participate in live polls during the sessions.

Don’t miss the opportunity to visit our Poster Viewing reception on Sunday and Monday evenings and note that all posters (including ePosters) are available for viewing during networking breaks in the Exhibit Hall.

We also would like to extend our gratitude and thanks to all sponsors and exhibitors for their continued support to WCLC and IASLC. Without them this Conference would not be possible.

Thank you for joining us in Barcelona. We wish all delegates an enjoyable and productive Conference in this historic and significant region of the world.

Yours sincerely,

Ramon Rami-Porta, MD PhD
Clinical Chief of the Department of Thoracic Surgery
Hospital Universitari Mutua Terrassa,
Terrassa, Barcelona, Spain

Antoni Rosell, MD PhD
Clinical Director of Pulmonology and Thoracic Surgery Department
Hospital Universitari Germans Trias i Pujol
Badalona, Barcelona, Spain

Enriqueta Felip, MD PhD
Chief Thoracic Cancer Unit, Oncology Department
Vall d’Hebron Hospital, Vall d’Hebron Institute of Oncology
Barcelona, Spain
Stay up to date with everything at WCLC 2019!

Get 24-hour access to all Conference related information

Access to full scientific program information including abstracts

Available for iPhone, iPad, and Android

Participate in Live Polling and Ask Questions

Connect and network with other delegates
Welcome Message from the IASLC President and CEO

Dear WCLC Participants,

As the President and the CEO of the IASLC, we are thrilled to welcome you to the IASLC 2019 World Conference on Lung Cancer (WCLC 2019) in beautiful Barcelona. We are honored that you have chosen to join us for what is sure to be a rigorous, fascinating and collaborative meeting.

This year marks the 20th WCLC, serving as a unique moment to pause and reflect on how this meeting and the thoracic oncology field have evolved over the past four decades. During that time, we’ve seen extraordinary progress in the field of lung cancer diagnosis and treatment, with the discovery of new biomarkers, new screening techniques and the rise of precision medicine leading to improvements in overall mortality and quality of life for patients.

Throughout its long history, the WCLC has played a strong role in facilitating that progress – providing a platform for sharing cutting-edge research, creating space for new collaborations and partnerships, connecting established researchers with young investigators and serving as a foundational meeting for health care professionals (representing the full spectrum of the multidisciplinary team), patients and advocates who have dedicated their lives to conquering these challenging diseases. This enduring importance is illustrated in how the WCLC has evolved over time – growing from a gathering of approximately 100 colleagues in the late-1970s to an expansive conference that regularly attracts over 7,500 international participants. Such growth in size, impact and relevance did not happen by accident. We are grateful to our previous WCLC conference presidents, organizers and participants. Additionally, we want to honor our past and current board members, as well as former CEOs Heine H. Hansen, Paul A. Bunn Jr. and Fred R. Hirsch for their leadership of the IASLC – from its formative years to the present day.

But while the story of the WCLC is well-established, we know that we must always be looking to the future if we are to continue making inroads in the treatment of thoracic cancers. That is why for WCLC 2019 we are proud to announce that the conference organizers have put together an incredible scientific program that includes over 2,400 abstracts – a landmark figure. We want to thank them for their hard work, and we are especially grateful for the dedication and leadership of our Conference Presidents: Drs. Enriqueta Felip, Ramon Rami-Porta and Antoni Rosell. The program is organized into 17+ specialized tracks and covers the latest advances in biology, prevention, screening, staging and treatment. With its ground-breaking plenaries, interactive breakfast sessions, research abstracts and specialized sessions, we have no doubt that you will find WCLC 2019 to be an exceptional educational experience.

Thank you for attending WCLC 2019 and thank you for your engagement with the IASLC. We hope you enjoy the meeting; have the opportunity to explore Barcelona and the surrounding countryside; find opportunities to develop new relationships and collaborations; and, finally, gain novel skills and insights that can be applied to improving the lives of thoracic cancer patients – both in your local communities and worldwide. Like so much of what the IASLC does, the success of the WCLC hinges on the passion, commitment and engagement of those who attend it. In short, your participation is one of the main reasons for why the event has remained the world’s leading thoracic cancer conference for over 40 years. We appreciate you being a part of our ongoing story.

Giorgio Scagliotti, MD, PhD
President, International Association for the Study of Lung Cancer (IASLC)

Dave Mesko, MBA
Chief Executive Officer, International Association for the Study of Lung Cancer (IASLC)
Conference Summary

ONSITE REGISTRATION
- Fira de Barcelona Gran Via
  North Access - Level 1, Hall 8.0

Friday, September 6: 14:00 – 18:00
Saturday, September 7: 06:30 – 20:00
Sunday, September 8: 06:30 – 15:30
Monday, September 9: 06:30 – 15:30
Tuesday, September 10: 06:30 – 16:30

EXHIBITION HALL
- Fira de Barcelona Gran Via
  North Access - Level 2, Hall 8.1

Saturday, September 7: 20:30 – 22:00
(Welcome Reception)
Sunday, September 8: 09:30 – 18:30
Monday, September 9: 09:30 – 18:30
Tuesday, September 10: 09:30 – 14:00

SPEAKER PREVIEW CENTER
- Fira de Barcelona Gran Via
  North Access - Level 1, Hall 8.0

Friday, September 6: 14:00 – 18:00
Saturday, September 7: 06:30 – 20:00
Sunday, September 8: 06:30 – 17:30
Monday, September 9: 06:30 – 17:30
Tuesday, September 10: 06:30 – 16:00

COAT AND BAGGAGE CHECK
- Fira de Barcelona Gran Via
  North Access - Level 1, Hall 8.0

Friday, September 6: 14:00 – 18:00
Saturday, September 7: 06:30 – 20:00
Sunday, September 8: 06:30 – 17:30
Monday, September 9: 06:30 – 17:30
Tuesday, September 10: 06:30 – 16:00
PRESS & MEDIA ROOM

- Fira de Barcelona Gran Via
  North Access - Level 2, Press Area

  Saturday, September 7  15:00 – 19:00
  Sunday, September 8   08:00 – 19:00
  Monday, September 9   08:00 – 19:00
  Tuesday, September 10 08:00 – 18:00

IASLC GENERAL ASSEMBLY

- Fira de Barcelona Gran Via
  North Access - Level 1, Hall 8.0, Tokyo (1982)

  Tuesday, September 10  08:00 – 08:45

POSTER PICK UP

- Fira de Barcelona Gran Via
  North Access - Level 1, Hall 8.0

  Sunday, September 8    08:00–18:00
  Monday, September 9    08:00 – 18:00
  Tuesday, September 10  08:00 – 14:30

IASLC AWARD SESSION

- Fira de Barcelona Gran Via
  North Access - Level 1, Hall 8.0, Toronto (1985)

  Saturday, September 7  17:45 – 18:45
MEMBERSHIP OFFER

We’re more than 7,500 strong! Won’t you join us?
Take advantage of this great value now!

New Members Only
WCLC Special Offer – Join during the WCLC and get two years for the price of one. Your membership starts immediately and doesn’t end until December 31, 2021.

<table>
<thead>
<tr>
<th>Membership Level</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>WCLC NEW Regular Member</td>
<td>US $250.00</td>
</tr>
<tr>
<td>WCLC NEW Developing Country Member</td>
<td>US $50.00</td>
</tr>
<tr>
<td>WCLC NEW Allied Professional Member</td>
<td>US $50.00</td>
</tr>
<tr>
<td>WCLC NEW Fellow/Resident/Trainee Member</td>
<td>Free</td>
</tr>
<tr>
<td>WCLC NEW Patient/Survivor/Caregiver Member</td>
<td>Free</td>
</tr>
</tbody>
</table>

Here are just some of the benefits you’ll receive when you become an IASLC member:

- Member access to the *Journal of Thoracic Oncology*
- Discounts to the IASLC World Conference on Lung Cancer and other scientific meetings
- Opportunity to make an impact by participating on IASLC member committees
- Access to the IASLC member directory

To learn more about levels of membership and benefits, visit: www.iaslc.org/membership.
IASLC & WCLC COMMITTEES
International Association for the Study of Lung Cancer (IASLC)

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1974, the association’s membership includes nearly 7,500 lung cancer specialists in over 100 countries.

IASLC members work to enhance the understanding of lung cancer among scientists, members of the medical community and the public. IASLC publishes the Journal of Thoracic Oncology, a valuable resource for medical specialists and scientists who focus on the detection, prevention, diagnosis and treatment of lung cancer.

The IASLC mission is:

• To embrace the study of the etiology, epidemiology, prevention, diagnosis, treatment and all other aspects of lung cancer and other thoracic malignancies
• To provide education and information about lung cancer and other thoracic malignancies to IASLC members, to the medical community at large, and to the public
• To use all available means to eliminate lung cancer and other thoracic malignancies as a health threat for the individual patient and throughout the world

IASLC Staff

Dave Mesko
Chief Executive Officer
dave.mesko@iaslc.org

John Skadow
Chief Financial Officer
john.skadow@iaslc.org

AnnMarie Estrada
Senior Director,
Corporate Relations;
Executive Director,
ILC Foundation
annmarie.estrada@iaslc.org

Kristin M. Richeimer
Senior Director,
Member Experience
kristin.richeimer@iaslc.org

Murry Wynes, PhD
Senior Director,
Scientific Affairs
murry.wynes@iaslc.org

Becky Bunn
Director,
Strategic Initiatives
and Public Relations;
Interim Director,
Communications
and Marketing
becky.bunn@iaslc.org

Kathy Doherty
Director,
Human Resources
kathy.doherty@iaslc.org

Jacinta Wiens, PhD
Associate Director,
Scientific Affairs
jacinta.wiens@iaslc.org

Mary Todd
Managing Editor,
Journal of Thoracic Oncology
mary.todd@iaslc.org

Karen Muth
Executive Assistant
and Board Liaison
karen.muth@iaslc.org

Kristin Ito
Patient Advocacy Manager
kristin.it@iaslc.org

Kelsey Wood
Membership Manager
kelsey.wood@iaslc.org

Adam Mohrbacher
Communications Manager
adam.mohrbacher@iaslc.org

Emily Petoskey
Foundation Coordinator
emily.petoskey@iaslc.org

Jeanette Stensgaard
Conference Planning Manager
jeanette.stensgaard@iaslc.org

Kexin Yu
Accountant
kexin.yu@iaslc.org

Stephanie Lenhart
Accounting Manager
stephanie.lenhart@iaslc.org

Jill Daigneault, PhD
Scientific Affairs
Project Manager
jill.daigneault@iaslc.org

Abigail Metzger
Corporate Relations
Coordinator
abigail.metzger@iaslc.org

Sara Lindsey
Administrative Assistant
sara.lindsey@iaslc.org

Kirsten Black, PhD
Educational Programs
Manager
kirsten.black@iaslc.org

Julie Bishop
Committee Coordinator
julie.bishop@iaslc.org

Debbie Platek
Education Consultant
debbie.platek@iaslc.org
IASLC Board of Directors 2017–2019

Officers

President
Giorgio Scagliotti, Italy

President Elect
Tetsuya Mitsudomi, Japan

Past President
David Carbone, United States of America

Chief Executive Officer
Dave Mesko, United States of America

Board of Directors

Michael Boyer, Australia
Julie Brahmer, United States of America
Enriqueta Felip, Spain
Anne Fraser, New Zealand
David Harpole, United States of America
Norihiko Ikeda, Japan
Clarissa Mathias, Brazil
Yuko Nakayama, Japan
Masayuki Noguchi, Japan
Robert Pirker, Austria
Suresh Ramalingam, United States of America
Martin Reck, Germany
Miyako Satouchi, Japan
Takashi Seto, Japan
Paul Van Schil, Belgium
Heather Wakelee, United States of America
James Yang, Taiwan

International Lung Cancer Foundation

International Lung Cancer Foundation Board 2019

Board of Directors

David Carbone, United States of America
Dave Mesko, United States of America
David Gandara, United States of America
Lauren Fisher, United States of America

Starting in 2019, the Foundation would like to announce its new name, the International Lung Cancer Foundation.

We wanted to share this exciting change first with you, our members, and WCLC delegates. The International Lung Cancer Foundation, *Inspiring Hope through Research*, aspires to cultivate innovation, dedication and inspiration to the lung cancer research space. Please join us on this journey moving forward and thank you to all who have continued to support our endeavor to conquer thoracic cancers together!

Road to HOPE

An evening for all celebrating research and hope!

TICKETED EVENT

Museu Nacional D’art De Catalunya, Parc de Montjuïc
Monday, September 9, 20:00-23:00

Join us for a unique networking event offering the exclusive opportunity to meet and interact with doctors, scientists and survivors in support of ongoing research dedicated to finding a cure for lung cancer! Taking place in one of the most iconic spaces of Barcelona, the Palau Nacional, you will be able to enjoy magnificent views of Barcelona.

Tickets are priced at 85 EUR each and can be purchased at the time of registration.

INSPIRING HOPE THROUGH RESEARCH
WCLC Committees

Regional Organizing Committee

Co-Presidents
Ramon Rami-Porta, Spain
Enriqueta Felip, Spain
Antoni Rosell, Spain

Members
Jouke Annema, Netherlands
Benjamin Besse, France
Elisabeth Brambilla, France
Paul De Leyn, Belgium
Dirk De Ruyscher, Netherlands
Christophe Dooms, Belgium
Wilfried Ernst Erich Eberhardt, Germany
Manel Esteller, Spain
Pilar Garrido, Spain
Felix JF Herth, Germany
Jenny Mitchell, United Kingdom
Laureano Molins, Spain
Eduard Monsó, Spain
Françoise Mornex, France
Andrew G Nicholson, United Kingdom
Silvia Novello, Italy
Solange Peters, Switzerland
José Ramírez, Spain
Rendina Erino Angelo, Italy
Luis M Seijo, Spain
Suresh Senan, Netherlands
Pallav L Shah, United Kingdom
Pascal Alexandre Thomas, France
Diego Villalón, Spain
Marcin Zielinski, Poland
Javier J. Zulueta, Spain

Advanced NSCLC
Silvia Novello, Chair, Italy
Fabrice Barlesi, Co-Chair, France
Leora Horn, United States of America
Pasi Janne, United States of America
Suresh Ramalingam, United States of America
Noemi Reguart, Spain
Clarissa Mathias, Brazil
Margarita Majem, Spain
Natasha Leighl, Canada
Geoffrey Oxnard, United States of America
Fernando Lopez-Rios, Spain
Shun Lu, China
Koaru Kubota, Japan
Daniel Tan, Singapore
Reinhard Buettner, Germany

Education
Luis Paz-Ares, Chair, Spain
Johan Vansteenkiste, Co-Chair, Belgium
Alex Adjei, United States of America
Michael Boyer, Australia
Federico Cappuzzo, Italy
Christian Rolfo, Belgium
Enric Carcereny, Spain

Immuno-oncology
Julie Brahmer, Chair, United States of America
Marina Garassino, Co-Chair, Italy
Solange Peters, Switzerland
Martin Reck, Germany
Naiyer Rizvi, United States of America
Ross Soo, Singapore
Matthew Hellman, United States of America
Dolores Isla, Spain
Gilberto Lopes, United States of America
Jhanelle Gray, United States of America
Kellie Smith, United States of America
Myung-Ju Ahn, Korea
Claudio Tripodo, Italy

Interventional Diagnostics/ Pulmonology
Antoni Rosell, Chair, Spain
Jouke Annema, Co-Chair, Netherlands
Kazuhiro Yasufuku, Canada
Kwun Fong, Australia
Felix Herth, Germany
Eric Edell, United States of America
Pallav Shah, United Kingdom
Ales Rozman, Slovenia
Tim Murgu, United States of America
Christophe Dooms, Belgium
Carla Lamb, United States of America
Felipe Andreo, Spain
Michaela Bezzi, Italy
Hans Daniels, Netherlands
Bin Hwangbo, Korea

Biology
Roman Thomas, Chair, Germany
Montserrat Sanchez-Cespedes, Co-Chair, Spain
Wan Lam, Canada
Oscar Arrieta, Mexico
Robert Doebele, United States of America
Katerina Politi, United States of America
Niki Karachaliou, Spain
Fred R. Hirsch, United States of America
Caroline Dive, United Kingdom
Matthew Meyerson, United States of America
Takashi Kohno, Japan
Hongbin Ji, China
Jin Jen, United States of America
Julie George, Germany
IASLC would like to thank the 2019 WCLC committees for their hard work and dedication for this year's conference.

**Mesothelioma**
- Isabelle Schmitt-Opitz, Chair, Switzerland
- Seiki Hasegaw, Co-Chair, Japan
- Anna Nowak, Australia
- Michele Carbone, United States of America
- Paul Carbone, Netherlands
- Kenneth Rosenzweig, United States of America
- Marc DePerrot, Canada
- Dean Fennell, United Kingdom
- Ernest Nadal, Spain
- Walter Weder, Switzerland
- Andrea Bille, Italy
- Arnaud Scherpereel, France
- Raphael Bueno, United States of America

**Pathology**
- Andrew Nicholson, Chair, United Kingdom
- Sylvie Lantuejoul, Co-Chair, France
- Mari Mino-Kenudson, United States of America
- Ming Tsao, Canada
- Ignacio Wistuba, United States of America
- Sanja Dacic, United States of America
- Yasushi Yatabe, Japan
- Wendy Cooper, Australia
- Teh-Ying Chou, Taiwan
- Lukas Bubendorf, Switzerland
- Mauro Papotti, Italy
- Mary Beth Beasley, United States of America
- Anja Roden, United States of America
- Keith Kerr, United Kingdom

**Small Cell Lung Cancer/NET**
- Charles Rudin, Chair, United States of America
- Raffaele Califano, Co-Chair, United Kingdom

**Nursing and Allied Professionals**
- Jenny Mitchell, Chair, United Kingdom
- Anne Fraser, Co-Chair, New Zealand
- Melissa Culligan, United States of America
- Maria Guerin, United Kingdom
- Dianne Zawisza, Canada
- Melissa Culligan, United States of America
- Maria Guerin, United Kingdom
- Dianne Zawisza, Canada

**Prevention and Tobacco Control**
- Carolyn Dresler, Chair, United States of America
- Matthew Stelig, Co-Chair, United States of America
- Jacek Jassem, Poland
- Emily Stone, Australia
- Nise Yamaguchi, Brazil
- Maciej Goniewicz, United States of America
- Babalola Faseru, United States of America
- Sita Andarini, Indonesia
- Pyng Lee, Singapore
- William Edwards, Canada

**Staging**
- Hisao Asamura, Chair, Japan
- Valerie W. Rusch, Co-Chair, United States of America

**Oligometastatic NSCLC**
- Anne Marie Dingemans, Chair, Netherlands
- Matthias Guckenberger, Co-Chair, Switzerland

**Screening and Early Detection**
- Javier Zulueta, Chair, Spain
- Claudia Henschke, Co-Chair, United States of America

**Pathology**
- Andrew Nicholson, Chair, United Kingdom
- Sylvie Lantuejoul, Co-Chair, France
- Mari Mino-Kenudson, United States of America
- Ming Tsao, Canada
- Ignacio Wistuba, United States of America
- Sanja Dacic, United States of America
- Yasushi Yatabe, Japan
- Wendy Cooper, Australia
- Teh-Ying Chou, Taiwan
- Lukas Bubendorf, Switzerland
- Mauro Papotti, Italy
- Mary Beth Beasley, United States of America
- Anja Roden, United States of America
- Keith Kerr, United Kingdom

**Prevention and Tobacco Control**
- Carolyn Dresler, Chair, United States of America
- Matthew Stelig, Co-Chair, United States of America
- Jacek Jassem, Poland
- Emily Stone, Australia
- Nise Yamaguchi, Brazil
- Maciej Goniewicz, United States of America
- Babalola Faseru, United States of America
- Sita Andarini, Indonesia
- Pyng Lee, Singapore
- William Edwards, Canada

**Screening and Early Detection**
- Javier Zulueta, Chair, Spain
- Claudia Henschke, Co-Chair, United States of America
- John Field, United Kingdom
- Stephen Lam, Canada
- Eduard Monsó, Spain
- Nir Peled, Israel
- Witold Rzyman, Poland
- Dorith Shaham, Israel
- Luis Montuenga, Spain
- Annette McWilliams, Australia
International Program Committee (continued)

Targeted Therapy
Tony Mok, Chair, China
Benjamin Besse, Co-Chair, France
Alexander Drilon, United States of America
David Ross Camidge, United States of America
Benjamin Solomon, Australia
James Yang, Taiwan
Lecia Sequist, United States of America
Rosario Garcia Campelo, Spain
Qing Zhou, China
Thanyan Reungwetwattana, Thailand
Rafal Dzidziszko, Poland
Elisa Gobbini, France
Matteo Giaj Levra, France
Jessica Menis, Italy

Thymoma/Other Thoracic Malignancies
Enrico Ruffini, Chair, Italy
Robert Korst, Co-Chair, United States of America
Anthony Brade, Canada
Nicolas Girard, France
David Waller, United Kingdom
Edith Marom, Israel
Meinoshin Okumura, Japan
Mirella Marino, Italy
Benny Weksler, United States of America

Treatment in the Real World - Support, Survivorship, Systems Research
Navneet Singh, Chair, India
Ricardo Terra, Co-Chair, Brazil
Carlos Barrios, Brazil
David Dawe, Canada
Ronan Kelly, United States of America
Taofeeq Owonikoko, United States of America
Ellen Nascimento, Brazil
Amanjit Bal, India
Martin Frueh, Switzerland
C.S. Pramesh, India
Ritu R. Gill, United States of America
Gustavo Lyons, Argentina
Shun-ichi Watanabe, Japan

Treatment of Early Stage/Localized Disease
Heather Wakelee, Chair, United States of America
Paula Ugalde, Co-Chair, Canada
Jessica Donington, United States of America
Janet Edwards, Canada
Tetsuya Mitsudomi, Japan
Luis Raez, United States of America
Suresh Senan, Netherlands
Elsamira da Silva Mascarenhas, Brazil
Rafael Gadia, Brazil
Yi-Long Wu, China
Max Diehn, United States of America
Cecile Le Pechoux, France

Treatment of Locoregional Disease – NSCLC
Pilar Garrido, Chair, Spain
Dirk De Ruyscher, Co-Chair, Belgium
Corinne Faiivre-Finn, United Kingdom
Eric Vallieres, United States of America
Hiroshi Date, Japan
Wilfried Eberhardt, Germany
Mariano Provencio, Spain
Fiona Hegi-Johnson, Australia
Houke Klomp, Netherlands
Keunchil Park, Korea
Charu Aggarwal, United States of America

Young Investigator Track
Clarissa Baldotto, Chair, Brazil
Sergi Call, Co-Chair, Spain
Lizza Hendriks, Netherlands
Mark Doherty, Canada
Yoshihisa Kobayashi, Japan
Celine Mascaux, France
Masaoki Ito, Japan
International Abstract Review Committee

Alex Adjei,
United States of America
Prasad Adusumilli,
United States of America
Charu Aggarwal,
United States of America
Samuel Aguayo,
United States of America
Myung-ju Ahn,
Republic of Korea
Christopher Amos,
United States of America
Sita Andarini, Indonesia
Mara Antonoff,
United States of America
Antonio Araujo, Portugal
Douglas Arenberg,
United States of America
Oscar Gerardo Arrieta, Mexico
Marisol Arroyo-Hernandez, Mexico
Hisao Asamura, Japan
Mark Awad, United States of America
Paul Baas, Netherlands
Anne-Marie Baird, Ireland
Amanjit Bal, India
Clarissa Baldotto, Brazil
David Ball, Australia
Fernando Barata, Portugal
Fabrice Barlesi, France
Fernando Barata, Portugal
David Ball, Australia
Raffaele Califano, United Kingdom
Sergi Call, Spain
Antonio Calles Blanco, Spain
Israel Canadas, United States of America
Federico Cappuzzo, Italy
Enric Carcereny, Spain
Julian Carretero, Spain
Susana Cedres, Spain
Alexandre Chan, Singapore
Teh-Ying Chou, Taiwan
Manuel Cobo, Spain
Wendy Cooper, Australia
Dégi Csaba, Hungary
Melissa Culligan, United States of America
Sanja Dacic, United States of America
Urania Dafni, Greece
Thomas D’Amico, United States of America
Johannes Daniels, Netherlands
Gail Darling, Canada
Liz Darlison, United Kingdom
Hiroshi Date, Japan
David Dawe, Canada
Javier De Castro Carpeno, Spain
Marc De Perrot, Canada
Dirk De Ruyschcer, Netherlands
Herbert Decaluwe, Belgium
Paul De-Leyn, Belgium
Margarida Dias, Portugal
Max Diehn, United States of America
Anne Marie Dingemans, Netherlands
Robert Doelebe, United States of America
Mark Doherty, Canada
Jessica Donington, United States of America
Carolyn Dresler, United States of America
Rafal Dzidziuszko, Poland
Wilfried Eberhardt, Germany
Janet Edwards, Canada
John Edwards, United Kingdom
Ivy Elkins, United States of America
William Evans, Canada
Corinne Faivre-Finn, United Kingdom
Wentao Fang, China
Anna Farago, United States of America
Enriqueta Felip, Spain
Emanuela Felley-Bosco, Switzerland
Lynnette Fernandez-Cuesta, France
Roberto Ferrara, Italy
Carlos Gil Ferreira, Brazil
John Field, United Kingdom
Pier Luigi Filosso, Italy
Kwun Fong, Australia
Patrick Forde, United States of America
Jesme Fox, New Zealand
Martin Fruhe, Switzerland
Shrish Gadgeel, United States of America
Rosario Garcia Campelo, Spain
Edward Garon, United States of America
Pilar Garrido, Spain
Laurie Gaspar, United States of America
Oliver Gautschi, Switzerland
Giuseppe Giaccone, United States of America
Matteo Giaj Levra, France
Ignacio Gil-Bazo, Spain
Ritu Gill, United States of America
Nicolas Giraud, France
Elisa Gobbini, France
Maciej Goniewicz, United States of America
Jin Mo Goo, Republic of Korea
Koichi Goto, Japan
Jhanelle Elaine Gray, United States of America
Francesco Grossi, Italy
Matthias Guckenberger, Switzerland
Christine Hann, United States of America
Gerard Hanna, Australia
David Harpole, United States of America
Kazu Hasegawa, Japan
Fiona Hegi-Johnson, Australia
Matthew Hellmann, United States of America
Lizza Hendriks, Netherlands
John Heymach, United States of America
Fred R. Hirsch, United States of America
Tomo Yuki Hishida, Japan
Edward Hollo, United Kingdom
Leora Horn, United States of America
Dolores Isla, Spain
Masaoki Ito, Japan
Pasi Jänne, United States of America
Eloisa Jantus-Lewintre, Spain
Jacek Jassem, Poland
Didier Jean, France
James Jett, United States of America
Hongbin Ji, China
Tom John, Australia
David Jones, United States of America
Oscar Juan, Spain
Ayten Kayi Cangir, Turkey
Kemp Kerstine, United States of America
Amy Kerr, United Kingdom
Jamal Khader, Jordan
Young Tae Kim, Republic of Korea
Hedy Kindler, United States of America
Jennifer King, United States of America
Michaela Kirschner, Switzerland
Yoshisasa Kobayashi, United States of America
Takashi Kohno, Japan
Haruhiko Kondo, Japan
International Abstract Review Committee (continued)

Robert Korst, United States of America
Hideo Kunitoh, Japan
Catherine Labbe, Canada
Pippa Labuc, United Kingdom
Stephen Lam, Canada
Carla Lamb, United States of America
Corey Langer, United States of America
Sylvie Lantuejoul, France
Cecile Le Pechoux, France
Jin-Soo Lee, Republic of Korea
Natasha Leighl, Canada
Rogerio Lilenbaum, United States of America
Eric Lim, United Kingdom
Hong-Xu Liu, China
Stephen Liu, United States of America
William Lockwood, Canada
Benjamin Lok, Canada
Gilberto Lopes, United States of America
Fernando Lopez-Rios, Spain
Shun Lu, China
Gustavo Lyons, Argentina
Margarita Majem, Spain
Aaron Mansfield, United States of America
Mirella Marino, Italy
Claudio Martin, Canada
Eldsamira Mascarenhas, Brazil
Celine Mascaux, France
Clarissa Mathias, Brazil
Jose Maria Matilla, Spain
Julien Mazieres, France
Michael Menefee, United States of America
Jessica Menis, Italy
Laura Mezquita, France
Stefan Michiels, France
Mari Mino-Kenudson, United States of America
Jenny Mitchell, United Kingdom
Tetsuya Mitsudomi, Japan
Tony Mok, China
Laureano Molins, Spain
Eduard Monsó, Spain
Luis Montuenga, Spain
Amy Moore, United States of America
Teresa Moran, Spain
Andre Moreira, United States of America
Françoise Mornex, France
Steven Mutsaers, Australia
Yuko Nakayama, United States of America
Alejandro Navarro, Spain
Andrew Nicholson, United Kingdom
Masayuki Noguchi, Japan
Iveta Novahova, Spain
Meinoshin Okumura, Japan
Ray Osaroigbion, United States of America
Taofeek Owonikoko, Nigeria
United States of America
Geoffrey Oxnard, United States of America
Giovanna Palmieri, Italy
Vassiliki Papadimitrakopoulou, United States of America
Mauro Giulio Papotti, Italy
Keunchil Park, Republic of Korea
Ugo Pastorino, Italy
Nir Peled, Israel
Maurice Perol, France
Matthew Peters, Australia
David Planchard, France
Katerina Politis, United States of America
Santiago Ponce, Spain
Sanjay Popat, United Kingdom
Mariano Provencio, Spain
Luis Raez, United States of America
Suresh Ramalingam, United States of America
Ramon Rami-Porta, Spain
Jose Ramirez, Spain
Martin Reck, Germany
Noemi Reguart, Spain
Thanyanan Reungwetwattana, Thailand
Eduardo Richardet, Argentina
Naiyer Rizvi, United States of America
Anja C. Roden, United States of America
Christian Rolfo, United States of America
Antoni Rosell, Spain
Luca Roz, Italy
Charles Rudin, United States of America
Enrico Rufini, Italy
Nagahiro Saijo, Japan
Montserrat Sanchez-Cespedes, Spain
Miyako Satouchi, Japan
Giorgio Scaglotti, Italy
Isabelle Schmitt-Opitz, Switzerland
Marta Scorrano, Italy
Suressen Senan, Netherlands
Alice Shaw, United States of America
Lynette Sholl, United States of America
Alan Shpoe, China
Navneet Singh, India
Ben Slotman, Netherlands
Egbert Smit, Netherlands
Kellie Smith, United States of America
Benjamin Solomon, Australia
Ross Soo, Singapore
Gabriella Sozzi, Italy
Rolof Stahl, Switzerland
Matthew Steliga, United States of America
Emily Stone, Australia
Jayuan Sun, China
Peter Szolesarek, United Kingdom
Luc Thiberville, France
Pascal Alexandre Thomas, France
Erik Thunnissen, Netherlands
Ming Tsao, Canada
Paula Ugalde, Canada
Eric Vallieres, United States of America
Nico Van Zandwijk, Australia
Johan Vansteenkiste, Belgium
Nuria Vihnolas, Spain
Heather Wakelee, United States of America
Shun-ichi Watanabe, Japan
Maria Werner Wasik, United States of America
Kahren White, Australia
Juergen Wolf, Germany
Yi-Long Wu, China
Murry Wynes, United States of America
Nise Yamaguchi, Brazil
James Yang, Taiwan
Dianne Zawisza, Canada
Wen-Zhao Zhong, China
Caiicun Zhou, China
Qing Zhou, China
Help change the landscape of lung cancer treatment for future patients!

- New clinical and molecular elements have been added
- International participation is crucial to the project’s success
- The 9th Edition recommendations will be developed in 2022

**TIMELINE:**
The study consists of lung cancer patients diagnosed between January 1, 2011 and December 31, 2019. Cases may be submitted through 2019, with follow-up for survival through 2021.

For more information: www.iaslc.org/staging
COMING THIS FALL!

Apply for Research Awards!

The Lung Cancer Foundation of America–Bristol Myers Squibb/ILCF Young Investigator Research Awards in Translational Immuno-oncology are two-year, $200,000 grants focused on lung cancer research. There are two awards available.

The ILCF Fellowship and Young Investigator Awards are one-year, $50,000 grants focused on lung cancer research. There are six awards available.

APPLICATIONS OPEN:
October 14
December 15, 2019

For more information, visit: www.IASLC.org/research-education/fellowships
3  GENERAL CONFERENCE INFORMATION

wclc2019.iaslc.org
@IASLC
iaslc.lung
facebook.com/IASLC
#WCLC19
Registration

LOCATION

Fira de Barcelona Gran Via, North Access

Hours of Operation

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday, September 6</td>
<td>14:00 – 18:00</td>
</tr>
<tr>
<td>Saturday, September 7</td>
<td>06:30 – 20:00</td>
</tr>
<tr>
<td>Sunday, September 8</td>
<td>06:30 – 15:30</td>
</tr>
<tr>
<td>Monday, September 9</td>
<td>06:30 – 15:30</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>06:30 – 16:30</td>
</tr>
</tbody>
</table>

NAME BADGES

Delegates and guests are requested to wear their name badge at all times in order to participate in the Scientific Sessions, Networking Events and Exhibition.

DELEGATE HELP AND VISIT BARCELONA DESK

Fira de Barcelona Gran Via, North Access - Level 1

Visit the Help Desk for information on the scientific sessions, networking events, mobile app and virtual library. Information on Barcelona tours and attractions, restaurant reservations and general information can also be found here!

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, September 7</td>
<td>08:30 – 20:00</td>
</tr>
<tr>
<td>Sunday, September 8</td>
<td>08:30 – 17:30</td>
</tr>
<tr>
<td>Monday, September 9</td>
<td>08:30 – 17:30</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>08:30 – 16:00</td>
</tr>
</tbody>
</table>

REGISTRATION MATERIALS

Registration Materials include:

- Name Badge including barcode for tickets
- Ribbons (if applicable)
- Mini Pocket Program

Delegate Bags include:

- Printed Conference Program
  (only if printed version selected during registration)
- Printed Abstract Book
  (only if printed version selected)
- Invitation Flyers for Industry Symposia
- Additional Promotional Flyers from Sponsors and Exhibitors
- IASLC Information
Press and Media

PRESS & MEDIA ROOM
- Fira de Barcelona Gran Via, North Access - Level 2, Press Area

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, Sept. 7</td>
<td>15:00 – 19:00</td>
</tr>
<tr>
<td>Sunday, Sept. 8</td>
<td>08:00 – 19:00</td>
</tr>
<tr>
<td>Monday, Sept. 9</td>
<td>08:00 – 19:00</td>
</tr>
<tr>
<td>Tuesday, Sept. 10</td>
<td>08:00 – 18:00</td>
</tr>
</tbody>
</table>

Wireless internet access, power bars and a printer are available in the Media Room to assist credentialed media representatives.

INTERVIEW ROOMS
(SIGN UP REQUIRED* – MAX. 2 HOURS)
* SIGN UP FOR INTERVIEW ROOMS IS LOCATED ONSITE IN THE PRESS AREA

- Fira de Barcelona Gran Via, North Access - Level 2, Press Area

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, Sept. 7</td>
<td>15:00 – 19:00</td>
</tr>
<tr>
<td>Sunday, Sept. 8</td>
<td>08:00 – 19:00</td>
</tr>
<tr>
<td>Monday, Sept. 9</td>
<td>08:00 – 19:00</td>
</tr>
<tr>
<td>Tuesday, Sept. 10</td>
<td>08:00 – 19:00</td>
</tr>
</tbody>
</table>

PRESS CONFERENCES
- Fira de Barcelona Gran Via, North Access

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, Sept. 7</td>
<td>16:00 – 16:45</td>
</tr>
<tr>
<td>CC7.1 A&amp;B</td>
<td></td>
</tr>
<tr>
<td>Sunday, Sept. 8</td>
<td>09:45 – 10:30</td>
</tr>
<tr>
<td>CC7.1 A&amp;B</td>
<td></td>
</tr>
<tr>
<td>Monday, Sept. 9</td>
<td>10:15 – 11:00</td>
</tr>
<tr>
<td>CC7.1 A&amp;B</td>
<td></td>
</tr>
<tr>
<td>Tuesday, Sept. 10</td>
<td>10:45 – 11:30</td>
</tr>
<tr>
<td>CC7.1 A&amp;B</td>
<td></td>
</tr>
</tbody>
</table>

Press releases will be posted on the Conference website at the conclusion of each Conference day and press conferences will be live streamed and are available via: wclc2019.iaslc.org/live-press-conference/

Press and Media Registration and Access
Press and Media passes are issued to journalists, including photographers and freelance journalists, after providing proof of accreditation. Pre-registered Press and Media representatives are required to check in at the regular Registration Counters. Non-registered Press and Media representatives should proceed to the New Registration counter.

Interview Policy
All interviews outside of press conferences must be arranged in advance with interviewees and must take place in IASLC approved and designated rooms. No last-minute or hallway interviews are permitted anywhere inside the conference facility. The IASLC provides designated complimentary interview rooms (Press Room 1 & Press Room 2) for up to two hours. Sign up is required (online via wclc2019.iaslc.org/press-media or onsite in the Press and Media Room, level 2 beside the Exhibit Hall - 8.0). For questions, please see the IASLC staff in the Media Room.

Use of the IASLC WCLC Scientific Program Content
Please be aware that the information and materials displayed and/or presented at all sessions of this meeting are the property of the IASLC World Conference on Lung Cancer. Members of the media are not permitted to photograph or record and transmit/share any presentation’s slides without approval from the presenter and/or the IASLC unless explicitly forbidden. All information distributed must adhere to the IASLC’s embargo policy. Commercial firms cannot copy, photocopy, transform to electronic format, reproduce or distribute information or materials displayed at this meeting without the written permission of the International Association for the Study of Lung Cancer. Use of the WCLC/IASLC name and/or logo in any fashion by any commercial entity for any purpose is expressly prohibited without the express written permission of the International Association for the Study of Lung Cancer.

Interviews conducted through photography, videotaping and audio recording are allowed for news coverage only in the following areas/events:
- Press Conferences
- Interview rooms
- Other designated locations
- Recording in common areas requires permission and/or an IASLC staff escort

Copyright
Reproduction of materials such as abstract data, posters, presentation slides, etc., requires first obtaining permission from the listed author(s) and/or presenter(s). Photography of sessions, trade show booths, event setup, etc. is prohibited by IASLC/WCLC. The WCLC has a designated staff photographer and can provide WCLC19 event photography for journalists who wish to run photos of the event in their given media.

Please contact Becky Bunn, Director, Strategic Initiatives and Public Relations; Interim Director, Communications and Marketing at Becky.Bunn@iaslc.org for any press and media related questions.

Social Media Policy
Organizations may use social media to disseminate news and information regarding abstracts being presented at the WCLC. All information distributed through social media channels must adhere to the IASLC’s embargo policy. Organizations promoting their research through Twitter are welcome to include the IASLC’s World Conference hashtag, #WCLC19. Members of the media are permitted to photograph or record and transmit/share on any social media platform any presentation’s slides without approval from the presenter and/or the IASLC unless explicitly forbidden. Representatives from academic institutions are permitted to share slides, but not for the media to re-transmit. Only non-flash photography is allowed of slide presentations.

For complete guidelines and media policies please refer to the Conference website at wclc2019.iaslc.org/press-media
Information for Invited Faculty and Abstract Presenters

DISCLOSURE INFORMATION
All invited speakers as well as oral and mini oral abstract presenters must include a slide with their financial disclosure information. Without a disclosure slide you will not be allowed to present!

PRESENTATION SLIDE TEMPLATE
All invited speakers as well as oral and mini oral abstract presenters are asked to use the IASLC/WCLC presentation slide template for their presentation.

REGISTRATION

INVITED FACULTY
‘Invited Faculty’ Registration Counter
(Session Chairs, Invited Speakers, Abstract Discussants)

ABSTRACT PRESENTERS
‘Registered Delegate’ Counter

SPEAKER PREVIEW CENTER
All invited speakers as well as oral and mini oral abstract presenters are required to report to the Speaker Preview Center at least 24 hours prior to their scheduled presentation in order to upload their presentation slides or to check their previously uploaded slides.

NO FILE SUBMISSIONS WILL BE ACCEPTED IN THE SESSION ROOMS.

Computers are available to preview and upload presentations. Presenters should make sure all fonts appear as expected and all sound/video clips are working properly. The final version must be submitted to the Speaker Preview Center, no presentation submissions will be accepted in the Session Rooms.

SPEAKER PREVIEW CENTER

Fira de Barcelona Gran Via, North Access - Level 1, Hall 8.0

<table>
<thead>
<tr>
<th>Day</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday, September 6</td>
<td>14:00 – 18:00</td>
</tr>
<tr>
<td>Saturday, September 7</td>
<td>06:30 – 20:00</td>
</tr>
<tr>
<td>Sunday, September 8</td>
<td>06:30 – 17:30</td>
</tr>
<tr>
<td>Monday, September 9</td>
<td>06:30 – 17:30</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>06:30 – 16:00</td>
</tr>
</tbody>
</table>
Oral Abstract Presenters

- You will have a total of 10 minutes; 8 minutes of presentation, followed by 2 minutes time for questions from the audience. Time limits will be strictly enforced.
- You are asked to prepare a PPT Presentation with maximum 10 slides (not including title and disclosure slide).
- Please be in room for your session 10 minutes before the start time of the session. The Session Chairs will start and end strictly on time.
- All presenters MUST include statement disclosing any conflict of interest related to your abstract as the first slide of your presentation.

Mini Oral Presenters

- You will have a total of 5 minutes (no Q&A). Time limits will be strictly enforced.
- Please be in room for your session 10 minutes before the start time of the session. The Session Chairs will start and end strictly on time.
- You are asked to prepare a PPT Presentation with maximum 6 slides (not including title and disclosure slide).
- All presenters MUST include statement disclosing any conflict of interest related to your abstract as the first slide of your presentation.

Poster Presenters

All Poster Presentations/Boards are located in the Exhibit Hall (Hall 8.1), Level 2, and each Poster Board is identified by a professionally lettered sign with the assigned Poster Number. The Poster Board Number corresponds with the pre-assigned Poster Number provided in your confirmation letter and printed in the Abstract Book and this Conference Program.

P1: Poster Session 1 Sunday, September 8
P2: Poster Session 2 Monday, September 9

Poster Display Time

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, September 8</td>
<td>09:45–18:00</td>
</tr>
<tr>
<td>Monday, September 9</td>
<td>09:45–18:00</td>
</tr>
</tbody>
</table>

Presenters in Attendance

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, September 8</td>
<td>09:45 – 10:30</td>
</tr>
<tr>
<td>Poster Viewing Reception*</td>
<td>16:45 – 18:00</td>
</tr>
<tr>
<td>Monday, September 9</td>
<td>10:15 – 11:00</td>
</tr>
<tr>
<td>Poster Viewing Reception*</td>
<td>17:15 – 18:15</td>
</tr>
</tbody>
</table>

* Complimentary drinks and snacks will be served during the Poster Viewing Receptions.

ePOSTERS

ePosters will be available for delegates to view within the exhibit hall during exhibit hall opening times.

POSTER VIEWING RECEPTIONS

On Sunday and Monday afternoon you will be able enjoy complimentary drinks and snacks while interacting with the presenters.

POSTER PRINTING SERVICE

If you have ordered to have your poster printed by the Conference at an additional charge, you may pick up your poster onsite.

POSTER PICK UP

📍 Fira de Barcelona Gran Via, North Access - Level 1, Hall 8.0

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, September 8</td>
<td>08:00–18:00</td>
</tr>
<tr>
<td>Monday, September 9</td>
<td>08:00–18:00</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>08:00–14:30</td>
</tr>
</tbody>
</table>
Continuing Medical Education (CME) Information

The International Association for the Study of Lung Cancer (IASLC) complies with the Standards for Commercial SupportSM of the Accreditation Council for Continuing Medical Education (ACCME). IASLC applies these Standards throughout the educational program process—from development through implementation—to ensure independence of educational activities. IASLC policies are outlined below.

CREDIT STATEMENT
The International Association for the Study of Lung Cancer is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The International Association for the Study of Lung Cancer designates this live activity for a maximum of 25.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

GOAL & PURPOSE
The WCLC 2019 is the world’s largest international gathering of clinicians, researchers, and scientists in the field of lung cancer and thoracic oncology. Bringing together lung cancer specialists from around the world and across disciplines, the meeting offers unique opportunities for collaboration, learning and sharing the latest developments in lung cancer and thoracic malignancy research, prevention, diagnosis, treatment and management. With 17 educational tracks and over 500 global experts as invited speakers, WCLC 2019 provides a robust, comprehensive scientific program encompassing cutting edge knowledge on subjects such as tumor biomarkers, clinical trials, targeted therapies, liquid biopsy, screening, immunotherapy, tobacco control and patient advocacy. Sessions include plenaries, expert panel discussions, hands-on workshops, symposia, interactive grand rounds, oral abstracts, and posters.

TARGET AUDIENCE
The 2019 World Conference on Lung Cancer is designed to meet the educational needs of researchers and healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists, advanced practice nurses, and physician assistants.
LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

1. Examine scientific advances in thoracic cancer including the pathogenesis, biology, and mechanisms of drug interactions that can be used to make evidence-based diagnosis and treatment decisions.

2. Synthesize cutting edge research from clinical trials and translational studies conducted around the world to deepen knowledge within primary specialty area(s) and broaden knowledge of other specialties.

3. Advocate for lung cancer prevention strategies including tobacco control, smoking cessation, reducing environmental risks, addressing the quality and value of healthcare, and implementing early screening.

4. Apply evidence-based recommendations and clinical practice guidelines to diagnose and manage patients.

5. Collaborate on multidisciplinary teams to improve patient outcomes through patient-centered diagnostic, therapeutic and palliative care.

6. Engage and empower patients to become active participants in their treatment.

OFFICIAL LANGUAGE
The official language of the IASLC 2019 World Conference on Lung Cancer is English.

DISCLAIMER
The information presented at the IASLC 2019 World Conference on Lung Cancer is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

HOW TO RECEIVE A CME CERTIFICATE
(PHYSICIANS ONLY)
Physicians are entitled to receive a CME certificate after completing the conference evaluation survey. A link to this survey will be emailed to all attendees at the conclusion of the conference; the survey can also be accessed from the conference website. After submitting the survey, physicians have the option to print or save their CME certificate.

CME certificates will reflect the number of accredited sessions attended. CME accredited activities are designated in the program guide. To receive credit for attending official CME sessions, each person must scan their badge as they enter the room. The deadline for claiming CME credit is December 31, 2019. Please direct any certificate inquiries to: wclc2019-registration@icsevents.com

HOW TO RECEIVE A CERTIFICATE OF ATTENDANCE
(NON-PHYSICIANS)
Non-physicians are entitled to receive a “Certificate of Attendance”. To claim a Certificate of Attendance, non-physicians must first complete the conference evaluation survey. A survey link will be emailed to all attendees at the conclusion of the conference; the survey can also be accessed from the conference website. After submitting the survey, attendees may print or save their Certificate of Attendance. The deadline for receiving a Certificate of Attendance is December 31, 2019. Please direct any certificate inquiries to: wclc2019-registration@icsevents.com
Onsite Services and General Information

**IASLC WORLD CONFERENCE MOBILE APP**
Download the free IASLC World Conference official mobile app for a convenient way to stay up-to-date via your phone or tablet. View the full scientific schedule, abstracts, exhibit information including floor plan and exhibitor biographies, and general Conference and venue information on our easy to use app!

The app is compatible with all iOS devices (iPhone, iTouch and iPad) and all Android mobile devices. Timely updates on program or room changes will be distributed through the mobile app via notification alerts. Search for: IASLC World Conference

**INTERACTIVE AUDIENCE RESPONSE TOOL**
**TAKE ACTION at IASLC WCLC 2019** and play an active role during the sessions by using the newly introduced interactive audience response tool. Accessible through the conference Mobile App, each session will have a link to a very simple and easy to use system that will allow you to respond to poll questions, provide valuable feedback and even ask questions, all in real time!

Be engaged and enhance your learning and experience by using this new interactive tool!

**IASLC WCLC 2019 VIRTUAL MEETING**
All audio and webcast recordings including presentations, abstracts and electronic versions of most posters will be available in the Virtual Meeting within 24 hours. Check your name badge for login details.

**JOIN THE CONVERSATION –**
**IASLC WCLC 2019 OFFICIAL SOCIAL MEDIA ACCOUNTS**
The IASLC Social Media Corner is back and better! Plan to stop by the IASLC Social Media Corner on Level 1 of the Fira de Barcelona Gran Via, North Access (opposite registration) as often as you like during the Conference — there will always be something going on. Not social media savvy? No problem. We’re here to help!

Here’s what’s happening:
- View live feeds from Twitter, Instagram and Facebook
- Take your photo in front of our special Barcelona backdrop
- Learn how to post on social media
- Get your free gift

**IASLC SOCIAL MEDIA ACCOUNTS TO FOLLOW**
- @IASLC
- iaslc.lung
- facebook.com/IASLC
- #WCLC19
ABSTRACTS
Abstracts selected for IASLC WCLC are presented in Oral, Mini Oral and Poster Sessions. The top seven abstracts featuring groundbreaking trials will be presented in the Presidential Symposium on Monday, September 9, 08:00 – 10:15. All accepted and confirmed abstracts are published in a supplement of the Journal of Thoracic Oncology, which will be posted online on the JTO website in December 2019. If you requested a printed version of the Abstract Book, please pick it up along with your delegate bag.

ABSTRACTS ONLINE
Attendees are invited to view the abstracts in the virtual meeting available on the Conference website. The virtual meeting allows searching for abstracts, topics, presenters, sessions and keywords, selecting abstracts of interest and building your own personal conference calendar. It is free for all WCLC delegates. All accepted abstracts are also included in the WCLC 2019 Mobile App.

GET THE WCLC 2019 VIRTUAL MEETING AT library.iaslc.org

ACCREDITATION
→ Please see page 26 in this book for further information.

ATTIRE
Business casual is appropriate for all sessions and networking events. Room temperature can vary in session rooms. We encourage attendees to dress in layers for their personal comfort.

ATM
There is one ATM machine located in the Foyer of the North Building of the Fira Grand Via, adjacent to registration.

BAGGAGE CHECK
→ Please see ‘Coat and Baggage Check’ on this page for further information.

BADGES AND ACCESS CONTROL
You will be required to wear your badge at all times within the venue.

BREAKFAST
The Conference does NOT provide breakfast except for the Interactive Breakfast Sessions (ticketed sessions) from Sunday – Tuesday 07:00 – 08:00 or otherwise indicated in the program.

BUSINESS CENTER
There is no business center located within the Fira Grand Via. Please visit: estudiesteve.es/contactanos for all your printing needs.

CELL PHONES
As a courtesy to fellow attendees, please turn off cell phones during scientific sessions.

CERTIFICATE OF ATTENDANCE
International attendees can request a ‘Certificate of Attendance’ by completing the Conference evaluation form available on the Conference website at the conclusion of the Conference. After completing the evaluation form you will be able to download your Certificate of Attendance.

CHARGING STATIONS
Charging Stations are located throughout the Exhibit Hall (Hall 8.1) allowing delegates to power up their cell phones, iPads and other electronic devices for free.

CME ACCREDITATION AND CME CERTIFICATE
→ Please see page 26 in this book for further information.

COAT AND BAGGAGE CHECK
● Fira de Barcelona Gran Via, North Access - Level 1, Hall 8.0

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday, September 6</td>
<td>14:00 – 18:00</td>
</tr>
<tr>
<td>Saturday, September 7</td>
<td>06:30 – 22:00</td>
</tr>
<tr>
<td>Sunday, September 8</td>
<td>06:30 – 17:30</td>
</tr>
<tr>
<td>Monday, September 9</td>
<td>06:30 – 17:30</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>06:30 – 16:00</td>
</tr>
</tbody>
</table>
Onsite Services and General Information (continued)

DELEGATE LOUNGES

• Exhibit Hall (Hall 8.1)

Delegate Lounges are available and located in the Exhibit Hall (Hall 8.1). These lounges are specifically designed to provide a comfortable seating area for delegates to rest, conduct brief meetings or network with colleagues.

IASLC Member Experience Lounge featuring the Committee Corner – Reserved for IASLC Members

Delegates Lounges
Patient Advocacy Lounge
Nurse & Allied Health Professional Lounge

EMERGENCY SERVICES AND FIRST AID

In case of an emergency inform Fira Barcelona staff and call the Control Center at: Gran Via: +34 93 223 41 00 or use the emergency buttons.

The first aid room is located in the Exhibit Hall 8.1.

ILC FOUNDATION ROAD TO HOPE

An evening for all celebrating research and hope!

• Museu Nacional D’art De Catalunya,
  Parc de Montjuïc

Monday, September 9 20:00 – 23:00

Join us for a unique networking event offering the exclusive opportunity to meet and interact with doctors, scientists and survivors in support of ongoing research dedicated to finding a cure for lung cancer!

Taking place in one of the most iconic spaces of Barcelona, the Palau Nacional, you will be able to enjoy magnificent views of Barcelona.

Tickets are priced at 85 EUR each and can be purchased at the time of registration, subject to availability.

INTERNET CAFÉ

• Exhibit Hall (Hall 8.1)
  attached to the Exhibit Showcase Theater

Keep in touch with home and office! Computers with internet and printers are available to delegates on a complimentary basis. The Internet Café is open during Exhibit Hall Hours. Internet sessions are limited to 15 minutes per delegate.

LACTATION ROOM

• Exhibit Hall (8.1), Room 8.A

IASLC is offering delegates the use of a private nursing room located on the 2nd floor within the Exhibit Hall

LOST AND FOUND

The lost & found collection point is centralized at the Service Desk located on each pavilion.

Every object founded around the Conference premises (by security, cleaning staff or attendees) is eventually delivered and centralized to the Service Desk at the end of the day.

MEDIA ROOM

• Fira de Barcelona Gran Via,
  North Access, Level 2, Press Area

Workstations with internet access, copier and refreshments are available.

IASLC

IASLC General Assembly

• Fira de Barcelona Gran Via,
  North Access - Level 1, 8.0 Tokyo (1982)

Tuesday, September 10 08:00 – 08:45

All IASLC Members are invited to attend the IASLC General Assembly.

IASLC Booth

• Booth #300, Exhibit Hall (Hall 8.1)

Please visit the IASLC Booth for updates on membership, society-sponsored meetings and events, the ILC Foundation, JTO and general information.

IASLC Social Media Booth

• Level 1 of the Fira de Barcelona Gran Via,
  North Access - opposite Registration

Please visit the IASLC Social Media Booth and share your WCLC experience with us.

IASLC Tobacco Exhibition

• Fira de Barcelona Gran Via,
  North Access - Level 1, Hall 8.0

Don’t miss out to visit our Tobacco Exhibits located in Hall 8.0 next to the scientific sessions.
NEWSPAPER
A daily Conference Newspaper will be available from Saturday to Tuesday at no charge to Conference delegates. The Newspaper will be distributed at various points at the Fira de Barcelona Gran Via. A PDF version of each edition will also be available on the Conference website.

OVERFLOW ROOMS
An overflow viewing area has been set up in the Exhibit Hall (8.1). Headsets will be provided; however, please return your headsets.

CME Sessions viewed from the overflow area are not eligible for CME credit.

PARKING
Delegate parking is provided in Parking F (outside of Hall 8) at a cost of EUR 3 per hour.

POSTERS ONLINE
All abstracts accepted for poster presentation will be presented as traditional printed posters to be displayed on poster boards in the Exhibit Hall (Hall 8.1). In addition to the printed poster, each presenter is required to submit an electronic version of their poster to be made available in the Virtual Meeting (library.iaslc.org), which is free of charge to all delegates.

New this year, IASLC is pleased to offer ePosters. These are located within the Exhibit Hall in the Poster Area. These ePosters will also be available online.

PRAYER ROOM
● Exhibit Hall (8.1), Room 8.C
IASLC is offering delegates the use of a multifaith prayer room. Delegates of differing religious beliefs, or none at all, are able to spend time in contemplation or prayer.

PRESS
Please see page 23 in this brochure for further information.

PUBLIC TRANSPORTATION
We strongly recommend that you take public transportation whenever possible. Barcelona offers modern and efficient public transportation networks. For assistance, please visit the Delegate Help and Visit Barcelona Desk in the Fira de Barcelona – Gran Via North Entrance, Level 1.

RESTAURANTS
There are plenty of restaurants choices in Barcelona and within walking distance from the Fira de Barcelona – Gran Via. The staff at the Delegate Help Desk will be happy to assist with recommendations and bookings.

SMOKING
The Fira de Barcelona Gran Via is a smoke-free environment. All public areas, rental space, corridors, loading docks, exhibit halls and parking lots are designated non-smoking. The Fira de Barcelona Gran Via is required to enforce the no-smoking rules.

SPEAKER PREVIEW CENTER
All Presenters are required to submit and/or preview their slides at least 24 hours prior to their scheduled presentation to ensure compatibility with the Conference AV Equipment.

● Fira de Barcelona Gran Via,
  North Access - Level 1, Hall 8.0

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday, September 6</td>
<td>14:00 – 18:00</td>
</tr>
<tr>
<td>Saturday, September 7</td>
<td>06:30 – 20:00</td>
</tr>
<tr>
<td>Sunday, September 8</td>
<td>06:30 – 17:30</td>
</tr>
<tr>
<td>Monday, September 9</td>
<td>06:30 – 17:30</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>06:30 – 16:00</td>
</tr>
</tbody>
</table>

VIRTUAL MEETING
All oral sessions are recorded (slides and audio) and will be made available as a Virtual Meeting through the IASLC Virtual Meeting within 24 hours.

The WCLC 2019 Virtual Meeting is included in your registration and can be accessed through library.iaslc.org

Your personal Virtual Meeting Access Code is the same as your Delegate ID Number and can be found on your badge or through your WCLC 2019 confirmation email. After you enter your Access Code and confirm your account details, you’ll be able to view any presentations that have been marked as “Now Available”.

To start viewing, please visit: library.iaslc.org.
**WIRELESS INTERNET**

Premium Attendee Wireless Internet Access is provided throughout the Fira de Barcelona Gran Via, North Access. Each user is allotted a download speed of 3 Mbps and an upload speed of 3 Mbps. This service is suited for attendee general usage such as checking e-mail, social media and web surfing. Users are restricted from Virtual Private Networks (VPN), Remote Desktop Protocols (RDP) and peer to peer protocols.

Wireless network is optimized to be used by devices operating in the 5GHz radio band (802.11 a/n ac). Although the service will be offered in the 2.4GHz radio band (802.11 g/n) the service is provided best effort due to the high levels of contention and interference present on the radio band.

To connect to the Wi-Fi, connect to

```
Network: #WCLC19
Password: conquer
```
TUNE IN NOW for the latest in lung cancer. All episodes can also be downloaded on SoundCloud.

Hosted by Dr. H. Jack West, “Lung Cancer Considered” is the official podcast of the International Association for the Study of Lung Cancer.

Tune in each month for conversations with the researchers, health care professionals, patients and advocates who are making a difference in the treatment of thoracic cancers.

New episodes are released on the first and third Monday of each month.
Get Social!

Visit the IASLC’s Social Media Hub Directly Behind Registration

JOIN THE CONVERSATION!

• View live feeds from Twitter and Instagram
• Take your picture in front of our special social media backdrop (select country flags or signs as props)
• Learn how to post on social media (we’ll walk you through it)
• Pick up our social media tip sheet

Official hashtag: #WCLC19
Visit the IASLC’s Social Media Hub
Directly Behind Registration
JOIN THE CONVERSATION!
• View live feeds from Twitter and Instagram
• Take your picture in front of our special social media backdrop (select country flags or signs as props)
• Learn how to post on social media (we’ll walk you through it)
• Pick up our social media tip sheet
Get Social!

Official hashtag:
#WCLC19
IASLC Distinguished Awards

2019 Mary J. Matthews Pathology/Translational Research Award

Andrew Nicholson, MD PhD

Prof Nicholson trained in medicine at Oxford University and St Bartholomew’s Medical School and then specialized in pathology, specifically thoracic pathology, trained under Professor Bryan Corrin at the Royal Brompton Hospital, London. He has since worked there as a consultant since 1995, and as Honorary Professor in Respiratory Pathology, at the National Heart and Lung Institute, Imperial College, London since 2002. As well as being the lead for local thoracic pathology, he is referred over 300 cases each year, mainly cancer related, from clinicians and other pathologists both nationally and internationally. His research interests are thoracic cancers - common and rare lung cancers, mesotheliomas, thymic tumours - as well other thoracic diseases such as interstitial lung disease, and he has published over 400 peer-reviewed papers. In relation to thoracic cancers, he is particularly interested in translational research. He is a Past Chair of the International Association for the Study of Lung Cancer (IASLC) Pathology Panel, and has been a longstanding member of the IASLC Staging and Prognostic Factors Committee. He has also sat on the IASLC Membership Committee. He was Specialist Advisory Panel for the Royal College of Pathologists, UK, for the past decade and is President Elect of the British Division of the International Academy of Pathologists. He has also co-authored Pathology of the Lung, second and third editions (Churchill Livingstone 2006 and 2011) with Bryan Corrin, was a Volume Editor of the 2015 WHO classification of lung, pleura, thymus and heart tumours and is an author of the AFIP Atlas of Tumor Pathology: Tumors of the Lower Respiratory Tract (2019).

2019 Paul A. Bunn, Jr Scientific Award

Charles Rudin, MD PhD

Dr. Rudin is Sylvia Hassenfeld Professor and Chief of Thoracic Oncology at MSKCC, where he also co-directs the Druckenmiller Center for Lung Cancer Research. Dr. Rudin oversees a broad and integrated program of preclinical and clinical research in lung cancer, spanning from basic discovery science, preclinical modeling and novel therapeutic target identification, first-in-human phase I clinical testing, through leadership of definitive national and international phase 3 studies. Dr. Rudin has a particular interest in small cell lung cancer (SCLC), and chairs the NCI SCLC Research Consortium, a national network of investigators studying SCLC oncogenesis, mouse and human preclinical modeling, genomic and epigenetic drivers, and therapeutic vulnerabilities. He also serves as the MSK PI for two Stand Up to Cancer (SU2C) grants, one focused on epigenetics and the other on KRAS targeting in lung cancer.
2019 Merit Award

Hisao Asamura, MD

Professor of Surgery, Chief, Division of Thoracic Surgery, Keio University School of Medicine, Tokyo, Japan

Born in Osaka in 1957. Graduated from Keio University School of Medicine in 1983. Internship at the Keio University Hospital and affiliated hospitals (1983-85). Residency in general surgery and Clinical fellow in thoracic surgery at the National Cancer Center Hospital (1986-91). Attending surgeon (Thoracic surgery, 1992-1998), Chief of Thoracic Surgery (1992-2014), and Deputy Director-Hospital (2012-2014) at the National Cancer Center Hospital, Tokyo. Professor of Surgery, Chief, Division of Thoracic Surgery, Keio University School of Medicine (2014-present). Visiting Professor at the Kyorin University in Tokyo (2007-2013) and at the Seoul National University in Seoul, Korea (1999-present). Doctor of Medical Science degree from Keio University in 1997. Chair of Staging and Prognostic Factors Committee (SPFC, 2016-present), Executive Board Director (2012-2016). A Congress President for 18th World Conference on Lung Cancer in Yokohama 2017 by IASLC (IASLC), Vice President, Japan Lung Cancer Society, National Committee Chair and Section Editor of UICC


2019 Joseph W. Cullen Prevention/Early Detection Award

Denise R. Aberle, MD

Denise R. Aberle, MD is Professor of Radiology and Bioengineering at UCLA. She has been Vice Chair for Research in Radiological Sciences in the David Geffen School of Medicine at UCLA for 19 years. She previously served as President of the Society of Thoracic Radiology, Chair of the Lung Committee of the American College of Radiology Imaging Network (ACRIN), Deputy Chair of ACRIN, and co-chair of the Early Diagnosis and Detection Committee of ECOG-ACRIN. She is a fellow of the American Institute for Medical and Biomedical Engineering (AIMBE) and has received awards from the IASLC, the UCLA Clinical Translational Science Institute, the American Lung Association, ACRIN, the Society of Thoracic Radiology, and others for her work in lung cancer early detection. From 2000 to 2012, Dr. Aberle led the National Lung Screening Trial-ACRIN as principal investigator.

Dr. Aberle obtained her MD degree from the University of Kansas Medical Center and completed a residency in internal medicine at Boston University Hospital (1980-1982), thereafter completing a residency in diagnostic radiology at UCLA. She completed fellowship training in thoracic imaging at the University of California San Francisco in 1987 before returning to UCLA to head the Thoracic Imaging Section. Her current research focuses on characterizing indeterminate lung nodules and early lung cancers using semantic, quantitative, and machine learning techniques in combination with clinical and molecular features.
## Previous IASLC Distinguished Award Winners

<table>
<thead>
<tr>
<th>Year</th>
<th>IASLC Merit Award</th>
<th>IASLC Mary J. Matthews Pathology/Translational Research Award</th>
<th>IASLC Joseph W. Cullen Prevention/Early Detection Award</th>
<th>IASLC Paul A. Bunn, Jr. Scientific Award (Formerly IASLC Scientific Award)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1991</td>
<td>Clifton F. Mountain</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1994</td>
<td>Y. Shimosato N. Bleehen</td>
<td>Geno Saccamanno</td>
<td>Jesse Steinfeld</td>
<td>Robert J. Ginsberg</td>
</tr>
<tr>
<td>1997</td>
<td>Heine H. Hansen</td>
<td>William Travis</td>
<td>Clifford Douglas</td>
<td>John D. Minna</td>
</tr>
<tr>
<td>2000</td>
<td>Desmond Carney</td>
<td>Yokio Shimosato</td>
<td></td>
<td>Daniel C. Ihde</td>
</tr>
<tr>
<td>2003</td>
<td>Paul A. Bunn, Jr.</td>
<td>Adi Gazdar</td>
<td></td>
<td>Paul van Houtte</td>
</tr>
<tr>
<td>2005</td>
<td>Harubumi Kato</td>
<td>Elisabeth Brambilla</td>
<td>Nigel Gray</td>
<td>Thierry LeChevalier</td>
</tr>
<tr>
<td>2007</td>
<td>Peter Goldstraw</td>
<td>Fred R. Hirsch</td>
<td>James Mulshine</td>
<td>Frances Shepherd</td>
</tr>
<tr>
<td>2009</td>
<td>Giorgio V. Scagliotti</td>
<td>Masayuki Noguchi</td>
<td>Stephen Lam</td>
<td>Bruce Johnson Tom Lynch</td>
</tr>
<tr>
<td>2011</td>
<td>David Ball</td>
<td>Philip Hasleton</td>
<td>John Field</td>
<td>Nagahiro Sajo</td>
</tr>
<tr>
<td>2013</td>
<td>James Jett</td>
<td>Tetsuya Mitsudomi</td>
<td>Pieter Postmus</td>
<td>David R. Gandara</td>
</tr>
<tr>
<td>2015</td>
<td>Harvey Pass</td>
<td>Ming Tsao</td>
<td>Jacek Jassem</td>
<td>Yi-Long Wu</td>
</tr>
<tr>
<td>2016</td>
<td>Sumitra Thongprasert Keunchil Park</td>
<td>Keith Kerr</td>
<td>Ugo Pastorino</td>
<td>Roy Herbst</td>
</tr>
<tr>
<td>2017</td>
<td>Ramon Rami-Porta</td>
<td>Yasushi Yatabe</td>
<td>Carolyn Dresler</td>
<td>Tony Mok</td>
</tr>
<tr>
<td>2018</td>
<td>Françoise Mornex</td>
<td>Ignacio I. Wistuba</td>
<td>Fadlo Khuri Nise Yamaguchi</td>
<td>Charles Swanton</td>
</tr>
</tbody>
</table>
IASLC Lectureship Award Winners

The IASLC International Lectureship Award Winners will receive their award during the IASLC Award Session on Saturday, September 7, 17:45 – 18:45, in Toronto (1985).

**Adi F. Gazdar Lectureship Award for Translational Science**

**ROBERT THOMAS, GERMANY**
MEDICAL ONCOLOGY

**Robert J. Ginsberg Lectureship Award for Surgery**

**GIULIA VERONESI, ITALY**
THORACIC SURGERY

**Heine H. Hansen Lectureship Award for Small Cell Lung Cancer**

**CAROLINE DIVE, UNITED KINGDOM**
BASIC SCIENCES

**Clifton F. Mountain Lectureship Award for Staging**

**PAULA UGALDE, CANADA**
THORACIC SURGERY

**Tsuguo Naruke Lectureship Award for Surgery**

**RAJA FLORES, USA**
THORACIC SURGERY

**IASLC Lectureship Award for Nursing and Allied Health**

**KAHREN WHITE, AUSTRALIA**
ALLIED HEALTH PROFESSIONAL
OCCUPATIONAL THERAPY

**James D. Cox Lectureship Award for Radiation Oncology**

**CORINNE FAIVRE-FINN, UNITED KINGDOM**
RADIATION ONCOLOGY

**IASLC Lectureship Award for Smoking Cessation**

**EMILY STONE, AUSTRALIA**
SMOKING CESSION

**Daniel C. Idhe Lectureship Award for Medical Oncology**

**DANIEL TAN, SINGAPORE**
MEDICAL ONCOLOGY
### IASLC Academy Award Winners

The IASLC Academy Award Winners will receive their award during the IASLC Award Session on **Saturday, September 7, 17:45 – 18:45, in Toronto (1985)**.

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>AARON TAN</td>
<td>National Cancer Centre, Singapore, Singapore</td>
</tr>
<tr>
<td>ALESSANDRO RUSSO</td>
<td>University of Messina, Italy</td>
</tr>
<tr>
<td>ANDREW BANG</td>
<td>Dana-Farber Cancer Institute, Canada</td>
</tr>
<tr>
<td>CARLO GENOVA</td>
<td>IRCCS Ospedale Policlinico San Martino, Italy</td>
</tr>
<tr>
<td>FÁBIO DE FIGUEIRÊDO CHAVES</td>
<td>Cancer Institute of Ceará, Brazil</td>
</tr>
<tr>
<td>JAMAL ZAINI</td>
<td>Department of Respiratory Medicine, University of Indonesia, Persahabatan Hospital, Indonesia</td>
</tr>
<tr>
<td>JIN KANG</td>
<td>Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital, China</td>
</tr>
<tr>
<td>MANOJ GOWDA</td>
<td>All India Institute of Medical Sciences, New Delhi, India</td>
</tr>
<tr>
<td>MARIA AIME GIORLANDO</td>
<td>Angel Roffo Oncology Institute, Argentina</td>
</tr>
<tr>
<td>MEHMET ALTAN</td>
<td>MD Anderson Cancer Center, United States of America</td>
</tr>
<tr>
<td>MOHAMED GOUDA</td>
<td>Faculty of Medicine, Menoufia University, Egypt</td>
</tr>
<tr>
<td>REBECCA MOOR</td>
<td>Royal Brisbane Hospital, Australia</td>
</tr>
<tr>
<td>SABINA BEREZOWSKA</td>
<td>Institute of Pathology, University of Bern, Switzerland</td>
</tr>
<tr>
<td>SHAHED BADIYAN</td>
<td>Washington University, United States of America</td>
</tr>
<tr>
<td>VICTORIA LAI</td>
<td>Memorial Sloan Kettering Cancer Center, United States of America</td>
</tr>
<tr>
<td>YU YANG SOON</td>
<td>National University Hospital, Singapore</td>
</tr>
</tbody>
</table>

### IASLC International Mentorship Award Winners

The IASLC International Mentorship Award Winners will receive their award during the IASLC Award Session on **Saturday, September 7, 17:45 – 18:45, in Toronto (1985)**.

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>JINGHUA CHEN</td>
<td>Guangdong Provincial People’s Hospital, Guangzhou Twelfth People’s Hospital, China</td>
</tr>
<tr>
<td>P2.14-36: Identification of Genomic Features in Tumor-Derived Organoids from Resectable NSCLC</td>
<td></td>
</tr>
<tr>
<td>Mentored by:</td>
<td>Rafael Rosell, Honorary Consultant, Catalan Institute of Oncology, Distinguished Researcher, Autonomous University of Barcelona (UAB)</td>
</tr>
<tr>
<td>RACHEL FREEMAN</td>
<td>University of Namibia, Namibia</td>
</tr>
<tr>
<td>P1.07-19: Palliative Care Social Workers Multi-Dimensional Roles: A Namibian Perspective</td>
<td></td>
</tr>
<tr>
<td>Mentored by:</td>
<td>Pippa Labuc, Guy’s and St Thomas’ NHA Foundation Trust, United Kingdom</td>
</tr>
<tr>
<td>WANNISA LAOSUANGKOON</td>
<td>Ramathibodi Hospital, Mahidol University, Thailand</td>
</tr>
<tr>
<td>P2.11-25: Pre- and Post-Surgery Metabolomic Profiles in Early-Stage NSCLC Patients</td>
<td></td>
</tr>
<tr>
<td>Mentored by:</td>
<td>Luis M. Montuenga, Professor of Cell Biology, Department of Pathology, Anatomy and Physiology, Schools of Medicine and Sciences</td>
</tr>
<tr>
<td>Jenegro MEENA</td>
<td>Geetanjali Medical College &amp; Hospital, Udaipur, India</td>
</tr>
<tr>
<td>EP1.11-05: Integration of Low Dose Computed Tomography (LDCT) for Lung Cancer Screening in the National Cancer Program in India: A Feasibility Study</td>
<td></td>
</tr>
<tr>
<td>Mentored by:</td>
<td>Nadal Alforia, Ernesto Samuel, Medical Oncology Department, Catalan Institute of Oncology (ICO), Duran i Reynals Hospital, Head of the Program of Thoracic Tumors in Medical Oncology</td>
</tr>
<tr>
<td>PUJI RAHARJA SANTOSA</td>
<td>Persahabatan Hospital, Indonesia</td>
</tr>
<tr>
<td>EP1.07-01: Effectiveness of Therapeutic Massage for Treating Anxiety in Suspected Lung Cancer Patient Pre-Broncoscopic Procedures</td>
<td></td>
</tr>
<tr>
<td>Mentored by:</td>
<td>Pippa Labuc, Guy’s and St Thomas’ NHA Foundation Trust, United Kingdom</td>
</tr>
</tbody>
</table>
The WCLC 2019 Early Career Award Winners will receive their award during the IASLC Award Session on Saturday, September 7, 17:45 – 18:45, in Toronto (1985).

DANIEL BREADNER
London Regional Cancer Program, Canada
EP.14-07: Efficacy and Safety of ALK Inhibitors in ALK-Rearranged Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

KATHRYN ARBOUR
Memorial Sloan Kettering Cancer Center, United States of America
MA11.01: Multifactorial Model to Predict Response to PD-(L)1 Blockade in Patients with High PD-L1 Metastatic Non-Small Cell Lung Cancer

DENNIS ADEEGBE
Moffitt Cancer Center, United States of America
P.04-35: Identification and Characterization of a Unique KLRG1-Expressing Subset of CD4+FOXP3+ Tregs in Non-Small Cell Lung Cancer

FRANCESCA AMBROSI
University of Bologna Medical Center, Italy
P.05-03: Tumor Atelectasis Gives Rise to Solide Appearance in Pulmonary Adenocarcinomas

JIAE KOH
Sungkyunkwan University, South Korea
P.04-24: Circulating Suppressive Immune Cells Predict the Efficacy of Anti PD-1 Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer

JOSEPH BARNETT
Royal Brompton Hospital, United Kingdom
P.11-30: Very Rapid Growth of Small Pulmonary Nodules Predicts Benignity

The WCLC 2019 Developing Nation Award Winners will receive their award during the IASLC Award Session on Saturday, September 07, 17:45 – 18:45, in Toronto (1985).

ANNA BASHARINA
N.N. Blokhin National Medical Research Center of Oncology of the Health Ministry of Russia, Russian Federation
P.03-28: Prognostic Value of Estrogen Receptor Beta Tumor Expression in Non-Small Cell Lung Cancer Patients After Radical Surgery

FRANCESCA AMBROSI
University of Bologna Medical Center, Italy
P.05-03: Tumor Atelectasis Gives Rise to Solide Appearance in Pulmonary Adenocarcinomas

JIAE KOH
Sungkyunkwan University, South Korea
P.04-24: Circulating Suppressive Immune Cells Predict the Efficacy of Anti PD-1 Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer

JOSEPH BARNETT
Royal Brompton Hospital, United Kingdom
P.11-30: Very Rapid Growth of Small Pulmonary Nodules Predicts Benignity

The WCLC 2019 Developing Nation Award Winners will receive their award during the IASLC Award Session on Saturday, September 07, 17:45 – 18:45, in Toronto (1985).

EVGENY DENISOV
Tomsk National Research Medical Center, Russian Federation
MA04.05: Deciphering the Molecular Mechanisms Underlying the Progression of Bronchial Premalignant Lesions

FREDRICK ASIRWA
Ampath_ICI Kenya, Kenya
P.16-16: Lung Cancer Control in Sub-Saharan Africa: Experience at Ampath Oncology in Western Kenya

MOHAMED AIT ERRAISSE
University Hospital Hassan II, Fes, Morocco
EP.01-79: Chemoradiotherapy in Advanced Non Small Cell Lung Cancer

VOC DANG
Vietnam National Cancer Hospital (K Hospital), Vietnam
EP.03-32: Prevalence of EGFR and ALK Mutations in Non Small Cell Lung Cancer in Viet Nam National Cancer Hospital

YUE CHENG
University of Liverpool, United Kingdom
EP.11-02: Implementation Planning of Lung Cancer Screening in China
IASLC Patient Advocacy Award Winners

The IASLC Patient Advocacy Award Winners will receive their award during the IASLC Award Session on Saturday, September 7, 17:45 – 18:45, in Toronto (1985).

CHRISTINE QIONG WU
Canada

PAUL BROWN
Australia

CSABA LASZLO DEGI
Romania

WEINI QIU
China

GINA HOLLENBECK
United States of America

IASLC Nurse and Allied Health Professional Award Winners

The IASLC Nurse and Allied Health Professional Award Winners will receive their award during the IASLC Award Session on Saturday, September 7, 17:45 – 18:45, in Toronto (1985).

ALLIED HEALTH PROFESSIONAL

GISELE MOREIRA
Grupo Oncoclinicas, Brazil

EP1.16-42: Pharmaceutical Follow-Up Program for Patients with Driver Mutation in Non-Small Cells Lung Cancer

CAROLYN ROBERTS
The Ottawa Hospital, Canada

WEINI QIU
China

MA22.07: A Culturally Safe Advocacy Model of Care for Inuit Cancer Patients and Their Families

SOMAYA ABOU-ABDOU
Faculty of Nursing Suez Canal University, Egypt

P1.07-16: Training Program for University Nursing Students to Reduce Lung Cancer Patient Emotional Distress

NURSE

PAUL BROWN
Australia

WEINI QIU
China

SUSAN MCCULLOUGH
Australia

UPAL BASU ROY
United States of America

WCLC 2019 STARS Awards

CALEB EGWUENU
Nigeria

JILL HAMER-WILSON
Canada

LAURA GRECO
United States of America

SUSAN MCCULLOUGH
Australia

DUSTY DONALDSON
United States of America

KIMBERLEY MACINTOSH
Canada

LILLIAN LEIGH
Australia

UPAL BASU ROY
United States of America

JILL FELDMAN
United States of America

SHELLY ENGFER-TRIEBENBACH
United States of America

The IASLC Patient Advocacy Award Winners will receive their award during the IASLC Award Session on Saturday, September 7, 17:45 – 18:45, in Toronto (1985).

The IASLC Nurse and Allied Health Professional Award Winners will receive their award during the IASLC Award Session on Saturday, September 7, 17:45 – 18:45, in Toronto (1985).

The IASLC Patient Advocacy Award Winners

The IASLC Nurse and Allied Health Professional Award Winners

The IASLC Nurse and Allied Health Professional Award Winners
Member Experience Lounge: Exhibit Hall next to the IASLC Booth

Features include:

• Opportunity to update your professional headshot
• Exclusive members-only gift (while supplies last)
• Charging stations for your devices
• Network with colleagues from around the globe

HOURS:
Sunday
09:30-18:30
Monday
09:30-18:30
Tuesday
09:30-14:00

COMMITTEE CORNER
Want to get involved with the IASLC?
Visit our Committee Corner located within the Member Experience Lounge to learn about current committee projects and initiatives.
To our members...

Thank you for your IASLC membership and dedication to conquering lung cancer and other thoracic malignancies.

Visit the IASLC Booth (#300) in the Exhibit Hall to renew, confirm account details and pick up your member appreciation gift!

IASLC member benefits include:

• Collaboration with thoracic oncology experts and thought leaders across all disciplines

• Access to the Journal of Thoracic Oncology, the premier journal in lung cancer

• Multidisciplinary education including the latest in groundbreaking research, treatment and standard of care

Come see us at the IASLC Booth in the Exhibit Hall (Sunday-Tuesday) or at the IASLC Membership Booth in the registration area (Friday and Saturday).
5 CONFERENCE PROGRAM
Program at a Glance

**SATURDAY**
September 7, 2019

- **07:00** 
  - Young Investigator Session (07:00–08:00)
  - Joint IASLC-CSCO-CAALC Session (07:00–11:15)
  - Pre-Conference Workshops (07:00–11:15)

- **08:00** 
  - Industry Symposium (09:45–11:15)

- **09:30** 
  - Plenary Session (08:15–09:45)

- **10:30** 
  - Oral and Mini Oral Sessions (10:30–12:00)
  - Invited Sessions (10:30–12:00)

- **13:30** 
  - Oral and Mini Oral Sessions (13:30–15:00)
  - Invited Sessions (13:30–15:00)

- **15:15** 
  - Oral and Mini Oral Sessions (15:15–16:45)
  - Invited Sessions (15:15–16:45)

- **16:45** 
  - Poster Session & Reception (16:45–18:00)

- **19:00** 
  - Opening Ceremony including the IASLC Distinguished Awards Presentation (19:00–20:30)

- **20:00** 
  - Welcome Reception (20:30–22:00)

**SUNDAY**
September 8, 2019

- **07:00** 
  - Interactive Breakfast Sessions (Ticketed Sessions) (07:00–08:00)
  - Industry Symposia (07:00–08:00)

- **08:15** 
  - Plenary Session (08:15–09:45)

- **09:45** 
  - Poster Session & Coffee Break (09:45–10:30)
  - Press Conference (09:45–10:30)

- **11:30** 
  - Industry Symposium (11:30–13:00)

- **12:00** 
  - Industry Symposium (12:00–13:30)

- **13:00** 
  - Oral and Mini Oral Sessions (13:30–15:00)
  - Invited Sessions (13:30–15:00)

- **13:00** 
  - Industry Symposium (13:00–14:30)

- **15:00** 
  - Oral and Mini Oral Sessions (14:30–16:00)
  - Invited Sessions (15:00–16:00)

- **15:15** 
  - Oral and Mini Oral Sessions (15:15–16:45)
  - Invited Sessions (15:15–16:45)

- **16:00** 
  - Industry Symposium (16:00–17:30)
  - Press Conference (16:00–17:30)

- **16:45** 
  - Poster Session & Reception (16:45–18:00)

- **17:45** 
  - IASLC Award Session (17:45–18:45)

- **18:00** 
  - Industry Symposium (18:00–19:30)

- **20:00** 
  - Faculty Networking Evening (20:00–22:00)
MONDAY
September 9, 2019

TUESDAY
September 10, 2019

Program listings are subject to change.

CME Accredited Session
## Session Overview  Saturday, September 7

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 07:00 – 11:15 | JCSE01 Joint IASLC-CSCO-CAALC Session  
- Toronto (1985)  
  Joint IASLC-CSCO-CAALC Session |
| 07:00 – 08:30 | YI01 Young Investigator Session  
- Dublin (1997)  
  First Time Attendee Session |
| 07:00 – 12:00 | S01 Symposium  
- Colorado Springs (1994)  
  IASLC CT Screening Symposium: Forefront Advances in Lung Cancer Screening |
| 07:00 – 12:00 | S01 Symposium  
- Colorado Springs (1994)  
  IASLC CT Screening Symposium: Forefront Advances in Lung Cancer Screening |
| 08:00 – 11:15 | WS01 Workshop  
- Tokyo (1982)  
  Cancer Genomics Workshop |
| 08:00 – 11:30 | WS02 Workshop  
- Interlaken (1988)  
  Mesothelioma Workshop |
| 09:00 – 10:30 | YI02 Young Investigator Session  
- Dublin (1997)  
  Clinical Trials |
| 11:00 – 18:00 | WS03 Workshop  
- San Francisco (2009)  
  ITONF Workshop: Bridging the Gaps in Thoracic Oncology Nursing - A Global Perspective |
| 16:00 – 16:45 | PR01 Press Conference  
- CC7.1 A&B  
  Press Conference |
| 17:30 – 19:00 | S02 Symposium  
- Tokyo (1982)  
  Symposium Honoring Dr. Gazdar’s Legacy |
| 17:45 – 18:45 | IASLC Award Session  
- Toronto (1985) |
| 19:00 – 20:30 | OC01 Opening Ceremony  
- Barcelona (2005)  
  Opening Ceremony |
| 20:30 – 22:00 | Welcome Reception  
- Exhibit Hall, Level 2, Hall 8.1 |
## Session Overview  Sunday, September 8

### 07:00 – 08:00

#### Parallel Sessions

<table>
<thead>
<tr>
<th>Session</th>
<th>Location</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>IBS01</td>
<td>Tokyo (1982)</td>
<td>Interactive Breakfast Session: My Oligometastatic Oncogene Driven Patient</td>
</tr>
<tr>
<td>IBS02</td>
<td>Toronto (1985)</td>
<td>Interactive Breakfast Session: Making Sense of Treatment with so Many Options: My Algorithm</td>
</tr>
<tr>
<td>IBS03</td>
<td>Interlaken (1988)</td>
<td>Interactive Breakfast Session: Personalized Management of Elderly Patients with Stage III NSCLC</td>
</tr>
<tr>
<td>IBS04</td>
<td>Amsterdam (2011)</td>
<td>Interactive Breakfast Session: Hyperprogressive Disease</td>
</tr>
<tr>
<td>IBS05</td>
<td>Colorado Springs (1994)</td>
<td>Interactive Breakfast Session: Lung Cancer Genetics to Beat Lung Cancer</td>
</tr>
<tr>
<td>IBS06</td>
<td>Dublin (1997)</td>
<td>Interactive Breakfast Session: Multimodality Treatment - Realtime Data from National Registries</td>
</tr>
<tr>
<td>IBS07</td>
<td>Vancouver (2003)</td>
<td>Interactive Breakfast Session: Enhancing Recovery in the Treatment of Thoracic Malignancy</td>
</tr>
<tr>
<td>IBS08</td>
<td>Melbourne (1991)</td>
<td>Interactive Breakfast Session: Role of Pathologist in the Era of Immunotherapies</td>
</tr>
<tr>
<td>IBS09</td>
<td>Seoul (2007)</td>
<td>Interactive Breakfast Session: Challenges in Translating Small Cell and Neuroendocrine Tumor Research into Clinical Practice</td>
</tr>
<tr>
<td>IBS10</td>
<td>San Francisco (2009)</td>
<td>Interactive Breakfast Session: Tracheal Tumours</td>
</tr>
</tbody>
</table>

**08:15 – 09:45**

#### Plenary Session

<table>
<thead>
<tr>
<th>Session</th>
<th>Location</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>PL01</td>
<td>Barcelona (2005)</td>
<td>Plenary Session: New Questions with Imaginative Answers</td>
</tr>
</tbody>
</table>

### 09:45 – 10:30

#### Poster Viewing

- Exhibit Hall, Level 2, Hall 8.1

#### PR02 Press Conference

- CC7.1 A&B Press Conference

### 10:30 – 12:00

#### Parallel Sessions

<table>
<thead>
<tr>
<th>Session</th>
<th>Location</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>ES01</td>
<td>Hilton Head (1978)</td>
<td>Educational Session: What is the Role of Chemotherapy in the Era of Immunotherapy in Advanced NSCLC</td>
</tr>
<tr>
<td>ES02</td>
<td>Vancouver (2003)</td>
<td>Educational Session: Management of Oncogene Addicted Patients with Stage III NSCLC</td>
</tr>
<tr>
<td>ES03</td>
<td>Tokyo (1982)</td>
<td>Educational Session: BAP-1 and Other Novel Molecular and Metabolic Targets in Mesothelioma</td>
</tr>
<tr>
<td>ES04</td>
<td>Toronto (1985)</td>
<td>Educational Session: Multimodality Management of Small Cell and Neuroendocrine Cancers</td>
</tr>
<tr>
<td>ES05</td>
<td>Amsterdam (2011)</td>
<td>Educational Session: Joint Session GLCC/IASLC: Hot Topics for Lung Cancer Advocates</td>
</tr>
<tr>
<td>MA01</td>
<td>Copenhagen (1980)</td>
<td>Mini Oral Session: Oligometastatic Disease</td>
</tr>
<tr>
<td>MA02</td>
<td>Interlaken (1988)</td>
<td>Mini Oral Session: Miscellaneous Topics in the Management of Early Stage Lung Cancer</td>
</tr>
<tr>
<td>MA03</td>
<td>Colorado Springs (1994)</td>
<td>Mini Symposium: Clinomics and Genomics</td>
</tr>
<tr>
<td>MS01</td>
<td>San Francisco (2009)</td>
<td>Mini Symposium: Immunotherapy Resistance</td>
</tr>
<tr>
<td>MS02</td>
<td>Vienna (2016)</td>
<td>Mini Symposium: What Molecular Screening for Which Patients?</td>
</tr>
<tr>
<td>OA01</td>
<td>Melbourne (1991)</td>
<td>Oral Session: Advanced Diagnostic Approaches for Intrathoracic Lymph Nodes and Peripheral Lung Tumors</td>
</tr>
<tr>
<td>YI03</td>
<td>Dublin (1997)</td>
<td>Young Investigator Session: Scientific Mentoring</td>
</tr>
</tbody>
</table>

---

**CS** Controversy Session  
**ES** Educational Session  
**GR** Grand Round Session  
**IBS** Interactive Breakfast Sessions (TICKETED SESSION, CONTINENTAL BREAKFAST PROVIDED)  
**MA** Mini Oral Abstract Session  
**MS** Mini Symposium  
**OA** Oral Abstract Session  
**OC** Opening Ceremony  
**PC** Pro-Con Session  
**PL** Plenary Session  
**S** Symposium  
**SH** Highlights of the Previous Day  
**WS** Workshop (ticketed sessions)  
**YI** Young Investigator Session
### SUNDAY SEPTEMBER 8

#### 13:30 – 15:00

<table>
<thead>
<tr>
<th>Parallel Sessions</th>
<th>13:30 – 15:00</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ES06 Educational Session</strong></td>
<td>Vienna (2016)</td>
</tr>
<tr>
<td><strong>ES07 Educational Session</strong></td>
<td>San Francisco (2009)</td>
</tr>
<tr>
<td><strong>ES08 Educational Session</strong></td>
<td>Copenhagen (1980)</td>
</tr>
<tr>
<td><strong>ES09 Educational Session</strong></td>
<td>Tokyo (1982)</td>
</tr>
<tr>
<td><strong>ES10 Educational Session</strong></td>
<td>Toronto (1985)</td>
</tr>
<tr>
<td><strong>GR01 Grand Rounds Session</strong></td>
<td>Seoul (2007)</td>
</tr>
<tr>
<td><strong>MA04 Mini Oral Session</strong></td>
<td>Interlaken (1988)</td>
</tr>
<tr>
<td><strong>MA05 Mini Oral Session</strong></td>
<td>Melbourne (1991)</td>
</tr>
<tr>
<td><strong>MA06 Mini Oral Session</strong></td>
<td>Colorado Springs (1994)</td>
</tr>
<tr>
<td><strong>MA07 Mini Oral Session</strong></td>
<td>Vancouver (2003)</td>
</tr>
<tr>
<td><strong>MS03 Mini Symposium</strong></td>
<td>Amsterdam (2011)</td>
</tr>
<tr>
<td><strong>OA03 Oral Session</strong></td>
<td>Hilton Head (1978)</td>
</tr>
<tr>
<td><strong>YI04 Young Investigator Session</strong></td>
<td>Dublin (1997)</td>
</tr>
</tbody>
</table>

#### 15:15 – 16:45

<table>
<thead>
<tr>
<th>Parallel Sessions</th>
<th>15:15 – 16:45</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ES11 Educational Session</strong></td>
<td>Colorado Springs (1994)</td>
</tr>
<tr>
<td><strong>ES12 Educational Session</strong></td>
<td>Toronto (1985)</td>
</tr>
<tr>
<td><strong>ES13 Educational Session</strong></td>
<td>Vienna (2016)</td>
</tr>
<tr>
<td><strong>GR02 Grand Rounds Session</strong></td>
<td>Interlaken (1988)</td>
</tr>
<tr>
<td><strong>MA08 Mini Oral Session</strong></td>
<td>Tokyo (1982)</td>
</tr>
<tr>
<td><strong>MA09 Mini Oral Session</strong></td>
<td>Melbourne (1991)</td>
</tr>
<tr>
<td><strong>MA10 Mini Oral Session</strong></td>
<td>Dublin (1997)</td>
</tr>
<tr>
<td><strong>MA11 Mini Oral Session</strong></td>
<td>Copenhagen (1980)</td>
</tr>
<tr>
<td><strong>MS04 Mini Symposium</strong></td>
<td>Hilton Head (1978)</td>
</tr>
<tr>
<td><strong>OA04 Oral Session</strong></td>
<td>Amsterdam (2011)</td>
</tr>
<tr>
<td><strong>OA05 Oral Session</strong></td>
<td>San Francisco (2009)</td>
</tr>
</tbody>
</table>

#### 16:45 – 18:00

<table>
<thead>
<tr>
<th>Poster Viewing Reception</th>
<th>Exhibit Hall, Level 2, Hall 8.1</th>
</tr>
</thead>
</table>

**CME Accredited Session**
### Session Overview  Monday, September 9

<table>
<thead>
<tr>
<th><strong>07:00 – 08:00</strong></th>
<th><strong>11:00 – 12:30</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Parallel Sessions</strong></td>
<td><strong>Parallel Sessions</strong></td>
</tr>
</tbody>
</table>
| IBS11 Interactive Breakfast Session  
Amsterdam (2011)  
Electronic Cigarettes and Heat-Not-Burn Tobacco Products - How Are They Different | CS01 Controversy Session  
Colorado Springs (1994)  
Controversies in NSCLC OMD |
| IBS12 Interactive Breakfast Session  
Toronto (1985)  
Case-Based Management of Brain Metastasis (Bm) in Advanced Lung Cancer Patients: Changing the Standards | ES15 Educational Session  
Amsterdam (2011)  
The Management of Cancer Treatment in Thoracic Malignancy |
| IBS13 Interactive Breakfast Session  
Interlaken (1988)  
How to Identify and Manage Toxicity in Stage III | ES16 Educational Session  
Dublin (1997)  
Modern Radiotherapy in Stage III NSCLC |
| IBS14 Interactive Breakfast Session  
Melbourne (1991)  
Best Management of Early Stage NSCLC in ILD Patients | ES17 Educational Session  
Tokyo (1982)  
Molecular Alterations and Heterogeneity in Mesothelioma |
| IBS15 Interactive Breakfast Session  
Colorado Springs (1994)  
Biology and Genetics in ICI Treatments | ES18 Educational Session  
Vienna (2016)  
Acquired Resistance to TKIs: The Rebiopsy Case and the Future Options |
| IBS16 Interactive Breakfast Session  
Dublin (1997)  
Invasive Diagnosis and Surgery in Lung Cancer Screening Participants | MS05 Mini Symposium  
Vancouver (2003)  
Novel Biological Pathways and Druggable Targets |
| IBS17 Interactive Breakfast Session  
Vancouver (2003)  
Undertaking Nursing and Allied Health Research...How to Survive It and Get Published | MS06 Mini Symposium  
Toronto (1985)  
An Interdisciplinary Approach to Optimal Nodal Staging |
| IBS18 Interactive Breakfast Session  
Tokyo (1982)  
Essentials in Biomarker Testing for Lung Cancer | OA06 Oral Session  
Hilton Head (1978)  
Refining Lung Cancer Screening |
| IBS19 Interactive Breakfast Session  
Seoul (2007)  
Novel Approaches in Radiation Oncology for Small Cell and Neuroendocrine Cancers | OA07 Oral Session  
Copenhagen (1980)  
Precision Medicine Involves Biology and Patients |
| IBS20 Interactive Breakfast Session  
San Francisco (2009)  
Endoscopic Solution to Iatrogenic Complications (Interactive O and A) | OA08 Oral Session  
Interlaken (1988)  
Advanced Models and “Omics” for Therapeutic Development |
| **08:00 – 10:15** | **10:15 – 11:00** |
| Plenary Session  
Barcelona (2005)  
Presidential Symposium including Top 7 Rated Abstracts | Poster Viewing  
Exhibit Hall, Level 2, Hall 8.1 |
| **10:15 – 11:00** | **11:00 – 12:30** |
| Press Conference  
CC7.1 A&B  
Press Conference | Press Conference  
CC7.1 A&B  
Press Conference |

**MONDAY**  
**SEPTEMBER 9**

<table>
<thead>
<tr>
<th>Session Type</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CS</td>
<td>Controversy Session</td>
</tr>
<tr>
<td>ES</td>
<td>Educational Session</td>
</tr>
<tr>
<td>GR</td>
<td>Grand Round Session</td>
</tr>
<tr>
<td>IBS</td>
<td>Interactive Breakfast Sessions (TICKETED SESSION, CONTINENTAL BREAKFAST PROVIDED)</td>
</tr>
<tr>
<td>MA</td>
<td>Mini Oral Abstract Session</td>
</tr>
<tr>
<td>MS</td>
<td>Mini Symposium</td>
</tr>
<tr>
<td>OA</td>
<td>Oral Abstract Session</td>
</tr>
<tr>
<td>OC</td>
<td>Opening Ceremony</td>
</tr>
<tr>
<td>PC</td>
<td>Pro-Con Session</td>
</tr>
<tr>
<td>PL</td>
<td>Plenary Session</td>
</tr>
<tr>
<td>S</td>
<td>Symposium</td>
</tr>
<tr>
<td>SH</td>
<td>Highlights of the Previous Day</td>
</tr>
<tr>
<td>WS</td>
<td>Workshop (ticked sessions)</td>
</tr>
<tr>
<td>YI</td>
<td>Young Investigator Session</td>
</tr>
<tr>
<td>Time</td>
<td>Session Type</td>
</tr>
<tr>
<td>-------------</td>
<td>--------------</td>
</tr>
<tr>
<td>14:00 – 15:30</td>
<td>Parallel Sessions</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>15:45 – 17:15</td>
<td>Parallel Sessions</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>17:15 – 18:15</td>
<td>Poster Viewing Reception</td>
</tr>
</tbody>
</table>
# Session Overview
**Tuesday, September 10**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00 – 08:00</td>
<td>Parallel Sessions</td>
</tr>
<tr>
<td></td>
<td><strong>IBS21 Interactive Breakfast Session</strong></td>
</tr>
<tr>
<td></td>
<td>Vienna (2016)</td>
</tr>
<tr>
<td></td>
<td>Combating Toxicity of IO-Chemotherapy Combinations</td>
</tr>
<tr>
<td></td>
<td><strong>IBS22 Interactive Breakfast Session</strong></td>
</tr>
<tr>
<td></td>
<td>Tokyo (1982)</td>
</tr>
<tr>
<td></td>
<td>JTO Workshop: How to Get Your Manuscript Published</td>
</tr>
<tr>
<td></td>
<td><strong>IBS23 Interactive Breakfast Session</strong></td>
</tr>
<tr>
<td></td>
<td>Toronto (1985)</td>
</tr>
<tr>
<td></td>
<td>Treatment of NSCLC OMD in Clinical Practice</td>
</tr>
<tr>
<td></td>
<td><strong>IBS24 Interactive Breakfast Session</strong></td>
</tr>
<tr>
<td></td>
<td>Interlaken (1988)</td>
</tr>
<tr>
<td></td>
<td>Optimal Immunotherapy Sequence in Stage IV NSCLC</td>
</tr>
<tr>
<td></td>
<td><strong>IBS25 Interactive Breakfast Session</strong></td>
</tr>
<tr>
<td></td>
<td>Melbourne (1991)</td>
</tr>
<tr>
<td></td>
<td>Optimal GGO Management</td>
</tr>
<tr>
<td></td>
<td><strong>IBS26 Interactive Breakfast Session</strong></td>
</tr>
<tr>
<td></td>
<td>Colorado Springs (1994)</td>
</tr>
<tr>
<td></td>
<td>Treatment Techniques for Localized Therapy in Malignant Pleural Mesothelioma</td>
</tr>
<tr>
<td></td>
<td><strong>IBS27 Interactive Breakfast Session</strong></td>
</tr>
<tr>
<td></td>
<td>Dublin (1997)</td>
</tr>
<tr>
<td></td>
<td>Chestwall Tumors</td>
</tr>
<tr>
<td></td>
<td><strong>IBS28 Interactive Breakfast Session</strong></td>
</tr>
<tr>
<td></td>
<td>Vancouver (2003)</td>
</tr>
<tr>
<td></td>
<td>Managing Side Effects for Better Quality of Life</td>
</tr>
<tr>
<td></td>
<td><strong>IBS29 Interactive Breakfast Session</strong></td>
</tr>
<tr>
<td></td>
<td>San Francisco (2009)</td>
</tr>
<tr>
<td></td>
<td>How to Successfully Run a Multidisciplinary Tumor Board</td>
</tr>
<tr>
<td></td>
<td><strong>IBS30 Interactive Breakfast Session</strong></td>
</tr>
<tr>
<td></td>
<td>Seoul (2007)</td>
</tr>
<tr>
<td></td>
<td>Risk Assessment in CT Screening</td>
</tr>
<tr>
<td></td>
<td><strong>IBS31 Interactive Breakfast Session</strong></td>
</tr>
<tr>
<td></td>
<td>Amsterdam (2011)</td>
</tr>
<tr>
<td></td>
<td>Trial Design and Novel Drug Accessibility</td>
</tr>
<tr>
<td></td>
<td><strong>WS06 Workshop</strong></td>
</tr>
<tr>
<td></td>
<td>Copenhagen (1980)</td>
</tr>
<tr>
<td></td>
<td>Women in Thoracic Oncology Networking Event</td>
</tr>
<tr>
<td>08:00 – 08:45</td>
<td>IASLC General Assembly</td>
</tr>
<tr>
<td></td>
<td>Tokyo (1982)</td>
</tr>
<tr>
<td>09:15 – 10:45</td>
<td><strong>PL03 Plenary Session</strong></td>
</tr>
<tr>
<td></td>
<td>Barcelona (2005)</td>
</tr>
<tr>
<td></td>
<td>Relevant Aspects of Lung Cancer Management</td>
</tr>
<tr>
<td>10:45 – 11:30</td>
<td><strong>OA13 Oral Session</strong></td>
</tr>
<tr>
<td></td>
<td>Toronto (1985)</td>
</tr>
<tr>
<td></td>
<td>Ideal Approach to Lung Resection and Novel Perioperative Therapy</td>
</tr>
<tr>
<td></td>
<td><strong>OA14 Oral Session</strong></td>
</tr>
<tr>
<td></td>
<td>Vienna (2016)</td>
</tr>
<tr>
<td></td>
<td>Update of Phase 3 Trials and the Role of HPD</td>
</tr>
<tr>
<td></td>
<td><strong>PC04 Pro-Con Session</strong></td>
</tr>
<tr>
<td></td>
<td>Copenhagen (1980)</td>
</tr>
<tr>
<td></td>
<td>Is Chemotherapy Necessary for Advanced NSCLC Patients With PD-L1 50% or More?</td>
</tr>
<tr>
<td>11:30 – 13:00</td>
<td>Parallel Sessions</td>
</tr>
<tr>
<td></td>
<td><strong>ES23 Educational Session</strong></td>
</tr>
<tr>
<td></td>
<td>Hilton Head (1978)</td>
</tr>
<tr>
<td></td>
<td>Optimal Management of N2 Disease in the Era of IO</td>
</tr>
<tr>
<td></td>
<td><strong>ES24 Educational Session</strong></td>
</tr>
<tr>
<td></td>
<td>Amsterdam (2011)</td>
</tr>
<tr>
<td></td>
<td>Diagnosis and Management of Side Effects of Immunotherapy</td>
</tr>
<tr>
<td></td>
<td><strong>MA18 Mini Oral Session</strong></td>
</tr>
<tr>
<td></td>
<td>Tokyo (1982)</td>
</tr>
<tr>
<td></td>
<td>Advances in Diagnosis of Common Types of NSCLC</td>
</tr>
<tr>
<td></td>
<td><strong>MA19 Mini Oral Session</strong></td>
</tr>
<tr>
<td></td>
<td>Interlaken (1988)</td>
</tr>
<tr>
<td></td>
<td>Looking at PROs in Greater Detail - What Patients Actually Want and Expect</td>
</tr>
<tr>
<td></td>
<td><strong>MA20 Mini Oral Session</strong></td>
</tr>
<tr>
<td></td>
<td>San Francisco (2009)</td>
</tr>
<tr>
<td></td>
<td>Thymic Tumors: From Molecular to Clinical Results and New Challenges in Other Rare Thoracic Tumors</td>
</tr>
<tr>
<td></td>
<td><strong>MS12 Mini Symposium</strong></td>
</tr>
<tr>
<td></td>
<td>Vancouver (2003)</td>
</tr>
<tr>
<td></td>
<td>Genome Screenings</td>
</tr>
<tr>
<td></td>
<td><strong>MS13 Mini Symposium</strong></td>
</tr>
<tr>
<td></td>
<td>Seoul (2007)</td>
</tr>
<tr>
<td></td>
<td>Immunotherapy for Mesothelioma</td>
</tr>
<tr>
<td></td>
<td><strong>MS14 Mini Symposium</strong></td>
</tr>
<tr>
<td></td>
<td>Colorado Springs (1994)</td>
</tr>
<tr>
<td></td>
<td>Molecular Subsets and Novel Targeted Approaches to Small Cell and Neuroendocrine Cancers</td>
</tr>
<tr>
<td></td>
<td><strong>MS15 Mini Symposium</strong></td>
</tr>
<tr>
<td></td>
<td>Dublin (1997)</td>
</tr>
<tr>
<td></td>
<td>How to Get Patients to Quit Smoking; Practical Implementation of Evidence-Based Cessation Practices</td>
</tr>
<tr>
<td></td>
<td><strong>OA13 Oral Session</strong></td>
</tr>
<tr>
<td></td>
<td>Vienna (2016)</td>
</tr>
<tr>
<td></td>
<td>Highlight of the Previous Day Session</td>
</tr>
<tr>
<td></td>
<td>Melbourne (1991)</td>
</tr>
<tr>
<td></td>
<td>Highlight of the Previous Day Session</td>
</tr>
</tbody>
</table>

**Abbreviations:**
- **CS** Controversy Session
- **ES** Educational Session
- **GR** Grand Round Session
- **IBS** Interactive Breakfast Sessions (TICKETED SESSION, CONTINENTAL BREAKFAST PROVIDED)
- **MA** Mini Oral Abstract Session
- **MS** Mini Symposium
- **OA** Oral Abstract Session
- **OC** Opening Ceremony
- **PC** Pro-Con Session
- **PL** Plenary Session
- **S** Symposium
- **SH** Highlights of the Previous Day
- **WS** Workshop (ticketed sessions)
- **YI** Young Investigator Session
14:30 – 16:00

**Parallel Sessions**

- **ES25 Educational Session**
  - Colorado Springs (1994)
  - Liquid Biopsy

- **ES26 Educational Session**
  - San Francisco (2009)
  - The Impact of Specialist Nursing and Allied Health Professionals in the Care of Thoracic Oncology Patients

- **MA21 Mini Oral Session**
  - Vienna (2016)
  - Non EGFR/MET Targeted Therapies

- **MA23 Mini Oral Session**
  - Copenhagen (1980)
  - Preclinical Models and Genetics of Malignant Pleural Mesothelioma

- **MA24 Mini Oral Session**
  - Melbourne (1991)
  - Initiatives to Improve Health in Lung Cancer Patients

- **MA25 Mini Oral Session**
  - Dublin (1997)
  - Precision Medicine in Advanced NSCLC

- **MS16 Mini Symposium**
  - Toronto (1985)
  - The Interventional Pulmonologist’s Contribution to Screen-Detected Nodules: From Diagnosis to Treatment

- **MS17 Mini Symposium**
  - Interlaken (1988)
  - Pathology of the Future

- **MS18 Mini Symposium**
  - Vancouver (2003)
  - Role of Biomarkers in Lung Cancer Screening

- **OA15 Oral Session**
  - Hilton Head (1978)
  - Targeted Agents and Immunotherapy for Small Cell Lung Cancer

- **PC05 Pro-Con Session**
  - Tokyo (1982)
  - Immune Checkpoint Inhibitors in Real World - How Do We Treat NSCLC “Special Populations”

16:15 – 17:00

**PL04 Plenary Session**

- **Barcelona (2005)**
  - Food for Thought in the Management of Thoracic Malignancies
## Program by Track

### Advanced NSCLC

<table>
<thead>
<tr>
<th>DATE</th>
<th>TIME</th>
<th>SESSION TYPE</th>
<th>#</th>
<th>SESSION TITLE</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, September 8</td>
<td>07:00 – 08:00</td>
<td>Interactive Breakfast Session</td>
<td>IBS02</td>
<td>Making Sense of Treatment with so Many Options: My Algorithm</td>
<td>Toronto (1985)</td>
</tr>
<tr>
<td>Sunday, September 8</td>
<td>08:15 – 09:45</td>
<td>Plenary Session</td>
<td>PL01</td>
<td>New Questions with Imaginative Answers</td>
<td>Barcelona (2005)</td>
</tr>
<tr>
<td>Sunday, September 8</td>
<td>10:30 – 12:00</td>
<td>Educational Session</td>
<td>ES01</td>
<td>What is the Role of Chemotherapy in the Era of Immunotherapy in Advanced NSCLC</td>
<td>Hilton Head (1978)</td>
</tr>
<tr>
<td>Sunday, September 8</td>
<td>10:30 – 12:00</td>
<td>Mini Oral Session</td>
<td>MA03</td>
<td>Cliniomics and Genomics</td>
<td>Colorado Springs (1994)</td>
</tr>
<tr>
<td>Sunday, September 8</td>
<td>13:30 – 15:00</td>
<td>Educational Session</td>
<td>ES10</td>
<td>Oncology Drug Approval: Challenges and Opportunities</td>
<td>Toronto (1985)</td>
</tr>
<tr>
<td>Sunday, September 8</td>
<td>15:15 – 16:45</td>
<td>Grand Rounds Session</td>
<td>GR02</td>
<td>Improving Patients Quality of Life During Treatment of Metastatic Disease</td>
<td>Interlaken (1988)</td>
</tr>
<tr>
<td>Monday, September 9</td>
<td>07:00 – 08:00</td>
<td>Interactive Breakfast Session</td>
<td>IBS12</td>
<td>Case-Based Management of Brain Metastasis (8m) in Advanced Lung Cancer Patients: Changing the Standards</td>
<td>Toronto (1985)</td>
</tr>
<tr>
<td>Monday, September 9</td>
<td>11:00 – 12:30</td>
<td>Oral Session</td>
<td>OA07</td>
<td>Precision Medicine Involves Biology and Patients</td>
<td>Copenhagen (1980)</td>
</tr>
<tr>
<td>Monday, September 9</td>
<td>14:00 – 15:30</td>
<td>Pro-Con Session</td>
<td>PC02</td>
<td>Combining with Chemo: Old School is New Again</td>
<td>Vienna (2016)</td>
</tr>
<tr>
<td>Monday, September 9</td>
<td>15:45 – 17:15</td>
<td>Mini Oral Session</td>
<td>MA14</td>
<td>The Adequate MTarget is Still the Issue</td>
<td>Hilton Head (1978)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>11:30 – 13:00</td>
<td>Pro-Con Session</td>
<td>PC04</td>
<td>Is Chemotherapy Necessary for Advanced NSCLC Patients With PD-L1 50% or More?</td>
<td>Copenhagen (1980)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>14:30 – 16:00</td>
<td>Pro-Con Session</td>
<td>PC05</td>
<td>Immune Chekpoint Inhibitors in Real World - How Do We Treat NSCLC “Special Populations”</td>
<td>Tokyo (1982)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>14:30 – 16:00</td>
<td>Mini Oral Session</td>
<td>MA25</td>
<td>Precision Medicine in Advanced NSCLC</td>
<td>Dublin (1997)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>16:15 – 17:00</td>
<td>Plenary Session</td>
<td>PLO4</td>
<td>Food for Thought in the Management of Thoracic Malignancies</td>
<td>Barcelona (2005)</td>
</tr>
</tbody>
</table>

**Abbreviations:**
- **CS**: Controversy Session
- **ES**: Educational Session
- **GR**: Grand Round Session
- **IBS**: Interactive Breakfast Sessions (TICKETED SESSION, CONTINENTAL BREAKFAST PROVIDED)
- **MA**: Mini Oral Abstract Session
- **MS**: Mini Symposium
- **OA**: Oral Abstract Session
- **OC**: Opening Ceremony
- **PC**: Pro-Con Session
- **PL**: Plenary Session
- **S**: Symposium
- **SH**: Highlights of the Previous Day
- **WS**: Workshop (ticketed sessions)
- **YI**: Young Investigator Session
## Advocacy

<table>
<thead>
<tr>
<th>DATE</th>
<th>TIME</th>
<th>SESSION TYPE</th>
<th>#</th>
<th>SESSION TITLE</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, September 8</td>
<td>08:15 – 09:45</td>
<td>Plenary Session</td>
<td>PL01</td>
<td>New Questions with Imaginative Answers</td>
<td>Barcelona (2005)</td>
</tr>
<tr>
<td>Sunday, September 8</td>
<td>10:30 – 12:00</td>
<td>Educational Session</td>
<td>ES05</td>
<td>Joint Session GLCC/IASLC: Hot Topics for Lung Cancer Advocates</td>
<td>Amsterdam (2011)</td>
</tr>
<tr>
<td>Monday, September 9</td>
<td>11:00 – 12:30</td>
<td>Pro-Con Session</td>
<td>PC01</td>
<td>Reinventing Clinical Trials</td>
<td>Seoul (2007)</td>
</tr>
<tr>
<td>Monday, September 9</td>
<td>15:45 – 17:15</td>
<td>Mini Oral Session</td>
<td>MA22</td>
<td>Partnering with Patients to Understand Stigma, Disparities and Values Leading to Improved Lung Cancer Care</td>
<td>Amsterdam (2011)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>07:00 – 08:00</td>
<td>Interactive Breakfast Session</td>
<td>IBS28</td>
<td>Managing Side Effects for Better Quality of Life</td>
<td>Vancouver (2003)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>09:15 – 10:45</td>
<td>Plenary Session</td>
<td>PL03</td>
<td>Relevant Aspects of Lung Cancer Management</td>
<td>Barcelona (2005)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>14:30 – 16:00</td>
<td>Mini Oral Session</td>
<td>MA24</td>
<td>Initiatives to Improve Health in Lung Cancer Patients</td>
<td>Melbourne (1991)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>16:15 – 17:00</td>
<td>Plenary Session</td>
<td>PL04</td>
<td>Food for Thought in the Management of Thoracic Malignancies</td>
<td>Barcelona (2005)</td>
</tr>
</tbody>
</table>

## Biology

<table>
<thead>
<tr>
<th>DATE</th>
<th>TIME</th>
<th>SESSION TYPE</th>
<th>#</th>
<th>SESSION TITLE</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, September 8</td>
<td>07:00 – 08:00</td>
<td>Interactive Breakfast Session</td>
<td>IBS05</td>
<td>Lung Cancer Genetics to Beat Lung Cancer</td>
<td>Colorado Springs (1994)</td>
</tr>
<tr>
<td>Sunday, September 8</td>
<td>08:15 – 09:45</td>
<td>Plenary Session</td>
<td>PL01</td>
<td>New Questions with Imaginative Answers</td>
<td>Barcelona (2005)</td>
</tr>
<tr>
<td>Sunday, September 8</td>
<td>13:30 – 15:00</td>
<td>Mini Oral Session</td>
<td>MA04</td>
<td>Models and Biomarkers</td>
<td>Interlaken (1988)</td>
</tr>
<tr>
<td>Monday, September 9</td>
<td>07:00 – 08:00</td>
<td>Interactive Breakfast Session</td>
<td>IBS15</td>
<td>Biology and Genetics in ICI Treatments</td>
<td>Colorado Springs (1994)</td>
</tr>
<tr>
<td>Monday, September 9</td>
<td>11:00 – 12:30</td>
<td>Mini Symposium</td>
<td>MS05</td>
<td>Novel Biological Pathways and Druggable Targets</td>
<td>Vancouver (2003)</td>
</tr>
<tr>
<td>Monday, September 9</td>
<td>11:00 – 12:30</td>
<td>Oral Session</td>
<td>OA08</td>
<td>Advanced Models and “Omics” for Therapeutic Development</td>
<td>Interlaken (1988)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>09:15 – 10:45</td>
<td>Plenary Session</td>
<td>PL03</td>
<td>Relevant Aspects of Lung Cancer Management</td>
<td>Barcelona (2005)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>11:30 – 13:00</td>
<td>Mini Symposium</td>
<td>MS12</td>
<td>Genome Screenings</td>
<td>Vancouver (2003)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>14:30 – 16:00</td>
<td>Mini Oral Session</td>
<td>MA25</td>
<td>Precision Medicine in Advanced NSCLC</td>
<td>Dublin (1997)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>16:15 – 17:00</td>
<td>Plenary Session</td>
<td>PL04</td>
<td>Food for Thought in the Management of Thoracic Malignancies</td>
<td>Barcelona (2005)</td>
</tr>
</tbody>
</table>
## Immuno-oncology

<table>
<thead>
<tr>
<th>DATE</th>
<th>TIME</th>
<th>SESSION TYPE</th>
<th>#</th>
<th>SESSION TITLE</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, September 8</td>
<td>07:00 – 08:00</td>
<td>Interactive Breakfast Session</td>
<td>IBS04</td>
<td>Hyperprogressive Disease</td>
<td>Amsterdam (2011)</td>
</tr>
<tr>
<td>Sunday, September 8</td>
<td>08:15 – 09:45</td>
<td>Plenary Session</td>
<td>PL01</td>
<td>New Questions with Imaginative Answers</td>
<td>Barcelona (2005)</td>
</tr>
<tr>
<td>Sunday, September 8</td>
<td>10:30 – 12:00</td>
<td>Mini Symposium</td>
<td>MS01</td>
<td>Immunotherapy Resistance</td>
<td>San Francisco (2009)</td>
</tr>
<tr>
<td>Sunday, September 8</td>
<td>15:15 – 16:45</td>
<td>Oral Session</td>
<td>OA04</td>
<td>Immuno Combinations and the Role of TMB</td>
<td>Copenhagen (1980)</td>
</tr>
<tr>
<td>Monday, September 9</td>
<td>14:00 – 15:30</td>
<td>Mini Oral Session</td>
<td>MA11</td>
<td>Immunotherapy in Special Populations and Predictive Markers</td>
<td>Hilton Head (1978)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>07:00 – 08:00</td>
<td>Interactive Breakfast Session</td>
<td>IBS24</td>
<td>Optimal Immunotherapy Sequence in Stage IV NSCLC</td>
<td>Interlaken (1988)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>09:15 – 10:45</td>
<td>Plenary Session</td>
<td>PL03</td>
<td>Relevant Aspects of Lung Cancer Management</td>
<td>Barcelona (2005)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>11:30 – 13:00</td>
<td>Educational Session</td>
<td>ES24</td>
<td>Diagnosis and Management of Side Effects of Immunotherapy</td>
<td>Amsterdam (2011)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>11:30 – 13:00</td>
<td>Oral Session</td>
<td>OA14</td>
<td>Update of Phase 3 Trials and the Role of HPD</td>
<td>Vienna (2016)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>14:30 – 16:00</td>
<td>Mini Oral Session</td>
<td>MA25</td>
<td>Precision Medicine in Advanced NSCLC</td>
<td>Dublin (1997)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>16:15 – 17:00</td>
<td>Plenary Session</td>
<td>PL04</td>
<td>Food for Thought in the Management of Thoracic Malignancies</td>
<td>Barcelona (2005)</td>
</tr>
</tbody>
</table>

## Interventional Diagnostics/Pulmonology

<table>
<thead>
<tr>
<th>DATE</th>
<th>TIME</th>
<th>SESSION TYPE</th>
<th>#</th>
<th>SESSION TITLE</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, September 8</td>
<td>10:30 – 12:00</td>
<td>Oral Session</td>
<td>OA01</td>
<td>Advanced Diagnostic Approaches for Intrathoracic Lymph Nodes and Peripheral Lung Tumors</td>
<td>Melbourne (1991)</td>
</tr>
<tr>
<td>Sunday, September 8</td>
<td>13:30 – 15:00</td>
<td>Educational Session</td>
<td>ES07</td>
<td>Thoracic Ultrasonography: Diagnosis and Staging</td>
<td>San Francisco (2009)</td>
</tr>
<tr>
<td>Monday, September 9</td>
<td>07:00 – 08:00</td>
<td>Interactive Breakfast Session</td>
<td>IBS20</td>
<td>Endoscopic Solution to Iatrogenic Complications (Interactive Q and A)</td>
<td>San Francisco (2009)</td>
</tr>
<tr>
<td>Monday, September 9</td>
<td>14:00 – 15:30</td>
<td>Educational Session</td>
<td>ES19</td>
<td>Recently Diagnosed Malignant Pleural Effusion</td>
<td>Tokyo (1982)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>07:00 – 08:00</td>
<td>Interactive Breakfast Session</td>
<td>IBS29</td>
<td>How to Successfully Run a Multidisciplinary Tumor Board</td>
<td>San Francisco (2009)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>09:15 – 10:45</td>
<td>Plenary Session</td>
<td>PL03</td>
<td>Relevant Aspects of Lung Cancer Management</td>
<td>Barcelona (2005)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>14:30 – 16:00</td>
<td>Mini Symposium</td>
<td>MS16</td>
<td>The Interventional Pulmonologist’s Contribution to Screen-Detected Nodules: From Diagnosis to Treatment</td>
<td>Toronto (1985)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>16:15 – 17:00</td>
<td>Plenary Session</td>
<td>PL04</td>
<td>Food for Thought in the Management of Thoracic Malignancies</td>
<td>Barcelona (2005)</td>
</tr>
</tbody>
</table>
## Mesothelioma

<table>
<thead>
<tr>
<th>DATE</th>
<th>TIME</th>
<th>SESSION TYPE</th>
<th>#</th>
<th>SESSION TITLE</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, September 7</td>
<td>08:00 – 11:30</td>
<td>Workshop</td>
<td>WS02</td>
<td>Mesothelioma Workshop</td>
<td>Interlaken (1988)</td>
</tr>
<tr>
<td>Sunday, September 8</td>
<td>07:00 – 08:00</td>
<td>Interactive Breakfast Session</td>
<td>IBS06</td>
<td>Multimodality Treatment - Realtime Data from National Registries</td>
<td>Dublin (1997)</td>
</tr>
<tr>
<td>Sunday, September 8</td>
<td>10:30 – 12:00</td>
<td>Educational Session</td>
<td>ES03</td>
<td>BAP-1 and Other Novel Molecular and Metabolic Targets in Mesothelioma</td>
<td>Tokyo (1982)</td>
</tr>
<tr>
<td>Sunday, September 8</td>
<td>13:30 – 15:00</td>
<td>Mini Oral Session</td>
<td>MA05</td>
<td>Update on Clinical Trials and Treatments</td>
<td>Melbourne (1991)</td>
</tr>
<tr>
<td>Monday, September 9</td>
<td>11:00 – 12:30</td>
<td>Educational Session</td>
<td>ES17</td>
<td>Molecular Alterations and Heterogeneity in Mesothelioma</td>
<td>Tokyo (1982)</td>
</tr>
<tr>
<td>Monday, September 9</td>
<td>14:00 – 15:30</td>
<td>Mini Oral Session</td>
<td>MA12</td>
<td>New Frontiers from Pathology to Genomics</td>
<td>Melbourne (1991)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>07:00 – 08:00</td>
<td>Interactive Breakfast Session</td>
<td>IBS26</td>
<td>Treatment Techniques for Localized Therapy in Malignant Pleural Mesothelioma</td>
<td>Colorado Springs (1994)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>09:15 – 10:45</td>
<td>Plenary Session</td>
<td>PL03</td>
<td>Relevant Aspects of Lung Cancer Management</td>
<td>Barcelona (2005)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>11:30 – 13:00</td>
<td>Mini Symposium</td>
<td>MS13</td>
<td>Immunotherapy for Mesothelioma</td>
<td>Seoul (2007)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>14:30 – 16:00</td>
<td>Mini Oral Session</td>
<td>MA23</td>
<td>Preclinical Models and Genetics of Malignant Pleural Mesothelioma</td>
<td>Copenhagen (1980)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>16:15 – 17:00</td>
<td>Plenary Session</td>
<td>PL04</td>
<td>Food for Thought in the Management of Thoracic Malignancies</td>
<td>Barcelona (2005)</td>
</tr>
</tbody>
</table>

## Nursing and Allied Professionals

<table>
<thead>
<tr>
<th>DATE</th>
<th>TIME</th>
<th>SESSION TYPE</th>
<th>#</th>
<th>SESSION TITLE</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, September 7</td>
<td>11:00 – 18:00</td>
<td>Workshop</td>
<td>WS03</td>
<td>ITONF Workshop: Bridging the Gaps in Thoracic Oncology Nursing - A Global Perspective</td>
<td>San Francisco (2009)</td>
</tr>
<tr>
<td>Sunday, September 8</td>
<td>07:00 – 08:00</td>
<td>Interactive Breakfast Session</td>
<td>IBS07</td>
<td>Enhancing Recovery in the Treatment of Thoracic Malignancy</td>
<td>Vancouver (2003)</td>
</tr>
<tr>
<td>Sunday, September 8</td>
<td>15:15 – 16:45</td>
<td>Oral Session</td>
<td>OA05</td>
<td>Increasing the Impact of Nursing and Allied Health Professional Interventions in Lung Cancer Care</td>
<td>San Francisco (2009)</td>
</tr>
<tr>
<td>Monday, September 9</td>
<td>07:00 – 08:00</td>
<td>Interactive Breakfast Session</td>
<td>IBS17</td>
<td>Undertaking Nursing and Allied Health Research...How to Survive It and Get Published</td>
<td>Vancouver (2003)</td>
</tr>
<tr>
<td>Monday, September 9</td>
<td>11:00 – 12:30</td>
<td>Educational Session</td>
<td>ES15</td>
<td>The Management of Cancer Treatment in Thoracic Malignancy</td>
<td>Amsterdam (2011)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>09:15 – 10:45</td>
<td>Plenary Session</td>
<td>PL03</td>
<td>Relevant Aspects of Lung Cancer Management</td>
<td>Barcelona (2005)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>14:30 – 16:00</td>
<td>Educational Session</td>
<td>ES26</td>
<td>The Impact of Specialist Nursing and Allied Health Professionals in the Care of Thoracic Oncology Patients</td>
<td>San Francisco (2009)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>16:15 – 17:00</td>
<td>Plenary Session</td>
<td>PL04</td>
<td>Food for Thought in the Management of Thoracic Malignancies</td>
<td>Barcelona (2005)</td>
</tr>
</tbody>
</table>

## Oligometastatic NSCLC

<table>
<thead>
<tr>
<th>DATE</th>
<th>TIME</th>
<th>SESSION TYPE</th>
<th>#</th>
<th>SESSION TITLE</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, September 8</td>
<td>10:30 – 12:00</td>
<td>Mini Oral Session</td>
<td>MA01</td>
<td>Oligometastatic Disease</td>
<td>Copenhagen (1980)</td>
</tr>
<tr>
<td>Sunday, September 8</td>
<td>13:30 – 15:00</td>
<td>Grand Rounds Session</td>
<td>GR01</td>
<td>Whether and How to Adapt Treatment of NSCLC Oligometastatic Disease to...</td>
<td>Seoul (2007)</td>
</tr>
<tr>
<td>Monday, September 9</td>
<td>11:00 – 12:30</td>
<td>Controversy Session</td>
<td>CS01</td>
<td>Controversies in NSCLC OMD</td>
<td>Colorado Springs (1994)</td>
</tr>
<tr>
<td>Monday, September 9</td>
<td>15:45 – 17:15</td>
<td>Educational Session</td>
<td>ES21</td>
<td>Current Strategies to Improve Outcome of Patients with Oligometastatic NSCLC</td>
<td>Dublin (1997)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>07:00 – 08:00</td>
<td>Interactive Breakfast Session</td>
<td>IBS23</td>
<td>Treatment of NSCLC OMD in Clinical Practice</td>
<td>Toronto (1985)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>16:15 – 17:00</td>
<td>Plenary Session</td>
<td>PL04</td>
<td>Food for Thought in the Management of Thoracic Malignancies</td>
<td>Barcelona (2005)</td>
</tr>
</tbody>
</table>
### Pathology

<table>
<thead>
<tr>
<th>DATE</th>
<th>TIME</th>
<th>SESSION TYPE</th>
<th>#</th>
<th>SESSION TITLE</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, Sept 7</td>
<td>17:30–19:00</td>
<td>Symposium</td>
<td>S02</td>
<td>Symposium Honoring Dr. Gazdar's Legacy</td>
<td>Tokyo (1982)</td>
</tr>
<tr>
<td>Sunday, Sept 8</td>
<td>07:00–08:00</td>
<td>Interactive Breakfast Session</td>
<td>IBS08</td>
<td>Role of Pathologist in the Era of Immunotherapies</td>
<td>Melbourne (1991)</td>
</tr>
<tr>
<td>Sunday, Sept 8</td>
<td>15:15–16:45</td>
<td>Educational Session</td>
<td>ES12</td>
<td>Lung Cancer Pathology in the Age of Genomics</td>
<td>Toronto (1985)</td>
</tr>
<tr>
<td>Monday, Sept 9</td>
<td>07:00–08:00</td>
<td>Interactive Breakfast Session</td>
<td>IBS18</td>
<td>Essentials in Biomarker Testing for Lung Cancer</td>
<td>Tokyo (1982)</td>
</tr>
<tr>
<td>Monday, Sept 9</td>
<td>15:45–17:15</td>
<td>Grand Rounds Session</td>
<td>GR03</td>
<td>Problem Areas for the Next WHO Classification of Lung Cancers</td>
<td>Toronto (1985)</td>
</tr>
<tr>
<td>Tuesday, Sept 10</td>
<td>09:15–10:45</td>
<td>Plenary Session</td>
<td>PL03</td>
<td>Relevant Aspects of Lung Cancer Management</td>
<td>Barcelona (2005)</td>
</tr>
<tr>
<td>Tuesday, Sept 10</td>
<td>11:30–13:00</td>
<td>Mini Oral Session</td>
<td>MA18</td>
<td>Advances in Diagnosis of Common Types of NSCLC</td>
<td>Tokyo (1982)</td>
</tr>
<tr>
<td>Tuesday, Sept 10</td>
<td>14:30–16:00</td>
<td>Mini Symposium</td>
<td>MS17</td>
<td>Pathology of the Future</td>
<td>Interlaken (1988)</td>
</tr>
<tr>
<td>Tuesday, Sept 10</td>
<td>16:15–17:00</td>
<td>Plenary Session</td>
<td>PL04</td>
<td>Food for Thought in the Management of Thoracic Malignancies</td>
<td>Barcelona (2005)</td>
</tr>
</tbody>
</table>

### Prevention and Tobacco Control

<table>
<thead>
<tr>
<th>DATE</th>
<th>TIME</th>
<th>SESSION TYPE</th>
<th>#</th>
<th>SESSION TITLE</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, Sept 8</td>
<td>15:15–16:45</td>
<td>Educational Session</td>
<td>ES13</td>
<td>Global Political, Legal, and Financial Strategies For Tobacco Control</td>
<td>Vienna (2016)</td>
</tr>
<tr>
<td>Monday, Sept 9</td>
<td>07:00–08:00</td>
<td>Interactive Breakfast Session</td>
<td>IBS11</td>
<td>Electronic Cigarettes and Heat-Not-Burn Tobacco Products - How Are They Different</td>
<td>Amsterdam (2011)</td>
</tr>
<tr>
<td>Tuesday, Sept 10</td>
<td>09:15–10:45</td>
<td>Plenary Session</td>
<td>PL03</td>
<td>Relevant Aspects of Lung Cancer Management</td>
<td>Barcelona (2005)</td>
</tr>
<tr>
<td>Tuesday, Sept 10</td>
<td>11:30–13:00</td>
<td>Mini Symposium</td>
<td>MS15</td>
<td>How to Get Patients to Quit Smoking; Practical Implementation of Evidence-Based Cessation Practices</td>
<td>Dublin (1997)</td>
</tr>
<tr>
<td>Tuesday, Sept 10</td>
<td>14:30–16:00</td>
<td>Mini Oral Session</td>
<td>MA25</td>
<td>Precision Medicine in Advanced NSCLC</td>
<td>Dublin (1997)</td>
</tr>
<tr>
<td>Tuesday, Sept 10</td>
<td>16:15–17:00</td>
<td>Plenary Session</td>
<td>PL04</td>
<td>Food for Thought in the Management of Thoracic Malignancies</td>
<td>Barcelona (2005)</td>
</tr>
</tbody>
</table>

CS  Controversy Session  
ES  Educational Session  
GR  Grand Rounds Session  
IBS  Interactive Breakfast Sessions  
OA  Oral Abstract Session  
OC  Opening Ceremony  
PC  Pro-Con Session  
MA  Mini Oral Abstract Session  
MS  Mini Symposium  
PL  Plenary Session  
S  Symposium  
SH  Highlights of the Previous Day  
WS  Workshop (ticketed sessions)  
YI  Young Investigator Session
### Screening and Early Detection

<table>
<thead>
<tr>
<th>DATE</th>
<th>TIME</th>
<th>SESSION TYPE</th>
<th>#</th>
<th>SESSION TITLE</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, September 7</td>
<td>07:00 – 12:00</td>
<td>Symposium</td>
<td>S01</td>
<td>IASLC CT Screening Symposium: Forefront Advances in Lung Cancer Screening</td>
<td>Colorado Springs (1994)</td>
</tr>
<tr>
<td>Sunday, September 8</td>
<td>13:30 – 15:00</td>
<td>Educational Session</td>
<td>ES08</td>
<td>Critical Concerns in Screening</td>
<td>Copenhagen (1980)</td>
</tr>
<tr>
<td>Monday, September 9</td>
<td>07:00 – 08:00</td>
<td>Interactive Breakfast Session</td>
<td>IBS16</td>
<td>Invasive Diagnosis and Surgery in Lung Cancer Screening Participants</td>
<td>Dublin (1997)</td>
</tr>
<tr>
<td>Monday, September 9</td>
<td>11:00 – 12:30</td>
<td>Oral Session</td>
<td>OA06</td>
<td>Refining Lung Cancer Screening</td>
<td>Hilton Head (1978)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>07:00 – 08:00</td>
<td>Interactive Breakfast Session</td>
<td>IBS30</td>
<td>Risk Assessment in CT Screening</td>
<td>Seoul (2007)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>09:15 – 10:45</td>
<td>Plenary Session</td>
<td>PL03</td>
<td>Relevant Aspects of Lung Cancer Management</td>
<td>Barcelona (2005)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>14:30 – 16:00</td>
<td>Mini Symposium</td>
<td>MS18</td>
<td>Role of Biomarkers in Lung Cancer Screening</td>
<td>Vancouver (2003)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>16:15 – 17:00</td>
<td>Plenary Session</td>
<td>PL04</td>
<td>Food for Thought in the Management of Thoracic Malignancies</td>
<td>Barcelona (2005)</td>
</tr>
</tbody>
</table>

### Small Cell Lung Cancer/NET

<table>
<thead>
<tr>
<th>DATE</th>
<th>TIME</th>
<th>SESSION TYPE</th>
<th>#</th>
<th>SESSION TITLE</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, September 8</td>
<td>07:00 – 08:00</td>
<td>Interactive Breakfast Session</td>
<td>IBS09</td>
<td>Challenges in Translating Small Cell and Neuroendocrine Tumor Research into Clinical Practice</td>
<td>Seoul (2007)</td>
</tr>
<tr>
<td>Sunday, September 8</td>
<td>10:30 – 12:00</td>
<td>Educational Session</td>
<td>ES04</td>
<td>Multimodality Management of Small Cell and Neuroendocrine Cancers</td>
<td>Toronto (1985)</td>
</tr>
<tr>
<td>Sunday, September 8</td>
<td>13:30 – 15:00</td>
<td>Oral Session</td>
<td>OA03</td>
<td>Systemic Therapies for SCLC: Novel Targets and Patients’ Selection</td>
<td>Hilton Head (1978)</td>
</tr>
<tr>
<td>Monday, September 9</td>
<td>07:00 – 08:00</td>
<td>Interactive Breakfast Session</td>
<td>IBS19</td>
<td>Novel Approaches in Radiation Oncology for Small Cell and Neuroendocrine Cancers</td>
<td>Seoul (2007)</td>
</tr>
<tr>
<td>Monday, September 9</td>
<td>14:00 – 15:30</td>
<td>Mini Symposium</td>
<td>MS09</td>
<td>Immunotherapy in Small Cell Lung Cancer</td>
<td>Copenhagen (1980)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>09:15 – 10:45</td>
<td>Plenary Session</td>
<td>PL03</td>
<td>Relevant Aspects of Lung Cancer Management</td>
<td>Barcelona (2005)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>11:30 – 13:00</td>
<td>Mini Symposium</td>
<td>MS14</td>
<td>Molecular Subsets and Novel Targeted Approaches to Small Cell and Neuroendocrine Cancers</td>
<td>Colorado Springs (1994)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>14:30 – 16:00</td>
<td>Oral Session</td>
<td>OA15</td>
<td>Targeted Agents and Immunotherapy for Small Cell Lung Cancer</td>
<td>Hilton Head (1978)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>16:15 – 17:00</td>
<td>Plenary Session</td>
<td>PL04</td>
<td>Food for Thought in the Management of Thoracic Malignancies</td>
<td>Barcelona (2005)</td>
</tr>
</tbody>
</table>

### Staging

<table>
<thead>
<tr>
<th>DATE</th>
<th>TIME</th>
<th>SESSION TYPE</th>
<th>#</th>
<th>SESSION TITLE</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday, September 9</td>
<td>11:00 – 12:30</td>
<td>Mini Symposium</td>
<td>MS06</td>
<td>An Interdisciplinary Approach to Optimal Nodal Staging</td>
<td>Toronto (1985)</td>
</tr>
<tr>
<td>Monday, September 9</td>
<td>14:00 – 15:30</td>
<td>Oral Session</td>
<td>OA10</td>
<td>Sophisticated TNM Staging System for Lung Cancer</td>
<td>Toronto (1985)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>09:15 – 10:45</td>
<td>Plenary Session</td>
<td>PL03</td>
<td>Relevant Aspects of Lung Cancer Management</td>
<td>Barcelona (2005)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>16:15 – 17:00</td>
<td>Plenary Session</td>
<td>PL04</td>
<td>Food for Thought in the Management of Thoracic Malignancies</td>
<td>Barcelona (2005)</td>
</tr>
</tbody>
</table>
### Targeted Therapy

<table>
<thead>
<tr>
<th>DATE</th>
<th>TIME</th>
<th>SESSION TYPE</th>
<th>#</th>
<th>SESSION TITLE</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, September 8</td>
<td>07:00 – 08:00</td>
<td>Interactive Breakfast Session</td>
<td>IBS01</td>
<td>My Oligometastatic Oncogene Driven Patient</td>
<td>Tokyo (1982)</td>
</tr>
<tr>
<td>Sunday, September 8</td>
<td>10:30 – 12:00</td>
<td>Mini Symposium</td>
<td>M502</td>
<td>What Molecular Screening for Which Patients?</td>
<td>Vienna (2016)</td>
</tr>
<tr>
<td>Sunday, September 8</td>
<td>10:30 – 12:00</td>
<td>Oral Session</td>
<td>OA02</td>
<td>A New Vision of Targets and Strategies</td>
<td>Seoul (2007)</td>
</tr>
<tr>
<td>Monday, September 9</td>
<td>11:00 – 12:30</td>
<td>Educational Session</td>
<td>E518</td>
<td>Acquired Resistance to TKIs: The Rebiopsy Case and the Future Options</td>
<td>Vienna (2016)</td>
</tr>
<tr>
<td>Monday, September 9</td>
<td>15:45 – 17:15</td>
<td>Pro-Con Session</td>
<td>PC03</td>
<td>Adjuvant Therapy for Resected NSCLC Harboring EGFR Mutation, Chemotherapy or Targeted Therapy</td>
<td>Colorado Springs (1994)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>07:00 – 08:00</td>
<td>Interactive Breakfast Session</td>
<td>IBS31</td>
<td>Trial Design and Novel Drug Accessibility</td>
<td>Amsterdam (2011)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>14:30 – 16:00</td>
<td>Mini Oral Session</td>
<td>MA21</td>
<td>Non EGFR/MET Targeted Therapies</td>
<td>Vienna (2016)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>16:15 – 17:00</td>
<td>Plenary Session</td>
<td>PLO4</td>
<td>Food for Thought in the Management of Thoracic Malignancies</td>
<td>Barcelona (2005)</td>
</tr>
</tbody>
</table>

### Thymoma/Other Thoracic Malignancies

<table>
<thead>
<tr>
<th>DATE</th>
<th>TIME</th>
<th>SESSION TYPE</th>
<th>#</th>
<th>SESSION TITLE</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, September 8</td>
<td>07:00 – 08:00</td>
<td>Interactive Breakfast Session</td>
<td>IBS10</td>
<td>Tracheal Tumours</td>
<td>San Francisco (2009)</td>
</tr>
<tr>
<td>Sunday, September 8</td>
<td>13:30 – 15:00</td>
<td>Mini Symposium</td>
<td>MS03</td>
<td>Workup and Management of Small Anterior Mediastinal Masses/Lesions</td>
<td>Amsterdam (2011)</td>
</tr>
<tr>
<td>Monday, September 9</td>
<td>14:00 – 15:30</td>
<td>Mini Symposium</td>
<td>MS08</td>
<td>Management of Thymic Carcinoma</td>
<td>Seoul (2007)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>07:00 – 08:00</td>
<td>Interactive Breakfast Session</td>
<td>IBS27</td>
<td>Chestwall Tumors</td>
<td>Dublin (1997)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>07:00 – 08:00</td>
<td>Workshop</td>
<td>WS06</td>
<td>Women in Thoracic Oncology Networking Event</td>
<td>Copenhagen (1980)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>11:30 – 13:00</td>
<td>Mini Oral Session</td>
<td>MA20</td>
<td>Thymic Tumors: From Molecular to Clinical Results and New Challenges in Other Rare Thoracic Tumors</td>
<td>San Francisco (2009)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>16:15 – 17:00</td>
<td>Plenary Session</td>
<td>PLO4</td>
<td>Food for Thought in the Management of Thoracic Malignancies</td>
<td>Barcelona (2005)</td>
</tr>
</tbody>
</table>

**Legend:**
- **CS** Controversy Session
- **ES** Educational Session
- **GR** Grand Round Session
- **IBS** Interactive Breakfast Sessions (Ticketed Session, Continental Breakfast Provided)
- **MA** Mini Oral Abstract Session
- **MS** Mini Symposium
- **OA** Oral Abstract Session
- **OC** Opening Ceremony
- **PC** Pro-Con Session
- **PL** Plenary Session
- **S** Symposium
- **SH** Highlights of the Previous Day
- **WS** Workshop (ticketed sessions)
- **YI** Young Investigator Session
# Treatment in the Real World - Support, Survivorship, Systems Research

<table>
<thead>
<tr>
<th>DATE</th>
<th>TIME</th>
<th>SESSION TYPE</th>
<th>#</th>
<th>SESSION TITLE</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, September 8</td>
<td>13:30 - 15:00</td>
<td>Educational Session</td>
<td>ES09</td>
<td>How I Do It - Real World Issues in the Diagnosis and Treatment of Metastatic NSCLC</td>
<td>Tokyo</td>
</tr>
<tr>
<td>Monday, September 9</td>
<td>14:00 - 15:30</td>
<td>Oral Session</td>
<td>OA11</td>
<td>Decomplexifying Molecular Targets, Immunotherapy and Treatment Settings in the Real World</td>
<td>Interlaken</td>
</tr>
<tr>
<td>Monday, September 9</td>
<td>15:45 - 17:15</td>
<td>Mini Oral Session</td>
<td>MA16</td>
<td>Prioritizing Use of Technology to Improve Survival of Lung Cancer Subgroups and Outcomes with Chemotherapy and Surgery</td>
<td>Interlaken</td>
</tr>
<tr>
<td>Monday, September 9</td>
<td>15:45 - 17:15</td>
<td>Mini Symposium</td>
<td>MS11</td>
<td>Addressing Challenges with Surgical Resection of Lung Cancer</td>
<td>Vancouver</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>07:00 - 08:00</td>
<td>Interactive Breakfast Session</td>
<td>IBS21</td>
<td>Combating Toxicity of IO-Chemotherapy Combinations</td>
<td>Vienna</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>09:15 - 10:45</td>
<td>Plenary Session</td>
<td>PL03</td>
<td>Relevant Aspects of Lung Cancer Management</td>
<td>Barcelona</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>11:30 - 13:00</td>
<td>Mini Oral Session</td>
<td>MA19</td>
<td>Looking at PROs in Greater Detail - What Patients Actually Want and Expect</td>
<td>Interlaken</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>16:15 - 17:00</td>
<td>Plenary Session</td>
<td>PL04</td>
<td>Food for Thought in the Management of Thoracic Malignancies</td>
<td>Barcelona</td>
</tr>
</tbody>
</table>

# Treatment of Early Stage/Localized Disease

<table>
<thead>
<tr>
<th>DATE</th>
<th>TIME</th>
<th>SESSION TYPE</th>
<th>#</th>
<th>SESSION TITLE</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, September 8</td>
<td>10:30 - 12:00</td>
<td>Mini Oral Session</td>
<td>MA02</td>
<td>Miscellaneous Topics in the Management of Early Stage Lung Cancer</td>
<td>Interlaken</td>
</tr>
<tr>
<td>Sunday, September 8</td>
<td>13:30 - 15:00</td>
<td>Mini Oral Session</td>
<td>MA06</td>
<td>Challenges in the Treatment of Early Stage NSCLC</td>
<td>Colorado Springs</td>
</tr>
<tr>
<td>Sunday, September 8</td>
<td>15:15 - 16:45</td>
<td>Mini Symposium</td>
<td>MS04</td>
<td>New Systemic Adjuvant/Neo-Adjuvant Strategies in Early Stage Lung Cancer: Targeted Therapy and I/O</td>
<td>Hilton Head</td>
</tr>
<tr>
<td>Monday, September 9</td>
<td>07:00 - 08:00</td>
<td>Interactive Breakfast Session</td>
<td>IBS14</td>
<td>Best Management of Early Stage NSCLC in ILD Patients</td>
<td>Melbourne</td>
</tr>
<tr>
<td>Monday, September 9</td>
<td>14:00 - 15:30</td>
<td>Mini Symposium</td>
<td>MS07</td>
<td>Controversies with Stereotactic Radiation in Early Stage Lung Cancer</td>
<td>Dublin</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>07:00 - 08:00</td>
<td>Interactive Breakfast Session</td>
<td>IBS25</td>
<td>Optimal GGO Management</td>
<td>Melbourne</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>09:15 - 10:45</td>
<td>Plenary Session</td>
<td>PL03</td>
<td>Relevant Aspects of Lung Cancer Management</td>
<td>Barcelona</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>11:30 - 13:00</td>
<td>Oral Session</td>
<td>OA13</td>
<td>Ideal Approach to Lung Resection and Novel Perioperative Therapy</td>
<td>Toronto</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>14:30 - 16:00</td>
<td>Educational Session</td>
<td>ES25</td>
<td>Liquid Biopsy</td>
<td>Colorado Springs</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>16:15 - 17:00</td>
<td>Plenary Session</td>
<td>PL04</td>
<td>Food for Thought in the Management of Thoracic Malignancies</td>
<td>Barcelona</td>
</tr>
</tbody>
</table>
### Treatment of Locoregional Disease - NSCLC

<table>
<thead>
<tr>
<th>DATE</th>
<th>TIME</th>
<th>SESSION TYPE</th>
<th>#</th>
<th>SESSION TITLE</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, September 8</td>
<td>07:00 - 08:00</td>
<td>Interactive Breakfast Session</td>
<td>IBS03</td>
<td>Personalized Management of Elderly Patients with Stage III NSCLC</td>
<td>Interlaken (1988)</td>
</tr>
<tr>
<td>Sunday, September 8</td>
<td>10:30 - 12:00</td>
<td>Educational Session</td>
<td>ES02</td>
<td>Management of Oncogene Addicted Patients with Stage III NSCLC</td>
<td>Vancouver (2003)</td>
</tr>
<tr>
<td>Sunday, September 8</td>
<td>15:15 - 16:45</td>
<td>Mini Oral Session</td>
<td>MA08</td>
<td>Pawing the Way to Improve Outcomes in Stage III NSCLC</td>
<td>Tokyo (1982)</td>
</tr>
<tr>
<td>Monday, September 9</td>
<td>07:00 - 08:00</td>
<td>Interactive Breakfast Session</td>
<td>IBS13</td>
<td>How to Identify and Manage Toxicity in Stage III</td>
<td>Interlaken (1988)</td>
</tr>
<tr>
<td>Monday, September 9</td>
<td>11:00 - 12:30</td>
<td>Educational Session</td>
<td>ES16</td>
<td>Modern Radiotherapy in Stage III NSCLC</td>
<td>Dublin (1997)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>09:15 - 10:45</td>
<td>Plenary Session</td>
<td>PL03</td>
<td>Relevant Aspects of Lung Cancer Management</td>
<td>Barcelona (2007)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>11:30 - 13:00</td>
<td>Educational Session</td>
<td>ES23</td>
<td>Optimal Management of N2 Disease in the Era Of IO</td>
<td>Hilton Head (1978)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>16:15 - 17:00</td>
<td>Plenary Session</td>
<td>PL04</td>
<td>Food for Thought in the Management of Thoracic Malignancies</td>
<td>Barcelona (2005)</td>
</tr>
</tbody>
</table>

### Young Investigators

<table>
<thead>
<tr>
<th>DATE</th>
<th>TIME</th>
<th>SESSION TYPE</th>
<th>#</th>
<th>SESSION TITLE</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, September 7</td>
<td>07:00 - 08:30</td>
<td>Young Investigator Session</td>
<td>YI01</td>
<td>First Time Attendee Session</td>
<td>Dublin (1997)</td>
</tr>
<tr>
<td>Saturday, September 7</td>
<td>09:00 - 10:30</td>
<td>Young Investigator Session</td>
<td>YI02</td>
<td>Clinical Trials</td>
<td>Dublin (1997)</td>
</tr>
<tr>
<td>Sunday, September 8</td>
<td>10:30 - 12:00</td>
<td>Young Investigator Session</td>
<td>YI03</td>
<td>Scientific Mentoring</td>
<td>Dublin (1997)</td>
</tr>
<tr>
<td>Sunday, September 8</td>
<td>13:30 - 15:00</td>
<td>Young Investigator Session</td>
<td>YI04</td>
<td>Basics of Immunology</td>
<td>Dublin (1997)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>07:00 - 08:00</td>
<td>Interactive Breakfast Session</td>
<td>IBS22</td>
<td>JTO Workshop: How to Get Your Manuscript Published</td>
<td>Tokyo (1982)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>09:15 - 10:45</td>
<td>Plenary Session</td>
<td>PL03</td>
<td>Relevant Aspects of Lung Cancer Management</td>
<td>Barcelona (2005)</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>16:15 - 17:00</td>
<td>Plenary Session</td>
<td>PL04</td>
<td>Food for Thought in the Management of Thoracic Malignancies</td>
<td>Barcelona (2005)</td>
</tr>
</tbody>
</table>
HOURS  Saturday, September 7  20:30 –  22:00
Sunday, September 8  09:30 –  18:30
Monday, September 9  09:30 –  18:30
Tuesday, September 10  09:30 –  14:00

Thank you
IASLC WCLC 2019
ADVOCACY
COMMITTEE

Patient Advocacy Lounge
LOCATED IN THE EXHIBIT HALL
A dedicated networking area exclusively accessible by all advocates and patients attending the IASLC WCLC 2019.
Located within the exhibits area, at the Patient Advocacy Lounge, you can just relax or meet with other advocates.
Refreshments will be served throughout the day and a variety of seating and charging stations will be available.

WCLC 2019
Interactive Tool

Social Q&A
Submit questions during sessions
Like submitted questions to make them move to the top of the list
Interact with other delegates

Live Audience Polling with Real-Time Results
Respond to polls and view results
Actively participate in sessions

Hassle-Free Session and Speaker Feedback
Help improve the scientific program and provide feedback with simple evaluations

Download the IASLC World Conference Mobile App and start participating!
Thank you
IASLC WCLC 2019
ADVOCACY COMMITTEE

Patient Advocacy Lounge
LOCATED IN THE EXHIBIT HALL

A dedicated networking area exclusively accessible by all advocates and patients attending the IASLC WCLC 2019. Located within the exhibits area, at the Patient Advocacy Lounge, you can just relax or meet with other advocates. Refreshments will be served throughout the day and a variety of seating and charging stations will be available.

HOURS
Saturday, September 7
Sunday, September 8
Monday, September 9
Tuesday, September 10
20:30 – 22:00
09:30 – 18:30
09:30 – 18:30
09:30 – 14:00
Donations to the ILCF support the education of research fellows who are the next generation of lung cancer physicians and scientists.

Donate at IASLC.org/ILCF

"The ILCF Young Investigator Award has been a terrific vote of confidence, not only for an early career clinician researcher, but more importantly for the entire multidisciplinary team I am part of. Recognition of our efforts with a grant from a prestigious international organization such as ILCF is validation that we are on track to do more for patients with lung cancer."

Dr. Ashanya Malalaserkera
ILCF Young Investigator Award Recipient
2019-2020
DAILY SCIENTIFIC PROGRAM
Daily Scientific Program  Friday, Sept. 6

14:00–18:00  Registration Open
  • North Entrance – Level 1
14:00–18:00  Speaker Preview Center Open
  • 8.0 – Level 1

IASLC Foundation RELAUNCH!

The IASLC Foundation has taken on a new name and a new look! The International Lung Cancer Foundation (ILCF) has adopted a striking new look to inspire confidence in our mission. Please join us on our journey and thank you to all who have continued to support us. Together we will fight to conquer thoracic malignancies!

For more information please visit: IASLC.org/ILCF

International Lung Cancer Foundation

Inspiring hope through research
**Daily Scientific Program**  
**Saturday, Sept. 7**

06:30–20:00  
Registration Open  
• North Entrance–Level 1

06:30–20:00  
Speaker Preview Center Open  
• 8.0–Level 1

15:00–19:00  
Media Room Open  
• Press Area: 8.1

20:30–22:00  
Exhibits Open–Welcome Reception  
• Exhibit Hall: 8.1

---

**JCSE01**  
**LIGHT BREAKFAST PROVIDED**

07:00–11:15  
**JOINT IASLC-CSCO-CAALC SESSION**  
• Toronto (1985)

Chair(s):  
Chunxue Bai, China; Tony Mok, China; Yi-Long Wu, China; Qing Zhou, China; Nan Wu, China

07:00–07:30  
JCSE01.01–Breakfast and Poster Viewing

07:30–07:50  
JCSE01.02–The Opportunity of Drugs Development on Immunotherapy in China
  Qing Zhou, Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People’s Hospital & Guangdong Academy of Medical Sciences, China

07:50–08:10  
JCSE01.03–Any Difference on Efficacy and Toxicity Between East and West?
  Jie Hu, Zhongshan Hospital, Fudan University, China

08:10–08:30  
JCSE01.04–Neo-Adjuvant Immunotherapy in Lung Cancer
  Nan Wu, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), China

08:30–08:50  
JCSE01.05–Biomarker in Immunotherapy: Myth or Reality?
  Alfredo Addeo, Hôpitaux Universitaires de Genève, Switzerland

08:50–09:10  
JCSE01.06–New Era Beyond PD-1/PD-L1
  Luis Paz-Ares, 12 de Octubre University Hospital, Spain

09:10–09:20  
JCSE01.07–Discussion

09:20–09:45  
JCSE01.08–Coffee Break and Poster Viewing

---

09:45–09:55  
JCSE01.09–A Phase II Umbrella Study of Camrelizumab in Different PD-L1 Expression Cohorts in Pre-Treated Advanced/Metastatic Non-Small Cell Lung Cancer
  Yi-Long Wu, Guangdong Lung Cancer Institute (GLCI), Guangdong Provincial People’s Hospital (GDPH), China

09:55–10:05  
JCSE01.10–Efficacy and Safety of Neoadjuvant PD-1 Blockade with Sintilimab in Resectable Squamous Non-Small Cell Lung Cancer (sqNSCLC)
  Ning Li, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China

10:05–10:15  
JCSE01.11–Efficacy and Safety of Sintilimab with Anlotinib as First-Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC)
  Baohui Han, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

10:15–10:30  
JCSE01.12–Discussant Oral Abstracts
  Bob Li, Memorial Sloan Kettering Cancer Center, United States of America

10:30–10:45  
JCSE01.13–Discussant Poster Abstracts
  Shun Lu, Chinese Society of Clinical Oncology CSCO, China

---

**Posters on Display**

JCSE01.14  
Higher Prevalence of EGFR Mutations Significantly Correlates with Lower PD-L1 Expression in Chinese Lung Adenocarcinoma
  Shiyoue Zhang, OrigiMed, China

JCSE01.15  
Liver Metastases Predicts Poorer Prognosis in Advanced NSCLC Patients Who Receiving Nivolumab Monotherapy
  Guowei Zhang, The Affiliated Cancer Hospital of Zhengzhou University, China

JCSE01.16  
Metastatic Lymph Nodes as High Immunogenicity Media for Perioperative Immunotherapy in Locally Advanced NSCLC
  Chao Zhang, Guangdong Lung Cancer Institute, China

JCSE01.17  
Modelling the Immunosuppressive Difference of SBRT and CRT by Simulating the Dose to Circulating Lymphocytes in Non-Small Cell Lung Cancer
  Haihua Yang, Radiation Oncology Institute of Enze Medical Health Academy, Affiliated Taizhou Hospital of Wenzhou Medical University, China

JCSE01.18  
A CT-Based Radiomics Approach to Predict PDI Inhibitor Response in Non-Small-Cell Lung Cancer
  Jialei Wang, Fudan University Shanghai Cancer Center, China
JCSE01.19  Tumor Mutation Score Is More Powerful Than Tumor Mutation Burden in Predicting Response to Immunotherapy in Non-Small Cell Lung Cancer  
Yuan Li, Fudan University Shanghai Cancer Center, China

JCSE01.20  Pilot Study on the Tumor Immune Microenvironment Between Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)  
Qian Chu, Tongji Hospital Tongji Medical College Huazhong University of Science and Tech, Wuhan, China, China

JCSE01.21  Changes of Peripheral Blood sPD-L1 in Patients with Small Cell Lung Cancer During Chemotherapy and Its Clinical Significance  
Hao Tian, Shaxi Medical University, China

JCSE01.22  Tumor Microenvironment Is Associated with Efficacy of PD-1/PD-L1 Inhibitors in Patients with Primary Pulmonary Lymphoepithelioma-Like Cancer  
Xu-Chao Zhang, Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People’s Hospital & Guangdong Academy of Medical Sciences, China

JCSE01.23  Specific TP53 Mutation Subtypes as Biomarker for Response to PD-1/L1 Blockade Immunotherapy in NSCLC  
Hao Sun, Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People’s Hospital & Guangdong Academy of Medical Sciences, China

JCSE01.24  Dynamic Changes of Plasma PD-L1 mRNA Expression Predict Response to Anti-PD-1/Anti-PD-L1 Treatment in Malignancies  
Jianguo Sun, Cancer Institute of People’s Liberation Army, China

JCSE01.25  TP53/KMT2C Co-Mutation as a Novel Biomarker for Immunotherapy in Non-Small Cell Lung Cancer Patients  
Qing Zhou, Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People’s Hospital & Guangdong Academy of Medical Sciences, China

JCSE01.26  PD-1 Inhibitor Plus Chemotherapy as 2nd/Subsequent Line Setting Demonstrate Superior Efficacy over PD-1 Inhibitor Alone in Pts of Advanced NSCLC  
Shengxiang Ren, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine, China

JCSE01.28  Changes of Brain Structure in Advanced NSCLC Patients Receiving EGFR-TKIs: Dynamic Analysis Based on Series MRI Images  
Chunli Luo, West China Hospital, Sichuan University, China
WS03

11:00–18:00 ITONF WORKSHOP: BRIDGING THE GAPS IN THORACIC ONCOLOGY NURSING—A GLOBAL PERSPECTIVE

Track(s): Nursing and Allied Professionals

San Francisco (2009)

11:00–11:30 WS03.01--Registration
11:30–12:00 WS03.02--Business Meeting
Maria Guerin, Aintree University Hospital, United Kingdom
12:00–12:40 WS03.03--Keynote Address
Gerry O Hare, Glasgow & Clyde Health Board, United Kingdom
12:40–13:00 WS03.04--Lung Cancer and Mesothelioma Nursing Care in Spain
Maria Fernandez, Spanish Lung Cancer Group, Spain
13:00–13:15 WS03.05--Break–Poster Viewing/Networking
13:15–14:15 WS03.06--Panel–Innovative Nursing Care in Early Stage Lung Cancer: A Global Perspective
Mark Shaw1, John Edwards2, Sarah Levy3; 1Peter MacCallum Cancer Centre, Australia, 2Northern General Hospital, United Kingdom, 3University of Maryland Medical Center, United States of America
14:15–14:35 WS03.07--Break Refreshments
14:35–15:35 WS03.08--Panel–Emerging Therapies–Immunotherapy
Marianne Davies1, Beth Eaby-Sandy2, Rachel Thomas3; 1Yale University, United States of America, 2University of Pennsylvania, United States of America, 3Guy’s and St Thomas’ NHS Trust, United Kingdom
15:35–15:50 WS03.09--Break–Poster Viewing/Networking
15:50–16:30 WS03.10--Bridging the Gap—Implement Knowledge into Local Practice
Roma Maguire, University of Strathclyde Livingston Tower, United Kingdom
16:30–16:50 WS03.11--Poster Session–What’s New in Global Thoracic Oncology Nursing
Melissa Culligan, University of Maryland School of Medicine, United States of America
16:50–17:00 WS03.12--ITONF Membership Meeting and Getting to Know Your Peers–ITONF Reception
Maria Guerin, Aintree University Hospital, United Kingdom

WS02

09:15–09:30 WS02.07--Palliative Care in MPM
Monica Malec, University of Chicago, United States of America
09:30–09:45 WS02.08--PROMs in MPM
Annelies Janssens, Antwerp University Hospital, Belgium
09:45–10:00 WS02.09--Questions

WS02.10--Immunotherapy and Novel Targets–Biomarker Driven MPM Treatment
Paul Baas, Netherlands Cancer Institute, Netherlands
10:00–10:10 WS02.11--Immunotherapy–Update on World Wide Studies
Anna Nowak, University of Western Australia, Australia
10:10–10:20 WS02.12--Translational Research MPM
Maria Disselhorst, Netherlands Cancer Institute, Netherlands
10:20–10:30 WS02.13--Immunotherapy–Biomarker Beyond PDL-1
Alessandra Curioni, University Hospital Zürich, Switzerland
10:30–10:40 WS02.14--Epigenetic Targets in MPM
Raphael Bueno, Brigham and Women’s Hospital, United States of America
10:40–10:50 WS02.15--NF2–Lessons Learned from Clinical Trials
Raphael Bueno, Brigham and Women’s Hospital, United States of America
10:50–11:00 WS02.16--Questions

YI02

09:00–10:30 CLINICAL TRIALS
● Dublin (1997)

Track(s): Young Investigators

Chair(s): Laura Mezquita, France; Frances Shepherd, Canada
09:00–09:15 YI02.01--Academic Versus Industrial Clinical Trials
Tony Mok, Chinese University of Hong Kong, China
09:15–09:30 YI02.02--Basket and Umbrella Trial Designs in Oncology
Jessica Menis, University of Padova, Istituto Oncologico Veneto (IOV), Italy
09:30–09:45 YI02.03--Statistical Pitfalls in Clinical Trial Design
Urania Dafni, University of Lausanne, Greece
09:45–10:00 YI02.04--Bioinformatics: The Basics
Yu Shyr, Vanderbilt University Medical Center, United States of America
10:00–10:15 YI02.05--Principles to Get Your Paper Published
Alex Adjei, Mayo Clinic, United States of America
10:15–10:30 YI02.06--Q&A
10:30–11:00 YI02.07--Break
## SATURDAY  SEPTEMBER 7

### OPENING CEREMONY

19:00–20:30  
**Barcelona (2005)**

- 19:00–19:40  
  **OC01.01**–Welcome Address

- 19:40–20:10  
  **OC01.02**–IASLC Distinguished Awards

- 20:10–20:15  
  **OC01.03**–Conference Presidents Announce New Things at WCLC 2019

### WELCOME RECEPTION

20:30–22:00  
**Exhibit Hall, Level 2, Hall 8.1**

### PR01  PRESS CONFERENCE

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
</table>
| 16:00–16:45 | PRESS CONFERENCE  
 CC7.1 A&B                                                                 |                               |
| 16:00–16:35 | PR01.01–IASLC Initiatives                                                               |                               |
| 16:00–16:14 | PR01.02–Welcome from Co-Chairs                                                           |                               |
| 16:14–16:21 | PR01.03–20th WCLC Highlights                                                             |                               |
| 16:21–16:28 | PR01.04–STARS Program Announcement                                                      |                               |
| 16:28–16:35 | PR01.05–Molecular Survey                                                                 |                               |
| 16:35–16:42 | PR01.06–Awards                                                                          |                               |
| 16:42–16:45 | PR01.07–Advocacy-Lung Ambition-Mobile CT                                                 |                               |

### S02  SYMPOSIUM HONORING DR. GAZDAR’S LEGACY

17:30–19:00  
**Tokyo (1982)**

- **S02.01**–Introduction  
  Ignacio Wistuba, The University of Texas MD Anderson Cancer Center, United States of America

- **S02.02**–Adi Gazdar’s Legacy  
  Peter Ujhazy, National Cancer Institute, United States of America

- **S02.03**–The Impact of Cell Line Development in Lung Cancer Research  
  Paul Bunn, Jr, University of Colorado Cancer Center, United States of America

- **S02.04**–Dr. Gazdar as a Mentor  
  Tetsuya Mitsudomi, Kindai University Faculty of Medicine, Japan

- **S02.05**–The Importance of Elucidating Genomic Events is Lung Premalignancy  
  Kwun Fong, The Prince Charles Hospital, Australia

- **S02.06**–New Developments in SCLC and Neuroendocrine Tumors  
  Lauren Byers, University of Texas MD Anderson Cancer Center, United States of America

- **S02.07**–Dr. Gazdar as a Friend and Final Remarks  
  Fred R Hirsch, Mount Sinai Hospital, United States of America

### IASLC AWARD SESSION

17:45–18:45  
**Toronto (1985)**

### PR01  PRESS CONFERENCE

16:00–16:45  
**PRESS CONFERENCE**  
CC7.1 A&B

16:00–16:07  
**PR01.01**–IASLC Initiatives

16:07–16:14  
**PR01.02**–Welcome from Co-Chairs

16:14–16:21  
**PR01.03**–20th WCLC Highlights

16:21–16:28  
**PR01.04**–STARS Program Announcement

16:28–16:35  
**PR01.05**–Molecular Survey

16:35–16:42  
**PR01.06**–Awards

16:42–16:45  
**PR01.07**–Advocacy-Lung Ambition-Mobile CT

### S02  SYMPOSIUM HONORING DR. GAZDAR’S LEGACY

17:30–19:00  
**SYMPOSIUM HONORING DR. GAZDAR’S LEGACY**  
**SIGN UP REQUIRED**

17:30–17:35  
**S02.01**–Introduction  
Ignacio Wistuba, The University of Texas MD Anderson Cancer Center, United States of America

17:35–17:45  
**S02.02**–Adi Gazdar’s Legacy  
Peter Ujhazy, National Cancer Institute, United States of America

17:45–18:00  
**S02.03**–The Impact of Cell Line Development in Lung Cancer Research  
Paul Bunn, Jr, University of Colorado Cancer Center, United States of America

18:00–18:15  
**S02.04**–Dr. Gazdar as a Mentor  
Tetsuya Mitsudomi, Kindai University Faculty of Medicine, Japan

18:15–18:30  
**S02.05**–The Importance of Elucidating Genomic Events is Lung Premalignancy  
Kwun Fong, The Prince Charles Hospital, Australia

18:30–18:45  
**S02.06**–New Developments in SCLC and Neuroendocrine Tumors  
Lauren Byers, University of Texas MD Anderson Cancer Center, United States of America

18:45–19:00  
**S02.07**–Dr. Gazdar as a Friend and Final Remarks  
Fred R Hirsch, Mount Sinai Hospital, United States of America

### IASLC AWARD SESSION

17:45–18:45  
**IASLC AWARD SESSION**  
**Toronto (1985)**
## Daily Scientific Program  Sunday, Sept. 8

### IBS01

**07:00–08:00** MY OLIGOMETASTATIC ONCOGENE DRIVEN PATIENT

- **Track(s):** Targeted Therapy

- **IBS01.01**– Systemic or Local Treatment: What to Do First?
  Benjamin Solomon, Peter MacCallum Cancer Center, Australia

- **IBS01.02**– Strategies Treatment After Oligoprogression
  Federico Cappuzzo, Medical Oncology Unit Ravenna, Italy

- **IBS01.03**– Q&A

### IBS02

**07:00–08:00** MAKING SENSE OF TREATMENT WITH SO MANY OPTIONS: MY ALGORITHM

- **Track(s):** Advanced NSCLC

- **IBS02.01**– Making Sense of Treatment with so Many Options: My Algorithm – A European View
  Noemi Reguart, Hospital Clínic Barcelona, Spain

- **IBS02.02**– Making Sense of Treatment with so Many Options: My Algorithm – A North American View
  Rogerio Lilenbaum, Yale Cancer Center, United States of America

### IBS03

**07:00–08:00** PERSONALIZED MANAGEMENT OF ELDERLY PATIENTS WITH STAGE III NSCLC

- **Track(s):** Treatment of Locoregional Disease–NSCLC

- **IBS03.01**– Managing Locally Advanced NSCLC in the Elderly in 2019
  Corey Langer, Perelman School of Medicine, United States of America

- **IBS03.02**– Surgery for Elderly Patients with Stage III Non-Small-Cell Lung Cancer (NSCLC)?
  Bernward Passlick, University of Freiburg, Germany

- **IBS03.03**– Q&A

### IBS04

**07:00–08:00** HYPERPROGRESSIVE DISEASE

- **Track(s):** Immuno-oncology

- **IBS04.01**– Biological Mechanisms
  Edward Garon, University of California Los Angeles, United States of America

- **IBS04.02**– Clinical Characteristics
  Benjamin Besse, Gustave Roussy Cancer Campus, France

- **IBS04.03**– Q&A

### IBS05

**07:00–08:00** LUNG CANCER GENETICS TO BEAT LUNG CANCER

- **Track(s):** Biology

- **IBS05.01**– KRAS Mutant Lung Cancer
  Pasi Jänne, Dana Farber Cancer Institute, United States of America

- **IBS05.02**– Functional Genomic Approaches to Identify Novel Therapeutic Targets in Lung Cancer
  Tao Zou, Dana-Farber Cancer Institute, United States of America

- **IBS05.03**– Q&A
**SUNDAY SEPTEMBER 8**

**CME Accredited Session**

---

### IBS06

**07:00–08:00** MULTIMODALITY TREATMENT – REALTIME DATA FROM NATIONAL REGISTRIES

*TICKETED SESSION*

- **Track(s):** Mesothelioma

- **07:00–07:15** IBS06.01 – Realtime Data from Europe ETOP / ESTS Database
  Isabelle Schmitt-Opitz, University of Zürich, Switzerland

- **07:15–07:30** IBS06.02 – Real Time Data from US (SEERS)
  Emanuela Taioli, Icahn School of Medicine at Mount Sinai, United States of America

- **07:30–07:45** IBS06.03 – Japanese Data
  Seiki Hasegawa, Hyogo College of Medicine, Japan

- **07:45–08:00** IBS06.04 – Q&A

### IBS07

**07:00–08:00** ENHANCING RECOVERY IN THE TREATMENT OF THORACIC MALIGNANCY

*TICKETED SESSION*

- **Track(s):** Nursing and Allied Professionals

- **07:00–07:20** IBS07.01 – Enhanced Recovery for Thoracic Surgery
  Amy Kerr, University Hospitals Birmingham, United Kingdom

- **07:20–07:40** IBS07.02 – The Role of Prehabilitation in the Optimisation of Patients with Thoracic Malignancy
  Faye Dickinson, Guys Hospital, United Kingdom

- **07:40–08:00** IBS07.03 – Q&A

### IBS08

**07:00–08:00** ROLE OF PATHOLOGIST IN THE ERA OF IMMUNOTHERAPIES

*TICKETED SESSION*

- **Track(s):** Pathology

- **07:00–07:20** IBS08.01 – Harmonization of PD-L1 IHC Including LDT
  Lukas Bubendorf, University Hospital Basel, Switzerland

- **07:20–07:40** IBS08.02 – Beyond PD-L1 IHC (TMB, Immune Microenvironment)
  Mari Mino-Kenudsen, Massachusetts General Hospital, United States of America

- **07:40–08:00** IBS08.03 – Q&A

---

### IBS09

**07:00–08:00** CHALLENGES IN TRANSLATING SMALL CELL AND NEUROENDOCRINE TUMOR RESEARCH INTO CLINICAL PRACTICE

*TICKETED SESSION*

- **Track(s):** Small Cell Lung Cancer/NET

- **07:00–07:20** IBS09.01 – Challenges in Translating Small Cell and Neuroendocrine Tumor Research into Clinical Practice
  Alex Adjei, Mayo Clinic, United States of America

- **07:20–07:40** IBS09.02 – Immunotherapy for Small Cell and Neuroendocrine Tumors
  Sarah Goldberg, Yale School of Medicine, United States of America

- **07:40–08:00** IBS09.03 – Q&A

### IBS10

**07:00–08:00** TRACHEAL TUMOURS

*TICKETED SESSION*

- **Track(s):** Thymoma/Other Thoracic Malignancies

- **07:00–07:20** IBS10.01 – Surgical Treatment of Tracheal Tumours
  Walter Klepetko, Medical University of Vienna, Austria

- **07:20–07:40** IBS10.02 – Endoscopic Treatment of Unresectable Tumors of the Trachea
  Jiayuan Sun, Shanghai Chest Hospital, China

- **07:40–08:00** IBS10.03 – Q&A
DAILY SCIENTIFIC PROGRAM

6 SUNDAY  SEPTEMBER 8

CME Accredited Session

**ES01**

**10:30–12:00** WHAT IS THE ROLE OF CHEMOTHERAPY IN THE ERA OF IMMUNOTHERAPY IN ADVANCED NSCLC?

- **Hilton Head (1978)**

**Chair(s):** Enriqueta Felip, Spain; Giorgio Scagliotti, Italy

**08:15–08:30**

**ES01.01**– Tumor-Agnostic Biologically Driven Treatments: An Endless Dream?

Robert Doebele, University of Colorado, United States of America

**08:30–08:45**

**ES01.02**– The Evolution of Tissue Testing for Immunotherapy—Where Next?

Keith Kerr, University of Aberdeen, School of Medicine and Dentistry, United Kingdom

**08:45–09:00**

**ES01.03**– Will the Immunotherapy with Newer Biomarkers, Combination Therapy or New Technology Eventually Cure Lung Cancer?

Tetsuya Mitsudomi, Kindai University Faculty of Medicine, Japan

**09:00–09:15**

**ES01.04**– Artificial Intelligence, Big Data and Lung Cancer: Ready to Implement?

Hugo Aerts, Harvard-DFCI, Netherlands

**09:45–10:30** POSTER VIEWING

- Exhibit Hall, Level 2, Hall 8.1

**ES02**

**10:30–12:00** MANAGEMENT OF ONCOGENE ADDICTED PATIENTS WITH STAGE III NSCLC

- **Vancouver (2003)**

**Chair(s):** Carlos Camps, Spain; Helena Yu, United States of America

**09:45–09:54**

**ES02.01**– Phase I Study of Safety, Tolerability, PK and Efficacy of AMG 510, a Novel KRAS G12C Inhibitor, Evaluated in NSCLC

Ramaswamy Govindan, Alvin J Siteman Cancer Center, Washington University School of Medicine, St. Louis, United States of America

**09:54–10:03**

**ES02.02**– Mutations Associated with Sensitivity or Resistance to Immunotherapy in mNSCLC: Analysis from the MYSTIC Trial

Naiyer Rizvi, Columbia University Medical Center, New York, United States of America

**10:03–10:12**

**ES02.03**– CheckMate 817: First-Line Nivolumab + Ipilimumab in Patients with ECOG PS 2 and Other Special Populations with Advanced NSCLC

Fabrice Barlesi, Aix-Marseille Université; CNRS, INSERM, CRCM; Assistance Publique-Hôpitaux de Marseille (APHM), Marseille, France

**10:12–10:21**

**PR02.04**– Evaluation of TMB in KEYNOTE-189: Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy for Nonsquamous NSCLC

Marina Garassino, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

**10:21–10:30**

**PR02.05**– KEYNOTE-021: TMB and Outcomes for Carboplatin and Pemetrexed With or Without Pembrolizumab for Nonsquamous NSCLC

Corey Langer, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, United States of America
11:00–11:15  ES02.03–Management of Other Non EGFR Oncogene Addicted Tumors  
Charu Aggarwal, Hospital of the University of Pennsylvania, United States of America

11:15–11:30  ES02.04–Concurrent, Sequential and Combination Immunotherapy Regimens in LA-NSSCLC  
Mariano Provencio, Puerta de Hierro University Hospital, Spain

11:30–12:00  ES02.05–Q&A

10:30–12:00  BAP-1 AND OTHER NOVEL MOLECULAR AND METABOLIC TARGETS IN MESOTHELIOMA  
★ Tokyo (1982)

Track(s):  Mesothelioma  
Chair(s):  Michele Carbone, United States of America; Miyako Satouchi, Japan

10:30–10:40  ES03.01–Targeting Altered microRNA Expression in Mesothelioma  
Glen Reid, University of Otago, New Zealand

10:40–10:50  ES03.02–Targeting Cdkn2a in Mesothelioma  
Dean Fennell, University Hospitals of Leicester NHS Trust, United Kingdom

10:50–11:00  ES03.03–Targeting Nf2 in Mesothelioma  
Yoshitaka Sekido, Aichi Cancer Center Research Institute, Japan

11:00–11:10  ES03.04–Pegargiminase to Treat Mesothelioma  
Peter Szlosarek, Barts Cancer Institute, United Kingdom

11:10–11:20  ES03.05–Inherited Predisposition to Mesothelioma, Biological and Clinical Differences with Sporadic Mesothelioma  
Jane E Churpek, University of Chicago, United States of America

11:20–12:00  ES03.06–Q&A

10:30–12:00  MULTIMODALITY MANAGEMENT OF SMALL CELL AND NEUROENDOCRINE CANCERS  
★ Toronto (1985)

Track(s):  Small Cell Lung Cancer/NET  
Chair(s):  Enric Carcereny, Spain; Ben Slotman, Netherlands

10:30–10:40  ES04.01–Update in Systemic Treatment of SCLC  
Sumitra Thongprasert, Bangkok Chiangmai Hospital, Thailand

10:40–10:50  ES04.02–Pathology Overview for Carcinoid and NE Spectrum  
Elisabeth Brambilla, Centre Hospitalier Universitaire de Grenoble, France

10:50–11:00  ES04.03–Surgery for Early and Locally Advanced Small Cell Lung Cancer  
Eric Lim, Royal Brompton Hospital, United Kingdom

11:00–11:10  ES04.04–Role of Stereotactic Body Radiation in Early and Advanced SCLC  
Roy Decker, Yale School of Medicine, United States of America

11:10–11:20  ES04.05–Advances in Radionuclide Treatment for Neuroendocrine Tumours  
Angela Lamarca, The Christie NHS Foundation Trust, United Kingdom

11:20–11:30  ES04.06–Systemic Treatment of Large Cell Neuroendocrine Cancer  
Fiona Blackhall, The Christie NHS Foundation Trust, United Kingdom

11:30–12:00  ES04.07–Q&A

10:30–12:00  JOINT SESSION GLCC/IASLC: HOT TOPICS FOR LUNG CANCER ADVOCATES  
★ Amsterdam (2011)

Track(s):  Advocacy  
Chair(s):  Anne-Marie Baird, Ireland; Matthew Peters, Australia

10:30–10:45  ES05.01–Lung Cancer Survival: Progress and Challenges  
Marianne Nicolson, Aberdeen University, United Kingdom

10:45–11:00  ES05.02–From Living Longer to Also Living Better—the Role of Communication and Interprofessional Collaboration in Metastatic Lung Cancer  
Matthias Villalobos, University Hospital Heidelberg, Germany

11:00–11:15  ES05.03–From Living Longer to Also Living Better; Managing Lung Cancer as a Chronic Disease—the Principle of Survivorship  
Maureen Rigney, Lung Cancer Alliance, United States of America

11:15–11:30  ES05.04–Social Media and Lung Cancer—a Global Picture  
Christina Sit, Lung Cancer Canada, Canada

11:30–11:45  ES05.05–Still Struggling for Traction—from Proving Lung Cancer Screening Works to Global Practical Implementation, Including Engagement of the Target Population  
James Mulshine, Rush University Medical Center, United States of America

11:45–12:00  ES05.06–Q&A
10:30–12:00 OLIGOMETASTATIC DISEASE

Chair(s): Anne Marie Dingemans, Netherlands; Matthias Guckenberger, Switzerland

Track(s): Oligometastatic NSCLC

10:30–10:35 MA01.01 – Safety of Pembrolizumab Combined with Stereotactic Ablative Body Radiotherapy (SABR) for Pulmonary Oligometastases
Shankar Siva, Peter MacCallum Cancer Centre, Australia

10:35–10:40 MA01.02 – Lung Stereotactic Body Radiotherapy and Concurrent Immuno-therapy: A Multi-Center Safety and Toxicity Analysis
Sibo Tian, Winship Cancer Institute, Emory University, United States of America

10:40–10:45 MA01.03 – Interim Safety Analysis of the Phase IB Trial of SBRT to All Sites of Oligometastatic NSCLC Combined with Durvalumab and Tremelimumab
Ticiana Leal, University of Wisconsin Carbone Cancer Center, United States of America

10:45–11:00 MA01.04 – Discussant – MA01.01, MA01.02, MA01.03
Fiona Mcdonald, The Royal Marsden, United Kingdom

11:00–11:05 MA01.05 – Progress of Accompanying GGN Beyond Pulmonary Resection for Non-Small Cell Lung Cancer
Kanghoon Lee, Catholic Kwandong University International St. Mary’s Hospital, Korea, Republic of

11:05–11:10 MA01.06 – Prognostic Factors of Oligometastatic Non-Small Cell Lung Cancer Following Radical Therapy: A Multicenter- Analysis
Isabelle Schmitt-Opitz, University of Zürich, Switzerland

11:10–11:15 MA01.07 – Prognostic Factors of Surgical Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients in Oligometastatic Stage-M1b of Disease
Dariusz Dziedzic, National Institute of Chest Diseases, Warsaw, Poland, Poland

11:15–11:30 MA01.08 – Discussant – MA01.05, MA01.06, MA01.07
Corey Langer, Perelman School of Medicine, United States of America

11:30–11:35 MA01.09 – Concomitant SBRT and EGFR-TKI Versus EGFR-TKI Alone for Oligometastatic NSCLC: A Multicenter, Randomized Phase II Study
Li Zhang, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China

11:35–11:40 MA01.10 – Additional Local Consolidative Therapy Showed Survival Benefit Than EGFR-TKIs Alone in Bone Oligometastatic Lung Adenocarcinoma Patients
Fang Hu, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

11:40–11:45 MA01.11 – Improving Survival in Lung Cancer Patients with Oligometastatic Disease Progression Using Stereotactic Body Radiation Therapy
Luis Raez, Memorial Cancer Institute/Florida International University, United States of America

11:45–12:00 MA01.12 – Discussant – MA01.09, MA01.10, MA01.11
Tomoyuki Hishida, Keio University School of Medicine, Japan

10:30–12:00 MISCELLANEOUS TOPICS IN THE MANAGEMENT OF EARLY STAGE LUNG CANCER

Chair(s): Mireia Serra-Mitjans, Spain; Thomas D’Amico, United States of America

Track(s): Treatment of Early Stage/Localized Disease

10:30–10:35 MA02.01 – Recurrence Pattern After Adjuvant Customized Chemotherapy Based on BRCA Expression Level (SCAT Trial)
Bartomeu Massuti, Hospital General Universitario de Alicante, Spain

10:35–10:40 MA02.02 – Toxicity of Lung SABR in Patients with Coexisting Interstitial Lung Disease
Tobias Finazzi, Amsterdam University Medical Centers, Location VUmc, Netherlands

10:40–10:45 MA02.03 – Impact of Coexisting Interstitial Lung Disease on Resected Non-Small Cell Lung Cancer Patients
Jin Gu Lee, College of Medicine, Yonsei University, Korea, Republic of

10:45–11:00 MA02.04 – Discussant – MA02.01, MA02.02, MA02.03
Yaxing Shen, Zhongshan Hospital, China

11:00–11:05 MA02.05 – Patient Selection and Early Clinical Outcomes of MR-Guided SABR in 54 Lung Tumors
Tobias Finazzi, Amsterdam University Medical Centers, Location VUmc, Netherlands

11:05–11:10 MA02.06 – Dose-Volume Factors Predicting Airway Stenosis After SBRT for Ultra-Central Lung Tumors
Andrew Jackson, Memorial Sloan Kettering Cancer Center, United States of America

11:10–11:15 MA02.07 – A Phase I Trial of an Immune Checkpoint Inhibitor Plus Stereotactic Ablative Radiotherapy in Patients with Early Stage Non-Small Cell Lung Cancer
Megan Daly, University of California Davis Comprehensive Cancer Center, United States of America

11:15–11:30 MA02.08 – Discussant – MA02.05, MA02.06, MA02.07
Mireia Serra-Mitjans, Hospital Universitari MutuaTerrassa, Spain

11:30–11:35 MA02.09 – Prognostic Impact of Immune Cell Biomarkers in Surgically Resectable Non-Small Cell Lung Cancer
Stephanie Tuminello, Icahn School of Medicine at Mount Sinai, United States of America
### MS02

**10:30–12:00 WHAT MOLECULAR SCREENING FOR WHICH PATIENTS?**  
*Vienna (2016)*

**Track(s):** Targeted Therapy

**Chair(s):** Rosario Garcia Campelo, Spain; Santiago Ponce, Spain

<table>
<thead>
<tr>
<th>Time</th>
<th>OA02.01</th>
<th>Platform Selection in an Era of Increasing Numbers and Types of Relevant Biomarkers</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30–10:50</td>
<td>David Carbone, The Ohio State University, United States of America</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>OA02.02</th>
<th>Liquid Biopsy: Who, When, What and How</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:50–11:10</td>
<td>Christian Rolfo, University of Maryland Greenebaum Comprehensive Cancer Center, United States of America</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>OA02.03</th>
<th>Achieving Effective Lung Cancer Genotyping While Balancing Constrained Resources</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:10–11:30</td>
<td>Lynette Sholl, Brigham and Women’s Hospital, United States of America</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>OA02.04</th>
<th>The Role of Molecular Board</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30–11:50</td>
<td>Lara Pijuan, Hospital del Mar, Spain</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>OA02.05</th>
<th>Q&amp;A</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:50–12:00</td>
<td>Lara Pijuan, Hospital del Mar, Spain</td>
<td></td>
</tr>
</tbody>
</table>

### OA01

**10:30–12:00 ADVANCED DIAGNOSTIC APPROACHES FOR INTRATHORACIC LYMPH NODES AND PERIPHERAL LUNG TUMORS**  
*Melbourne (1991)*

**Track(s):** Interventional Diagnostics/Pulmonology

**Chair(s):** Marioara Simon, Romania; Tim Murgu, United States of America

<table>
<thead>
<tr>
<th>Time</th>
<th>OA01.01</th>
<th>Predictive Value of EBUS Strain Elastography in Mediastinal Lymph Node Staging; The E-Predict Multicenter Study Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30–10:40</td>
<td>Roel Verhoeven, Radboud University Medical Center, Netherlands</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>OA01.02</th>
<th>Endobronchial Ultrasound Staging of Operable NSCLC: Triple Negative Lymph Nodes May Not Require Routine Biopsy</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:40–10:50</td>
<td>Danielle Hytton, McMaster University, Canada</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>OA01.03</th>
<th>Probability Model for Malignancy in Hilar and Mediastinal Lymph Nodes in Lung Cancer Based on PET-CT and EBUS</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:50–11:00</td>
<td>Jaume Bordas-Martinez, Hospital Universitario Bellvitge, Spain</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>OA01.04</th>
<th>Discussant–OA01.01, OA01.02, OA01.03</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00–11:15</td>
<td>Rocco Trisolini, Policlinico S. Orsola, Italy</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>OA01.05</th>
<th>Cryobiopsy Compared with Forceps Biopsy in Pathological Diagnosis and Biomarker Research in Lung Cancer: A Prospective, Single-Arm Study</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:15–11:25</td>
<td>Tomoyuki Naito, National Cancer Center Hospital East, Japan</td>
<td></td>
</tr>
</tbody>
</table>

### OA02

**10:30–12:00 A NEW VISION OF TARGETS AND STRATEGIES**  
*Seoul (2007)*

**Track(s):** Targeted Therapy

**Chair(s):** Frank Griesinger, Germany; Luis Paz-Ares, Spain

<table>
<thead>
<tr>
<th>Time</th>
<th>OA02.01</th>
<th>Alectinib in Previously Treated RET-Rearranged Advanced Non-Small-Cell Lung Cancer: A Phase 1/2 Trial (ALL-RET)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30–10:40</td>
<td>Noriko Yanagitani, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Japan</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>OA02.02</th>
<th>Phase 1 Study of Safety, Tolerability, PK and Efficacy of AMG 510, a Novel KRASG12C Inhibitor, Evaluated in NSCLC</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:40–10:50</td>
<td>Ramaswamy Govindan, Section of Medical Oncology, Division of Oncology, Washington University School of Medicine, United States of America</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>OA02.03</th>
<th>The Third Generation EGFR Inhibitor (EGFR-TKI) HS-10296 in Advanced NSCLC Patients with Resistance to First Generation EGFR-TKI</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:50–11:00</td>
<td>Shun Lu, Shanghai Chest Hospital, China</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>OA02.04</th>
<th>Discussant–OA02.01, OA02.02, OA02.03</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00–11:15</td>
<td>Jon Zugazagoitia, Hospital Universitario 12 de Octubre, Spain</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>OA02.05</th>
<th>First-In-Human Phase 1/2 Trial of Anti-AXL Antibody–Drug Conjugate (ADC) Enapotamab Vedotin (EnaV) in Advanced NSCLC</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:15–11:25</td>
<td>Suresh Ramalingam, Winship Cancer Institute of Emory University, United States of America</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>OA02.06</th>
<th>Discussant–OA02.05, OA02.06, OA02.07</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:25–11:35</td>
<td>Juergen Wolf, Universitätsklinikum Köln, Germany</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>OA02.07</th>
<th>Phase 3 ALUR Study of Alectinib in Pretreated ALK+ NSCLC: Final Efficacy, Safety and Targeted Genomic Sequencing Analyses</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:35–11:45</td>
<td>WCLC2019.IASLC.ORG</td>
<td></td>
</tr>
</tbody>
</table>
### Sunday, September 8

#### 10:30–12:00
**SCIENTIFIC MENTORING**

*Dublin (1997)*

**Track(s):** Young Investigators

**Chair(s):** Lizza Hendriks, Netherlands; Carme Obiols, Spain

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30–10:50</td>
<td><strong>YI03.01</strong>–Why to Apply for International Fellowship? Celine Mascaux, Strasbourg University Hospital, France</td>
</tr>
<tr>
<td>10:50–11:10</td>
<td><strong>YI03.02</strong>–How to Apply for International Fellowship? Ming Tsao, University Health Network, Canada</td>
</tr>
<tr>
<td>11:10–11:30</td>
<td><strong>YI03.03</strong>–Scientific Mentorship: What Should You Expect? Rafael Rosell, Germans Trias i Pujol Sci Inst., Catalan Institute of Oncology (ICO Badalona), Spain</td>
</tr>
<tr>
<td>11:30–11:50</td>
<td><strong>YI03.04</strong>–Oncology Fellows’ Career Plans and Expectations Masaoki Ito, Hiroshima University, Japan</td>
</tr>
<tr>
<td>11:50–12:00</td>
<td><strong>YI03.05</strong>–Q&amp;A</td>
</tr>
</tbody>
</table>

#### 13:30–15:00
**NEW APPROACHES IN SECOND LINE TREATMENT IN NSCLC**

*Vienna (2016)*

**Track(s):** Advanced NSCLC

**Chair(s):** Susana Cedres, Spain; Oliver Gautschi, Switzerland

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30–13:50</td>
<td><strong>ES06.01</strong>–Recent Advances in Second Line Treatment Roy Herbst, Yale University School of Medicine, United States of America</td>
</tr>
<tr>
<td>13:50–14:10</td>
<td><strong>ES06.02</strong>–What is the Best Strategy in Progressive Disease After Consolidation with Durvalumab, or Rapid Progressors to First Line? Fabrice Barlesi, Aix Marseille University and Assistance Publique des Hôpitaux de Marseille, France</td>
</tr>
<tr>
<td>14:10–14:30</td>
<td><strong>ES06.03</strong>–Future Strategies in Second Line Treatment Gregory Riely, Memorial Sloan Kettering Cancer Center, United States of America</td>
</tr>
</tbody>
</table>

#### 14:30–15:40
**ES06.04**–The Best Treatment Sequence for Advanced NSCLC EGFR/ALK/ROS/BRAF wt Juergen Wolf, Universitätssklinikum Köln, Germany

#### 14:50–15:00
**ES06.05**–Q&A

#### 13:30–15:00
**THORACIC ULTRASONOGRAPHY: DIAGNOSIS AND STAGING**

*San Francisco (2009)*

**Track(s):** Interventional Diagnostics/Pulmonology

**Chair(s):** Felipe Andreo, Spain; Bin Hwangbo, Korea, Republic of

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30–13:50</td>
<td><strong>ES07.01</strong>–Transthoracic Ultrasonography Najib Rahman, University of Oxford, United Kingdom</td>
</tr>
<tr>
<td>13:50–14:10</td>
<td><strong>ES07.02</strong>–Linear Endosonography (EBUS &amp; EUS) Jouke Annema, Amsterdam UMC, Netherlands</td>
</tr>
<tr>
<td>14:10–14:30</td>
<td><strong>ES07.03</strong>–Radial Endosonography Laurence Crombag, Amsterdam UMC, Netherlands</td>
</tr>
<tr>
<td>14:30–14:50</td>
<td><strong>ES07.04</strong>–Predictive Molecular Testing on Small Biopsy Samples Christophe Dooms, University Hospitals KU Leuven, Belgium</td>
</tr>
</tbody>
</table>

#### 14:50–15:00
**ES07.05**–Q&A

#### 13:30–15:00
**CRITICAL CONCERNS IN SCREENING**

*Copenhagen (1980)*

**Track(s):** Screening and Early Detection

**Chair(s):** Ugo Pastorino, Italy; John Field, United Kingdom

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30–13:40</td>
<td><strong>ES08.01</strong>–Participation of the Target Population in Lung Cancer Screening Robin Cornelissen, Erasmus MC, Netherlands</td>
</tr>
<tr>
<td>13:40–13:50</td>
<td><strong>ES08.02</strong>–Nodule Growth Assessment Matthijs Oudkerk, University of Groningen, Netherlands</td>
</tr>
<tr>
<td>13:50–14:00</td>
<td><strong>ES08.03</strong>–The Magnitude of the Benefit David Yankelevitz, Icahn School of Medicine, United States of America</td>
</tr>
<tr>
<td>14:00–14:10</td>
<td><strong>ES08.04</strong>–Management Algorithms Claudia Henschke, Icahn School of Medicine at Mount Sinai, United States of America</td>
</tr>
<tr>
<td>14:10–14:20</td>
<td><strong>ES08.05</strong>–Advances in Artificial Intelligence–How Lung Cancer CT Screening Will Progress? Debora Gil, Computer Vision Center, Spain</td>
</tr>
</tbody>
</table>

**CME Accredited Session**
### CME Accredited Session

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00–14:15</td>
<td><strong>ES10.03</strong> – China National Medical Products Administration (Formerly CFDA)</td>
</tr>
<tr>
<td></td>
<td>Tony Mok, Chinese University of Hong Kong, China</td>
</tr>
<tr>
<td>14:15–14:30</td>
<td><strong>ES10.04</strong> – European Medicines Agency</td>
</tr>
<tr>
<td></td>
<td>Jorge Camarero, Spanish Medicines Agency, Spain</td>
</tr>
<tr>
<td>14:30–14:45</td>
<td><strong>ES10.05</strong> – Brazilian Health Regulatory Agency – Agência Nacional de Vigilância Sanitária</td>
</tr>
<tr>
<td></td>
<td>Carlos Gil Ferreira, Oncoclinicas, Brazil</td>
</tr>
</tbody>
</table>

### SUNDAY SEPTEMBER 8

#### DAILY SCIENTIFIC PROGRAM

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00–14:15</td>
<td><strong>ES08.06</strong> – Cost Effectiveness of Comprehensive Screening and Smoking Cessation Programmes</td>
</tr>
<tr>
<td></td>
<td>Bruce Pyenson, Milliman, Inc., United States of America</td>
</tr>
<tr>
<td>14:15–14:30</td>
<td><strong>ES09.01</strong> – How I Optimize Tissue Specimen Processing for Histopathological and Molecular Profiling</td>
</tr>
<tr>
<td></td>
<td>Amanjit Bal, PGIMER, India</td>
</tr>
<tr>
<td>14:30–14:45</td>
<td><strong>ES09.02</strong> – How I Report Imaging for Assessment of Responses to Targeted Therapies vs. Immune Checkpoint Inhibitors vs. Chemotherapy</td>
</tr>
<tr>
<td></td>
<td>Ritu Gill, Beth Israel Deaconess Medical Center, United States of America</td>
</tr>
<tr>
<td>14:45–15:00</td>
<td><strong>ES09.03</strong> – How I Decide 1st Line Treatment Options for Metastatic NSCLC Without Driver Mutations – Balancing Efficacy, Toxicity and Cost</td>
</tr>
<tr>
<td></td>
<td>Martin Frueh, Kantonsspital St. Gallen, Switzerland</td>
</tr>
<tr>
<td></td>
<td><strong>ES09.04</strong> – How I Decide 2nd Line Treatment Options for Relapsed/Refractory Metastatic NSCLC</td>
</tr>
<tr>
<td></td>
<td>Navneet Singh, Postgraduate Institute of Medical Education &amp; Research (PGIMER), India</td>
</tr>
<tr>
<td>13:30–13:45</td>
<td><strong>ES09.01</strong> – How I Optimize Tissue Specimen Processing for Histopathological and Molecular Profiling</td>
</tr>
<tr>
<td></td>
<td>Amanjit Bal, PGIMER, India</td>
</tr>
<tr>
<td>13:45–14:00</td>
<td><strong>ES09.02</strong> – How I Report Imaging for Assessment of Responses to Targeted Therapies vs. Immune Checkpoint Inhibitors vs. Chemotherapy</td>
</tr>
<tr>
<td></td>
<td>Ritu Gill, Beth Israel Deaconess Medical Center, United States of America</td>
</tr>
<tr>
<td>14:00–14:15</td>
<td><strong>ES09.03</strong> – How I Decide 1st Line Treatment Options for Metastatic NSCLC Without Driver Mutations – Balancing Efficacy, Toxicity and Cost</td>
</tr>
<tr>
<td></td>
<td>Martin Frueh, Kantonsspital St. Gallen, Switzerland</td>
</tr>
<tr>
<td></td>
<td>Kelsie Thu, Princess Margaret Cancer Centre, United States of America</td>
</tr>
<tr>
<td>13:45–14:00</td>
<td><strong>MA04.02</strong> – Molecular Profiling of Adenocarcinoma and Squamous Cell Lung Cancer at Single Cell Resolution</td>
</tr>
<tr>
<td></td>
<td>Fengyue Wu, Tongji University, China</td>
</tr>
</tbody>
</table>

### MA04

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30–14:45</td>
<td><strong>MA04.01</strong> – Development of an in Vivo Platform to Identify Novel Mechanisms Governing Lung Cancer Response to Immunotherapy</td>
</tr>
<tr>
<td></td>
<td>Kelsie Thu, Princess Margaret Cancer Centre, United States of America</td>
</tr>
<tr>
<td>13:45–15:00</td>
<td><strong>MA04.02</strong> – Molecular Profiling of Adenocarcinoma and Squamous Cell Lung Cancer at Single Cell Resolution</td>
</tr>
<tr>
<td></td>
<td>Fengyue Wu, Tongji University, China</td>
</tr>
</tbody>
</table>

### GR01

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30–13:45</td>
<td><strong>GR01.01</strong> – Definition and Minimal Staging in Oligometastatic Disease</td>
</tr>
<tr>
<td></td>
<td>Anne Marie Dingemans, Maastricht UMC+, Netherlands</td>
</tr>
<tr>
<td>13:45–14:00</td>
<td><strong>GR01.02</strong> – Local Stage of the Primary Disease?</td>
</tr>
<tr>
<td></td>
<td>Valerie Rusch, Memorial Sloan Kettering Cancer Center, United States of America</td>
</tr>
<tr>
<td>14:00–14:15</td>
<td><strong>GR01.03</strong> – Nodal Status of the Primary Disease?</td>
</tr>
<tr>
<td></td>
<td>David Ball, Peter MacCallum Cancer Centre, Australia</td>
</tr>
<tr>
<td>14:15–14:30</td>
<td><strong>GR01.04</strong> – The Rationale for Local Consolidative Therapy in Oncogene-driven, Oligo- and Poly-metastatic NSCLC</td>
</tr>
<tr>
<td></td>
<td>John Heymach, The University of Texas MD Anderson Cancer Center, United States of America</td>
</tr>
</tbody>
</table>

### MA04

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30–14:45</td>
<td><strong>MA04.01</strong> – Development of an in Vivo Platform to Identify Novel Mechanisms Governing Lung Cancer Response to Immunotherapy</td>
</tr>
<tr>
<td></td>
<td>Kelsie Thu, Princess Margaret Cancer Centre, United States of America</td>
</tr>
<tr>
<td>13:45–15:00</td>
<td><strong>MA04.02</strong> – Molecular Profiling of Adenocarcinoma and Squamous Cell Lung Cancer at Single Cell Resolution</td>
</tr>
<tr>
<td></td>
<td>Fengyue Wu, Tongji University, China</td>
</tr>
</tbody>
</table>

### ESI0

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30–13:45</td>
<td><strong>ES08.06</strong> – Cost Effectiveness of Comprehensive Screening and Smoking Cessation Programmes</td>
</tr>
<tr>
<td></td>
<td>Bruce Pyenson, Milliman, Inc., United States of America</td>
</tr>
<tr>
<td>13:45–14:00</td>
<td><strong>ES09.02</strong> – How I Report Imaging for Assessment of Responses to Targeted Therapies vs. Immune Checkpoint Inhibitors vs. Chemotherapy</td>
</tr>
<tr>
<td></td>
<td>Ritu Gill, Beth Israel Deaconess Medical Center, United States of America</td>
</tr>
<tr>
<td>14:00–14:15</td>
<td><strong>ES09.03</strong> – How I Decide 1st Line Treatment Options for Metastatic NSCLC Without Driver Mutations – Balancing Efficacy, Toxicity and Cost</td>
</tr>
<tr>
<td></td>
<td>Martin Frueh, Kantonsspital St. Gallen, Switzerland</td>
</tr>
<tr>
<td>14:15–14:30</td>
<td><strong>ES09.04</strong> – How I Decide 2nd Line Treatment Options for Relapsed/Refractory Metastatic NSCLC</td>
</tr>
<tr>
<td></td>
<td>Navneet Singh, Postgraduate Institute of Medical Education &amp; Research (PGIMER), India</td>
</tr>
<tr>
<td>14:30–14:45</td>
<td><strong>ES09.05</strong> – Limitations in the Availability of Radiotherapy</td>
</tr>
<tr>
<td></td>
<td>Jamal Khader, King Hussein Cancer Center, Jordan</td>
</tr>
<tr>
<td>14:45–15:00</td>
<td><strong>ES09.06</strong> – Q&amp;A</td>
</tr>
</tbody>
</table>

### ESI0

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30–13:45</td>
<td><strong>ES08.06</strong> – Cost Effectiveness of Comprehensive Screening and Smoking Cessation Programmes</td>
</tr>
<tr>
<td></td>
<td>Bruce Pyenson, Milliman, Inc., United States of America</td>
</tr>
<tr>
<td>13:45–14:00</td>
<td><strong>ES09.02</strong> – How I Report Imaging for Assessment of Responses to Targeted Therapies vs. Immune Checkpoint Inhibitors vs. Chemotherapy</td>
</tr>
<tr>
<td></td>
<td>Ritu Gill, Beth Israel Deaconess Medical Center, United States of America</td>
</tr>
<tr>
<td>14:00–14:15</td>
<td><strong>ES09.03</strong> – How I Decide 1st Line Treatment Options for Metastatic NSCLC Without Driver Mutations – Balancing Efficacy, Toxicity and Cost</td>
</tr>
<tr>
<td></td>
<td>Martin Frueh, Kantonsspital St. Gallen, Switzerland</td>
</tr>
<tr>
<td>14:15–14:30</td>
<td><strong>ES09.04</strong> – How I Decide 2nd Line Treatment Options for Relapsed/Refractory Metastatic NSCLC</td>
</tr>
<tr>
<td></td>
<td>Navneet Singh, Postgraduate Institute of Medical Education &amp; Research (PGIMER), India</td>
</tr>
<tr>
<td>14:30–14:45</td>
<td><strong>ES09.05</strong> – Limitations in the Availability of Radiotherapy</td>
</tr>
<tr>
<td></td>
<td>Jamal Khader, King Hussein Cancer Center, Jordan</td>
</tr>
<tr>
<td>14:45–15:00</td>
<td><strong>ES09.06</strong> – Q&amp;A</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
</tr>
<tr>
<td>-----------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| 13:40–13:45 | **MA04.03** – Lung Tumorspheres Characterization Reveals Cancer Stem-Like Cells Potential Targets and Prognostic Markers in Non-Small Cell Lung Cancer  
Alejandro Herreros-Pomares, Fundación Hospital General Universitario de Valencia, Spain |
| 13:45–14:00 | **MA04.04** – Discussant – MA04.01, MA04.02, MA04.03  
David Santamaria, Institut European de Chimie & Biologie (IECB), France |
| 14:00–14:05 | **MA04.05** – Deciphering the Molecular Mechanisms Underlying the Progression of Bronchial Premalignant Lesions  
Evgeny Denisov, Cancer Research Institute, Tomsk National Research Medical Center, Russian Federation |
| 14:05–14:10 | **MA04.06** – Lung Epithelium Whole Transcriptome Signatures That Reflect Incident Lung Cancer Case-Control Status  
Simon Spivack, Albert Einstein College of Medicine, United States of America |
| 14:10–14:15 | **MA04.07** – Inhibition of CXCR2+ Neutrophil Migration as a Targeted Therapy in KRAS-Driven Lung Adenocarcinoma  
Meghan De Meo, McGill University Health Center, Canada |
| 14:15–14:30 | **MA04.08** – Discussant – MA04.05, MA04.06, MA04.07  
Triantafillos (Lakis) Liloglou, University of Liverpool, United Kingdom |
| 14:30–14:35 | **MA04.09** – Study of Exosomes in NSCLC for Biomarkers Searching  
Elena Durendez-Saez, CIBERONC, Spain |
| 14:35–14:40 | **MA04.10** – Development and Validation of a Gene Expression-Based Prognostic Signature in Early-Stage Squamous Cell Carcinoma of the Lung  
Pinaki Bose, University of Calgary, Canada |
| 14:40–14:45 | **MA04.11** – Biological and Prognostic Implications of the Long Non-Coding Transcriptome in Tumour-Infiltrating Immune Cells  
Kevin Ng, BC Cancer Research Centre, Canada |
| 14:45–15:00 | **MA04.12** – Discussant – MA04.09, MA04.10, MA04.11  
Alfonso Calvo, IDISNA and Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra, Spain |
| 13:30–15:00 | **MA05** – UPDATE ON CLINICAL TRIALS AND TREATMENTS  
Melbourne (1991) |
| 13:30–13:35 | **MA05.01** – Second or Third Line Anti-PD-1 Therapy After Multimodality Therapy Including Total Pleurectomy in Malignant Pleural Mesothelioma  
Loic Lang-Lazdunski, Bupa Cromwell Hospital, United Kingdom |
| 13:35–13:40 | **MA05.02** – Log Odds of Positive Lymph Nodes Predicts Overall Survival and the Benefit of Postoperative Radiotherapy in Malignant Pleural Mesothelioma  
Yang Wo, Affiliated Hospital of Qingdao University, China |
| 13:40–13:45 | **MA05.03** – Impact of Time to Surgery on Outcomes in Patients Undergoing Outright Resection for Malignant Pleural Mesothelioma  
Soraya Voigt, Duke University, United States of America |
| 13:45–14:00 | **MA05.04** – Discussant – MA05.01, MA05.02, MA05.03  
Clarissa Baldotto, Oncologia D’Or, Brazil |
| 14:00–14:05 | **MA05.05** – Post-Discontinuation Treatments in IFCT-GFPC-0701 MAPS Trial: Real-World Effectiveness of 2nd-Line (2L) Treatments for Mesothelioma  
Gerard Zalcman, AP-HP Hôpital Bichat, France |
| 14:05–14:10 | **MA05.06** – Feasibility and Safety of Transarterial Chemoperfusion for Advanced Pleural Mesothelioma: Interim Results of a Phase 2 Study  
Ben Creegan, Moffitt Cancer Center, United States of America |
| 14:10–14:15 | **MA05.07** – Efficacy and Safety of Re-Treatment with Tremelimumab and Durvalumab Within the NIBUT-MESO-1 Study  
Luana Calabro’, Center for Immuno-Oncology, University Hospital of Siena, Italy |
| 14:15–14:30 | **MA05.08** – Discussant – MA05.05, MA05.06, MA05.07  
James Spicer, King’s College London, Guy’s Hospital, United Kingdom |
| 14:30–14:35 | **MA05.09** – Real-World Data of Nivolumab and Pembrolizumab in Chemotherapy Pre-Treated Mesothelioma Patients  
Daphne Dumoulin, Erasmus MC, Netherlands |
| 14:35–14:40 | **MA05.10** – Pembrolizumab in the Treatment of Patients with Malignant Pleural Mesothelioma Following Progression After Initial Chemotherapy  
Keith Cengel, University of Pennsylvania, United States of America |
14:40–14:45 MA05.11-Safety and Efficacy of Nintedanib in Combination with Pembrolizumab in Patients with Refractory/Relapsing Malignant Pleural Mesothelioma
Andreea Varga, Gustave Roussy Cancer Campus, France

14:45–15:00 MA05.12-Discussant–MA05.09, MA05.10, MA05.11
Anna Nowak, University of Western Australia, Australia

13:30–15:00 CHALLENGES IN THE TREATMENT OF EARLY STAGE NSCLC
Track(s): Treatment of Early Stage/Localized Disease
Chair(s): Florentino Hernando-Trancho, Spain; Ayten Kayi Cangir, Turkey

13:30–13:35 MA06.01-Mediastinal Lymph Node Dissection (MLND) v Systematic Sampling (SS) v Neither (NN) in Population-Based Cohort
Meredith Ray, University of Memphis, United States of America

13:35–13:40 MA06.02-NSCLC Surgery Outcomes Between Facility Types and Association with Guideline Directed Surgical Quality of Care Metrics
David Gerber, UT Southwestern Medical Center, United States of America

13:40–13:45 MA06.03-Poor Pulmonary Function Does Not Define “Medical Inoperability”: Short and Long Term Results of a Matched Lung Cancer Cohort
Brendon Stiles, New York Presbyterian Hospital-Weill Cornell Medical College, United States of America

13:45–13:55 MA06.04-Discussant–MA06.01, MA06.02, MA06.03
Daniel Boffa, Yale School of Medicine, United States of America

13:55–14:00 MA06.05-Predictive Performance of Quantitative Metabolic Metrics of FDG-PET/CT on Survival and the Effect of Adjuvant Chemotherapy in Lung Cancer
Yojiro Makino, Tokyo Medical University, Japan

14:00–14:05 MA06.06-A Phase III Study of Adjuvant Chemotherapy in Patients with Completely Resected, Node-Negative Non-Small Cell Lung Cancer
Hideo Kunitoh, Japanese Red Cross Medical Center, Japan

14:05–14:10 MA06.07–E1505: Adjuvant Chemotherapy +/-Bevacizumab for Early Stage NSCLC: Updated Chemotherapy Subset Analysis
Heather Wakelee, Stanford University, United States of America

14:10–14:20 MA06.08–Discussant–MA06.05, MA06.06, MA06.07
Jordi Remon, Hospital HM Delfos, Spain

14:20–14:25 MA06.09-Timing of Driver Mutation Development and the Genetic Evolution of Semi-Solid Lung Nodules into Early NSCLC
Gavitt Woodard, University of California San Francisco, United States of America

14:25–14:30 MA06.10-Stereotactic Ablative Radiotherapy in the Management of Synchronous Early Stage Non-Small Cell Lung Cancers
Zeina Ayoub, American University of Beirut Medical Center, Lebanon

14:30–14:35 MA06.11-CT-Guided Percutaneous Radiotracer Localization and Resection of Indistinct/Small Pulmonary Lesions
Domenico Galetta, European Institute of Oncology, Italy

14:35–14:50 MA06.12-Discussant–MA06.09, MA06.10, MA06.11
Samina Park, Seoul National University Hospital, Korea, Republic of

14:50–15:00 MA06.13-Tsuguo Naruke Lectureship Award for Surgery
Raja Flores, Icahn School of Medicine at Mount Sinai, United States of America
14:25–14:30 MA07.08–The Role of a Cachexia Grading System in Patients with NSCLC Treated with Immunotherapy: Implications for Response and Survival
Jenny Turcott, Instituto Nacional de Cancerología, Mexico

14:30–14:35 MA07.09–Impact of Body Mass Index on Clinical Outcomes of Immune Checkpoint Blockers in Advanced Non-Small Cell Lung Cancer
Amit Kulkarni, University of Minnesota MN 55455, United States of America

14:35–14:40 MA07.10–The Influence of Sex on Immunotherapy Efficacy in Non-Small Cell Lung Cancer
Stephanie Tuminello, Icahn School of Medicine at Mount Sinai, United States of America

14:40–14:45 MA07.11–Survival Outcomes Based on Gender of Advanced Nonsmall Cell Lung Cancer Patients Treated with Pembrolizumab or Nivolumab in Everyday Clinical Practice
Doran Ksienki, BC Cancer-Victoria, Canada

14:45–15:00 MA07.12–Discussant–MA07.08, MA07.09, MA07.10, MA07.11
Sonja Loges, Universitätsklinikum Hamburg-Eppendorf, Germany

MS03

13:30–15:00 WORKUP AND MANAGEMENT OF SMALL ANTERIOR MEDIASTINAL MASSES/LESIONS
Amsterdam (2011)

Track(s): Thymoma/Other Thoracic Malignancies

Chair(s): Meinoshin Okumura, Japan; Pier Luigi Filosso, Italy
13:30–13:45 MS03.01–Differentiation of Small Anterior Mediastinal Lesions Using Imaging
Edith Marom, The Chaim Sheba Medical Center, Israel
13:45–14:00 MS03.02–Resection, Biopsy or Observation of Small Anterior Mediastinal Lesions
Frank Detterbeck, Yale University, United States of America
14:00–14:15 MS03.03–Minimally Invasive Surgical Strategies and Considerations for Small Anterior Mediastinal Lesions
Benny Weksler, Allegheny Health Network, United States of America
14:15–14:30 MS03.04–Followup/Surveillance of Small Anterior Mediastinal Lesions
Wentao Fang, Shanghai Chest Hospital, China

14:30–14:45 MS03.05–Relevance of Nodal Involvement and the Thymic Lymph Node Map
Jhingook Kim, Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, Korea, Republic of

14:45–15:00 MS03.06–Q&A

13:30–15:00 SYSTEMIC THERAPIES FOR SCLC: NOVEL TARGETS AND PATIENTS’ SELECTION

Track(s): Small Cell Lung Cancer/NET

Chair(s): Christine Hann, United States of America; Makoto Nishio, Japan
13:30–13:40 OA03.01–A Non-Randomized, Open-Label, Prospective, Multicenter Study of Apatinib as Second-Line and Later-Line Therapy in Patients with ES-SCLC
Quan Liu, Affiliated Hospital of Jhangnan University (Wuxi Fourth People’s Hospital), China
13:40–13:50 OA03.02–Effect of Anlotinib in Advanced Small Cell Lung Cancer Patients Previously Received Chemoradiotherapy: A Subgroup Analysis in ALTER 1202 Trial
Qiming Wang, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, China
13:50–14:00 OA03.03–Initial Efficacy and Safety Results of Irinotecan Liposome Injection (nal-IRI) in Patients with Small Cell Lung Cancer
Luis Paz-Ares Rodriguez, Hospital Universitario, Spain
14:00–14:15 OA03.04–Discussant–OA03.01, OA03.02, OA03.03
Flavia Amaral Duarte, Oncocentro, Brazil
14:15–14:25 OA03.05–Characterization of Genomic Alterations in Chinese LCNEC and SCLC via Comprehensive Genomic Profiling
Lin Wu, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/ Hunan Cancer Hospital, China
14:25–14:35 OA03.06–ASCL1, NEUROD1, and POU2F3 Drive Distinct Subtypes of Small Cell Lung Cancer with Unique Therapeutic Vulnerabilities
Carl Gay, University of Texas MD Anderson Cancer Center, United States of America
14:35–14:45 OA03.07–Immune-Related Adverse Events and Clinical Outcome to Anti PD-1 Axis Inhibition in SCLC: A Multicenter Retrospective Analysis
Biagio Ricciuti, Dana-Farber Cancer Institute, United States of America
14:45–15:00 OA03.08–Discussant–OA03.05, OA03.06, OA03.07
Herbert Loong, Prince of Wales Hospital, Hong Kong Prc
### YI04

**13:30–15:00**  
**Basics of Immunology**  
*Dublin (1997)*

**Track(s):** Young Investigators

**Chair(s):** Noemi Reguart, Spain; Julie Brahmer, United States of America

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Institution/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30–13:50</td>
<td>YI04.01–PD-L1: Basics of Biology</td>
<td>Ignacio Gil-Bazo, Universidad de Navarra, Spain</td>
<td></td>
</tr>
<tr>
<td>13:50–14:10</td>
<td>YI04.02–Immuno-Oncology Trials: Other Endpoints Needed?</td>
<td>Martin Reck, Lung Clinic Grosshansdorf, Germany</td>
<td></td>
</tr>
<tr>
<td>14:10–14:30</td>
<td>YI04.03–The Place of Immunotherapy in NSCLC Therapeutic Algorithm</td>
<td>Rolf Stahel, University Hospital Zurich, Switzerland</td>
<td></td>
</tr>
<tr>
<td>14:30–14:50</td>
<td>YI04.04–How to Select Patients for Immunotherapy</td>
<td>Naifyer Rizvi, Columbia University Medical Center, United States of America</td>
<td></td>
</tr>
<tr>
<td>14:50–15:00</td>
<td>YI04.05–Q&amp;A</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### ES12

**15:15–16:45**  
**Lung Cancer Pathology in the Age of Genomics**  
*Toronto (1985)*

**Track(s):** Pathology

**Chair(s):** Masayuki Noguchi, Japan; Beatriz Bellosillo, Spain

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Institution/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:15–15:30</td>
<td>ES12.01–Multiple Lung Nodules</td>
<td>Sanja Dacic, UPMC, United States of America</td>
<td></td>
</tr>
<tr>
<td>15:30–15:45</td>
<td>ES12.02–Invasive Mucinous Adenocarcinoma</td>
<td>Yasushi Yatabe, National Cancer Center Hospital, Japan</td>
<td></td>
</tr>
<tr>
<td>15:45–16:00</td>
<td>ES12.03–Tumor Heterogeneity</td>
<td>Wendy Cooper, Royal Prince Alfred Hospital, Australia</td>
<td></td>
</tr>
<tr>
<td>16:00–16:15</td>
<td>ES12.04–Machine Learning and Integrative Multi-Omics Analysis Identify Novel Molecular Groups of Lung Neuroendocrine Tumors</td>
<td>Lynnette Fernandez-Cuesta, IARC, France</td>
<td></td>
</tr>
<tr>
<td>16:15–16:30</td>
<td>ES12.05–Impact of STAS in Lung Cancer Staging</td>
<td>William Travis, Memorial Sloan Kettering Cancer Center, United States of America</td>
<td></td>
</tr>
<tr>
<td>16:30–16:45</td>
<td>ES12.06–Q&amp;A</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### ES11

**15:15–16:45**  
**Lung Cancer Plasticity and Drug Resistance**  
*Colorado Springs (1994)*

**Track(s):** Biology

**Chair(s):** Luca Roz, Italy; Nagahiro Saijo, Japan

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Institution/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:15–15:25</td>
<td>ES11.01–Lung Adenocarcinoma to Squamous Cell Carcinoma Transdifferentiation and Drug Resistance</td>
<td>Hongbin Ji, Institute of Biochemistry and Cell Biology Shanghai Institutes for Biological Sciences Chinese Academy of Sciences, China</td>
<td></td>
</tr>
<tr>
<td>15:35–15:45</td>
<td>ES11.03–Immunotherapy and Endogenous Retroviruses in Small-Cell Lung Cancer</td>
<td>Israel Canadas, Dana Farber Cancer Institute, United States of America</td>
<td></td>
</tr>
<tr>
<td>15:45–15:55</td>
<td>ES11.04–Mechanisms for Resistance to TKI and ICI</td>
<td>Katerina Polit, Yale School of Medicine, United States of America</td>
<td></td>
</tr>
<tr>
<td>15:55–16:05</td>
<td>ES11.05–MSK-IMPACT, a Hospital Based Genetic Screening Using FDA-Approved NGS System</td>
<td>Alexander Drilon, Memorial Sloan Kettering Cancer Center, United States of America</td>
<td></td>
</tr>
<tr>
<td>16:05–16:15</td>
<td>ES11.06–Toxicology of Tobacco and Metabolites, and Impact on Cancer</td>
<td>Maciej Goniewicz, Roswell Park Comprehensive Cancer Center, United States of America</td>
<td></td>
</tr>
<tr>
<td>16:15–16:45</td>
<td>ES11.07–Q&amp;A</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### ES13

**15:15–16:45**  
**Global Political, Legal, and Financial Strategies for Tobacco Control**  
*Vienna (2016)*

**Track(s):** Prevention and Tobacco Control

**Chair(s):** Desmond Carney, Ireland; Esteve Fernandez, Spain

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Institution/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:15–15:30</td>
<td>ES13.01–Tobacco Cessation and Cancer Patients</td>
<td>Esteve Fernandez, ICO, Spain</td>
<td></td>
</tr>
<tr>
<td>15:30–15:45</td>
<td>ES13.02–Pursuing Criminal Charges Against Big Tobacco</td>
<td>Wanda De Kanter, Netherlands Cancer Institute, Netherlands</td>
<td></td>
</tr>
<tr>
<td>15:45–16:00</td>
<td>ES13.03–Foundation for a Smoke Free Future: Funding Opportunities or Smoke Screen for the Tobacco Industry?</td>
<td>Emily Stone, St Vincent’s Hospital Sydney, Australia</td>
<td></td>
</tr>
<tr>
<td>16:00–16:15</td>
<td>ES13.04–Comparing ENDS to NRT for Smoking Cessation</td>
<td>Hayden Mcrobbie, University of New South Wales, Australia</td>
<td></td>
</tr>
<tr>
<td>16:15–16:30</td>
<td>ES13.05–Stigma and Impact of Tobacco Control Policy</td>
<td>Andrea Borondy Kitts, Lahey Hospital &amp; Medical Center, United States of America</td>
<td></td>
</tr>
<tr>
<td>16:30–16:45</td>
<td>ES13.06–Q&amp;A</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### MA08

**15:15–16:45**  
**PAWING THE WAY TO IMPROVE OUTCOMES IN STAGE III NSCLC**  
📍 Tokyo (1982)

<table>
<thead>
<tr>
<th>Track(s):</th>
<th>Treatment of Locoregional Disease-NSCLC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair(s):</td>
<td>Simon Ekman, Sweden; Helena Yu, United States of America</td>
</tr>
</tbody>
</table>

#### MA08.01
- **15:15–15:20**  
  - Analysis of PD-L1 Expression on Circulating Stromal and Tumor Cells in Lung Cancer Patients Treated with Chemoradiation Therapy and Atezolizumab  
  - Steven Lin, MD Anderson, United States of America

#### MA08.02
- **15:20–15:25**  
  - Durvalumab Impact in the Treatment Strategy of Stage III Non-Small Cell Lung Cancer (NSCLC): An EORTC Young Investigator Lung Cancer Group Survey  
  - Matteo Giaj Levra, CHU Grenoble, France

#### MA08.03
- **15:25–15:30**  
  - Adjuvant Pembrolizumab in N2 Positive NSCLC Treated with Concurrent Chemoradiation Followed by Surgery: Phase II, Prospective Study  
  - Sehhoon Park, Samsung Medical Center, Korea, Republic of

#### MA08.04
- **15:30–15:45**  
  - Discussant – MA08.01, MA08.02, MA08.03  
  - Delvys Rodriguez-Abreu, Hospital Insular de Gran Canaria, Spain

#### MA08.05
- **15:45–15:50**  
  - A Multi-Center Analysis of Right vs Left-Sided Pneumonectomy Following Induction Therapy  
  - Chi-Fu Jeffrey Yang, Duke University, United States of America

#### MA08.06
- **15:50–15:55**  
  - The Concordance Between Patient Reported Outcomes and Clinician Reported Outcomes During Radiotherapy in Lung Cancer Patients  
  - Evalien Veldhuijzen, Netherlands Cancer Institute, Netherlands

#### MA08.07
- **15:55–16:00**  
  - Discussant – MA08.01, MA08.02, MA08.03  
  - Norihiko Ikeda, Tokyo Medical University, Japan

#### MA08.08
- **16:00–16:15**  
  - Patients Harbouring a Driven-Mutation: Pro and Patient’s Perspective  
  - Karen Reckamp, City of Hope Comprehensive Cancer Center, United States of America

#### MA08.09
- **16:15–16:30**  
  - Immunotherapy: Hyperprogression and Treatment Beyond Progression  
  - David Gandara, UC Davis Comprehensive Cancer Center, United States of America

#### MA08.10
- **16:30–16:45**  
  - Q&A  
  - 

---

### ES14

**15:15–16:45**  
**WHAT FIRST LINE IN ONCOGENE ADDICTED NSCLC**  
📍 Vancouver (2003)

<table>
<thead>
<tr>
<th>Track(s):</th>
<th>Targeted Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair(s):</td>
<td>Dolores Isla, Spain; Jessica Menis, Italy</td>
</tr>
</tbody>
</table>

#### ES14.01
- **15:15–15:30**  
  - First Line in EGFR Mutated Patients  
  - Thanyanan Reungwattana, Ramathibodi Hospital, Mahidol University, Thailand

#### ES14.02
- **15:30–15:45**  
  - First Line in ALK Translocated Patients  
  - Alice Shaw, Massachusetts General Hospital, United States of America

#### ES14.03
- **15:45–16:00**  
  - First Line in ROS1 Translocated Patients  
  - Frances Shepherd, University Health Network, Canada

#### ES14.04
- **16:00–16:15**  
  - First Line for Rare Mutations (RET, BRAF, HER2)  
  - David Planchard, Gustave Roussy, France

#### ES14.05
- **16:15–16:30**  
  - Patients Harbouring a Driven-Mutation: Pro and Patient’s Perspective  
  - Karen Reckamp, City of Hope Comprehensive Cancer Center, United States of America

#### ES14.06
- **16:30–16:45**  
  - Q&A  
  - 

---

### GR02

**15:15–16:45**  
**IMPROVING PATIENTS QUALITY OF LIFE DURING TREATMENT OF METASTATIC DISEASE**  
📍 Interlaken (1988)

<table>
<thead>
<tr>
<th>Track(s):</th>
<th>Advanced NSCLC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair(s):</td>
<td>Eduardo Richardet, Argentina; Jesús González Barboteo, Spain; Manuel Domine, Spain</td>
</tr>
</tbody>
</table>

#### GR02.01
- **15:15–15:35**  
  - How Can We Incorporate Exercise Practices into Patient’s Lives?  
  - Clarissa Mathias, NOB/ Grupo Oncoclinicas, Brazil

#### GR02.02
- **15:35–15:55**  
  - What is the Best Management of Targeted Therapy Toxicity?  
  - Glenwood Goss, The Ottawa Hospital, Canada

#### GR02.03
- **15:55–16:15**  
  - What is the Best Management of Immunotherapy Toxicity?  
  - Jean-Marie Michot, Gustave Roussy Cancer Campus, France

#### GR02.04
- **16:15–16:35**  
  - Immunotherapy: Hyperprogression and Treatment Beyond Progression  
  - David Gandara, UC Davis Comprehensive Cancer Center, United States of America

#### GR02.05
- **16:35–16:45**  
  - Q&A  
  - 

---

---

---
16:25–16:30  MA08.11–SLCG SCAT Trial: Surgical Audit to Lymph Node Assessment Based on IASLC Recommendations
Jose Ramon, Jarabo Sarceda, Hospital Clínico San Carlos, Spain

16:30–16:45  MA08.12–Discussant–MA08.09, MA08.010, MA08.11
Leah Backhus, Stanford University School of Medicine, United States of America

MA09
15:15–16:45  EGFR & MET
● Melbourne (1991)

Track(s): Targeted Therapy

15:15–15:20  MA09.01–A Phase I/II Trial of Dasatinib and Osimertinib in TKI Naïve Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Chul Kim, Georgetown University Hospital, United States of America

15:20–15:25  MA09.02–In Vivo, Ex Vivo and Early Clinical Activity of EGFR Monoclonal Antibody and Osimertinib in EGFR Exon 20 Insertion NSCLC
Jonathan Riess, UC Davis Comprehensive Cancer Center, United States of America

Yasir Elamin, MD Anderson Cancer Center, United States of America

15:30–15:45  MA09.04–Discussant–MA09.01, MA09.02, MA09.03
Juergen Wolf, Universitätshklinikum Köln, Germany

15:45–15:50  MA09.05–Genomic Correlates of Differential Response to EGFR-Directed Tyrosine Kinase Inhibitors
Natalie Vokes, Dana Farber Cancer Institute, United States of America

15:50–15:55  MA09.06–Adaptive Mechanisms of Resistance to Targeted Therapy in EGFR Mutant Brain Metastasis
Don Nguyen, Yale University School of Medicine, United States of America

15:55–16:00  MA09.07–Activity of Larotrectinib in TRK Fusion Lung Cancer
Anna Farago, Massachusetts General Hospital, United States of America

16:00–16:15  MA09.08–Discussant–MA09.05, MA09.06, MA09.07
Ana Vivancos, Vall d’Hebron University Hospital and Institute of Oncology (VHIO), Spain

16:15–16:20  MA09.09–Long-Term Outcomes to Tepotinib Plus Gefitinib in Patients with EGFR-Mutant NSCLC and MET Dysregulation: 18-Month Follow-Up
Yi-Long Wu, Guangdong Lung Cancer Institute (GLCI), Guangdong Provincial People’s Hospital (GDPH), China

MA10
15:15–16:45  EMERGING TECHNOLOGIES FOR LUNG CANCER DETECTION
● Dublin (1997)

Track(s): Screening and Early Detection

15:15–15:20  MA10.01–Invasive Adenocarcinoma in Screen Detected Pure Ground-Glass Nodules (GGN)
Renelle Myers, BC Cancer, Canada

15:20–15:25  MA10.02–Deep Learning with Radiomics May Predict High-Grade Lung Adenocarcinoma Based on Histological Patterns in Ground Glass Opacity Lesions
Xing Wang, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), China

15:25–15:30  MA10.03–Quantitative Computed Tomography (CT) Based Texture Analysis; Could We Predict the Future Growth of the Pure Ground Glass Nodules?
Joosung Sun, Ajou University School of Medicine, Korea, Republic of

15:30–15:45  MA10.04–Discussant–MA10.01, MA10.02, MA10.03
Marcelo Sanchez, Hospital Clinic Barcelona, Spain

15:45–15:50  MA10.05–Breath Analysis: New Key-Challenges for Early Detection of Lung and Pleural Neoplasms
Annamaria Catino, Clinical Cancer Centre, Italy

15:50–15:55  MA10.06–Randomized Clinical Trial with Computer Assisted Diagnosis (CAD) Versus Radiologist as First Reader of Lung Screening LDCT
Ren Yuan, BC Cancer Vancouver Center, Canada

15:55–16:00  MA10.07–Integrative Analysis of Epistasis Involving Oncogenesis-Related Genes in Lung Cancer Risk Development
Yafang Li, Baylor College of Medicine, United States of America

16:00–16:15  MA10.08–Discussant–MA10.05, MA10.06, MA10.07
Fabrizio Bianchi, Fondazione IRCCS Casa Sollievo della Sofferenza
Renelle Myers, BC Cancer, Canada

16:20–16:25 MA10.10—Uptake in Lung Cancer Screening—Does CT Location Matter? A Pilot Study Comparison of a Mobile and Hospital Based CT Scanner
Emily Bartlett, Royal Brompton Hospital, United Kingdom

Masaoki Ito, Hiroshima University, Japan

16:30–16:45 MA10.12—Discussant—MA10.09, MA10.10, MA10.11
Christine Berg, National Cancer Institute, USA, United States of America

15:15–16:45 IMMUNO COMBINATIONS AND THE ROLE OF TMB
Chair(s): Solange Peters, Switzerland; Martin Reck, Germany

15:15–15:25 OA04.01—A Phase III Randomized Study of Nivolumab/Ipilimumab vs Nivolumab for Previously Treated Stage IV Squamous Cell Lung Cancer
Lyudmila Bazhenova, University of California San Diego (UCSD) Moores Cancer Center, United States of America

15:25–15:35 OA04.02—CheckMate 817: First-Line Nivolumab + Ipilimumab in Patients with ECOG PS 2 and Other Special Populations with Advanced NSCLC
Fabrice Barlesi, Aix Marseille University and Assistance Publique des Hôpitaux de Marseille, France

15:35–15:45 OA04.03—A Randomized, Phase III Study of Camrelizumab Plus Chemotherapy as 1st line Treatment of Chemo-Naive Patients with Advanced NSCLC
Caicun Zhou, Shanghai Pulmonary Hospital, China

15:45–16:00 OA04.04—Discussant—OA04.01, OA04.02, OA04.03
Martin Sebastian, Department of Medicine II, University Hospital Goethe Frankfurt, Germany

16:00–16:10 OA04.05—KEYNOTE-021: TMB and Outcomes for Carboplatin and Pemetrexed With or Without Pembrolizumab for Nonsquamous NSCLC
Corey Langer, Perelman School of Medicine, United States of America

Marina Garassino, INT, Italy

16:20–16:30 OA04.07—Mutations Associated with Sensitivity or Resistance to Immunotherapy in mNSCLC: Analysis from the MYSTIC Trial
Naiyer Rizvi, Columbia University Medical Center, United States of America

16:30–16:45 OA04.08—Discussant—OA04.05, OA04.06, OA04.07
Melissa Johnson, Sarah Cannon Research Institute, United States of America
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:15-16:45</td>
<td><strong>INCREASING THE IMPACT OF NURSING AND ALLIED HEALTH PROFESSIONAL INTERVENTIONS IN LUNG CANCER CARE</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Track(s):</strong> Nursing and Allied Professionals</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Chair(s):</strong> Dianne Zawisza, Canada; Maria Guerin, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>15:15-15:25</td>
<td><strong>OA05.01</strong> – A Prospective Study of Swallowing and Voice Outcomes After Treatment for Small-Cell Lung Cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jacqui Frowen, Peter MacCallum Cancer Centre, Australia</td>
<td></td>
</tr>
<tr>
<td>15:25-15:35</td>
<td><strong>OA05.02</strong> – Patient Experience, Expectations and Knowledge: Lung Cancer in Australia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Catherine Holliday, Centre for Community-Driven Research, Switzerland</td>
<td></td>
</tr>
<tr>
<td>15:35-15:45</td>
<td><strong>OA05.03</strong> – Development of a Fatigue and Breathlessness Group for Thoracic Oncology Patients</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pippa Labuc, Guys Hospital, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>15:45-15:55</td>
<td><strong>OA05.04</strong> – Discussant – OA05.01, OA05.02, OA05.03</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Melissa Culligan, University of Maryland School of Medicine, United States of America</td>
<td></td>
</tr>
<tr>
<td>15:55-16:05</td>
<td><strong>OA05.05</strong> – Transforming the Patient Experience in Lung Cancer Through the Use of Clinical Nurse Specialist Virtual Clinics – The Liverpool Experience</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Andrea Vanessa Mciver1, Nicola Maddock2; Liverpool Heart &amp; Chest Hospital &amp; The Royal Broadgreen University Hospital NHS Trust, United Kingdom, 2Liverpool Heart &amp; Chest Hospital &amp; Royal Liverpool Broadgreen University Hospital NHS Trusts., United Kingdom</td>
<td></td>
</tr>
<tr>
<td>16:05-16:15</td>
<td><strong>OA05.06</strong> – Nursing Intervention on Immuno-Related Adverse Events in Lung Cancer Patients</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mònica Arellano, Institut Català d’Oncologia, Spain</td>
<td></td>
</tr>
<tr>
<td>16:15-16:25</td>
<td><strong>OA05.07</strong> – Co-Operation Between the Cities of Glasgow and Bethlehem and the Development of a Cancer Nursing Diploma at Bethlehem University Palestine</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gerry O Hare, Glasgow &amp; Clyde Health Board, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>16:25-16:35</td>
<td><strong>OA05.08</strong> – Discussant – OA05.05, OA05.06, OA05.07</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mary Duffy, Peter MacCallum Cancer Centre, Australia</td>
<td></td>
</tr>
<tr>
<td>16:35-16:45</td>
<td><strong>OA05.09</strong> – IASLC Lectureship Award for Nursing and Allied Health</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Kahren White, Cancer Institute NSW, Australia</td>
<td></td>
</tr>
</tbody>
</table>
**Daily Scientific Program**  
**Monday, Sept. 9**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 06:30–15:30| Registration Open  
  - North Entrance—Level 1                                                                                           |
| 06:30–16:00| Speaker Preview Center Open  
  - 8.0–Level 1                                                                                                           |
| 08:00–18:00| Poster Pick Up Open  
  - North Entrance–Level 1                                                                                             |
| 08:00–19:00| Media Room Open  
  - Press Area: 8.1                                                                                                    |
| 08:30–18:30| Exhibits Open  
  - Exhibit Hall: 8.1                                                                                                  |

**IBS11**

**07:00–08:00** ELECTRONIC CIGARETTES AND HEAT-NOT-BURN TOBACCO PRODUCTS—HOW ARE THEY DIFFERENT  
- Amsterdam (2011)

**Track(s):** Prevention and Tobacco Control

07:00–07:10  
IBS11.01—Electronic Cigarettes and Heat-Not-Burn Tobacco Products—How Are They Different  
Maciej Goniewicz, Roswell Park Comprehensive Cancer Center, United States of America

07:10–07:20  
IBS11.02—E Cigarettes/Electronic Nicotine Delivery Systems: A Word of Caution on Health  
Michael Unger, Thomas Jefferson University, United States of America

07:20–07:30  
IBS11.03—Cannabis and Lung Cancer  
James Jett, National Jewish Health, United States of America

07:30–08:00  
IBS11.04—Q&A

**IBS12**

**07:00–08:00** CASE-BASED MANAGEMENT OF BRAIN METASTASIS (BM) IN ADVANCED LUNG CANCER PATIENTS: CHANGING THE STANDARDS  
- Toronto (1985)

**Track(s):** Advanced NSCLC

07:00–07:20  
IBS12.01—Questions to Be Addressed  
Matthias Guckenberger, University Hospital Zurich, Switzerland

07:20–07:40  
IBS12.02—Questions to Be Addressed  
Egbert Smit, Netherlands Cancer Institute, Netherlands

07:40–08:00  
IBS12.03—Q&A

**IBS13**

**07:00–08:00** HOW TO IDENTIFY AND MANAGE TOXICITY IN STAGE III  
- Interlaken (1988)

**Track(s):** Treatment of Locoregional Disease—NSCLC

07:00–07:20  
IBS13.01—Radiation Related Toxicities in Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC)  
Alexander Sun, Princess Margaret Cancer Centre, Canada

07:20–07:40  
IBS13.02—Surgical Management for Perioperative Complications in Advanced Lung Cancer After Chemoradiotherapy  
Hiroshi Date, Kyoto University, Japan

07:40–08:00  
IBS13.03—Q&A

**IBS14**

**07:00–08:00** BEST MANAGEMENT OF EARLY STAGE NSCLC IN ILD PATIENTS  
- Melbourne (1991)

**Track(s):** Treatment of Early Stage/Localized Disease

07:00–07:20  
IBS14.01—Surgery  
Masahiro Tsuboi, National Cancer Center Hospital East, Japan

---

**CS** Controversy Session  
**ES** Educational Session  
**GR** Grand Round Session  
**IBS** Interactive Breakfast Sessions (TICKETED SESSION)  
**MA** Mini Oral Abstract Session  
**MS** Mini Symposium  
**OA** Oral Abstract Session  
**OC** Opening Ceremony  
**PC** Pro-Con Session  
**PL** Plenary Session  
**S** Symposium  
**SH** Highlights of the Previous Day  
**WS** Workshop (ticketed sessions)  
**YI** Young Investigator Session
### IBS18

**07:00–08:00 ESSENTIALS IN BIOMARKER TESTING FOR LUNG CANCER**

- **Track(s):** Pathology
- **Track(s):** Biology

#### IBS18.01
07:00–07:20
Mary Beth Beasley, Mount Sinai Medical Center, United States of America

#### IBS18.02
07:20–07:40
Lynette Sholl, Brigham and Women's Hospital, United States of America

#### IBS18.03
07:40–08:00

### IBS19

**07:00–08:00 NOVEL APPROACHES IN RADIATION ONCOLOGY FOR SMALL CELL AND NEUROENDOCRINE CANCERS**

- **Track(s):** Small Cell Lung Cancer/NET
- **Track(s):** Seoul (2007)

#### IBS19.01
07:00–07:20
Andrea Bezjak, Princess Margaret Cancer Centre, Canada

#### IBS19.02
07:20–07:40
Gerard Hanna, Peter MacCallum Cancer Centre, Australia

#### IBS19.03
07:40–08:00

### IBS20

**07:00–08:00 ENDOSCOPIC SOLUTION TO IATROGENIC COMPLICATIONS (INTERACTIVE Q AND A)**

- **Track(s):** Interventional Diagnostics/Pulmonology
- **Track(s):** San Francisco (2009)

#### IBS20.01
07:00–07:20
Johannes Daniels, Amsterdam UMC, Netherlands

#### IBS20.02
07:20–07:40
Michela Bezzi, Azienda Ospedaliera Universitaria di Careggi, Italy

#### IBS20.03
07:40–08:00

11:20–11:40  CS01.02  – “Hunting a Ghost for 25 Years—Will We Ever Catch OMD?”—Yes
José Belderbos, The Netherlands Cancer Institute, Netherlands

11:40–12:00  CS01.03  – Technical Reasons of Local Treatment Define the Limits of NSCLC OMD in Terms of Number of Metastases, Not a Fixed Number
Marta Scorsetti, Humanitas University, Department of Biomedical Sciences, Italy

12:00–12:20  CS01.04  – NSCLC OMD is Defined by a Fixed Maximum Number of Metastases, Not Technical Reasons of Local Treatment
Gavin Wright, Peter MacCallum Cancer Centre, Australia

12:20–12:30  CS01.05  – Q&A

ES16

11:00–12:30  MODERN RADIOTHERAPY IN STAGE III NSCLC
• Dublin (1997)

Track(s): Treatment of Locoregional Disease—NSCLC

Chair(s): Maria Werner Wasik, United States of America; Alexandra Giraldo, Spain

11:00–11:15  ES16.01  – Proton Therapy
Corinne Faiivre-Finn, The Christie—University of Manchester, United Kingdom

11:15–11:30  ES16.02  – MRI-Based Radiotherapy
Fiona Mcdonald, The Royal Marsden, United Kingdom

11:30–11:45  ES16.03  – Optimal Integration of Radiotherapy, TKIs and I/O
Umberto Ricardi, University of Turin, Italy

11:45–12:00  ES16.04  – Molecular Biology of Radiation Toxicity
Fiona Hegi-Johnson, Peter MacCallum Cancer Centre, Australia

12:00–12:30  ES16.05  – Q&A

ES17

11:00–12:30  MOLECULAR ALTERATIONS AND HETEROGENEITY IN MESOTHELIOMA
• Tokyo (1982)

Track(s): Mesothelioma

Chair(s): Steven Mutsaers, Australia; Emanuela Felley-Bosco, Switzerland

11:00–11:20  ES17.01  – Mesothelioma Evolution
Edward Hollox, University of Leicester, United Kingdom

11:20–11:40  ES17.02  – Molecular Heterogeneity
Didier Jean, Centre de Recherche des Cordeliers–Inserm UMRS 1138, France

11:40–12:00  ES17.03  – Heterogeneity & Immune Checkpoint Expression
Aaron Mansfield, Mayo Clinic, United States of America

12:00–12:20  ES17.04  – New Insights into the Molecular Characteristics and Intra-Tumor Heterogeneity of Malignant Pleural Mesothelioma from the MESOMICS Project
Lynnette Fernandez-Cuesta, IARC, France

12:20–12:30  ES17.05  – Q&A

ES18

11:00–12:30  ACQUIRED RESISTANCE TO TKIS: THE REBIOPSY CASE AND THE FUTURE OPTIONS
• Vienna (2016)

Track(s): Targeted Therapy

Chair(s): Teresa Moran, Spain; Matteo Giaj Levra, France

11:00–11:20  ES18.01  – Rebiopsy in Oncogene Addicted NSCLC at Progression
D Ross Camidge, University of Colorado Cancer Center, United States of America

11:20–11:40  ES18.02  – When to Switch to a New TKI: Imaging Based Criteria or Positive Liquid Biopsy?
James Yang, National Taiwan University Hospital, Taiwan

11:40–12:00  ES18.03  – New Strategies to Overcome Resistance in EGFR Mutated NSCLC
Paul Bunn, Jr, University of Colorado, United States of America
11:00–11:15 MS05.01–Epigenetic Therapeutics in Lung Cancer
Kwok-kim Wong, NYU Langone Perlmutter Cancer Center, United States of America

11:15–11:30 MS05.02–Genetics Abnormalities in Chromatin Modifiers: Connection with MYC Pathway and Exploration for Therapeutics
Montserrat Sanchez-Cespedes, Cancer Epigenetics and Biology Program-PEBC (IDIBELL), Spain

11:30–11:45 MS05.03–Notch Signalling
Shirish Gadgeel, University of Michigan, United States of America

11:45–12:00 MS05.04–Innate Immune Mediators in Lung Cancer
Antonio Calles Blanco, Hospital General Universitario Gregorio Maranon, Spain

12:00–12:15 MS05.05–Harnessing Oncogene Dependencies in Lung Cancer
Martin Sos, Molecular Pathology, Germany

12:15–12:30 MS05.06–Q&A

11:00–11:10 OA06.01–Comparison Between Radiomics-Based Machines Learning and Deep Learning Image Classification for Sub-Cm Lung Nodules
Calum Macaulay, BC Cancer Research Centre, Canada

11:10–11:20 OA06.02–The Role of Simulation Modeling in Shaping Lung Cancer Screening Policies in the US and Elsewhere
Rafael Meza, University of Michigan, United States of America

11:20–11:30 OA06.03–An Open Source Lung Screening Management System
Claudia Henschke, Icahn School of Medicine at Mount Sinai, United States of America

11:30–11:45 OA06.04–Discussant–OA06.01, OA06.02, OA06.03
Betty Tong, Duke University, United States of America

11:45–12:05 OA06.05–Evaluation of a Deep Learning-Based Automatic Classifier for the Classification of Perifissural Nodules
Tobias Peikert, Mayo Clinic Rochester, United States of America

12:00–12:20 ES18.04–New Strategies to Overcome Resistance in ALK Rearranged NSCLC
Sai-Hong Ou, University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, United States of America

12:20–12:30 ES18.05–Q&A

11:20–11:30 MS06.03–Pathologic Staging: Operative Events
Thomas D’amico, Duke Cancer Institute, United States of America

11:30–11:40 MS06.04–Approaches to Overcoming the Nodal Staging Quality Gap
Ray Osarogiagbon, Baptist Cancer Center, United States of America

11:40–11:50 MS06.05–Transcervical Lymphadenectomies
Marcin Zielinski, Pulmonary Hospital, Poland

11:50–12:00 MS06.06–The Concept of Complete Resection
John Edwards, Northern General Hospital, United Kingdom

12:00–12:30 MS06.07–Q&A

11:10–11:20 MS05.04–Genetics Abnormalities in Chromatin Modifiers: Connection with MYC Pathway and Exploration for Therapeutics
Montserrat Sanchez-Cespedes, Cancer Epigenetics and Biology Program-PEBC (IDIBELL), Spain

11:30–11:45 MS05.03–Notch Signalling
Shirish Gadgeel, University of Michigan, United States of America

11:45–12:00 MS05.02–Genetics Abnormalities in Chromatin Modifiers: Connection with MYC Pathway and Exploration for Therapeutics
Montserrat Sanchez-Cespedes, Cancer Epigenetics and Biology Program-PEBC (IDIBELL), Spain

11:00–11:15 MS06.01–Radiologic Staging
Jin Mo Goo, Departments of Radiology, Seoul National University College of Medicine, Korea, Republic of

11:15–11:30 MS06.02–Endoscopic Nodal Staging
Jose Sanz Santos, Hospital Universitari Mutua Terrassa, Spain

11:00–12:30 AN INTERDISCIPLINARY APPROACH TO OPTIMAL NODAL STAGING
• Toronto (1985)

Track(s): Staging

Chair(s): Roser Saumench Perramon, Spain; Souheil Boubia, Morocco

11:00–11:10 MS06.01–Radiologic Staging
Jin Mo Goo, Departments of Radiology, Seoul National University College of Medicine, Korea, Republic of

11:10–11:20 MS06.02–Endoscopic Nodal Staging
Jose Sanz Santos, Hospital Universitari Mutua Terrassa, Spain

11:10–11:20 OA06.06–Discussant–OA06.01, OA06.02, OA06.03
Betty Tong, Duke University, United States of America

11:45–11:55 OA06.05–Evaluation of a Deep Learning-Based Automatic Classifier for the Classification of Perifissural Nodules
Daiwei Han, University Medical Center Groningen, University of Groningen, Netherlands

11:55–12:05 OA06.06–Independent Validation of a Novel High-Resolution Computed Tomography-Based Radiomic Classifier for Indeterminate Lung Nodules
Tobias Peikert, Mayo Clinic Rochester, United States of America

12:05–12:15 OA06.07–Discrimination of Lung Invasive Adenocarcinoma with Micropapillary Pattern Based on CT Radiomics
Haihua Yang, Radiation Oncology Institute of Enze Medical Health Academy, Affiliated Taizhou Hospital of Wenzhou Medical University, China

11:00–11:10 OA06.01–Comparison Between Radiomics-Based Machines Learning and Deep Learning Image Classification for Sub-Cm Lung Nodules
Calum Macaulay, BC Cancer Research Centre, Canada

11:10–11:20 OA06.02–The Role of Simulation Modeling in Shaping Lung Cancer Screening Policies in the US and Elsewhere
Rafael Meza, University of Michigan, United States of America

11:20–11:30 OA06.03–An Open Source Lung Screening Management System
Claudia Henschke, Icahn School of Medicine at Mount Sinai, United States of America

11:30–11:45 OA06.04–Discussant–OA06.01, OA06.02, OA06.03
Betty Tong, Duke University, United States of America

11:45–12:05 OA06.05–Evaluation of a Deep Learning-Based Automatic Classifier for the Classification of Perifissural Nodules
Daiwei Han, University Medical Center Groningen, University of Groningen, Netherlands

12:00–12:15 OA06.06–Independent Validation of a Novel High-Resolution Computed Tomography-Based Radiomic Classifier for Indeterminate Lung Nodules
Tobias Peikert, Mayo Clinic Rochester, United States of America

12:05–12:15 OA06.07–Discrimination of Lung Invasive Adenocarcinoma with Micropapillary Pattern Based on CT Radiomics
Haihua Yang, Radiation Oncology Institute of Enze Medical Health Academy, Affiliated Taizhou Hospital of Wenzhou Medical University, China

11:00–11:15 MS05.01–Epigenetic Therapeutics in Lung Cancer
Kwok-kim Wong, NYU Langone Perlmutter Cancer Center, United States of America

11:15–11:30 MS05.02–Genetics Abnormalities in Chromatin Modifiers: Connection with MYC Pathway and Exploration for Therapeutics
Montserrat Sanchez-Cespedes, Cancer Epigenetics and Biology Program-PEBC (IDIBELL), Spain

11:30–11:45 MS05.03–Notch Signalling
Shirish Gadgeel, University of Michigan, United States of America

11:45–12:00 MS05.04–Innate Immune Mediators in Lung Cancer
Antonio Calles Blanco, Hospital General Universitario Gregorio Maranon, Spain

12:00–12:15 MS05.05–Harnessing Oncogene Dependencies in Lung Cancer
Martin Sos, Molecular Pathology, Germany

12:15–12:30 MS05.06–Q&A

11:00–11:10 OA06.01–Comparison Between Radiomics-Based Machines Learning and Deep Learning Image Classification for Sub-Cm Lung Nodules
Calum Macaulay, BC Cancer Research Centre, Canada

11:10–11:20 OA06.02–The Role of Simulation Modeling in Shaping Lung Cancer Screening Policies in the US and Elsewhere
Rafael Meza, University of Michigan, United States of America

11:20–11:30 OA06.03–An Open Source Lung Screening Management System
Claudia Henschke, Icahn School of Medicine at Mount Sinai, United States of America

11:30–11:45 OA06.04–Discussant–OA06.01, OA06.02, OA06.03
Betty Tong, Duke University, United States of America

11:45–12:05 OA06.05–Evaluation of a Deep Learning-Based Automatic Classifier for the Classification of Perifissural Nodules
Daiwei Han, University Medical Center Groningen, University of Groningen, Netherlands

12:00–12:15 OA06.06–Independent Validation of a Novel High-Resolution Computed Tomography-Based Radiomic Classifier for Indeterminate Lung Nodules
Tobias Peikert, Mayo Clinic Rochester, United States of America

12:05–12:15 OA06.07–Discrimination of Lung Invasive Adenocarcinoma with Micropapillary Pattern Based on CT Radiomics
Haihua Yang, Radiation Oncology Institute of Enze Medical Health Academy, Affiliated Taizhou Hospital of Wenzhou Medical University, China

11:00–11:10 OA06.01–Comparison Between Radiomics-Based Machines Learning and Deep Learning Image Classification for Sub-Cm Lung Nodules
Calum Macaulay, BC Cancer Research Centre, Canada

11:10–11:20 OA06.02–The Role of Simulation Modeling in Shaping Lung Cancer Screening Policies in the US and Elsewhere
Rafael Meza, University of Michigan, United States of America

11:20–11:30 OA06.03–An Open Source Lung Screening Management System
Claudia Henschke, Icahn School of Medicine at Mount Sinai, United States of America

11:30–11:45 OA06.04–Discussant–OA06.01, OA06.02, OA06.03
Betty Tong, Duke University, United States of America

11:45–12:05 OA06.05–Evaluation of a Deep Learning-Based Automatic Classifier for the Classification of Perifissural Nodules
Daiwei Han, University Medical Center Groningen, University of Groningen, Netherlands

12:00–12:15 OA06.06–Independent Validation of a Novel High-Resolution Computed Tomography-Based Radiomic Classifier for Indeterminate Lung Nodules
Tobias Peikert, Mayo Clinic Rochester, United States of America

12:05–12:15 OA06.07–Discrimination of Lung Invasive Adenocarcinoma with Micropapillary Pattern Based on CT Radiomics
Haihua Yang, Radiation Oncology Institute of Enze Medical Health Academy, Affiliated Taizhou Hospital of Wenzhou Medical University, China
11:00–12:30 ADVANCED MODELS AND “OMICs” FOR THERAPEUTIC DEVELOPMENT
● Interlaken (1988)

Track(s): Biology

Chair(s): Luis Montuenga, Spain; Julie George, Germany

11:00–11:10 OA08.01 – Organoid Cultures as Novel Preclinical Models of Non-Small Cell Lung Cancer
Ming Tsao, University Health Network, Canada

11:10–11:20 OA08.02 – A Multidisciplinary Multi-Omics Study of Spatial and Temporal Tumor Evolution in Thoracic Cancers with Clinical Implications
Matthieu Foll, International Agency for Research on Cancer, France

11:20–11:30 OA08.03 – A Single-Cell Resolution Map of EMT and Drug Resistance States for Evaluating NSCLC Clinical Specimens
Loukia Karacosta, Stanford University, United States of America

11:30–11:40 OA08.04 – Discussant – OA08.01, OA08.02, OA08.03
Luca Roz, Istituto Nazionale dei Tumori, Italy

11:40–11:50 OA08.05 – Notch Inhibition Overcomes Resistance to Tyrosine Kinase Inhibitors Promoted by Gate-Keeper Mutations in EGFR-Driven Lung Adenocarcinoma
Antonio Maraver, INSERM, France

11:50–12:00 OA08.06 – Reciprocal Change in Glucose Metabolism of Cancer and Immune Cells Mediated by Different GLUT Predicts Immunotherapy Response
Hongyoon Choi, Seoul National University Hospital, Korea, Republic of

12:00–12:10 OA08.07 – Aberrant Epigenetic SMAD3 Signaling in Tumor-Associated Fibroblasts Modulates Fibrosis and Response to Nintedanib in NSCLC
Rafael Iemomi, University of Barcelona – Faculty of Medicine, Spain

12:10–12:20 OA08.08 – Discussant – OA08.05, OA08.06, OA08.07
Takashi Kohno, National Cancer Center Research Institute, Japan

12:20–12:30 OA08.09 – Adi F. Gazdar Lectureship Award for Translational Science
Roman Thomas, University of Cologne, Germany
11:10–11:20  OA09.02 – Smoking Cessation Counseling in a Surgical Clinic Is Effective  
Matthew Steliga, University of Arkansas, United States of America

11:20–11:30  OA09.03 – Patterns of Birth Cohort-Specific Smoking Histories by Family Income in the USA, 1982–2017  
Jihyoun Jeon, University of Michigan, United States of America

11:30–11:40  OA09.04 – Discussant – OA09.01, OA09.02, OA09.03  
Magdalena Cedzynska, Centrum Onkologii-Instytutu im. Marii Sklodowskiej-Curie, Poland

11:40–11:50  OA09.05 – Lung Cancer as a Second Primary Malignancy Among Women with Breast Cancer: The Role of Hormone Replacement and Smoking  
J Nicholas Bodor, Fox Chase Cancer Center, United States of America

11:50–12:00  OA09.06 – Residential Radon, Smoking and Lung Cancer Risk. A Case-Control Study in a Radon Prone Area  
Alberto Ruano-Ravina, University of Santiago de Compostela, Spain

12:00–12:10  OA09.07 – Implementing an Opt-Out Approach to Smoking Cessation Referrals for Cancer Patients in Ontario, Canada  
William Evans, McMaster University, Canada

12:10–12:20  OA09.08 – Discussant – OA09.05, OA09.06, OA09.07  
Haval Balata, Manchester University Foundation Trust, United Kingdom

12:20–12:30  OA09.09 – ISLC Lectureship Award for Smoking Cessation  
Emily Stone, St Vincent’s Hospital Sydney, Australia

11:00–12:45  PC01  
Reinventing Clinical Trials  
Track(s): Advocacy

Chair(s): Ivy Elkins, United States of America; Jose Luis Gonzalez Larriba, Spain

11:00–11:15  PC01.01 – Setting the Stage: Tension Between Patient Safety, Scientific Purity and Patient Inclusion  
Jacob Sands, Dana-Farber Cancer Institute, United States of America

11:15–11:30  PC01.02 – Real World Research Groups – ROS1ders  
Merel Hennink, longkanker Nederland, Netherlands

11:30–11:45  PC01.03 – Real World Research Groups – ALK+ Group  
Linnea Olson, www.outlivinglungcancer.com, United States of America

11:45–12:00  PC01.04 – Lung Cancer Patients Should Have Better Access to Clinical Research: Relax the Eligibility Criteria  
Janet Freeman-Daily, The ROS1ders, United States of America

12:00–12:15  PC01.05 – Strict Criteria Are Crucial in Clinical Trials to Ensure Patient Safety and Data Integrity. Do Not Relax Eligibility  
Omar Macedo-Perez, Instituto Nacional de Cancerologia, Mexico

12:15–12:30  PC01.06 – Representation of Minorities and Women in Oncology Clinical Trials  
Narjust Duma, University of Wisconsin, United States of America

12:30–12:45  PC01.07 – Q&A

11:00–12:30  SH01  
Highlight of the Previous Day  
Track(s): Interventional Diagnostics/Pulmonology

Chair(s): Isabelle Schmitt-Opitz, Switzerland; Ritsuko Komaki-Cox, United States of America

11:00–11:15  SH01.01 – Surgery  
Khaled Alkattan, King Faisal Hospital, Saudi Arabia

11:15–11:30  SH01.02 – Radiation  
Laurie Gaspar, University of Colorado and Banner MD Anderson, United States of America

11:30–11:45  SH01.03 – Advanced Lung Cancer  
Digambar Behera, Postgraduate Institute of Medical Education and Research, India

11:45–12:00  SH01.04 – Targeted Therapy  
Rosario Garcia Campelo, Complejo Hospitalario Universitario A Coruna, Spain

12:00–12:15  SH01.05 – Mesothelioma  
Michele Carbone, University of Hawaii Cancer Center, United States of America

12:15–12:30  SH01.06 – Immuno therapy  
Margarita Majem, Hospital de la Santa Creu i Sant Pau, Spain

14:00–15:30  ES19  
Recently Diagnosed Malignant Pleural Effusion  
Track(s): Interventional Diagnostics/Pulmonology

Chair(s): Juan Carlos Trujillo-Reyes, Spain; Julius Janssen, Netherlands

14:00–14:15  ES19.01 – Benefits and Limitations of Systemic Therapy for Malignant Pleural Effusion  
Anne Tsao, MD Anderson Cancer Center, United States of America
14:15–14:30  **ES19.02**–Best Endoscopic Tools for the Best Results
Mohammed Munavvar, Lancashire Teaching Hospitals, United States of America

14:30–14:45  **ES19.03**–RCT's on Malignant Pleural Effusion
Talc Pleurodesis Management
Nick Maskell, University of Bristol, United States of America

14:45–15:00  **ES19.04**–How to Deal with a Trapped Lung
Y.C. Gary Lee, Sir Charles Gairdner Hospital, Australia

15:00–15:15  **ES19.05**–Surgical Management of Malignant Pleural Effusion
Alan Sihoe, International Medical Centre Hong Kong, China

15:15–15:30  **ES19.06**–Q&A

---

14:00–15:30  **ES20**
**STRATEGIES FOR CANCER PATIENTS TO HAVE OPTIMAL OUTCOMES**
*Colorado Springs (1994)*

**Track(s):** Prevention and Tobacco Control

**Chair(s):** Yuko Nakayama, Japan; Michael Menefee, United States of America

14:00–14:15  **ES20.01**–Why It Matters for Patients to Quit—What We’ve Done
Abhishek Shankar, DRBRAIRCH, All India Institute of Medical Sciences, India

14:15–14:30  **ES20.02**–Tobacco Control Integration in Cancer Care: The Canadian Experience
William Evans, McMaster University, Canada

14:30–14:45  **ES20.03**–Tobacco Control Integration in Cancer Care: The Jordan Experience
Feras Hawari, King Hussein Cancer Center, Jordan

14:45–15:00  **ES20.04**–Tobacco Control in Indonesia
Sita Andarini, Faculty of Medicine University of Indonesia Persahabatan Hospital, Indonesia, Indonesia

15:00–15:15  **ES20.05**–Tobacco Cessation After Cancer Diagnosis: Declaration from IASLC
Jacek Jassem, Medical University of Gdańsk, Poland

15:15–15:30  **ES20.06**–Q&A

---

14:00–15:30  **MA11**
**IMMUNOTHERAPY IN SPECIAL POPULATIONS AND PREDICTIVE MARKERS**
*Hilton Head (1978)*

**Track(s):** Immo-oncology

**Chair(s):** Frank Griesinger, Germany; Lecia Sequist, United States of America

14:00–14:05  **MA11.01**–Multifactorial Model to Predict Response to PD-(L)1 Blockade in Patients with High PD-L1 Metastatic Non-Small Cell Lung Cancer
Kathryn Arbour, Memorial Sloan Kettering Cancer Center, United States of America

14:05–14:10  **MA11.02**–KEYNOTE-042 China Study: First-Line Pembrolizumab vs Chemotherapy in Chinese Patients with Advanced NSCLC with PD-L1 TPS ≥1%
Yi-Long Wu, Guangdong Lung Cancer Institute (GLCI), Guangdong Provincial People’s Hospital (GDPH), China

14:10–14:15  **MA11.03**–Pembrolizumab Plus Docetaxel Increases Progression-Free Survival Compared with Docetaxel Alone in Previously Treated Advanced Non-Small Cell Lung Cancer Patients
Oscar Gerardo Arrieta, Instituto Nacional de Cancerologa, Mexico

14:15–14:20  **MA11.04**–Platinum Doublet + Durvalumab +/- Tremelimumab in Patients with Advanced NSCLC: A CCTG Phase IB Study–IND.226
Rosalyn Juergens, Juravinski Cancer Centre, Canada

14:20–14:35  **MA11.05**–Discussant–MA11.01, MA11.02, MA11.03, MA11.04
Lizza Hendriks, Maastricht umc+, Netherlands

14:35–14:40  **MA11.06**–A PII Study of Toripalimab, a PD-1 mAb, in Combination with Chemotherapy in EGFR+ Advanced NSCLC Patients Failed to Prior EGFR TKI Therapies
Jie Zhang, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China

14:40–14:45  **MA11.07**–Efficacy of Immune-Checkpoint Inhibitors and EGFR-TKIs in NSCLC Patients with High PD-L1 Expression
Ken Masuda, National Cancer Center Hospital, Japan

14:45–15:00  **MA11.08**–Discussant–MA11.06, MA11.07
Qing Zhou, Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People’s Hospital & Guangdong Academy of Medical Sciences, China

15:00–15:05  **MA11.09**–Increased Frequency of Bystander T Cells in the Lungs Is Associated with Recurrence in Localized Non-Small Cell Lung Cancer
Alexandre Reuben, MD Anderson Cancer Center, United States of America

15:05–15:10  **MA11.10**–Peripheral T Cell Repertoire Evolution in Resectable NSCLC Treated with Neoadjuvant PD-1 Blockade
Justina Caushi, Johns Hopkins University, United States of America

15:10–15:15  **MA11.11**–STK11/LKB1 Genomic Alterations Are Associated with Inferior Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLC
Ferdinandos Skoulidis, UT MD Anderson Cancer Center, United States of America

Ana Gelatti, Hospital Mãe de Deus, Brazil
14:00–15:30  NEW FRONTIERS FROM PATHOLOGY TO GENOMICS  
Melbourne (1991)

**Track(s):** Mesothelioma

**Chair(s):** Prasad Adusumilli, United States of America; Francisco Perez Ochoa, Spain

14:00–14:05  MA12.01–Redefining Malignant Pleural Mesothelioma Types as a Continuum UnCOVERS Immune-Vascular Interactions  
Matthieu Foll, International Agency for Research on Cancer, France

14:05–14:10  MA12.02–Growth Patterns in Epithelioid Malignant Pleural Mesothelioma: A Clinicopathological Review of 614 Cases Over 15 Years  
Yu Zhi Zhang, Imperial College London, United Kingdom

14:10–14:15  MA12.03–PARP Inhibitor Sensitivity Does Not Depend on BAP1 but is Enhanced by Temozolomide in MGMT Deficient Human Mesothelioma Cells  
Raffit Hassan, National Institutes of Health, United States of America

14:15–14:30  MA12.04–Discussant–MA12.01, MA12.02, MA12.03  
Erik Thunnissen, VUmc, Netherlands

14:30–14:35  MA12.05–Genomic Analysis of Long Term Malignant Pleural Mesothelioma Patients Treated with Palliative Chemotherapy  
Andrea Bilie, Guy’s Hospital Nhs Funation Trust, United Kingdom

14:35–14:40  MA12.06–Patient-Derived Organotypic Tumor Spheroids (PDOTS) Facilitate Therapeutic Screening for Malignant Pleural Mesothelioma  
Raphael Bueno, Brigham and Women’s Hospital, United States of America

14:40–14:45  MA12.07–Integrative Transcriptome Analysis of Malignant Pleural Mesothelioma Reveals a Clinically-Relevant Immune-Based Classification  
Ania Alay, Bellvitge Biomedical Research Institute (IDIBELL), Spain

14:45–15:00  MA12.08–Discussant–MA12.05, MA12.06, MA12.07  
Ying Liang, Sun Yat-sen University Cancer Center, China

15:00–15:05  MA12.09–Checkpoint Inhibitors Synergize with Dendritic Cell-Therapy in Pre-Clinical Models and Mesothelioma Patients  
Robert Belderbos, Erasmus MC, Netherlands

15:05–15:10  MA12.10–Novel Germline Mutations in DNA-Damage Repair and DNA Replication Identified in Patients with Malignant Pleural Mesothelioma (MPM)  
Robin Guo, Memorial Sloan Kettering Cancer Center, United States of America

15:10–15:15  MA12.11–Anti-Tumor Efficacy of Meposerin Targeted Immunotoxin LMB-100 Plus Pembrolizumab in Mesothelioma Patients and Mouse Models  
Raffit Hassan, National Institutes of Health, United States of America

Steven Belinsky, Lovelace Respiratory Research Institute, United States of America

14:00–15:30  GOING BACK TO THE ROOTS!  
Vancouver (2003)

**Track(s):** Advanced NSCLC

**Chair(s):** Kaoru Kubota, Japan; Maurice Perol, France

14:00–14:05  MA13.01–Associations Between Baseline Serum Biomarker Levels and Cachexia/Pre-Cachexia in Pretreated Non-Small Cell Lung Cancer (NSCLC) Patients  
Jeffrey Borgia, Rush University Medical Center, United States of America

14:05–14:10  MA13.02–Incidence of Venous Thromboembolism at the Time of Lung Cancer Diagnosis: A Multicenter, Prospective Observational Trial (Rising-VTE/NEJ037)  
Kosuke Hamai, Hiroshima Prefectural Hospital, Japan

14:10–14:15  MA13.03–Retrospective Study of Intrathecal Therapy for Non-Small Cell Lung Cancer (NSCLC) Patients with Leptomeningeal Carcinomatosis  
Noelia Vilarino, Institut Català d’Oncologia, Spain

Ramsswamy Govindan, Section of Medical Oncology, Division of Oncology, Washington University School of Medicine, United States of America

14:30–14:35  MA13.05–Nab-Paclitaxel Maintenance in Squamous Non-Small Cell Lung Cancer (NSCLC): Updated Results of the Phase III ABOUND.sqm Study  
David Spigel, Sarah Cannon Research Institute, United States of America

14:35–14:40  MA13.06–Ph3 Study of Maintenance Therapy with S-1 vs BSC After Induction Therapy with Carboplatin + S-1 for Advanced Squamous Cell Lung Cancer (WJOG7512L)  
Kaoru Tanaka, Kindai University Faculty of Medicine, Japan

14:40–14:45  MA13.07–Phase I/II Study of Carboplatin Plus Weekly Nab-Paclitaxel in Aged ≥75 Patients with Squamous-Cell Lung Cancer: TORG1322  
Yoshitaka Zenke, National Cancer Center Hospital East, Japan
### MS08

**14:00–15:30 MANAGEMENT OF THYMIC CARCINOMA**

**Track(s):** Thymoma/Other Thoracic Malignancies

**Chair(s):** Enrico Ruffini, Italy; Giovannella Palmieri, Italy

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td>MS08.01–Adjuvant Radiotherapy for Resected Thymic Carcinoma</td>
<td>Anthony Brade, Trillium Health Partners, Canada</td>
</tr>
<tr>
<td>14:15</td>
<td>MS08.02–Induction Therapy for Locally Advanced Thymic Carcinoma</td>
<td>Robert Korst, Mount Sinai Health System, United States of America</td>
</tr>
<tr>
<td>14:45</td>
<td>MS08.03–Optimal Management of Metastatic Thymic Carcinoma</td>
<td>Giuseppe Giaccone, Georgetown University, United States of America</td>
</tr>
<tr>
<td>15:00</td>
<td>MS08.04–Novel Biomarkers for Thymic Carcinoma</td>
<td>Mirella Marino, IRCCS Regina Elena National Cancer Institute, Italy</td>
</tr>
<tr>
<td>15:05</td>
<td>MS08.05–Basic Pathological Features</td>
<td>Cesar Moran, MD Anderson Cancer Center, United States of America</td>
</tr>
</tbody>
</table>

### MS07

**14:00–15:30 CONTROVERSIES WITH STEREOTACTIC RADIATION IN EARLY STAGE LUNG CANCER**

**Track(s):** Treatment of Early Stage/Localized Disease

**Chair(s):** Laureano Molins, Spain; Salvador Villa, Spain

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td>MS07.01–Preoperative Optimization: Reducing Surgery Complications Through Tobacco Cessation</td>
<td>David Harpole, Duke University, United States of America</td>
</tr>
<tr>
<td>14:00</td>
<td>MS07.02–Post SBRT Management: Surgery</td>
<td>Mara Antinoff, UT MD Anderson Cancer Center, United States of America</td>
</tr>
<tr>
<td>14:20</td>
<td>MS07.03–Post SBRT Management: vs Radiation</td>
<td>Marco Trovo, ASUIUD, Italy</td>
</tr>
<tr>
<td>14:30</td>
<td>MS07.04–Stage I (Resectable) NSCLC: Surgery</td>
<td>Ryota Tanaka, Kyorin University School of Medicine, Japan</td>
</tr>
<tr>
<td>14:40</td>
<td>MS07.05–Stage I (Resectable) NSCLC: Radiation</td>
<td>Suresh Senan, Amsterdam University Medical Center, Netherlands</td>
</tr>
<tr>
<td>15:00</td>
<td>MS07.06–Hot Topics in SBRT–Biopsy, Central Lesions, Radiologic Evaluation</td>
<td>Cecile Le Pechoux, Gustave Roussy Cancer Campus, France</td>
</tr>
<tr>
<td>15:05</td>
<td>MS07.07–Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>
**DAILY SCIENTIFIC PROGRAM**

### OA10

**14:00–15:30**  
**SOPHISTICATED TNM STAGING SYSTEM FOR LUNG CANCER**  
**Track(s):** Staging  
**Chair(s):** Ke-Neng Chen, China; Pedro Lopez De Castro, Spain

- **14:00–14:10**  
  **OA10.01**–Impact of Pre-Ordered Staging Tests on Timeliness of Lung Cancer Diagnosis and Staging: A Quality Improvement Initiative  
  Monica Mullin, Internal Medicine, Canada

- **14:10–14:20**  
  **OA10.02**–Recommended Change for N Descriptor Proposed by the IASLC: A Validation Study from a Single-Center Experience  
  Byung Jo Park, Samsung Medical Center, Korea, Republic of

- **14:20–14:30**  
  **OA10.03**–MacroScore: A Prognostic Model for Supplementing the TNM Stage in Resectable Non-Small Cell Lung Cancer  
  Rui Mao, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China

- **14:30–14:40**  
  **OA10.04**–Discussant–OA10.01, OA10.02, OA10.03  
  Valerie Rusch, Memorial Sloan Kettering Cancer Center, United States of America

- **14:40–14:50**  
  **OA10.05**–Which is Better for TNM Stage Assessment Among Whole-Body MRI and PET/MRI at 1.5 Tesla and 3 Tesla and FDG-PET/CT in Non-Small Cell Lung Cancer?  
  Yoshiharu Ohno, Fujita Health University School of Medicine, Japan

- **14:50–15:00**  
  **OA10.06**–Transition Patterns Between N1 and N2 Stations Discovered from Data-Driven Lymphatic Metastasis Study in Non-Small Cell Lung Cancer  
  Xing Wang, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), China

- **15:00–15:10**  
  **OA10.07**–Concordance Between ROSE and Final Diagnosis in Patients Undergoing EBUS-TBNA for Non-Small Cell Lung Cancer Staging  
  Cristina Caupena Auledas, Hospital Mutua de Terrassa, Spain

- **15:10–15:20**  
  **OA10.08**–Discussant–OA10.05, OA10.06, OA10.07  
  Akif Turna, Istanbul University, Turkey

- **15:20–15:30**  
  **OA10.09**–Clifton F. Mountain Lectureship Award for Staging  
  Paula Ugalde, Institut Universitaire de Cardiologie et Pneumologie de Quebec

### OA11

**14:00–15:30**  
**DECOMPLEXIFYING MOLECULAR TARGETS, IMMUNOTHERAPY AND TREATMENT SETTINGS IN THE REAL WORLD**  
**Track(s):** Treatment in the Real World–Support, Survivorship, Systems Research  
**Chair(s):** Kumar Prabhash, India; Jyoti Patel, United States of America

- **14:00–14:10**  
  **OA11.01**–Complex EGFR Mutations in Lung Adenocarcinoma  
  Shang-Gin Wu, National Taiwan University Hospital, Taiwan

- **14:10–14:20**  
  **OA11.02**–Changes of Brain Structure in Advanced NSCLC Patients Receiving EGFR-TKIs: Dynamic Analysis Based on Series MRI Images  
  Chunli Luo, West China Hospital, Sichuan University, China

- **14:20–14:30**  
  **OA11.03**–Survival Disparities Between Academic and Community Centers in Advanced Lung Cancer in the US: Can We Bridge the Gap?  
  Sendilnathan Ramalingam, Duke Cancer Institute, United States of America

- **14:30–14:45**  
  **OA11.04**–Discussant–OA11.01, OA11.02, OA11.03  
  Joel Neal, Stanford Cancer Institute, United States of America

- **14:45–14:55**  
  **OA11.05**–Optimizing Resources with Immunotherapy in Developing Countries: Experience in a Reference Center in Mexico  
  Omar Macedo-Perez, Instituto Nacional de Cancerologia, Mexico

- **14:55–15:05**  
  **OA11.06**–Alternative Nivolumab (N) Duration and Scheduling in Advanced Non-Small Cell Lung Cancer (aNSCLC): Real-Life Data  
  Elizabeth Dudnik, Davidoff Cancer Center Rabin Medical Center, Israel

- **15:05–15:15**  
  **OA11.07**–Chemotherapy Plus EGFR-TKI as First-Line Treatment Provides Better Survival for EGFR Mutation NSCLC Patients: Update Data for NCT02148380  
  Wei Zhang, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

- **15:15–15:30**  
  **OA11.08**–Discussant–OA11.05, OA11.06, OA11.07  
  Ullas Batra, Rajiv Gandhi Cancer Institute and Research Centre, India
14:00–15:30  COMBINING WITH CHEMO: OLD SCHOOL IS NEW AGAIN
Track(s): Advanced NSCLC
Chair(s): Julien Mazieres, France; Javier De Castro Carpeno, Spain

14:00–14:20  PC02.01–TKIs Should Be Given as Single Agent
Tony Mok, Chinese University of Hong Kong, China

14:20–14:40  PC02.02–TKIs Should Be Given with Chemo
Rafael Rosell, Germans Trias i Pujol Science Inst., Catalan Institute of Oncology (ICO Badalona), Spain

14:40–15:00  PC02.03–IO Should Be Given as a Single Agent
Julie Brahmer, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, United States of America

15:00–15:20  PC02.04–IO Should Be Given with Chemo
Luis Paz-Ares, 12 de Octubre University Hospital, Spain

15:20–15:30  PC02.05–Q&A

14:00–15:30  STAGING WORKSHOP PART 1: IASLC DATABASE CHALLENGES AND APPLICATION
Track(s): Staging
Chair(s): Paula Ugalde, Canada; Maria Teresa Tsukazan, Brazil

14:00–14:10  WS04.01–Challenges of Data Entry in IASLC Database
Brigitte Fournier, IUCPQ-Laval University, Canada

14:10–14:20  WS04.02–Challenges in Imaging Evaluation to Enter Data in the IASLC Database
Helmut Prosch, Medical University of Vienna, Austria

14:20–14:30  WS04.03–How to Adjust Pathology Evaluation According to IASLC Database
Philippe Joubert, Quebec Heart and Lung Institute Research Center, Canada

14:30–14:40  WS04.04–Institutional Benefits of Adherence to IASLC Database
Catherine Labbe, IUCPQ, Canada

14:40–15:00  WS04.05–Developing the IASLC Lung Cancer Staging Database and Recommendations for the 9th Edition
Dori Giroux, Cancer Research And Biostatistics (CRAB), United States of America

15:00–15:15  STAGING WORKSHOP PART 2: THE IMPORTANCE OF INVASIVE NODAL STAGING IN THORACIC MALIGNANCIES
Track(s): Staging
Chair(s): Jose Matilla, Spain; Ricardo Beyruti, Brazil

15:45–16:00  Introduction/Poll

16:00–16:10  WS05.01–Invasive Pre-Operative Staging of Lung Cancer
Sergi Call, Hospital Univeristari MútuaTerrassa, Spain

16:10–16:20  WS05.02–“Loge De Baréty”: What and Where It Is and Its Relation with the IASLC Lymph Node Map
Françoise Le Pimpec-Barthes, Assistance publique – Hôpitaux de Paris, France

16:20–16:30  WS05.03–How to Perform a Proper Systematic Nodal Dissection in Lung Cancer Surgery
Kyohei Masai, Keio University School of Medicine, Japan

16:30–16:40  WS05.04–Particularities of Lymphadenectomy in Malignant Pleural Mesothelioma
Andrea Bille, Guy’s Hospital NHS Foundation Trust, United Kingdom

16:40–16:50  WS05.05–Lymphnode Dissection in Thymic Malignancies: Implications of the ITMIG/IASLC Lymph Node Map of the Tnm Classification and Staging
Young Tae Kim, Seoul National University Hospital, Korea, Republic of

16:50–17:00  WS05.06–Relevance of Lymphadenectomy in Carcinoma of the Esophagus and of the Esophagogastric Junction
Gail Darling, University of Toronto, Canada

17:00–17:15  Q&A/Poll

15:45–17:15  CURRENT STRATEGIES TO IMPROVE OUTCOME OF PATIENTS WITH OLGOMETASTATIC NSCLC
Track(s): Oligometastatic NSCLC
Chair(s): Ernest Nadal, Spain; Françoise Mornex, France

15:45–16:00  ES21.01–Optimal Imaging for Staging of OMD
Klaus Irion, UT Southwestern Medical Center, United States of America

16:00–16:15  ES21.02–Biological Disease Characterization of OMD
Rafael Rosell, UT Southwestern Medical Center, United States of America

16:15–16:30  ES21.03–Interpreting the Current Data for Local Consolidative Treatment in the Setting of Oligometastatic Disease: Where Do We Stand?
Daniel Gomez, Memorial Sloan Kettering Cancer Center, United States of America
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30–16:45</td>
<td><strong>ES21.04</strong>– Optimal Systemic Treatment of OMD</td>
</tr>
<tr>
<td></td>
<td>Hideo Kunitoh, Japanese Red Cross Medical Center, Japan</td>
</tr>
<tr>
<td>16:45–17:00</td>
<td><strong>ES21.05</strong>– Clinical Trials to Advance the Field of OMD</td>
</tr>
<tr>
<td></td>
<td>Thierry Berghmans, Institut Jules Bordet, Belgium</td>
</tr>
<tr>
<td>17:00–17:15</td>
<td><strong>ES21.06</strong>– Q&amp;A</td>
</tr>
<tr>
<td></td>
<td><strong>GR03.04</strong>– Molecularly-Defined Thoracic Malignancies (NUT, SMARCA4 and Others Sarcomas) Akihiko Yoshida, National Cancer Center Hospital, Japan</td>
</tr>
<tr>
<td>16:45–17:00</td>
<td><strong>GR03.05</strong>– Grading of NSCLCs– Problems and Solutions</td>
</tr>
<tr>
<td></td>
<td>Andre Moreira, New York University School of Medicine, United States of America</td>
</tr>
<tr>
<td>17:00–17:15</td>
<td><strong>GR03.06</strong>– Q&amp;A</td>
</tr>
</tbody>
</table>

**MONDAY  SEPTEMBER 9**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30–16:45</td>
<td><strong>MA14.01</strong>– Clinical and Genomic Features of Chinese Lung Cancer Patients with Germline Mutations Wenying Peng, Hunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, China</td>
</tr>
<tr>
<td>15:45–15:50</td>
<td><strong>MA14.02</strong>– Entrectinib in Patients with ROS1-Positive NSCLC or NTRK Fusion-Positive Solid Tumors with CNS Metastases Luis Paz-Ares, 12 de Octubre University Hospital, Spain</td>
</tr>
<tr>
<td>15:50–15:55</td>
<td><strong>MA14.03</strong>– Discussant– MA14.01, MA14.02, MA14.03 Yuichiro Ohe, National Cancer Center Hospital, Japan</td>
</tr>
<tr>
<td></td>
<td><strong>MA14.04</strong>– A Randomized Phase III Trial of Fruquintinib Versus Placebo in Patients with Advanced Non-Small Cell Lung Cancer (FALUCA) Shun Lu, Shanghai Chest Hospital, China</td>
</tr>
<tr>
<td>16:15–16:20</td>
<td><strong>MA14.05</strong>– New Hope in SCLC? Leora Horn, Vanderbilt Ingram Cancer Center, United States of America</td>
</tr>
<tr>
<td>16:15–16:30</td>
<td><strong>MA14.06</strong>– A Randomized Phase III Trial of Fruquintinib Versus Placebo in Patients with Advanced Non-Small Cell Lung Cancer (FALUCA) Shun Lu, Shanghai Chest Hospital, China</td>
</tr>
<tr>
<td>16:25–16:30</td>
<td><strong>MA14.07</strong>– Phase I Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naïve Non-Small Cell Lung Cancer (JVDF) Roy Herbst, Yale University School of Medicine, United States of America</td>
</tr>
</tbody>
</table>

**ES22**

15:45–17:15 **IMMUNOTHERAPY–DISCOVERING NEW AREAS**

- **Vienna (2016)**

<table>
<thead>
<tr>
<th>Track(s):</th>
<th>Immuno-oncology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair(s):</td>
<td>Manuel Cobo, Spain; Antonio Araujo, Portugal</td>
</tr>
</tbody>
</table>

15:45–16:00 **ES22.01**– Immunotherapy in Resectable NSCLC

- Patrick Forde, Johns Hopkins University School of Medicine, United States of America

16:00–16:15 **ES22.02**– A Milestone in Locally Advanced NSCLC

- Solange Peters, Centre Hospitalier Universitaire Vaudois, Lausanne University, Switzerland

16:15–16:30 **ES22.03**– New Hope in SCLC?

- Leora Horn, Vanderbilt Ingram Cancer Center, United States of America

16:30–16:45 **ES22.04**– Any Chance in Mesothelioma

- Giorgio Scagliotti, University of Turin; San Luigi Gonzaga Hospital, Italy

16:45–17:00 **ES22.05**– Role in Thymic Epithelial Tumours

- Rina Hui, Westmead Hospital and the University of Sydney, Australia

17:00–17:15 **ES22.06**– Q&A

**GR03**

15:45–17:15 **PROBLEM AREAS FOR THE NEXT WHO CLASSIFICATION OF LUNG CANCERS**

- **Toronto (1985)**

<table>
<thead>
<tr>
<th>Track(s):</th>
<th>Pathology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair(s):</td>
<td>Ming Tsao, Canada; Johan Botling, Sweden</td>
</tr>
</tbody>
</table>

15:45–16:00 **GR03.01**– High Grade Neuroendocrine Tumors

- Mauro Giulio Papotti, University of Torino at Città della Salute Hospital, Italy

16:00–16:15 **GR03.02**– Adenocarcinoma

- Andrew Nicholson, Royal Brompton and Harefield NHS Trust, United Kingdom

16:15–16:30 **GR03.03**– Pleomorphic Carcinomas

- Alain Borczuk, Weill Cornell, United States of America
15:45–17:15 USAGE OF COMPUTER AND MOLECULAR ANALYSIS IN TREATMENT SELECTION AND DISEASE PROGNOSTICATION

**Track(s):** Pathology

**Chair(s):** John Le Quesne, United Kingdom; Noriko Motoi, Japan

**15:45–15:50 MA15.01**–Cellular Prion Protein Transcriptionally Regulated by NFIL3 Enhances Lung Cancer Cell Lamellipodium Formation and Migration
Shin-Chih Lin, Institute of Biochemistry and Molecular Biology, National Yang-Ming University, Taiwan

Jianghua Wu, Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), China

**15:55–16:00 MA15.03**–Exploring Digital Pathology-Based Morphological Biomarkers for a Better Patients’ Selection to the Immune Checkpoint Inhibitor of Lung Cancer
Noriko Motoi, National Cancer Center Hospital, Japan

**16:00–16:15 MA15.04**–Discussant—MA15.01, MA15.02, MA15.03
Anja C Roden, Mayo Clinic Rochester, United States of America

**16:15–16:20 MA15.05**–Computerized Measurements of Cellular Diversity on H&E Tissue Are Prognostic of OS and Associated with Mutational Status in NSCLC
Vamsidhar Velcheti, NYU Langone Cancer Center, United States of America

**16:20–16:25 MA15.06**–Stage I Lung Adenocarcinoma Gene Expression Associated with Aggressive Histologic Features for Guiding Precision Surgery and Therapy
Jiarui Zhang, Boston University, United States of America

**16:25–16:30 MA15.07**–Circulating miRNA: A Biomarker for Classification of Lung Cancer and Benign Lung Disease
Alvida Qvick, Region Örebro län, Sweden

**16:30–16:45 MA15.08**–Discussant—MA15.05, MA15.06, MA15.07
John Longshore, Carolinas Pathology Group, United States of America

**16:45–16:50 MA15.09**–PD-L1 Status in Relation with Non-Small Cell Lung Cancer Major Subtypes, Differentiation, Molecular Profiling and Smoking History
Zhaolin Xu, Dalhousie University/QUEII HSC, Canada

**16:50–16:55 MA15.10**–Stromal Markers of Activated Tumor Associated Fibroblasts Predict Poor Survival and Are Associated with Necrosis in Non-Small Cell Lung Cancer
Jordi Alcaraz, University of Barcelona, Spain

**16:55–17:00 MA15.11**–Establishing a Cell Sociology Platform for the Assessment of Targetable Interactions to Predict Lung Cancer Outcome
Erin Marshall, BC Cancer Research Centre, Canada

**17:00–17:15 MA15.12**–Discussant—MA15.09, MA15.10, MA15.11
David Hwang, Sunnybrook Heath Sciences Centre, Canada

**MA16**

**15:45–17:15 PRIORITIZING USE OF TECHNOLOGY TO IMPROVE SURVIVAL OF LUNG CANCER SUBGROUPS AND OUTCOMES WITH CHEMOTHERAPY AND SURGERY

**Track(s):** Treatment in the Real World—Support, Survivorship, Systems Research

**Chair(s):** Jair Bar, Israel; Manjit Bains, United States of America

**15:45–15:50 MA16.01**–Project PRIORITY: A Patient-Founded and Patient-Driven Research Partnership on Real-World Data on EGFR-Positive Lung Cancer
Ivy Ekins, EGFR Registers, United States of America

**15:50–15:55 MA16.02**–T790M Allelic Fraction Level Did Not Correlate Survival in T790M Positive NSCLC—Observations from an Early Access Program
Oscar Siu Hong Chan, Hong Kong Integrated Oncology Centre, Hong Kong PRC

**15:55–16:00 MA16.03**–Big Data Analysis for Personalized Medicine in Lung Cancer Patients
Maria Torrente, Hospital Puerta de Hierro, Spain

**16:00–16:15 MA16.04**–Discussant—MA16.01, MA16.02, MA16.03
Sukhmani Padda, Stanford Cancer Institute, United States of America
MA16.05 – Wearable Technology for Preconditioning Before Thoracic Surgery: A Feasibility Study
Yogita Patel, McMaster University / St. Joseph’s Healthcare Hamilton, Canada

16:15–16:20

16:20–16:25
MA16.06 – Deterioration in Health-Related Quality of Life Diminishes Benefit of Lung Cancer Resection in Older Adults
Jae Kim, City of Hope National Medical Center, United States of America

16:25–16:30
MA16.07 – Implementation of a Smartphone App to Face Postoperative Period in Patients with NSCLC Undergoing Lung Resection Surgery
Carlos Fraile Olivo, Hospital Universitari Arnau de Vilanova, Spain

16:30–16:45
MA16.08 – Discussant – MA16.05, MA16.06, MA16.07
Sabita Jiwnani, Tata Memorial Hospital, India

16:45–16:50
MA16.09 – Clinical Practice and Outcomes in Patients with Stage III Unresectable Non-Small-Cell Lung Cancer at an Academic Centre, Canada
Jason Agulnik, Jewish General Hospital, Lady Davis Institute, McGill University, Canada

16:50–16:55
MA16.10 – Antioxidative Effect of Erdosteine on Platinum-Based Doublet Chemotherapy Induced Nephrotoxicity
Chang Youl Lee, Hallym University Medical Center, Republic of Korea

16:55–17:00
MA16.11 – Early and Late Survival Comparison Between Oncological Versus Non-Oncological Patients Admitted to a General Intensive Care Unit in Chile
Suji Samtani, Clinica Alemana, Chile

17:00–17:15
Apar Kishor Ganti, University of Nebraska Medical Center, United States of America

MA17 – Molecular Mechanisms and Therapies

15:45–17:15

• Melbourne (1991)

Track(s): Biology

Chair(s): Eloisa Jantus-Lewintre, Spain; Hongbin Ji, China

15:45–15:50
MA17.01 – Cell Lineage and Chromatin Landscape of Lung Cancer Are Controlled by GATA6
Anna Arnal Estapé, Yale University School of Medicine, United States of America

15:50–15:55
MA17.02 – Identify Vulnerable Pathways and Improve Treatment Outcomes in LKB1-Deficient Lung Tumors
Meng Welliver, The Ohio State University, United States of America

15:55–16:00
MA17.03 – Importance of Cullin4 Ubiquitin Ligase in Malignant Pleural Mesothelioma
Mayura Meerang, University Hospital Zurich, Switzerland

16:00–16:15
MA17.04 – Discussant – MA17.01, MA17.02, MA17.03
Julian Carretero, University of Valencia, Spain

16:15–16:20
MA17.05 – DNA-Binding and Gene Expression Profiles in Max Deficient Small Cell Lung Cancer
Paula Llabata, Cancer Epigenetics and Biology Program-PEBC (IDIBELL), Spain

16:20–16:25
MA17.06 – Plakophilin 1 Enhances MYC Expression, Promoting Squamous Cell Lung Cancer
Pedro Medina, GENYO. Centre for Genomics and Oncological Research: Pfizer / University of Granada / Andalusian Regional Government, Spain

16:25–16:30
MA17.07 – Identification of AHR as a Novel Regulator of Lung Cancer Metastasis
Silke Nothdurft, University Hospital Essen, Germany

16:30–16:45
MA17.08 – Discussant – MA17.05, MA17.06, MA17.07
Paul Paik, Memorial Sloan Kettering Cancer Center, United States of America

16:45–16:50
MA17.09 – 5-Azacytidine Inhaled Dry Powder Formulation Profoundly Improves Pharmacokinetics and Efficacy for Lung Cancer Therapy
Steven Belinsky, Lovelace Respiratory Research Institute, United States of America

16:50–16:55
MA17.10 – Lactate Transporter Blockade as a Strategy to Overcome VEGF Inhibitor-Resistance in LKB1-Deficient NSCLC
John Heymach, The University of Texas MD Anderson Cancer Center, United States of America

16:55–17:00
MA17.11 – High Sensitivity to PD-1 Blockade Therapy After Ld1 Depletion in KRAS-Driven Lung Cancer Through CD8+/CD3+ Tumor Infiltration and PD-L1 Induction
Iosune Baraibar, Clínica Universidad de Navarra, Spain

17:00–17:15
MA17.12 – Discussant – MA17.09, MA17.10, MA17.11
Shantanu Banerji, CancerCare Manitoba, Canada
MA22 Accredited Session

15:45–17:15 PARTNERING WITH PATIENTS TO UNDERSTAND STIGMA, DISPARITIES AND VALUES LEADING TO IMPROVED LUNG CANCER CARE

Chair(s): Diego Villalón, Spain; Christina Sit, Canada

15:45–15:55 MA22.01–Lung Cancer Patients’ Unique Values and Preferences Lead to Clinical Trial Preferences
Andrew Ciupek, GO2 Foundation for Lung Cancer, United States of America

15:50–15:55 MA22.02–The Impact of Patient Engagement on Study Design and Patient Recruitment in a Pragmatic Trial to Improve Cancer Care Delivery
Bernardo Haddock Lobo Goulart, Fred Hutchinson Cancer Research Center, United States of America

15:55–16:00 MA22.03–The ROS1ders: Partnering to Drive Research and Improve Outcomes in ROS1+ Cancers
Janet Freeman-Daily, The ROS1ders, United States of America

16:00–16:15 MA22.04–Discussant–MA22.01, MA22.02, MA22.03
Kazuhiro Hasegawa, Japan Lung Cancer Alliance, Japan

16:15–16:20 MA22.05–Assessment of Gender Differences in the Psychosocial and Economic Impact on Patients with Stage IV Non-Small Cell Lung Cancer
Pilar Garrido, Hospital Universitario Ramón y Cajal, Spain

16:20–16:25 MA22.06–Longer Lung Cancer Time Intervals Amongst Culturally and Linguistically Diverse Patient Than Anglo-Australian Patients
Kenneth O’Byrne, Princess Alexandra Hospital and Queensland University of Technology, Australia

16:25–16:30 MA22.07–A Culturally Safe Advocacy Model of Care for Inuit Cancer Patients and Their Families
Carolyn Roberts, The Ottawa Hospital, Canada

16:30–16:45 MA22.08–Discussant–MA22.05, MA22.06, MA22.07
Clarissa Baldotto, Oncologia D’Or, Brazil

16:45–16:50 MA22.09–Challenging Negative Stereotypes Around Lung Cancer in Ireland
Anne-Marie Baird, Trinity College Dublin, Ireland

16:50–16:55 MA22.10–The Role of Stigma in Differential Care for Lung Cancer Patients: A Decade of Patient and Oncologist Attitudes
Jennifer King, GO2 Foundation for Lung Cancer, United States of America

16:55–17:00 MA22.11–An Empathic Communication Skills Training Module to Reduce Lung Cancer Stigma in Patients with Lung Cancer: Pilot Results
Jamie Ostroff, Memorial Sloan Kettering Cancer Center, United States of America

17:00–17:15 MA22.12–Discussant–MA22.09, MA22.10, MA22.11
Lisa Carter-Harris, Memorial Sloan Kettering Cancer Center, United States of America

MS1 Accredited Session

15:45–17:15 LUNG CANCER SCREENING, OPPORTUNISTIC EVALUATION OF FINDINGS

Chair(s): Dorith Shaham, Israel; Eduard Monsó, Spain

15:45–15:55 MS10.01–COPD/Emphysema
Javier Zulueta, Clinica Universidad de Navarra, Spain

15:55–16:05 MS10.02–Coronary Artery Diseases
Joseph Shemesh, Sheba Medical Center Affiliated to Tel Aviv University, Israel

16:05–16:15 MS10.03–Aortic Valve Calcifications
Yeqing Zhu, Icahn School of Medicine at Mount Sinai Hospital, United States of America

16:15–16:25 MS10.04–Liver–Pulmonary Disease
Andrea Branch, Icahn School of Medicine at Mount Sinai, United States of America

16:25–16:35 MS10.05–Osteoporosis
Jessica Gonzalez-Gutierrez, Arnau de Vilanova-Santa María University Hospital, Spain

16:35–16:45 MS10.06–Interstitial Lung Diseases
Mary Salvatore, Columbia University Medical Center, United States of America

16:45–16:55 MS10.07–Breast Evaluation
Laurie Margolies, Icahn School of Medicine at Mount Sinai, United States of America

16:55–17:15 MS10.08–Q&A

MS11 Accredited Session

15:45–17:30 ADDRESSING CHALLENGES WITH SURGICAL RESECTION OF LUNG CANCER

Chair(s): Ramon Rami-Porta, Spain; Haruhiko Kondo, Japan

15:45–16:00 MS11.01–Neoadjuvant Chemotherapy or Neoadjuvant Chemoradiation for Potentially Resectable NSCLC—a Surgeon’s Perspective
Ricardo Terra, Cancer Institute, University of São Paulo, Brazil

16:00–16:15 MS11.02–Role of Surgery in Oligometastatic NSCLC
C S Pramesh, Tata Memorial Centre, India

16:15–16:30 MS11.03–Minimizing Peri-Operative Morbidity with Pneumonectomy
Shun-ichi Watanabe, National Cancer Center Hospital, Japan
**MS11.04 – Surgical Resection of SCLC – Not so Obsolete Any Longer**
Gustavo Lyons, Buenos Aires British Hospital, Argentina

**MS11.05 – Pathological Reporting of Resected Lung Cancer – the Importance of Using Additional TNM Descriptors**
Ellen Nascimento, Hospital das Clínicas, Faculdade de Medicina, Universidade de Sao Paulo, Brazil

**MS11.06 – The Impact of Prehabilitation on Patients Having Lung Cancer Surgery**
David Sanchez-Lorente, Hospital Clinic of Barcelona, Spain

**OA12.01 – PCI for Radically Treated Non-Small Cell Lung Cancer: A Meta-Analysis Using Updated Individual Patient Data of Randomized Trials**
Willem Witlox, Maastricht University Medical Center, Netherlands

**OA12.02 – Randomized Phase II Study of CDDP+S-1 vs CDDP+PEM Combined with Thoracic RT for Locally Advanced Non-Sq NSCLC: SPECTRA Study**
Takashi Seto, National Organization Hospital Kyushu Cancer Center, Japan

**OA12.03 – Initial Reporting of NRG-LU001, Randomized Phase II Trial of Concurrent Chemoradiotherapy +/- Metformin HCL in Locally Advanced NSCLC**
Heath Skinner, UPMC Hillman Cancer Center, United States of America

**OA12.04 – Discussant – OA12.01, OA12.02, OA12.03**
Everett Vokes, University of Chicago Medical Center, United States of America

**OA12.05 – Imaging-Guided Target Volume Reduction in Radiotherapy of Lung Cancer: The Prospective Randomized Multinational PET-Plan Trial**
Eleni Gkika, University Medical Center, Germany

**OA12.06 – A Prospective Randomized Phase III Study of Precise PORT for Patients with pIIIA-N2 NSCLC After Complete Resection and Adjuvant Chemotherapy**
Zhouguang Hui, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China

**OA12.07 – Discussant – OA12.05, OA12.06, OA12.07**
José Belderbos, The Netherlands Cancer Institute, Netherlands

**OA12.08 – James D. Cox Lectureship Award for Radiation Oncology**
Corinne Faivre-Finn, The Christie-University of Manchester, United Kingdom

**PC03**

**15:45 – 17:15 ADJUVANT THERAPY FOR RESECTED NSCLC HARBORING EGFR MUTATION, CHEMOTHERAPY OR TARGETED THERAPY**

**Track(s):**
- Targeted Therapy

**Chair(s):**
- James Yang, Taiwan
- Elisa Gobbini, France

**15:45 – 16:05 PC03.01 – PROs**
Wen-Zhao Zhong, Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital & Guangdong Academy of Medical Sciences, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, China

**16:05 – 16:25 PC03.02 – CONs**
Jyoti Patel, University of Chicago, United States of America

**16:25 – 16:45 PC03.03 – Future Strategies in Early Stage EGFR-mut NSCLC**
Vassiliki Papadimitrakopoulou, UT/MD Anderson Cancer Center, United States of America

**16:45 – 17:15 PC03.04 – Q&A**

**17:15 – 18:15 POSTER VIEWING RECEPTION**
- Exhibit Hall, Level 2, Hall 8.1
Nurse & Allied Health Professional Lounge

LOCATED JUST OUTSIDE THE EXHIBIT HALL

A dedicated networking area exclusively accessible to all nurses and allied health professionals attending the IASLC 2019 WCLC. Located just outside the exhibit hall, you can just relax or meet with other colleagues. Refreshments will be served throughout the day and a variety of seating will be available.

HOURS
Saturday, September 7  20:30 – 22:00
Sunday, September 8  09:30 – 18:30
Monday, September 9  09:30 – 18:30
Tuesday, September 10  09:30 – 14:00
Daily Scientific Program  Tuesday, Sept. 10

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>06:30–17:00</td>
<td>Coat and Baggage Check</td>
</tr>
<tr>
<td>06:30–15:30</td>
<td>Registration Open</td>
</tr>
<tr>
<td>06:30–15:00</td>
<td>Speaker Preview Center Open</td>
</tr>
<tr>
<td>08:00–18:00</td>
<td>Media Room Open</td>
</tr>
<tr>
<td>08:30–14:00</td>
<td>Exhibits Open</td>
</tr>
<tr>
<td>07:00–08:00</td>
<td>CME Accredited Session</td>
</tr>
</tbody>
</table>

**IBS23**

**TREATMENT OF NSCLC OMD IN CLINICAL PRACTICE**

- **Track(s):** Oligometastatic NSCLC
- **Toronto (1985)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00–07:10</td>
<td>IBS23.01—Radiotherapy of OMD in Daily Clinical Practice</td>
</tr>
<tr>
<td>07:10–07:20</td>
<td>IBS23.02—Oncological Treatment of Omd in Daily Clinical Practice</td>
</tr>
<tr>
<td>07:20–07:30</td>
<td>IBS23.03—Surgical Treatment of OMD in Daily Clinical Practice</td>
</tr>
</tbody>
</table>

**IBS21**

**COMBATING TOXICITY OF IO-CHEMOTHERAPY COMBINATIONS**

- **Track(s):** Treatment in the Real World—Support, Survivorship, Systems Research
- **Vienna (2016)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00–07:20</td>
<td>IBS21.01—Enhanced Toxicity of IO with Concurrent Chemotherapy</td>
</tr>
<tr>
<td>07:20–07:40</td>
<td>IBS21.02—Real World Toxicities of Radiation Plus IO in NSCLC</td>
</tr>
</tbody>
</table>

**IBS24**

**OPTIMAL IMMUNOTHERAPY SEQUENCE IN STAGE IV NSCLC**

- **Track(s):** Immuno-oncology
- **Interlaken (1988)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00–07:20</td>
<td>IBS24.01—IO/CT First line Always</td>
</tr>
<tr>
<td>07:20–07:40</td>
<td>IBS24.02—IO Followed by Chemo or Chemo Followed by IO</td>
</tr>
</tbody>
</table>

**IBS22**

**JTO WORKSHOP: HOW TO GET YOUR MANUSCRIPT PUBLISHED**

- **Track(s):** Young Investigators
- **Tokyo (1982)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00–07:20</td>
<td>IBS22.01—JTO Workshop: How to Get Your Manuscript Published</td>
</tr>
<tr>
<td>07:20–07:40</td>
<td>IBS22.02—JTO Workshop: The Life Cycle of a Manuscript</td>
</tr>
</tbody>
</table>

**IBS25**

**OPTIMAL GGO MANAGEMENT**

- **Track(s):** Treatment of Early Stage/Localized Disease
- **Melbourne (1991)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00–07:20</td>
<td>IBS25.01—Eastern Perspective</td>
</tr>
<tr>
<td>07:20–07:40</td>
<td>IBS25.02—Western Perspective</td>
</tr>
</tbody>
</table>

**IBS20**

**IBS20**

**TREATMENT OF NSCLC OMD IN CLINICAL PRACTICE**

- **Track(s):** Oligometastatic NSCLC
- **Toronto (1985)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00–07:10</td>
<td>IBS20.01—Radiotherapy of OMD in Daily Clinical Practice</td>
</tr>
<tr>
<td>07:10–07:20</td>
<td>IBS20.02—Oncological Treatment of Omd in Daily Clinical Practice</td>
</tr>
<tr>
<td>07:20–07:30</td>
<td>IBS20.03—Surgical Treatment of OMD in Daily Clinical Practice</td>
</tr>
</tbody>
</table>

**IBS21**

**COMBATING TOXICITY OF IO-CHEMOTHERAPY COMBINATIONS**

- **Track(s):** Treatment in the Real World—Support, Survivorship, Systems Research
- **Vienna (2016)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00–07:20</td>
<td>IBS21.01—Enhanced Toxicity of IO with Concurrent Chemotherapy</td>
</tr>
<tr>
<td>07:20–07:40</td>
<td>IBS21.02—Real World Toxicities of Radiation Plus IO in NSCLC</td>
</tr>
</tbody>
</table>

**IBS24**

**OPTIMAL IMMUNOTHERAPY SEQUENCE IN STAGE IV NSCLC**

- **Track(s):** Immuno-oncology
- **Interlaken (1988)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00–07:20</td>
<td>IBS24.01—IO/CT First line Always</td>
</tr>
<tr>
<td>07:20–07:40</td>
<td>IBS24.02—IO Followed by Chemo or Chemo Followed by IO</td>
</tr>
</tbody>
</table>

**IBS22**

**JTO WORKSHOP: HOW TO GET YOUR MANUSCRIPT PUBLISHED**

- **Track(s):** Young Investigators
- **Tokyo (1982)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00–07:20</td>
<td>IBS22.01—JTO Workshop: How to Get Your Manuscript Published</td>
</tr>
<tr>
<td>07:20–07:40</td>
<td>IBS22.02—JTO Workshop: The Life Cycle of a Manuscript</td>
</tr>
</tbody>
</table>

**IBS25**

**OPTIMAL GGO MANAGEMENT**

- **Track(s):** Treatment of Early Stage/Localized Disease
- **Melbourne (1991)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00–07:20</td>
<td>IBS25.01—Eastern Perspective</td>
</tr>
<tr>
<td>07:20–07:40</td>
<td>IBS25.02—Western Perspective</td>
</tr>
</tbody>
</table>
**TUESDAY SEPTEMBER 10**

**07:00–08:00 TREATMENT TECHNIQUES FOR LOCALIZED THERAPY IN MALIGNANT PLEURAL MESOTHELIOMA**

Track(s): Mesothelioma

- IBS26.01–Treatment Planning for Pleural Imrt (Imprint)
  Andreas Rimner, Memorial Sloan Kettering Cancer Center, United States of America

- IBS26.02–Role of Extrapleural Pneumonectomy Compared to Pleurectomy Decortication: When and How?
  Walter Weder, University of Zürich, Switzerland

- IBS26.03–Surgical Technique of Pleurectomy/Decortication
  David Waller, St Bartholomew’s Hospital, Barts Health NHS Trust, United Kingdom

- IBS26.04–Q&A

**07:00–08:00 CHESTWALL TUMORS**

Track(s): Thymoma/Other Thoracic Malignancies

- IBS27.01–Endoscopic Treatment of Unresectable Management of Chest Wall Tumors (Except Sternum)
  Gaetano Rocco, Memorial Sloan Kettering Cancer Center, United States of America

- IBS27.02–Sternal Resection and Reconstruction
  Stephen Cassivi, Mayo Clinic, United States of America

- IBS27.03–Q&A

**07:00–08:00 RISK ASSESSMENT IN CT SCREENING**

Track(s): Screening and Early Detection

- IBS30.01–Risk Assessment to Establish Screening Programs: The Australian Point of View
  Annette Mcwilliams, University of Western Australia, Australia

- IBS30.02–Risk Assessment to Establish Screening Programs: The European Point of View
  Marjolein Heuvelmans, University Medical Center Groningen, Netherlands

---

**IBS26**

**IBS28**

**IBS29**

**IBS27**

**IBS30**
07:20–07:30  IBS30.03–Risk Assessment to Establish Screening Programs: The Canadian Point of View  
Stephen Lam, BC Cancer Agency, Canada

07:30–08:00  IBS30.04–Q&A

**DAILY SCIENTIFIC PROGRAM**

**6**  
**TUESDAY**  
**SEPTEMBER 10**  
**CME Accredited Session**

**PL03**  
**PLENARY SESSION**

09:15–10:45  
**RELEVANT ASPECTS OF LUNG CANCER MANAGEMENT**

- Barcelona (2005)

**Track(s):** Advanced NSCLC, Advocacy, Biology, Immuno-oncology, Interventional Diagnostics/Pulmonology, Mesothelioma, Nursing and Allied Professionals, Oligometastatic NSCLC, Pathology, Prevention and Tobacco Control, Screening and Early Detection, Small Cell Lung Cancer/NET, Staging, Targeted Therapy, Thymoma/Other Thoracic Malignancies, Treatment in the Real World–Support, Survivorship, Systems Research, Treatment of Early Stage/Localized Disease, Treatment of Locoregional Disease–NSCLC

**Chair(s):** Rakesh Kapoor, India; Antoni Rosell, Spain

09:15–09:30  
**PL03.01**–Establishing a Nurse Led Follow-Up Service for Patients With Resected Early Stage Lung Cancer  
Jenny Mitchell, Oxford University Hospitals NHS Foundation Trust, United Kingdom

09:30–09:45  
**PL03.02**–Bringing Immunotherapy into the Curative Setting: Emerging Data on Neoadjuvant Strategies  
Jamie Chaft, Memorial Sloan Kettering Cancer Center, United States of America

09:45–10:00  
**PL03.03**–The Disparity of Lung Cancer Prevention, Diagnosis and Treatment Around the World…What Is the Role of IASLC  
Suresh Ramalingam, Winship Cancer Institute of Emory University, United States of America

10:00–10:15  
**PL03.04**–Lung Cancer and Tuberculosis: Parallel Lives  
T Molnar, University of Pécs, Hungary

**PR04**  
**PRESS CONFERENCE**

10:45–11:30  
**PRESS CONFERENCE**

- CC7.1 A&B

10:45–10:54  
**PR04.01**–Impower131: Final OS Results of Carboplatin + Nab-Paclitaxel ± Atezolizumab in Advanced Squamous NSCLC  
Federico Cappuzzo, Azienda Unità Sanitaria Locale della Romagna, Ravenna, Italy

10:54–11:03  
**PR04.02**–Five-Year Outcomes From the Randomized, Phase 3 Trials CheckMate 017/057: Nivolumab vs Docetaxel in Previously Treated NSCLC  
Scott Gettinger, Yale Comprehensive Cancer Center, New Haven, United States

11:03–11:12  
**PR04.03**–KEYNOTE-024 3-Year Survival Update: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer  
Martin Reck, Lung Clinic Grosshansdorf, Airway Research Center North (ARCN), Grosshansdorf, Germany

11:12–11:21  
**PR04.04**–Challenges in Lung Cancer Clinical Trials: A European Perspective  
Anne-Marie Baird, Lung Cancer Europe, Dublin, Ireland
11:30–13:00 ES23
OPTIMAL MANAGEMENT OF N2 DISEASE IN THE ERA OF IO

Track(s): Treatment of Locoregional Disease–NSCLC

ES23.01 – Mediastinoscopy with Invasive Staging: Are They Still Crucial?
Akif Turna, İstanbul University, Turkey

ES23.02 – Which N2 Patients Are Candidates to Surgery in the Era If I/O?
Eric Vallieres, Swedish Cancer Institute, United States of America

ES23.03 – Is CT/RT Followed by I/O the Standard of Care for All N2 and Selected N3 Patients?
Wilfried Eberhardt, West German Cancer Centre, Germany

ES23.04 – Optimal Supportive Care During and After Concurrent Chemoradiotherapy and I/O
Dirk De Ruyscher, Maastricht University Medical Center, Netherlands

ES23.05 – The Future of Systemic Therapy in Stage III
Pilar Garrido, Hospital Universitario Ramón y Cajal, Spain

11:30–13:00 MA18
ADVANCES IN DIAGNOSIS OF COMMON TYPES OF NSCLC

Track(s): Pathology

MA18.01 – Patient-Derived Xenografts of Lung Squamous Cell Carcinoma Show a Characteristic Genetic Profile Indicating a Specific Biological Subtype
Yunjung Kim, University of Tsukuba, Japan

MA18.02 – S100A10 Upregulation Associates with Poor Prognosis in Lung Squamous Cell Carcinoma
Kimiaki Sato, Institution of Development, Aging and Cancer, Tohoku University, Japan

MA18.03 – Distinction Between Primary Lung Cancer and Pulmonary Metastasis of Esophageal Cancer Using the Nanostring nCounter System
Junji Ichinose, Cancer Institute Hospital, JFCR, Japan

MA18.04 – Discussant – MA18.01, MA18.02, MA18.03
Jin-Haeng Chung, Seoul National University, Korea, Republic of

MA18.05 – Diagnostic Difference Between Neuroendocrine Markers in Pulmonary Cancers: A Comprehensive Study and Review of the Literature
Hans Brunnström, Laboratory Medicine Region Skåne, Sweden

MA18.06 – Gene Expression and Clustering of Pulmonary Neuroendocrine Tumors at the Border of Low/Intermediate and High Grade Morphology
Olga Sazonova, University Laval, Canada

MA18.07 – Identification of Neuroendocrine Transformation in Anaplastic Lymphoma Kinase Rearranged (ALK+) Tumors After Tyrosine Kinase Inhibitors
Prodipto Pal, University Health Network, Canada

MA18.08 – Discussant – MA18.05, MA18.06, MA18.07
Giuseppe Pelosi, University of Milan, Italy

MA18.09 – Protein Profiling of Small Lung Adenocarcinomas: An In-Depth Analysis
Tomoko Dai, University of Tsukuba Hospital, Japan

11:30–13:00 ES24
DIAGNOSIS AND MANAGEMENT OF SIDE EFFECTS OF IMMUNOTHERAPY

Track(s): Immuno-oncology

ES24.01 – Recognizing Toxicities in an Early Phase in PDL1 Treatment
Hossein Borghaei, Fox Chase Cancer Center, United States of America

ES24.02 – Renal Toxicities in Combination I/O Chemotherapy Treatment
Joachim Aerts, Erasmus Cancer Institute, Erasmus Medical Centre, Netherlands

11:30–13:00 WCLC2019.IASLC.ORG
DAILY SCIENTIFIC PROGRAM
6
CS Controversy Session
ES Educational Session
GR Grand Round Session
IBS Interactive Breakfast Sessions (TICKETED SESSION)
MA Mini Oral Abstract Session
MS Mini Symposium
OA Oral Abstract Session
OC Opening Ceremony
PC Pro-Con Session
PL Plenary Session
SH Highlights of the Previous Day
WS Workshop (ticketed sessions)
YI Young Investigator Session

11:21–11:30 PR04.05 – Establishing a Nurse Led Follow-Up Service for Patients With Resected Early Stage Lung Cancer
Jenny Mitchell, Oxford University Hospitals NHS Foundation Trust, Thoracic Surgery, Oxford, United Kingdom

12:10–12:30 ES24.03 – Management of Immunerelated Toxicities Unresponsive to Steroids
Anne Tsao, MD Anderson Cancer Center, United States of America

12:30–13:00 ES24.04 – Q&A
12:35–12:40 **MA18.10**–Multicenter Study of Intraoperative Rapid IHC for Undiagnosed Pulmonary Tumor Using Non-Contact Alternating-Current Electric-Field Mixing
Kazuhiro Imai, Akita University Graduate School of Medicine, Japan

12:40–12:45 **MA18.11**–SNA12 Is the Most Highly Differential Expressed Genes Between the Adenomatous and Squamous Components of Lung Adenosquamous Cell Carcinoma
Xiaohua Shi, Peking Union Medical College Hospital, China

12:45–13:00 **MA18.12**–Discussant–MA18.09, MA18.10, MA18.11
Deepali Jain, All India Institute of Medical Sciences, India

**MA19**

**LOOKING AT PROS IN GREATER DETAIL—WHAT PATIENTS ACTUALLY WANT AND EXPECT**

<table>
<thead>
<tr>
<th>Track(s):</th>
<th>Treatment in the Real World—Support, Survivorship, Systems Research</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair(s):</td>
<td>Joaquin Bosch-Barrera, Spain; Virginia Calvo De Juan, Spain</td>
</tr>
</tbody>
</table>

11:30–11:35 **MA19.01**–Empirical Identification of Distress Clusters in Lung Cancer Patients
Mary Ellen Hand, Rush University Cancer Center, United States of America

Bea Brown, University of Sydney, Australia

11:40–11:45 **MA19.03**–Differences in Symptom Burden Between Responsive and Progressive Disease in Advanced Non-Small Cell Lung Cancer (aNSCLC)
George Simon, UT/MD Anderson Cancer Center, United States of America

11:45–12:00 **MA19.04**–Discussant–MA19.01, MA19.02, MA19.03
Gilberto Castro, Instituto do Cáncer do Estado de São Paulo, Brazil

12:00–12:05 **MA19.05**–Improving Lung Cancer Outcomes and Quality in the US Community Setting with the Creation of Lung Cancer Centers of Excellence Program
Luis Raez, Memorial Cancer Institute/Florida International University, United States of America

12:05–12:10 **MA19.06**–Successful Development of Realtime Automatically Updated Data Warehouse in Health Care (ROOT-S)
Hyon Ae Jung, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea, Republic of

12:10–12:15 **MA19.07**–Testing an Optimal Care Coordination Model (OCCM) for Lung Cancer in a Multi-Site Study
Matthew Smeltzer, University of Memphis, United States of America

12:15–12:30 **MA19.08**–Discussant–MA19.05, MA19.06, MA19.07
Riyaz Shah, Kent Oncology Centre, United Kingdom

Fabio Gomes, The Christie NHS Foundation Trust, United Kingdom

12:35–12:40 **MA19.10**–Estimation of Quality-Adjusted Life Expectancy for Stage and Systemic Treatment in Non-Small Cell Lung Cancer in Rajavithi Hospital, Thailand
Sunatee Sa-Nguansai, College of Medicine, Rangsit University, Thailand

12:40–12:45 **MA19.11**–Population Based Analysis of End of Life Treatment Patterns in Thoracic Malignancies
Graham Pitson, Barwon Health, Australia

Flavia Amaral Duarte, Oncocentro, Brazil

**MA20**

**THYMIC TUMORS: FROM MOLECULAR TO CLINICAL RESULTS AND NEW CHALLENGES IN OTHER RARE THORACIC TUMORS**

<table>
<thead>
<tr>
<th>Track(s):</th>
<th>Thymoma/Other Thoracic Malignancies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair(s):</td>
<td>Kazuya Kondo, Japan; Edith Marom, Israel</td>
</tr>
</tbody>
</table>

11:30–11:35 **MA20.01**–Global Quantitative Mass Spectrometry Reveals Potential Novel Actionable Targets in Thymic Epithelial Tumors (TET)
Udayan Guha, Center for Cancer Research, NCI, NIH, United States of America

11:35–11:40 **MA20.02**–GADI Expression and Its Methylation Become Indicators of Malignant Behavior in Thymic Epithelial Tumor
Shiho Soejima, Graduate School of Biomedical Sciences, Tokushima University, Japan

11:40–11:45 **MA20.03**–DNA Methylation of MT1A and NPTX2 Genes Predict Malignant Behavior of Thymic Epithelial Tumors
Sunatee Sa-Nguansai, College of Medicine, Rangsit University, Thailand

11:45–12:00 **MA20.04**–Discussant–MA20.01, MA20.02, MA20.03
Nicolas Girard, Institut Curie, France

12:00–12:05 **MA20.05**–Follow-Up Update of 2 Phase II Studies of Pembrolizumab in Thymic Carcinoma
Giuseppe Giaccone, Georgetown University, United States of America

12:05–12:10 **MA20.06**–Neutrophil to Lymphocyte Ratio Is an Independent Prognostic Predictor in Thymoma
Paulo De Sousa, Royal Brompton & Harefield NHS Foundation Trust, United Kingdom

12:10–12:15 **MA20.07**–Thymectomy and Total Thymectomy or Simple Thymectomy for Early Stage Thymoma Without Myasthenia
Gravis: An ESTS Thymic Working Group Study
Francesco Guerrera, University of Torino, Italy
12:15–12:30  **MA20.08**–Discussant–**MA20.05, MA20.06, MA20.07**
Meinoshin Okumura, Osaka Toneyama Medical Center, Japan

12:30–12:35  **MA20.09**–Breast Implant Associated Anaplastic Large Cell Lymphoma: Outcomes of a Newly-Recognized Malignancy of the Thoracic Wall
Mark Clemens, MD Anderson Cancer Center, University of Texas, United States of America

12:35–12:40  **MA20.10**–Long-Term Prognostic Factors After Minimally Invasive Esophagectomy (MIE) for Esophageal Cancer
Yu-Han Huang, National Taiwan University Hospital, Taiwan

12:40–12:45  **MA20.11**–Surgical Treatment for Metastatic Lung Tumors from Sarcomas of Soft Tissue and Bone
Hiromasa Yamamoto, Okayama University Hospital, Japan

12:45–13:00  **MA20.12**–Discussant–**MA20.09, MA20.10, MA20.11**
Scott Swanson, Brigham and Women’s Hospital, United States of America

---

**MS13**

11:30–13:00  **IMMUNOTHERAPY FOR MESOTHELIOMA**
● Seoul (2007)

**Track(s):** Mesothelioma

**Chair(s):** Arnaud Scherpereel, France; Roberto Ferrara, Italy

11:30–11:40  **MS13.01**–Immunotherapy and Mesothelioma: Rationale and Strategies
Jan Van Meerbeeck, Antwerp University Hospital, Belgium

11:40–12:00  **MS13.02**–Pro–Hedy Kindler Is Right (Immunotherapies Work for Mesothelioma)
Hedy Kindler, University of Chicago, United States of America

12:00–12:20  **MS13.03**–Con–Raphael Bueno Is Right (It Does Not Work)
Raphael Bueno, Brigham and Women’s Hospital, United States of America

12:20–12:30  **MS13.04**–Biomarkers of Anti-PD1 Therapy in Mesothelioma
Paul Baas, Netherlands Cancer Institute, Netherlands

12:30–12:40  **MS13.05**–CAR T Cell in Mesothelioma
Prasad Adusumilli, Memorial Sloan Kettering Cancer Center, United States of America

12:40–12:50  **MS13.06**–Role of Second Line Chemotherapy and New Target Treatment in Recurrent Mesothelioma
Silvia Novello, University of Turin, Italy

12:50–13:00  **MS13.07**–Q&A

---

**MS12**

11:30–13:00  **GENOME SCREENINGS**
● Vancouver (2003)

**Track(s):** Biology

**Chair(s):** Wan Lam, Canada; Julian Carretero, Spain

11:30–11:45  **MS12.01**–Circulating Biomarkers
Caroline Dive, University of Manchester, United Kingdom

11:45–12:00  **MS12.02**–Genomic and Functional Approaches to Understanding Cancer Aneuploidy
Alison Taylor, Dana-Farber Cancer Institute and Broad Institute, United States of America

12:00–12:15  **MS12.03**–LC-SCRM-Japan, a Pan-Japan Genetic Screening of Lung Cancer
Koichi Goto, National Cancer Center Hospital East, Japan

12:15–12:30  **MS12.04**–The International Lung Cancer Consortium (ILCCO), an International Study to Identify Risk Factors for Lung Cancer Development
Rayjean J Hung On Behalf Of The International Lung Cancer Consortium, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Canada

12:30–12:45  **MS12.05**–Genomic Studies on Small Cell Lung Cancer
Julie George, University of Cologne, Germany

12:45–13:00  **MS12.06**–Q&A

---

**MS14**

11:30–13:00  **MOLECULAR SUBSETS AND NOVEL TARGETED APPROACHES TO SMALL CELL AND NEUROENDOCRINE CANCERS**
● Colorado Springs (1994)

**Track(s):** Small Cell Lung Cancer/NET

**Chair(s):** Anna Farago, United States of America; Raffaele Califano, United Kingdom

11:30–11:45  **MS14.01**–Molecular Subsets of Neuroendocrine Tumors
Christine Hann, Johns Hopkins University School of Medicine, United States of America

11:45–12:00  **MS14.02**–Subclonal Architecture and Genomic Evolution of SCLC
Jinghui Wang, Beijing Chest Hospital, China

12:00–12:15  **MS14.03**–Targeting Transcription (Including Lurbinectedin)
Camilla Christensen, Dana-Farber Cancer Institute, United States of America
11:50 – 12:00 | OA13.03 – OA13.03-Predicting Postoperative Recurrence in Completely Resected EGFR-Mutant Non-Small Cell Lung Cancer: Value of IHC Markers
Zhengfei Zhu, Fudan University Shanghai Cancer Center, China

12:00 – 12:10 | OA13.04 – Discussant – OA13.01, OA13.02, OA13.03
Kemp Kernstine, University of Texas Southwestern, United States of America

12:10 – 12:20 | OA13.05 – NADIM Study: Updated Clinical Research and Outcomes
Mariano Provencio, Spain

11:30 – 11:40 | OA14.01 – KEYNOTE-024 3-Year Survival Update: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer
Martin Reck, Lung Cancer Grosshansdorf, Germany

11:40 – 11:50 | OA14.02 – IMpower131: Final OS Results of Carboplatin + Nab-Paclitaxel ± Atezolizumab in Advanced Squamous NSCLC
Federico Cappuzzo, Azienda Unità Sanitaria Locale della Romagna, Italy

11:50 – 12:00 | OA14.03 – Clinical Rationale and Preclinical Evidence for Chimeric Antigen Receptor (CAR) T Cell Therapy Clinical Trial in KRAS-Mutant Lung Cancer
Janna Minehart, Memorial Sloan Kettering Cancer Center, United States of America
12:00–12:10 OA14.04—Five-Year Survival Outcomes from CheckMate 017/057: Nivolumab Versus Docetaxel in Previously Treated Advanced NSCLC
Scott Gettinger, Yale Comprehensive Cancer Center, United States of America
Jay Lee, UCLA, United States of America
12:25–12:35 OA14.06—Hyperprogressive Disease in Advanced Non–Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors
Giuseppe Lo Russo, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Italy
12:35–12:45 OA14.07—Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced NSCLC Treated with Immunotherapy
Youjin Kim, Samsung Medical Center, Sungkyunkwan University School of Medicine; Samsung Changwon Hospital; Sungkyunkwan University School of Medicine, Changwon, Republic of Korea
12:45–13:00 OA14.08—Discussant—OA14.06, OA14.07
Kazuhiko Nakagawa, Kindai University Faculty of Medicine, Japan

ES25
14:30–16:00 LIQUID BIOPSY
● Colorado Springs (1994)
Track(s): Treatment of Early Stage/Localized Disease
Chair(s): Caroline Dive, United Kingdom; Max Diehn, United States of America
14:30–14:50 ES25.01—Liquid Biopsy: State of the Science
Eloisa Jantus-Lewintre, Molecular Oncology Laboratory, General University Hospital Research Foundation, Spain
14:50–15:10 ES25.02—Liquid Biopsy: Utility for Surveillance in Early Stage
Lecia Sequist, Harvard Medical School and Massachusetts General Hospital, United States of America
15:10–15:30 ES25.03—Leveraging the Quantitative Nature of Cfdna Genotyping for Lung Cancer Care
Cloud Paweletz, Dana-Farber Cancer Institute, United States of America
Ana Vivancos, Vall d’Hebron University Hospital and Institute of Oncology (VHIO), Spain
15:50–16:00 ES25.05—Q&A

PC04
11:30–13:00 IS CHEMOTHERAPY NECESSARY FOR ADVANCED NSCLC PATIENTS WITH PD-L1 50% OR MORE?
● Copenhagen (1980)
Track(s): Advanced NSCLC
Chair(s): Margarita Majem, Spain; Carlos Carracedo Gonzales, Peru
11:30–12:00 PC04.01—Pro: Chemotherapy Is Necessary
Marina Garassino, INT, Italy
12:00–12:30 PC04.02—CON: ICI Is Enough
Martin Reck, Lung Clinic Grosshansdorf, Germany
12:30–13:00 PC04.03—Q&A

SH02
11:30–13:00 HIGHLIGHT OF THE PREVIOUS DAY
● Melbourne (1991)
Chair(s): Grace Yang, Singapore; Debora Gil, Spain
11:30–11:45 SH02.01—Locally Advanced
Rolf Stahel, University Hospital Zurich, Switzerland
11:45–12:00 SH02.02—Pathology
Francisco Perez Ochoa, Hospital Quironsalud Teknon, Spain
14:45–15:00  ES26.02–Rehabilitation After Treatment of Thoracic Malignancies
Chris Wells, University of Maryland Medical Center, United States of America

15:00–15:15  ES26.03–Achieving Holistic Care in Hard to Reach Patient Cohorts
Phemelo Magabanyane, Asbestos Relief Trust, South Africa

15:15–15:30  ES26.04–The Impact of Early Nursing Intervention on Outcomes for Thoracic Oncology Patients
Iveta Nohavova, Charles University in Prague, Spain

15:30–15:45  ES26.05–Early Intervention and Rehabilitation for Patients Newly Diagnosed with Thoracic Malignancies
Morten Quist, Copenhagen University Hospital, Denmark

15:45–16:00  ES26.06–Q&A

MA21

14:30–16:00  NON EGFR/MET TARGETED THERAPIES
Vienna (2016)

Track(s): Targeted Therapy

Chair(s): Benjamin Besse, France; Michael Thomas, Germany

14:30–14:35  MA21.01–Generation and Characterization of Novel Preclinical Disease Models of NSCLC with NRG1 Rearrangements to Improve Therapy
Eric Gladstone, Memorial Sloan Kettering Cancer Center, United States of America

14:35–14:40  MA21.02–Genomic Origin and EGFR-TKI Efficacy of Pulmonary Adenosquamous Carcinoma
Gen Lin, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, China

14:40–14:45  MA21.03–The International Association for the Study of Lung Cancer (IASLC) Global Survey on Molecular Testing in Lung Cancer
Matthew Smeltzer, University of Memphis, United States of America

14:45–15:00  MA21.04–Discussant–MA21.01, MA21.02, MA21.03
Michael Duruisseaux, Hôpital Louis Pradel, France

15:00–15:05  MA21.05–Phase II Trial of the Combination of Alectinib with Bevacizumab in ALK-Positive Nonsquamous Non-Small Cell Lung Cancer
Satoshi Watanabe, Niigata University Medical and Dental Hospital, Japan

15:05–15:10  MA21.06–Preliminary Phase I Results of U3-1402–A Novel HER3-Targeted Antibody Drug Conjugate–In EGFR TKI-Resistant, EGFR-Mutant NSCLC
Helena Yu, Memorial Sloan Kettering Cancer Center, United States of America

Sandra Ortiz-Cuaron, Cancer Research Center of Lyon / Centre Léon Berard, France

Toyoaki Hida, Aichi Cancer Center, Japan

Arthur Geraud, Institut Gustave Roussy, France

15:35–15:40  MA21.10–Phase II Study of 160mg of Osimertinib in EGFR T790M Positive NSCLC with Brain or Leptomeningeal Metastases Who Progressed on Prior EGFR TKI
Myung-Ju Ahn, Sungkyunkwan University, Korea, Republic of

15:40–15:45  MA21.11–A Multicenter Phase II Study of Low-Dose Erlotinib in Frail Patients with EGFR Mutation-Positive, Non-Small Cell Lung Cancer: TORG1425
Sakiko Otani, Kitasato University School of Medicine, Japan

Hongxu Liu, Liaoning Cancer Hospital & Institute, China

MA23

14:30–16:00  PRECLINICAL MODELS AND GENETICS OF MALIGNANT PLEURAL MESOTHELIOMA
Copenhagen (1980)

Track(s): Mesothelioma

Chair(s): Ramon Palermo Sánchez, Spain; Raphael Bueno, United States of America

14:30–14:35  MA23.01–Phase II Trial of an Oral FGFR Inhibitor AZD4547 as Second or Third Line Therapy in Malignant Pleural Mesothelioma: Final Results of FRAME Study
Wei-Sen Lam, Fiona Stanley Hospital, Australia

14:35–14:40  MA23.02–CDK4/6 Inhibitors Show Antitumor Effects in Preclinical Models of Malignant Pleural Mesothelioma
Elisabeth Aliagas, IDIBELL-ICO, Spain

14:40–14:45  MA23.03–BAP1 Loss Induces Genome Instability Through BRCA1-Dependent and Independent Mechanisms in Mesothelioma
Anita Singh, University of Leicester, United Kingdom

14:45–15:00  MA23.04–Discussant–MA23.01, MA23.02, MA23.03

15:00–15:05  MA23.05–A Phase II Trial of Nintedanib in Recurrent Malignant Pleural Mesothelioma (MPM)
Antoinette Wozniak, UPMC Hillman Cancer Center, United States of America

15:05–15:10  MA23.06–Development of a Novel Genetically Engineered Mouse Model of Malignant Pleural Mesothelioma
Katarina Gyuraszova, Institute for Cancer Sciences, United Kingdom
MA24.01 – Challenges in Lung Cancer Clinical Trials: A European Perspective
Anne-Marie Baird, Trinity College Dublin, Ireland

MA24.02 – Developing Regional Activity for a National Charity: The Lung Cancer Canada Experience
Paul Wheatley-Price, The Ottawa Hospital, Canada

MA24.03 – Factors Impacting Patients’ Worries (Accessing Treatment, Treatment Toxicity, & Emotional Burden) Associated with Lung Cancer Treatments
Andrea Ferris, LUNGevity Foundation, United States of America

MA24.04 – Discussant – MA24.01, MA24.02, MA24.03
Deb Whippen, Editorial Rx, Inc., United States of America

MA24.05 – Lung Cancer in Europe: Strengthening Policy Responses One Country at a Time
Mary Bussell, The Economist Intelligence Unit, United Kingdom

Winfield Boerckel, CancerCare, United States of America

MA24.07 – Impact of Radiologist Recommendations on Timeliness of Lung Cancer Referral: Baseline Data to Guide a Quality Improvement Initiative
Monica Mullin, Internal Medicine, Canada

Hossein Borghaei, Fox Chase Cancer Center, United States of America

MA25.02 – Loss of Expression of BAP1 and/or MTAP Aids in the Diagnosis of Malignant Mesothelioma Metastatic to Lymph Nodes
Anja C Roden, Mayo Clinic Rochester, United States of America

MA25.03 – Discussant – MA25.01, MA25.02
Kemp Kernstine, University of Texas Southwestern, United States of America

MA25.04 – Fusion Genes Identified from Whole Genome and Whole Transcriptome Sequencing of Malignant Pleural Mesothelioma Tumours
Tian Mun Chee, University of Queensland, Australia

MA25.05 – Low Number of Mutations and Frequent Co-Deletions of CDKN2A and IFN Type I Characterize Malignant Pleural Mesothelioma
Anca Nastase, Imperial College London, United Kingdom

MA25.06 – Analysis of Immune Phenotype Composition in Malignant Pleural Mesothelioma (MPM) Using Bulk RNA Sequencing
Amit Mandal, Imperial College London, United Kingdom

MA25.07 – Discussant – MA25.04, MA25.05, MA25.06
Kenneth O’Byrne, Queensland Health, Australia

MA25.08 – Estimation of Deaths Due to Lack of Access to Immunotherapy for Brazilian Patients Diagnosed with Advanced NSCLC Without Any Driver Mutation
Vinicius Goncalves, Hospital Mãe de Deus, Brazil

MA25.09 – A Project to Control Passive Smoking by Lung Cancer Patients “Don’t Smoke Near Me! Don’t Be Like Me!”
Kazuo Hasegawa, Japan Lung Cancer Alliance, Japan

MA25.10 – Stigma in Early Stage Lung Cancer
Bonnie Addario, GO2 Foundation for Lung Cancer, United States of America

MA25.11 – Low Number of Mutations and Frequent Co-Deletions of CDKN2A and IFN Type I Characterize Malignant Pleural Mesothelioma
Anca Nastase, Imperial College London, United Kingdom

MA25.12 – Analysis of Immune Phenotype Composition in Malignant Pleural Mesothelioma (MPM) Using Bulk RNA Sequencing
Amit Mandal, Imperial College London, United Kingdom

Kenneth O’Byrne, Queensland Health, Australia

MA25.14 – Precision Medicine in Advanced NSCLC
Dublin (1997)

Chair(s): Sebastian Defranchi, Argentina; Karen Kelly, United States of America

Hossein Borghaei, Fox Chase Cancer Center, United States of America
14:30–16:00 THE INTERVENTIONAL PULMONOLOGIST’S CONTRIBUTION TO SCREEN-DETECTED NODULES: FROM DIAGNOSIS TO TREATMENT

**Track(s):** Interventional Diagnostics/Pulmonology

**Chair(s):** Luc Thiberville, France; Carla Lamb, United States of America

14:30–14:40 **MS16.01**– Getting to the Target: Transparenchimal Approaches
Daniela Gompelmann, Thoraxklinik at University of Heidelberg, Germany

14:40–14:50 **MS16.02**– Robotic Bronchoscopy: Driveless IP?
David Fielding, Royal Brisbane and Womens Hospital, Australia

14:50–15:00 **MS16.03**– Bronchoscopy and Optical Biopsy
Lizzy Wijmans, GZO Wetzikon, Switzerland

15:00–15:10 **MS16.04**– Bronchoscopic Lung Cancer Ablation
Kazuhiro Yasufuku, Toronto General Hospital, University of Toronto, Canada

15:10–15:20 **MS16.05**– Optimal Treatment Selection for Screen-Detected Lung Cancers
Norihiko Ikeda, Tokyo Medical University, Japan

15:20–15:30 **MS16.06**– Smoking Cessation in a Pulmonary Clinic
Pyng Lee, National University Hospital, Singapore

14:30–16:00 PATHOLOGY OF THE FUTURE

**Track(s):** Pathology

**Chair(s):** Erik Thunnissen, Netherlands; Teh-Ying Chou, Taiwan

14:30–14:45 **MS17.01**– Role of Liquid Biopsy in the Pathology Diagnosis Workflow (Including DNA, RNA Ad Exosomes)
Fernando Lopez-Rios, HM Hospitales, Spain

14:45–15:00 **MS17.02**– Major Pathological Evaluation in Neoadjuvant Immunotherapy
Jose Ramirez, Hospital Clinic, Spain

15:00–15:15 **MS17.03**– Quantitative Image Analysis, Image-Based Profiling Including 3D Digital Printing and AI
Sylvie Lantuejoul, Centre Léon Bérard, France

15:15–15:30 **MS17.04**– Multiplex Immunohistochemistry
Ignacio Wistuba, The University of Texas MD Anderson Cancer Center, United States of America

15:30–15:45 **MS17.05**– Controversies in Pathologic Staging
Masaya Yotsukura, National Cancer Center Hospital, Japan

15:45–16:00 **MS17.06**– Q&A
**MS18**

**14:30–16:00 ROLE OF BIOMARKERS IN LUNG CANCER SCREENING**

*Vancouver (2003)*

**Track(s):** Screening and Early Detection

**Chair(s):** Luis Montuenga, Spain; Luis M Seijo, Spain

**14:30–14:40**
**MS18.01**–Exhaled Breath Biomarkers
Nir Peled, Soroka Medical Center, Israel

**14:40–14:50**
**MS18.02**–Circulating Nucleic Acid Biomarkers
Gabriella Sozzi, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy

**14:50–15:00**
**MS18.03**–Amolecular Diagnostics, Incorporating GWAS and Risk Models: Future Approaches to the Identification of High-Risk Individuals
Paul Brennan, International Agency for Research on Cancer, France

**15:00–15:10**
**MS18.04**–Alternative and Promising Biomarkers
Ruben Pio, Center for Applied Medical Research (CIMA), University of Navarra, IDISNA, Spain

**15:10–15:20**
**MS18.05**–Sputum Biomarkers, Dysplasia and Chemoprevention
Robert Keith, Univ of Colorado/RMRVAMC, United States of America

**15:20–15:30**
**MS18.06**–Captive Audience, Teachable Moment–Integrating Tobacco Cessation in Lung Cancer Screening
Martin Tammemagi, Brock University, Canada

**15:30–16:00**
**MS18.07**–Q&A

**OA15**

**14:30–16:00 TARGETED AGENTS AND IMMUNOTHERAPY FOR SMALL CELL LUNG CANCER**

*Hilton Head (1978)*

**Track(s):** Small Cell Lung Cancer/NET

**Chair(s):** Raffaele Califano, United Kingdom; Charles Rudin, United States of America

**14:30–14:40**
**OA15.01**–Combination Olaparib and Temozolomide in Relapsed Small Cell Lung Cancer: Updated Results from Phase 1/2 Clinical Trial
Anna Farago, Massachusetts General Hospital, United States of America

**14:40–14:50**
**OA15.02**–Carboplatin-Etoposide Versus Topotecan as Second-Line Treatment for Sensitive Relapsed Small-Cell Lung Cancer: Phase 3 Trial
Isabelle Monnet, CHI Creteil, France

**14:50–15:05**
**OA15.03**–Discussant–OA15.01, OA15.02
Mary O’Brien, Royal Marsden, United Kingdom

**15:05–15:15**
**OA15.04**–Genomic and TCR Intrasatum Heterogeneity of Small-Cell Lung Cancer by Multiregion Sequencing: An Association with Survival
Jianjun Zhang, MD Anderson Cancer Center, United States of America

**15:15–15:25**
**OA15.05**–BIOLUMA: A Phase II Trial of Nivolumab and Ipilimumab in Lung Cancer–Prospective Evaluation of TMB in SCLC Patients
Julie George, University of Cologne, Germany

**15:25–15:40**
**OA15.06**–Discussant–OA15.04, OA15.05
Hidehito Horinouchi, National Cancer Center Hospital, Japan

**15:40–16:00**
**OA15.07**–Heine H. Hansen Lectureship Award for Small Cell Lung Cancer
Caroline Dive, Cancer Research UK Manchester Institute, United Kingdom

**PC05**

**14:30–16:00 IMMUNE CHEKPOINT INHIBITORS IN REAL WORLD–HOW DO WE TREAT NSCLC “SPECIAL POPULATIONS”**

*Tokyo (1982)*

**Track(s):** Advanced NSCLC

**Chair(s):** Oscar Juan, Spain; Fernando Barata, Portugal

**14:30–14:45**
**PC05.01**–ICIs for Patients with Interstitial Pneumonia
Terufumi Kato, Kanagawa Cancer Center, Japan

**14:45–15:00**
**PC05.02**–Are ICIs Effective for Poor Performance Status Patients with Advanced NSCLC?
Francesco Grossi, Ospedale Maggiore Policlinico, Italy

**15:00–15:10**
**PC05.03**–ICIs for Patients with Immune-Related Comorbidity
Robert Pirker, Medical University of Vienna, Austria

**15:10–15:20**
**PC05.04**–ICIs for Elderly Patients with Advanced NSCLC
Hossein Borghaei, Fox Chase Cancer Center, United States of America

**15:20–15:30**
**PC05.05**–ICIs in Patients with HIV Infection
Mark Awad, Dana-Farber Cancer Institute, United States of America

**15:30–16:00**
**PC05.06**–Q&A
**16:15–17:00 FOOD FOR THOUGHT IN THE MANAGEMENT OF THORACIC MALIGNANCIES**

Track(s): Advanced NSCLC, Advocacy, Biology, Immuno-oncology, Interventional Diagnostics/ Pulmonology, Mesothelioma, Nursing and Allied Professionals, Oligometastatic NSCLC, Pathology, Prevention and Tobacco Control, Screening and Early Detection, Small Cell Lung Cancer/NET, Staging, Targeted Therapy, Thymoma/Other Thoracic Malignancies, Treatment in the Real World–Support, Survivorship, Systems Research, Treatment of Early Stage/Localized Disease, Treatment of Locoregional Disease–NSCLC

Chair(s): Daniel Tan, Singapore; Ramon Rami-Porta, Spain

16:15–16:25 **PL04.01**–Epidemiology and Clinical Characteristics of Lung Cancer in Women

Enriqueta Felip, Vall d’Hebron Institute of Oncology, Spain

16:25–16:35 **PL04.02**–What Does Survivorship Mean in the World of Immunotherapy (Physical and Financial)?

Michelle Turner, Johns Hopkins Kimmel Cancer Center, United States of America

16:35–16:45 **PL04.03**–The Relevance of an International Database for the Study of Thymic Neoplasms

Vanessa Boilejack, Cancer Research and Biostatistics, United States of America

16:45–16:55 **PL04.04**–Prognostic Factors in Malignant Pleural Mesothelioma

Michaela Kirschner, University Hospital Zurich, Switzerland

16:55–17:00 **PL04.05**–Q&A
Help us fight stigma and spread HOPE!

Whether you are a patient, caregiver, advocate or physician, YOU can take action to contribute to Lung Cancer Awareness Month.

How to spread HOPE

Share or download resources: LCAM.org/resources | LCAM.org/share-your-story

Connect on social media:

www.facebook.com/LCAM.org/  @LCAM_org

Visit the IASLC booth in the Exhibit Hall to learn more!

The LCAM Coalition is supported by over 40 partner organizations from around the world. Key focus topics:

- Clinical Trials
- Screening & Early Detection
- Advocacy
- Precision Medicine
JTO Impact Factor increases to 12.460!

Ranked 10th among 229 oncology journals

Ranked 3rd among 63 respiratory medicine journals

JTO is the #1 journal in thoracic malignancies, according to Editor-in-Chief, Alex A. Adjei, MD, PhD
POSTER SESSIONS
## P1.01

### ADVANCED NSCLC

#### 09:45 – 18:00

**Track(s): Advanced NSCLC**

### Exhibit Hall

<table>
<thead>
<tr>
<th>Session ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1.01-01</td>
<td>Clinical Relevance of Targeting Proteins Required for Mitotic Progression to Improve Chemotherapy Response in Non-Small Cell Lung Cancer</td>
<td>Mark Adams, Institute of Health and Biomedical Innovation, Queensland University of Technology, Australia</td>
</tr>
<tr>
<td>P1.01-02</td>
<td>Pemetrexed-Carboplatin Versus Paclitaxel (Weekly)-Carboplatin as First Line Chemotherapy in Advanced Non-Squamous NSCLC</td>
<td>Prabhat Malik, All India Institute of Medical Sciences, India</td>
</tr>
<tr>
<td>P1.01-03</td>
<td>Efficacy and Safety of Biosimilar QL1101 Compared with Avastin in Patients with Non-Squamous Non-Small Cell Lung Cancer</td>
<td>Baohui Han, Shanghai Chest Hospital, Shanghai Jiao Tong University, China</td>
</tr>
<tr>
<td>P1.01-04</td>
<td>A Phase II Trial of Weekly Nab-Paclitaxel in the Salvage Setting for Advanced Non-Small Cell Lung Cancer: Results of NICE Salvage Study</td>
<td>Yoshihito Kogure, Nagoya Medical Center, Japan</td>
</tr>
<tr>
<td>P1.01-05</td>
<td>Phase I Study of Inhaled 5-Azacytidine (5-Aza) in Patients (Pts) with Advanced Non-Small Cell Lung Cancer (NSCLC)</td>
<td>Haiying Cheng, Montefiore Medical Center/Albert Einstein College of Medicine, United States of America</td>
</tr>
<tr>
<td>P1.01-06</td>
<td>Comparative Effectiveness of First Line (IL) Therapies for Advanced Non-Small Cell Lung Cancer (aNSCLC): A Systematic Literature Review (SLR)</td>
<td>Beata Korytowsky, Bristol-Myers Squibb, United States of America</td>
</tr>
<tr>
<td>P1.01-07</td>
<td>Real World Data of Docetaxel Plus Nintedanib for Pretreated NSCLC Patients: 4 Yrs Update Compassionate Use Program Single Institution in Mexico</td>
<td>Saul Campos-Gomez, Centro Oncologico Estatal ISSEyM, Mexico</td>
</tr>
<tr>
<td>P1.01-08</td>
<td>Randomized Phase II Trial of CBDA+nab-PTX vs CDDP+GEM in Patients with Chemo-Naïve Squamous Cell Lung Cancer: NJLCG1302</td>
<td>Toshiyuki Harada, JCHO Hokkaido Hospital, Japan</td>
</tr>
<tr>
<td>P1.01-09</td>
<td>Randomized Trial Comparing Maintenance Pemetrexed with Observation Followed by Pemetrexed at Progression in Advanced NSCLC</td>
<td>Kristin Stokke, NTNU, Norwegian University of Technology and Science, Norway</td>
</tr>
<tr>
<td>P1.01-10</td>
<td>Impact of Anti-COPD Support Treatment in Advanced NSCLC Patients with COPD Undergoing Chemotherapy as First-Line Treatment</td>
<td>Fei Wang, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China</td>
</tr>
<tr>
<td>P1.01-11</td>
<td>Quality of Life in NSCLC Patients Treated with Docetaxel and Either Plinabulin or Pegfilgrastim for Prevention of Neutropenia</td>
<td>Yvette Leloirer, BeyondSpring, United States of America</td>
</tr>
<tr>
<td>P1.01-12</td>
<td>Trends in the National Cancer Institute (NCI) Sponsored Lung Cancer Clinical Trials Pre and Post NCI’s National Clinical Trials Network (NCTN)</td>
<td>Shakun Malik, National Cancer Institute/NIH, United States of America</td>
</tr>
<tr>
<td>P1.01-13</td>
<td>Efficacy and Safety of Concurrent Anti-Tuberculosis Treatment and Chemotherapy in Lung Cancer Patients with Co-Existing Tuberculosis</td>
<td>Shan Su, Guangzhou Chest Hospital, China</td>
</tr>
<tr>
<td>P1.01-14</td>
<td>The Impact of Systemic Treatment on Brain Metastasis in Patients with Non-Small-Cell Lung Cancer: A Nationwide Population-Based Cohort Study</td>
<td>Yoon Ho Ko, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, Republic of Korea</td>
</tr>
<tr>
<td>P1.01-15</td>
<td>Multicenter, Single-Arm Phase II Study of Nab-Paclitaxel/Carboplatin in Untreated PS2 Patients with Advanced NSCLC: TORG1426</td>
<td>Katsuhiro Naoki, Kitasato University, School of Medicine, Japan</td>
</tr>
<tr>
<td>P1.01-16</td>
<td>Evolution of Systemic Therapy Uptake in NSCLC Over Time: The Impact of New Therapies</td>
<td>Paul Wheatley-Price, The Ottawa Hospital, Canada</td>
</tr>
<tr>
<td>P1.01-17</td>
<td>Changes in Pulmonary Function During Platinum-Doublet Chemotherapy for Lung Cancer</td>
<td>Jeremias Götschke, Ludwig-Maximilians-University of Munich, Germany</td>
</tr>
<tr>
<td>P1.01-18</td>
<td>Integrated Genomic and DNA Methylation Analyses of Non-Small Cell Lung Cancer Patients with Brain Metastases</td>
<td>Yun Fan, Zhejiang Cancer Hospital, China</td>
</tr>
<tr>
<td>P1.01-19</td>
<td>Predictive and Prognostic Values of ctDNA Clearance in Osimertinib Treated Advanced Non-Small Cell Lung Cancer Cohort</td>
<td>Yong Song, Jinling Hospital, China</td>
</tr>
<tr>
<td>P1.01-20</td>
<td>The Association Between BRAF Mutation Class and Clinical Features in BRAF-Mutant Chinese Non-Small Cell Lung Cancer Patients</td>
<td>Quan Lin, The First Affiliated Hospital of Wenzhou Medical University, China</td>
</tr>
<tr>
<td>P1.01-21</td>
<td>Sputum Can Serve as an Alternative Source for Liquid Biopsy in Patients with Lung Cancer</td>
<td>Ling Qin, Xiangya Hospital, Central South University, China</td>
</tr>
<tr>
<td>P1.01-22</td>
<td>Investigation of Acquired Resistance for EGFR-TKI Plus Bevacizumab as 1st Line Treatment in Patients with EGFR Sensitive Mutant NSCLC</td>
<td>Yongchang Zhang, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, China</td>
</tr>
<tr>
<td>P1.01-23</td>
<td>Retrospective Analysis of Real-World Clinico-Genomic Data for Clinical Impact of Genomic Profiling of ctDNA in NSCLC</td>
<td>Russell Madison, Foundation Medicine, United States of America</td>
</tr>
<tr>
<td>P1.01-24</td>
<td>Preclinical Proteomic Evaluation of Alternating ALK TKI Therapy Versus Continuous Dosing in ALK NSCLC to Inform the ALKternate Clinical Trial</td>
<td>Malinda Itchins, Royal North Shore Hospital, Australia</td>
</tr>
<tr>
<td>P1.01-25</td>
<td>Real-World Outcomes of Advanced NSCLC Patients with Common and Uncommon/Complex EGFR Mutation Profiles</td>
<td>Gregory Riely, Memorial Sloan Kettering Cancer Center, United States of America</td>
</tr>
<tr>
<td>P1.01-26</td>
<td>TP53 Mutations in EGFR mt+ NSCLC IV: Strong Independent Predictive Factor for ORR, PFS and OS Irrespective of T790M</td>
<td>Julia Roepke, Pius Hospital Oldenburg, Germany, Germany</td>
</tr>
</tbody>
</table>
P1.01-27 Serial Circulating Tumor DNA (ctDNA) Analysis of Blood and Saliva Predicts Osimertinib Response and Resistance in EGFR-Mutant NSCLC
Chul Kim, Georgetown University Hospital, United States of America

P1.01-28 Mutational Heterogeneity Between Primary Pulmonary Cancer Lesions and Matched Brain Metastases
Linlin Li, Guangdong Lung Cancer Institute, China

P1.01-29 MLPH Promotes Epithelial–Mesenchymal Transition and Brain Metastasis via Cdc42/PAK1 Signaling in Non-Small Cell Lung Cancer
Xiaorang Dong, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, China

P1.01-30 Non-Small Cell Lung Cancer (NSCLC) Next Generation Sequencing (NGS): Integrating Genomic Sequencing into a Publicly Funded Health Care Model
Natasha Leighl, Princess Margaret Cancer Centre, Canada

P1.01-31 Evaluating Engineered Heme-Sequestering Peptides for Treating Non-Small Cell Lung Cancer Orthotopic Tumor Model Using Multi-Modality Imaging
Li Liu, The University of Texas Southwestern Medical Center, United States of America

P1.01-32 Bronchoalveolar Lavage as an Alternative to Rebiopsy for Detection of T790M Mutation in NSCLC Patients with Acquired Resistance to EGFR-TKIs
Heejeong Kim, Konkuk University Medical Center, Korea, Republic of

P1.01-33 Genetic Variants in FIG4 and IGFIR in the Endosome-Related Genes Are Associated with Non-Small Cell Lung Cancer Survival
Qiming Wang, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, China

P1.01-34 Early Assessment of Therapy Response in Non-Small Cell Lung Cancer (NSCLC) via Longitudinal ctDNA Analysis
Stephanie Yang, Roche, United States of America

P1.01-35 Real World Characterization of Advanced Non-Small Cell Lung Cancer in Never Smokers
Katie Kerrigan, Huntsman Cancer Institute, United States of America

P1.01-36 Clinical Potential of Tissue Tumor Mutational Burden (tTMB) and Blood TMB (bTMB) as a Biomarker in Non-Small Cell Lung Cancer
Jianya Zhou, The First Affiliated Hospital of Medical School of Zhejiang University, China

P1.01-37 Radiotherapy Changed the Subclonal Composition of Brain Metastasis from Non Small Cell Lung Cancer: NGS-Based Analysis of Cerebrospinal Fluid
Xiaoxia Zhu, Nanfang Hospital, Southern Medical University, China

P1.01-38 Clinical Significance According to EGFR Mutation Subtypes in Lung Adenocarcinoma: Korean Multicenter Experience
Jung Chang, Ewha Womans University, Korea, Republic of

P1.01-39 Is There an Association Between Intracranial Progression and Overall Survival or Neurologic Death in Patients with EGFR Positive NSCLC?
Mark Doherty, Sunnybrook Odette Cancer Centre, United States of America

P1.01-40 EGFR ctDNA Detection: The Impact of Site of Progression and Burden of Progressive Disease
Alexandra Pender, BC Cancer, Canada

P1.01-41 Involvement of the JNK Pathway in Brucine D-Induced Apoptosis in Human Non-Small Cell Lung Cancer Cells
Bi Tan, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

P1.01-42 Whole-Exome Sequencing Identifies Novel Somatic Mutations Associated with Prognosis in Lung Cancer Metastatic to the Brain
Chunxia Su, Shanghai Pulmonary Hospital, China

P1.01-43 Programmed-Death Ligand 1 Spectrum in a Large Cohort of Genetically Characterized Non-Small Cell Lung Cancer Patients
Elba Marín, IDIBAPS, Spain

P1.01-44 The Role of Microbiota on the Development of Non-Small-Cell Lung Cancer
Xiaorang Dong, Wuhan Union Hospital Tongji Medical College, Huazhong University of Science and Tech, China

P1.01-45 A NGS-Based ctDNA Test to Monitor Disease Progression and Treatment Response in Advanced Stage Non-Small Cell Lung Cancer
Jin Jen, Mayo Clinic, United States of America

P1.01-46 Response Assessment Using Plasma Cell-Free DNA (cfDNA) - When Is the Optimal Time to Assess Response? Michael Cheng, Dana-Farber Cancer Institute, United States of America

P1.01-47 Prospective Study for Usefulness of Plasma DNA on Prediction of Third Generation EGFR Tyrosine Kinase Inhibitors (S-PLAT Study)
Chiho Nakashima, Saga University, Japan

P1.01-48 EGFR Testing in England – Real World Evidence from the National Lung Cancer Audit (NLCA) Spotlight on Molecular Testing
Neal Navani, University College London Hospital, United Kingdom

P1.01-49 Serial Changes in Whole-Genome Cell-Free DNA (cfDNA) to Identify Disease Progression Prior to Imaging in Advanced NSCLC
Young Kwang Chae, Northwestern Medicine Developmental Therapeutics Institute, United States of America

P1.01-50 Impact of Concomitant HER2 Alterations in Mediating Clinical Outcomes of EGFR-Mutant Patients to Different Generation of EGFR-TKIs
Ying Cheng, JinJin Cancer Hospital, China

P1.01-51 Micropapillary Predominant and Pathologic Stage Were Risk Factors for Postoperative Brain Metastasis in Lung Adenocarcinoma
Takao Shigenobu, Saiseikai Utsunomiya Hospital, Japan

P1.01-52 Cell-Free Tumor DNA (ctDNA) Utility in Detection of Original Sensitizing and Resistant EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC)
Jason Agulnik, Jewish General Hospital, Lady Davis Institute, McGill University, Canada

P1.01-53 Clinical Utility of Two Different Plasma-Based EGFR Mutation Tests in Patients with Advanced Non-Small Cell Lung Cancer
Yun-Gyoo Lee, Kangbuk Samsung Hospital, Korea, Republic of

P1.01-54 Somatic Genome Alterations in Lung Cancer Patients Diagnosed with Li Fraumeni Syndrome
Maria Jove, Institut Català d’Oncologia, Spain

P1.01-55 Updated Analysis of Outcomes by Histology vs Cytology PD-L1 22C3 Antibody Testing in Advanced Non-Small Cell Lung Cancer
Chul Kim, Georgetown University Hospital, United States of America

P1.01-56 Increased ROS1 and RET Transcripts in Fusion-Negative NSCLC Patients
Noemi Reguart, Hospital Clinic, Barcelona, Spain
EXPANDING ACCESS TO LARGE-SCALE GENOMIC MUTATIONAL ANALYSES FOR PATIENTS WITH ADVANCED NSCLC IN ITALY

Vanesa Gregorc, IRCCS San Raffaele Hospital, Italy

PROGNOSTIC IMPACT OF PD-L1 EXPRESSION ON EGFR TYROSINE KINASE INHIBITION IN LUNG ADENOCARCINOMA

Minsu Kang, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea, Korea, Republic of

A CT-BASED RADIOMICS APPROACH TO PREDICT PD1 INHIBITOR RESPONSE IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER

Shiqi Mao, Shanghai Pulmonary Hospital, China

IMPACT OF PRIOR RADIATION PNEUMONITIS ON INCIDENCE OF IMMUNOTHERAPY RELATED PNEUMONITIS

Charu Aggarwal, Hospital of the University of Pennsylvania, United States of America

PREDICTIVE VALUE OF K-RAS SUBSET MUTATIONS AND PD-L1 IN PULMONARY SARCOMATOID CARCINOMA (PSC)

Nagla Abdel Karim, Medical College of Georgia/ Augusta University, United States of America

IMMUNE GENE EXPRESSION, BAYESIAN NETWORK AND GENETIC MUTATION ANALYSIS IN ADVANCED NSCLC PATIENTS TREATED WITH IMMUNOTHERAPY

Vincenzo Minotti, Santa Maria della Misericordia Hospital, Italy

A CT-BASED RADIOMICS APPROACH TO PREDICT PD1 INHIBITOR RESPONSE IN NON-SMALL CELL LUNG CANCER

Jialei Wang, Fudan University Shanghai Cancer Center, China

PH I/II CARBOPATIN, NAB-PACLITAXEL AND PEMBROLIZUMAB FOR ADVANCED NSCLC (HCRN LUN13-175): OUTCOMES BY NAB-PACLITAXEL DOSE

Ryan Gentzler, University of Virginia, United States of America

MONITORING CLINICAL RESPONSES MEASURING PD-L1 IN CRFNA IN PLASMA OF NON-SMALL CELL LUNG CANCER PATIENTS UNDERGOING SYSTEMIC THERAPY

Luis Raez, Memorial Cancer Institute/Florida International University, United States of America

BLOOD SERUM AMYLOID A AS POTENTIAL PREDICTOR OF RESPONSE TO FIRST-LINE PEMBROLIZUMAB IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER

Vincenzo Di Noia, Universita' Cattolica del Sacro Cuore, Italy

DOMINANT CIRCULATING MYELOID POPULATIONS ARE ASSOCIATED WITH POOR RESPONSE IN NSCLC TREATED WITH 1ST LINE PD-1 MONOTHERAPY

Sally Lau, Princess Margaret Cancer Centre, Canada

BONE METASTASES AND SKELETAL-RELATED EVENTS IN PATIENTS WITH METASTATIC NSCLC TREATED WITH ICIS: A MULTI-INSTITUTIONAL STUDY

Angel Qin, University of Michigan, United States of America

A PHASE II UMBRELLA STUDY OF CAMRELIZUMAB IN DIFFERENT PD-L1 EXPRESSION COHORTS IN PRE-TREATED ADVANCED/METASTATIC NON-SMALL CELL LUNG CANCER

Yi-Long Wu, Guangdong Lung Cancer Institute (GLCI), Guangdong Provincial People's Hospital (GDPH), China

ASSOCIATION OF BASELINE PULMONARY FIBROSIS WITH THE OUTCOME OF PD-1 INHIBITOR IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER

Angel Qin, University of Michigan, United States of America
P1.01-86 Occurrence of de Novo HER2/HER3 or HER2/EGFR TMD Mutations: Extending the Spectrum of Targetable Mono-HER2 TMD in NSCLC?
Sai-Hong Ou, Chao Family Comprehensive Cancer Center, University of California Irvine, United States of America

P1.01-87 Osimertinib Acquired Resistance Mechanisms and Post-Progression Outcomes in Stage IV EGFR Positive Non-Small Lung Cancer
Tejas Patil, University of Colorado, United States of America

P1.01-88 PS 2 Patients with Advanced NSCLC Patients with EGFR Exon 20 Insertion Mutations: Subset Analysis of a Phase III Randomized Trial Comparing Gefitinib to Gefitinib with Chemotherapy
Kumar Prabhakar, Tata Memorial Center, India

P1.01-89 A Multicenter Phase 1/2a Trial of CLN-081 in NSCLC with EGFR Exon 20 Insertion Mutations
Zofia Pietrowska, Massachusetts General Hospital, United States of America

P1.01-90 Update Phase II Results of Early Primary Tumor Stereotactic Body Radiotherapy Combined with First-Line EGFR-TKI in Advanced EGFR Mutated NSCLC
Dongqing Lv, Affiliated Zhaitou Hospital at Enze of Wenzhou Medical University, China

P1.01-91 Clinical Outcomes of Various Resistance Mechanisms of Osimertinib in Chinese Advanced Non-Small Cell Lung Cancer Patients
Puyuan Xing, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China

P1.01-92 Underlying Mechanisms That Potentially Affect Prognosis to EGFR-TKI in EGFR-Positive Patients with Non-Small Cell Lung Cancer
Ying Cheng, Jilin Cancer Hospital, China

P1.01-93 Metastases Sites as a Prognostic Factor in a Real-World Multicenter Cohort Study of Spanish ALK-Positive NSCLC Patients (p)
Laura Angelats, Catalan Institute of Oncology-Badalona; Hospital Universitari Germans Trias I Pujol; B-ARGO; IGTP, Spain

P1.01-94 JNJ-61186372, an EGFR-cMet Bispecific Antibody, in EGFR Exon 20 Insertion-Driven Advanced NSCLC
Byoung Chul Cho, Yonsei Cancer Center, Yonsei University College of Medicine, Korea, Republic of

P1.01-95 Efficacy and Safety of Anlotinib in Combination with Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
Tianqing Chu, Shanghai Chest Hospital, China

P1.01-96 US Real-World Management of EGFR-Mutated Advanced NSCLC: Survival After First-Line EGFR-Tyrosine Kinase Inhibitor Treatment
Jorge Nieva, University of Southern California, United States of America

P1.01-97 Modified RANO-LM Criteria to Evaluate the Radiological Response of Osimertinib in EGFR T790M Positive NSCLC with Leptomeningeal Metastases
Sehoon Park, Samsung Medical Center, Korea, Republic of

P1.01-98 Outcomes in Advanced NSCLC Patients Treated with 1st Line EGFR-TKI Based on Mutation Detection from Tissue or cfDNA-Based Genomic Sequencing
Hai Tran, The University of Texas MD Anderson Cancer Center, United States of America

P1.01-99 EGFR-Wild Type Patients Responding to TKI: Revisiting Pathology with Newer Technology
Jason Agulnik, Jewish General Hospital, Lady Davis Institute, McGill University, Canada

P1.01-100 Effect of Osimertinib in Non-Small Cell Lung Cancer Patients with Brain Metastases After Progression Following Front-Line EGFR-TKI Therapy
Yun Fan, Zhejiang Cancer Hospital, China

P1.01-101 Efficacy of Immune Checkpoint Inhibition in RET Fusion Positive Non-Small Cell Lung Cancer Patients
Anthony Sireci, Loxo Oncology, Inc, a wholly owned subsidiary of Eli Lilly, United States of America

P1.01-102 Actionable Gene Aberration and the Response of Clinical Features and Tumor Immune Microenvironment Related to Acquired Resistance to EGFR-TKI in NSCLC Patients with EGFR Mutation
Pei Zhang, The First Affiliated Hospital of Zhejiang University, China

P1.01-103 Preliminary Results of Brigatinib in Japanese Patients (Pts) Who Previously Received Alectinib: Brigatinib-2001 Study
Shuji Murakami, National Cancer Center Hospital, Japan

P1.01-104 Survivals in ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer Treated with First-Line Crizotinib
Yu-Er Gao, Guangdong Lung Cancer Institute (GLCI), Guangdong Provincial People’s Hospital (GDPH), China

P1.01-105 US Real-World Management of EGFR-Mutated Advanced NSCLC: Prescribing and Attirbution Data from First-To-Second-Line Treatment
Karen Reckamp, City of Hope Comprehensive Cancer Center, United States of America

P1.01-106 Clinical Features and Tumor Immune Microenvironment Related to Acquired Resistance to EGFR-TKI in NSCLC Patients with EGFR Mutation
Pei Zhang, The First Affiliated Hospital of Zhejiang University, China

P1.01-107 KEYNOTE-495/KeyImPaCT: Phase 2 Biomarker-Directed Study of Pembrolizumab-Based Therapy for Non-Small Cell Lung Cancer
Martin Gutierrez, Hackensack University Medical Center, United States of America

P1.01-108 PACIFIC-6: A Phase II Study of Durvalumab Following Sequential Chemoradiotherapy in Patients with Stage III, Unresectable NSCLC
Marina Garassino, INT, Italy

P1.01-109 Phase II Trial of Pemetrexed/Carboplatin/Bevacizumab +/- Atezolizumab in NSCLC Patients That Are EGFR Mutated or Never Smoked
J Nicholas Bodor, Fox Chase Cancer Center, United States of America

P1.01-110 Novel Regimens Versus Standard-of-Care in NSCLC: A Phase II, Randomized, Open-Label, Platform Trial Using a Master Protocol
David Spigel, Sarah Cannon Research Institute, United States of America

P1.01-111 ATEZO-BRAIN, A Single-Arm Phase II Study of Atezolizumab Combined with Chemotherapy in Stage IV NSCLC Patients with Untreated Brain Metastases
Ernest Nadal, Institut Català d’Oncologia, Spain

P1.01-112 Phase 3, Randomized, Double-Blind Trial of First-Line Pembrolizumab With or Without Lenvatinib in Metastatic NSCLC: LEAP-007
Tarek Mekhail, Advent Health Cancer Institute, United States of America

P1.01-113 Phase IIb Trial of Cabozantinib or Cabozantinib Plus Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Farah Lim, Saint Bartholomew’s Hospital, United Kingdom
P1.01-114 A Phase 2 Study of MLN4924 (Pevonedistat) in Combination with Carboplatin and Paclitaxel in Advanced NSCLC Previously Treated with Immunotherapy
Ticiana Leal, University of Wisconsin Carbone Cancer Center, United States of America

P1.01-115 Long-Term Effects of Concurrent Chemoradiotherapy on Quality of Life in Locally Advanced Non-Small Cell Lung Cancer Patients
Evelien Veldhuizen, Netherlands Cancer Institute, Netherlands

P1.01-116 Early Immune-Related Adverse Events Under PD-1/PD-L1 Inhibitors Predict Better Progression-Free Survival in NSCLC
Maxime Boussageon, Centre Leon Berard, France

P1.01-117 Pulmonary Function Monitoring in Patients with Oligometastatic NSCLC Who Receive Stereotactic Body Radiation Therapy
Marisol Arroyo-Hernandez, Instituto Nacional de Cancerologia, Mexico

P1.01-118 Overall Survival in Pts with EGFRm+ NSCLC Receiving Sequential Afatinib and Osimertinib: Updated Analysis of the GioTag Study
Maximinian J Hochmair, Department of Respiratory and Critical Care Medicine, and Ludwig Boltzmann Institute of COPD and Respiratory Epidemiology, Otto Wagner Hospital, Austria

P1.01-119 Modified Lung Immune Prognostic Index (mLIPI) as a Predictive Tool of Nivolumab Outcomes in Advanced NSCLC Patients
Rebecca Moor, Princess Alexandra Hospital, Australia

P1.01-120 Immune Checkpoint Inhibitors Versus Second Line Chemotherapy for Patients with Lung Cancer Refractory to First Line Chemotherapy
Corentin Lefebvre, Institut Bergonié, France

P1.01-121 Superior Outcomes of 1st Line EGFR TKI in Next-Generation Sequencing Identified Uncommon EGFR Exon 19delins Mutation Non-Small Cell Lung Cancer
Yongchang Zhang, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, China

P1.01-122 A Clinical Utility Study of Plasma DNA Next Generation Sequencing Guided Treatment of Uncommon Drivers in Advanced Non-Small-Cell Lung Cancers
Hai-Yan Tu, Guangdong Lung Cancer Institute, China

P1.01-123 Recent Clinical Outcomes of Upfront Surgery Followed by Adjuvant Therapy for Resectable Pathological N2 Non-Small Cell Lung Cancer
Jae Kwang Yun, Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, Korea

P1.01-124 Health-Related Quality of Life (HRQoL) Data in a Phase 3 Study of First-Line Brigatinib vs Crizotinib in NSCLC (ALTA-1L)
Rosario Garcia Campelo, Complejo Hospitalario Universitario A Coruna, Spain

P1.01-125 Uniportal Versus MultiportalThoracoscopic Lobectomy with Systematic Mediastinal Lymphadenectomy for N2(+) Stage III NSCLC
You-Jun Deng, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China

P1.01-126 The Co-Occurring Genomic Landscape of ERBB2 Exon 20 Insertion in Non-Small Cell Lung Cancer (NSCLC) and the Potential Indicator of Response to Afatinib
Bo Yuan, The Second Affiliated Hospital of Xi’an Jiaotong University, China

P1.01-127 Antitumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 in NSCLC with EGFR Exon 20 Insertions
Gregory Riely, Memorial Sloan Kettering Cancer Center, United States of America

P1.01-128 Choice of Postoperative Radiotherapy for Resected IIIA-N2 Non-Small Cell Lung Cancer: Impact of Log Odds of Positive Lymph Nodes
Yang Wo, Affiliated Hospital of Qingdao University, China

P1.01-129 Preclinical Genetic Evaluation of Alternating ALK TKI Therapy Versus Continuous Dosing in ALK NSCLC to Inform the ALKternate Clinical Trial
Malinda Itchins, Royal North Shore Hospital, Australia

P1.01-130 Clinical Experience with Nintedanib in Previously Treated Non-Small Cell Lung Cancer in Spain: A Retrospective Multicenter Study
Laura Gutiérrez Sainz, La Paz University Hospital, Spain

P1.01-131 The Comparison Between Non-Intubated and Intubated Anesthesia Video-Assisted Thoracoscopic Surgery: A Meta-Analysis
Guanping Qiu, Guangzhou Medical University, China

P1.01-132 Clinicopathological and Genomic Comparisons Between Different Histologic Components in Combined Small Cell and Non-Small Cell Lung Cancer
Mong-Wei Lin, National Taiwan University Hospital, Taiwan

P1.01-133 Randomized Open-Label Study of Binrafusp Alfa (M7824) vs Pembrolizumab in Patients with PD-L1 Expressing Advanced IL NSCLC
Myung-Ju Ahn, Sungkyunkwan University, Korea

P1.01-134 SAVANNAH: Phase II Trial of Osimertinib + Savolitinib in EGFR-Mutant, MET-Driven Advanced NSCLC, Following Prior Osimertinib
Myung-Ju Ahn, Sungkyunkwan University, Korea

P1.01-135 Salvage Chemotherapy After Immunotherapy Failure in Non-Small-Cell Lung Cancer Patients
Giuseppe Lo Russo, Fondazione IRCCS Istituto Nazionale Tumori of Milan, Italy

P1.01-136 Uncommon EGFR Mutations in Non-Small Cell Lung Cancer: A Systematic Literature Review of Prevalence and Clinical Outcomes
Tom John, Olivia Newton-John Cancer Research Institute, Australia

P1.01-137 KNSTRN Promotes Non-Small Cell Lung Cancer Progress and Attenuates Radiosensitivity via Activating EGFR-ERK1/2-E2F1 Pathway
Conghua Xie, Zhongnan Hospital Wuhan, China

P1.03 Antitumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 in NSCLC with EGFR Exon 20 Insertions
Gregory Riely, Memorial Sloan Kettering Cancer Center, United States of America

P1.03-01 Polymorphisms in Glycolysis-Related Genes Are Associated with Clinical Outcomes of Paclitaxel-Cisplatin Chemotherapy in NSCLC
Sun Ha Choi, Kyungpook National University Chilgok Hospital, Korea

P1.03-02 Nintedanib Selectively Inhibits Angiogenesis Induced by the Conditioned Medium of Lung Adenocarcinoma TAFs in Vitro
Natalia Diaz-Valdivia, Universidad de Barcelona, Spain
P1.03-03 Inhibition of H1299 Lung Cancer Cell Proliferation and Survival by Rosemary Extract Is Associated with AMPK Activation
Evangelia Tsiani, Brock University, Canada

P1.03-04 Use Supernatant of Malignant Pleural Effusion to Identify Driver Mutants and Monitor Response to Targeted Therapy
Rui Lin, Hangzhou Repugene Technology Co., Ltd., China

P1.03-05 COMMD4 in Lung Cancer: Towards a New Therapeutic Target and Diagnostic Biomarker
Kenneth O’byrne, Institute of Health and Biomedical Innovation, Queensland University of Technology Translational Research Institute, Australia

P1.03-06 Integrative Omics Analysis Reveals Important Roles of Adenosine Diphosphate in Haemostasis and Platelet Activation in NSCLC
Long Hoang, Imperial College London, United Kingdom

P1.03-07 Advantages and Setbacks of EGFR Mutation Testing from Liquid Biopsy of Advanced Lung Adenocarcinoma Patients in Serbia
Jelena Spasic, Institute for Oncology and Radiology of Serbia, Serbia

P1.03-08 RNF43 Ubiquitinates and Degradates Phosphorylated E-Cadherin by c-Src to Facilitate Epithelial-Mesenchymal Transition in Lung Adenocarcinoma
Yang Zhao, Second Affiliated Hospital of Xi’an Jiaotong University, China

P1.03-09 Atypical Ubiquitin as a Molecular Target in Lung Cancer
Seshiru Nakazawa, Gunma University Hospital, Japan

P1.03-11 Molecular Testing of Small Bronchoscopy Specimens Using NanoString Technology
Brielle Parris, The Prince Charles Hospital, Australia

P1.03-12 Preclinical Validation of an Epigenetic Panel of Seven miRNAs at Early Stages NSCLC Patients and Its Prognostic Implications
Dario Sanchez Cabrero, University Hospital La Paz, Spain

P1.03-13 Genomic Landscape of Brazilian Non-Small Cell Lung Cancer
Letícia Leal, Barretos Cancer Hospital, Brazil

P1.03-14 Delta-Like 1 Homolog (DLK1) Expression in Non-Small-Cell Lung Adenocarcinoma Cell Lines
Maria Sereno Moyano, Infanta Sofía University Hospital, Spain

P1.03-15 Non-Invasive Detection of Secondary Resistance Mutations in ALK-Positive NSCLC Patients by Next-Generation Sequencing
Atocha Romero, Hospital Puerta De Hierro Majadahonda, Spain

P1.03-16 Anti-Tumor Effect of Pan-RAF Inhibitor in NSCLC Cells Harboring BRAF Mutation
Bo Su, Shanghai Pulmonary Hospital, China

P1.03-17 Function of Antisense LncRNA RP11-539E17.5 and FAM83A-AS1 Up-Regulating FAM83A in Lung Adenocarcinoma Tumorigenesis and Development
Xuequan Wang, Radiation Oncology Institute of Enze Medical Health Academy, Affiliated Taizhou Hospital of Wenzhou Medical University, China

P1.03-18 OCIAD2 Impairs Mitochondria-Mediated Apoptosis Through Substantial Alteration of Crista Structure in Lung Adenocarcinoma
Jeongmin Hong, University of Tsukuba, Japan

P1.03-19 Circulating Tumour Cells in Non-Small Cell Lung Cancer
Kenneth O’byrne, Institute of Health and Biomedical Innovation, Queensland University of Technology Translational Research Institute, Australia

P1.03-20 Exploring Driver Mutations in Non-Coding RNAs in Lung Adenocarcinoma
Alvaro Andrades, GENYO, Centre for Genomics and Oncological Research: Pfizer / University of Granada / Andalusian Regional Government, Spain

P1.03-21 Epigenome-Wide Association Study of Cancer Associated Fibroblasts-Induced Oncogenic Transformation of Lung Epithelial Cells
Sheng-Fang Su, National Taiwan University, Taiwan

P1.03-22 A Novel Method for Detecting Low Abundant Mutants in Three Types of Liquid Biopsies by Capturing Mutant-Alleles
Rui Lin, Hangzhou Repugene Technology Co., Ltd., China

P1.03-23 Delta-Like 1 Homolog (DLK1) Expression in Non-Small-Cell Lung Cancer and the Development of Radioimmunotherapy Targeting DLK1
Hironori Takagi, Fukushima Medical University, Japan

P1.03-24 Thoracic Injection of PD-1 Blocking Antibody Improves the Murine Model of Malignant Pleural Effusion
Tangfeng Lv, Jiniling Hospital, China

P1.03-25 Synergistic Lethality of Ferroptosis Inducer-Disulfiram/Copper Complex and WEE1 Kinase Inhibitor for RAS/TP53 Mutant NSCLC
Bo Su, Shanghai Pulmonary Hospital, China

P1.03-26 Genetic and Molecular Profiling of Non-Smoking Related Lung Adenocarcinomas
Eva Pros, PEBC-IDIBELL, Spain

P1.03-27 Aspirin Overcomes Acquired Resistance to Osimertinib in Human Lung Cancer Cells via BIM-Dependent Apoptosis Induction
He Yong, Daping Hospital, Army Medical University, China

P1.03-28 Prognostic Value of Estrogen Receptor Beta Tumor Expression in Non-Small Cell Lung Cancer Patients After Radical Surgery
Anna Basharina, “N.N. Blokhin National Medical Research Center of Oncology” of the Health Ministry of Russia, Russian Federation

P1.03-29 Cellular Biology Determines Ability of XIST to Act as a miRNA Sponge in Non-Small Cell Lung Cancer
Greg Stewart, BC Cancer Research Centre, Canada

P1.03-30 Transcriptome Signatures of Tobacco Carcinogens on Lung Adenocarcinoma Cell Lines
Mario Pepe, ILBD/CPC Helmholtz Zentrum Munchen, Germany

P1.03-31 BRAF Mutations: Classes I, II and III in NSCLC Patients Included in the SLLIP Trial, Targeted Treatment According to Class
Jill Bracht, Quirón-Dexeus University Institute, Spain

P1.03-32 Knockdown of CENPF Gene Inhibits the Progression of Lung Adenocarcinoma Mediated by ERβ2/5 Pathway
Hexiao Tang, Zhongnan Hospital of Wuhan University, China

P1.03-33 Analysis of Lipid Metabolism Genes in Advanced Small Cell Lung Cancer
Maria Sereno Moyano, Infanta Sofia University Hospital, Spain
P1.03-34 The IncRNA NEAT1 Promotes Radioresistance via the MiR-491-5p/CAPG Axis in NSCLC
Suna Zhou, The Affiliated Taizhou Hospital, Wenzhou Medical University, China

P1.03-35 Analysis of TET2 Gene Aberrations in East Asian Non-Small-Cell Lung Cancer Patients and Evaluation of Their Prognosis
Chunwei Xu, Fujian Cancer Hospital, China

P1.03-36 Cell-Free DNA Levels in Liquid Biopsy from Patients with Non-Small Cell Lung Cancer and Association with Clinical Parameters and Disease Outcome
Leticia Leal, Barretos Cancer Hospital, Brazil

P1.03-37 Impacts of DSB Repair Protein, NBS1, on Lung Cancer
Yu-Feng Wei, E-Da Hospital, Taiwan

P1.03-38 EGFR Mutation Status as a Prognostic Marker in Stage 1 Lung Adenocarcinoma After Definitive Surgical Resection
Carlos Galve, Northwestern University Feinberg School of Medicine, United States of America

P1.03-39 Intra-Tumoral CD61+ Megakaryocytes Predicts Poor Prognosis in Non-Small Cell Lung Cancer
Wenhua Liang, Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University; State Key Laboratory of Respiratory Disease; National Clinical Research Center for Respiratory Disease, China

P1.03-40 Using Model Systems to Improve Outcomes for Early Stage NSCLC
Matthew Steliga, University of Arkansas, United States of America

P1.03-41 Chronic Nicotine Exposure Affects PD-L1 Expression and Sensitivity to EGFR-TKI in Lung Cancer
Changdong Yeo, Eunpyeong St. Mary’s Hospital, Korea, Republic of

P1.03-42 Angiotensin System Inhibitors Improve Survival in Stage IIIA NSCLC and Show Anti-Tumor Effect in Combination with Chemotherapy in a Model of NSCLC
Hexiao Tang, Zhongnan Hospital of Wuhan University, China

P1.03-43 Preoperative Prognostic Value of Immune-Inflammation Index in Patients with Operable Non-Small Cell Lung Cancer
Carlos Fraile Olivero, Hospital Universitari Arnau de Vilanova, Spain

P1.03-44 Role of Serum Procalcitonin as Diagnostic Biomarker of Pneumonia in Lung Cancer Patient
Atit Dewi, Universitas Indonesia, Indonesia

P1.03-45 Circulating Tumor Cells’ Clearance in Blood Samples After Chemotherapy: A Good Prognostic Factor for OS in Advanced NSCLC
Lucia Milla Collado, Hospital Arnau Vilanova, Spain

P1.03-46 lncRNA H19 Downregulation Promoted Resistance to EGFR-TKIs Through Regulating AKT and SRC Activating in NSCLC Cells
Chenguang Li, Tianjin Medical University Cancer Institute and Research Center, China

P1.03-47 KEAP1 Mutations in East Asian Patients with NSCLC: An Investigation of Prevalence, Clinicopathologic Characteristics and Prognosis
Chunwei Xu, Fujian Cancer Hospital, China

P1.03-48 Vasohibin 2 Promotes Angiogenesis and Lymphangiogenesis of Lung Squamous Cell Carcinoma Through Snail-Dependent VEGF-D Signaling Pathway
Pengpeng Liu, Tianjin Medical University Cancer Institute & Hospital, China

P1.03-49 Systematic Dysregulation of Cell Cycle by IncRNAs in Lung Adenocarcinoma
Xiaoshun Shi, Nanfang Hospital, China

P1.03-50 Type- and Stage-Specific Genomic Profiles in East Asian Lung Cancer Patients with No TKI-Related Driver Gene Mutations
Yayi He, Shanghai Pulmonary Hospital, Tongji University, China

P1.03-51 MUC3A Induces PD-L1 and Reduces Tyrosine Kinase Inhibitor Effects in EGFR-Mutant Non-Small Cell Lung Cancer
Conghua Xie, Zhongnan Hospital of Wuhan University, China

P1.04 09:45 – 18:00 IMMUNO-ONCOLOGY

P1.04-01 Body Mass Index and Age Do Not Influence Survival in Patients with Lung Cancers Treated with PDI/PDL1 Immune Checkpoint Inhibitors
Corentin Richard, Centre Georges François Leclerc, France

P1.04-02 Efficacy and Safety of Sintilimab Plus Anlotinib as First-Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC)
Baozhi Han, Shandong Chest Hospital, China

P1.04-03 HLA Affinity for Mutant EGFR Derived Peptides Identifies a Group of Patients with EGFR Driven NSCLC and Favorable Prognosis
Anastasios Dimou, University of Colorado Denver, United States of America

P1.04-04 DNA Damage Response Gene Alterations Are Associated with High Tumor Mutational Burden and Clinical Benefit from PD-1 Axis Inhibition in NSCLC
Biagio Ricciuti, Dana-Farber Cancer Institute, United States of America

P1.04-05 PD-L1 Expression (SP263) in Lung Cancer and Paired Brain Metastases – A Single Center Study in 211 Patients
Sabina Berezowska, Institute of Pathology, University of Bern, Switzerland

P1.04-06 Tumor Microenvironment Landscape in Lung Adenocarcinoma by Single-Cell Sequencing
Bo Mi Ku, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea, Republic of

P1.04-07 Immune Suppressive Microenvironment and Highly Clonal Concordance of TCR Repertoire in Brain Metastases from Non-Small Cell Lung Cancer
Yujin Kudo, Tokyo Medical University, Japan

P1.04-08 Randomized Controlled Phase III Trial of Adjuvant Chemoimmunotherapy to Lung Cancer Patients: Results of Malignant Effusions
Hideki Kimura, Chiba Cancer Center, Japan

P1.04-09 Predictive Clinical and Molecular Features of Long-Term Survivors Receiving Immune Checkpoint Inhibitors for Stage 4 Non-Small Cell Lung Cancer
Aaron Franke, Moffitt Cancer Center, United States of America

P1.04-10 Identification of Immunotherapy Targets in STK11 Mutant Non-Squamous Non-Small Cell Lung Cancer
Edwin Yau, Roswell Park Comprehensive Cancer Center, United States of America
P1.04-11 Depicting the Intra-Tumoral Viral and Microbial Landscape of Localized NSCLC Using Standard Next Generation Sequencing Data
Pierre-Olivier Gaudreau, The University of Texas MD Anderson Cancer Center, United States of America

P1.04-12Tumor Uptake and Biodistribution of 89Zr-Labeled Pembrolizumab in Patients with Metastatic Non-Small-Cell Lung Cancer
Anna-Larissa Niemeijer, Amsterdam Universitair Medisch Centrum, Netherlands

P1.04-13 Delineating Spatial Heterogeneity of Tumor Mutational Burden (TMB) Counts in Pulmonary Adenocarcinoma
Daniel Kzdal, University Hospital Heidelberg, Germany

P1.04-14 Early Changes in Plasma CXCL2 and MMP2 Levels Predicts the Response to Anti-PD-1 Therapy in Non-Small-Cell Lung Cancer
Norikazu Matsuo, Kurume University Hospital, Japan

P1.04-15 Smoking Status is Not a Replacement Biomarker for Tumor Mutation Burden in Non-Small Lung Cancer
Kai He, The Ohio State University, United States of America

P1.04-16 Early Antibiotic Use Affects the Efficacy of First Line Immunotherapy in Lung Cancer Patients but Route of Administration Seems to be Decisive
Xabier Miéigo Rubio, Hospital Universitario Fundación Alcorcón, Spain

P1.04-17 Phase I/II Study of Nivolumab and Vorolanib in Patients with Refractory Thoracic Tumors
Leora Horn, Vanderbilt Ingram Cancer Center, United States of America

P1.04-18 Interleukin-5 Drives the Expansion of Pulmonary B-1 B Cells and Restricts Lung Tumor Growth
Rachel Cederberg, BC Cancer, Canada

P1.04-19 Association Between Efficacy and irAEs in Patients with Advanced Non-Small Cell Lung Cancer Receiving Immune-Checkpoint Inhibitors
Mariona Ruadavets, Hospital de la Santa Creu i Sant Pau, Spain

P1.04-20 PD-L1 mRNA Derived from Tumor-Educated Platelets Predicts the Clinical Outcome of Immunotherapy in Non-Small Cell Lung Cancer
Jianhua Chang, Fudan University Shanghai Cancer Center, China

P1.04-21 Cellular Landscape of Normal Adjacent to Tumor Microenvironment in Non-Small Cell Lung Cancer
Yuan Li, Renmin Hospital of Wuhan University, China

P1.04-22 Potential DNA Repair Biomarker for Response to Immunotherapy of Lung Cancer Patients
Zvi Livneh, Weizmann Institute of Science, Israel

P1.04-23 Characterizing the Tumor Immune Microenvironment of Non-Small Cell Lung Carcinoma in People Living with HIV Using Imaging Mass Cytometry
Ramsey Yusuf, Yale School of Medicine, United States of America

P1.04-24 Circulating Suppressive Immune Cells Predict the Efficacy of Anti PD-1 Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer
Jiae Koh, Sungkyunkwan University, Korea, Republic of

P1.04-25 CT Based Vessel Tortuosity Features Are Prognostic of Overall Survival and Predictive of Immunotherpay Response in NSCLC Patients
Pranjal Vaidya, Case Western Reserve University, United States of America

P1.04-26 EMT-Associated Response and Resistance to MEK Inhibitor and Immune Checkpoint Blockade Combinations in KRAS-Mutant NSCLC
Pierre-Olivier Gaudreau, The University of Texas MD Anderson Cancer Center, United States of America

Michael Wessolly, German Cancer Consortium (DKTK), Germany

P1.04-28 COAST: Durvalumab Alone or with Novel Agents for Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer
Roy Herbst, Yale University School of Medicine, United States of America

P1.04-29 Dynamic Changes of Plasma PD-L1 mRNA Expression Predict Response to Anti-PD-1/Anti-PD-L1 Treatment in Malignancies
Jianguo Sun, Cancer Institute of People’s Liberation Army, China

P1.04-30 Pioneer Study: Precision Immuno-Oncology for Advanced Non-Small Cell Lung Cancer Patients with PD/L1 ICI Resistance
Fabrice Barlesi, Aix Marseille University and Assistance Publique des Hôpitaux de Marseille, France

P1.04-31 Immunosenescence Correlates with Poor Outcome from PD- (L)1 Blockade but Not Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)
Roberto Ferrara, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy

P1.04-32 Ki67+PD-1+ Central Memory CD8 T-Cell Frequencies Predict Response Upon Nivolumab+Ipilimumab in Malignant Pleural Mesothelioma
Joanne Mankor, Erasmus MC, Netherlands

P1.04-33 Deep Phenotyping of Immune Populations Reveals Baseline Predictors of Pembrolizumab Efficacy in NSCLC on KEYNOTE-001
Philippe Rochigneux, Institut Paoli Calmettes, France

P1.04-34 Efficacy and Safety of First-Line Pembrolizumab Monotherapy in Elderly Patients (Aged ≥ 75 years) with Non-Small Cell Lung Cancer
Tomohide Sugiyama, Tochigi Cancer Center, Japan

P1.04-35 Identification and Characterization of a Unique KLRG1-Expressing Subset of CD4+FOXP3+ Tregs in Non-Small Cell Lung Cancer
Dennis Adegbe, Moffitt Cancer Center, United States of America

P1.04-36 An in Vivo Inflammatory Loop Potentiates KRAS Blockade
Kristina Arendt, Helmholtz Center, Germany

P1.04-37 Dioscin Elicits Anti-Tumor Immunity by Inhibiting Macrophages M2 Polarization via JNK and STAT3 Pathways in Lung Cancer
Yinan Yao, The First Affiliated Hospital, College of Medicine, Zhejiang University, China

P1.04-38 Efficacy and Safety of Immunotherapy in Elderly Patients with Non-Small Cell Lung Cancer
Giuseppe Lo Russo, Fondazione IRCCS Istituto Nazionale dei Tumori di Milan, Italy

P1.04-39 Molecular Characteristics, Immunophenotype, and Immune Checkpoint Inhibitor Response in BRAF Non-V600 Mutant Lung Cancers
Michael Ollfin, Memorial Sloan Kettering Cancer Center, United States of America

P1.04-40 Serum Perforin Levels During the First Cycle of Anti-PD-1 Antibody Therapies in Non-Small Cell Lung Cancer
Takayo Ota, Izumi City General Hospital, Japan
P1.04-41 Immunotherapy Concomitant to Radiotherapy: A Multicentric Retrospective Study on 179 Patients with Advanced Non-Small Cell Lung Cancer
Alessio Bruni, University Hospital of Modena, Italy

P1.04-42 Tumor Microenvironment Is Associated with Efficacy of PD-1/PD-L1 Inhibitors in Patients with Primary Pulmonary Lymphoepithelioma-Like Cancer
Xu-Chao Zhang, Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People’s Hospital & Guangdong Academy of Medical Sciences, China

P1.04-43 PD-RAD: A Translational Study Investigating PD-L1 Expression After Radiotherapy for Non-Small Cell Lung Cancer - Trial in Progress
Tiana Kordbacheh, Alderley Park, United Kingdom

P1.04-44 Radiomics for Predicting Response to First-Line Anti-PD1 Therapy in Advanced NSCLC
Christoph Ackermann, The Christie NHS Foundation Trust, United Kingdom

P1.04-45 Immune-Oncology Gene Expression Profiles Allow Lung Cancer Patients’ Stratification and Identification of Responders to Immunotherapy
Fabrizio Tabbò, University of Turin, Italy

P1.04-46 PD-1 Inhibitor Plus Chemotherapy as 2nd/Subsequent Line Setting Demonstrate Superior Efficacy Over PD-1 Inhibitor Alone in Pts of Advanced NSCLC
Shengxiang Ren, Shanghai Pulmonary Hospital, China

P1.04-47 Tumor Mutation Burden Through Hybrid Capture – Circulating Tumor DNA May Predict Response to Immunotherapy in NSCLC
Roxana Grinberg, Soroka University Medical Center, Israel

P1.04-48 Prediction of Tumor Doubling Time of Lung Adenocarcinoma Using Radiomics Margin Characteristics
Hyun Jung Yoon, VHS Medical Center, Korea, Republic of Korea

P1.04-49 Quantitative Computed Tomography (CT) Based Texture Analysis (QTA) Might Identify Responders to Immunotherapy in Non-Small Cell Lung Cancer
Zsolt Megyesfalvi, National Koranyi Institute for Pulmonology, Hungary

P1.04-50 Real World Efficacy of Pembrolizumab of as a 1st Line Treatment in Metastatic Non-Small Cell Lung Cancer with PD-L1 High Expression
Kazuo Kasahara, Kanazawa University, Japan

P1.04-51 Treatment with Immune Checkpoint Inhibitors for Advanced NSCLC in Elderly and Frail Patients. A Real-Life Experience
Mette Pøhl, Rigshospitalet University of Copenhagen, Denmark

P1.04-52 The Role of Blood Biomarkers in Radiation Therapy for Thoracic Malignancies
Eleni Gkika, University Medical Center, Germany

P1.04-53 A High PD-L1 Expression in Non-Small Cell Lung Cancer Correlates with Expression of SPOP and CD8 Tumor-Infiltrating Lymphocytes
Masaaki Inoue, Shimonoseki City Hospital, Japan

P1.04-54 Inter-Tumor Heterogeneity of PD-L1 Expressions in Non-Small Cell Lung Cancer
Yuichi Saito, Saitama Cardiovascular and Respiratory Center, Japan

P1.04-55 Comparison of PD-L1 Expression Status Between Pure-Solid Versus Part-Solid Tumors in Lung Adenocarcinomas
Kenichi Suda, Kindai University Faculty of Medicine, Japan

P1.04-56 Landscape of Tumor Mutational Burden in Indian NSCLC Patients
Prashant Mehta, Positive Bioscience, India

P1.04-57 Metronomic Dosing of Chemotherapy Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Non-Small Cell Lung Cancer
Yijun Jia, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine, China

P1.04-58 Uncovering the Tumor Microenvironment of KRAS-Driven Lung Adenocarcinoma: The Link Between Th17 Signaling and B Cell
Stefania Tommasi, Pharmacogenetic and Molecular Diagnostic Unit, Clinical Cancer Centre “Giovanni Paolo II”, Italy

P1.04-59 Modified Glasgow Prognostic Score Predict Survival Among Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors
Cláudia Freitas, Centro Hospitalar Universitário de São João, Portugal

P1.04-60 Impact of Metastatic Location on Survival in Stage-IV Non-Small Cell Lung Cancer (NSCLC) Treated with Immunotherapy
Sweta Jomnalagadda, East Carolina University, United States of America

P1.04-61 Neutrophil-Lymphocyte Ratio: A Predictive Biomarker of Immunotherapy in Lung Cancer?
Nuno China, Vila Nova de Gaia-Espinho Hospital Center, Portugal

P1.04-62 Nomogram Based on Multivariable Regression Model Estimates the Overall Survival of Nivolumab for Previously Treated Advanced NSCLC
Motohiro Tamiya, Osaka International Cancer Institute, Japan

P1.04-63 Correlation of Mutations in TP53, CDKN2A and PIK3CA with VISTA Expression in Pleomorphic Lung Carcinoma
Adam Januszewski, The Royal Marsden Hospital, United Kingdom

P1.04-64 The Opposite Role of PD-L1 Expression in EGFR Mutant Lung Cancer Treated with PD-1 Inhibitor Before and After EGFR TKI: Pilot Study
Hyung Soon Park, St. Vincent Hospital, Korea, Republic of Korea

P1.04-65 Microenvironment-Derived ADAM28 Impacts the Onset of Lung Cancer
Céline Hubeau, University of Liège (Uliege), Belgium

P1.04-66 The Percentage of PD-L1 Besides 50% Positivity Predicts Objective Response to Pembrolizumab in Non-Small Cell Lung Cancer
Anello Poma, University of Pisa, Italy

P1.04-67 First-Line Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer (NSCLC) – A Network Meta-Analysis by PD-L1
Gilberto Lopes, Sylvester Comprehensive Cancer Center, United States of America

P1.04-68 Liver Metastases Predicts Poorer Prognosis in Advanced NSCLC Patients Who Receiving Nivolumab Monotherapy
Guowei Zhang, The Affiliated Cancer Hospital of Zhengzhou University, China

P1.04-69 Modelling the Immunosuppressive Difference of SBRT and CRT by Simulating the Dose to Circulating Lymphocytes in Non-Small Cell Lung Cancer
Haihua Yang, Radiation Oncology Institute of Enze Medical Health Academy, Affiliated Taizhou Hospital of Wenzhou Medical University, China

P1.04-70 B Cell Driven Lung Adenocarcinoma: The Link Between Th17 Signaling and B Cell
Vesna Kljavin, Institute for Hygiene and Epidemiology, Serbia

P1.04-71 Immune-Oncology Gene Expression Profiles Allow Lung Cancer Patients’ Stratification and Identification of Responders to Immunotherapy
Fabrizio Tabbò, University of Turin, Italy

P1.04-72 Quantitative Computed Tomography (CT) Based Texture Analysis (QTA) Might Identify Responders to Immunotherapy in Non-Small Cell Lung Cancer
Zsolt Megyesfalvi, National Koranyi Institute for Pulmonology, Hungary

P1.04-73 Real World Efficacy of Pembrolizumab of as a 1st Line Treatment in Metastatic Non-Small Cell Lung Cancer with PD-L1 High Expression
Kazuo Kasahara, Kanazawa University, Japan

P1.04-74 Treatment with Immune Checkpoint Inhibitors for Advanced NSCLC in Elderly and Frail Patients. A Real-Life Experience
Mette Pøhl, Rigshospitalet University of Copenhagen, Denmark

P1.04-75 The Role of Blood Biomarkers in Radiation Therapy for Thoracic Malignancies
Eleni Gkika, University Medical Center, Germany

P1.04-76 A High PD-L1 Expression in Non-Small Cell Lung Cancer Correlates with Expression of SPOP and CD8 Tumor-Infiltrating Lymphocytes
Masaaki Inoue, Shimonoseki City Hospital, Japan

P1.04-77 Inter-Tumor Heterogeneity of PD-L1 Expressions in Non-Small Cell Lung Cancer
Yuichi Saito, Saitama Cardiovascular and Respiratory Center, Japan

P1.04-78 Comparison of PD-L1 Expression Status Between Pure-Solid Versus Part-Solid Tumors in Lung Adenocarcinomas
Kenichi Suda, Kindai University Faculty of Medicine, Japan

P1.04-79 Landscape of Tumor Mutational Burden in Indian NSCLC Patients
Prashant Mehta, Positive Bioscience, India

P1.04-80 Metronomic Dosing of Chemotherapy Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Non-Small Cell Lung Cancer
Yijun Jia, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine, China

P1.04-81 Uncovering the Tumor Microenvironment of KRAS-Driven Lung Adenocarcinoma: The Link Between Th17 Signaling and B Cell
Stefania Tommasi, Pharmacogenetic and Molecular Diagnostic Unit, Clinical Cancer Centre “Giovanni Paolo II”, Italy

P1.04-82 Modified Glasgow Prognostic Score Predict Survival Among Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors
Cláudia Freitas, Centro Hospitalar Universitário de São João, Portugal

P1.04-83 Impact of Metastatic Location on Survival in Stage-IV Non-Small Cell Lung Cancer (NSCLC) Treated with Immunotherapy
Sweta Jomnalagadda, East Carolina University, United States of America

P1.04-84 Neutrophil-Lymphocyte Ratio: A Predictive Biomarker of Immunotherapy in Lung Cancer?
Nuno China, Vila Nova de Gaia-Espinho Hospital Center, Portugal

P1.04-85 Nomogram Based on Multivariable Regression Model Estimates the Overall Survival of Nivolumab for Previously Treated Advanced NSCLC
Motohiro Tamiya, Osaka International Cancer Institute, Japan

P1.04-86 Correlation of Mutations in TP53, CDKN2A and PIK3CA with VISTA Expression in Pleomorphic Lung Carcinoma
Adam Januszewski, The Royal Marsden Hospital, United Kingdom

P1.04-87 The Opposite Role of PD-L1 Expression in EGFR Mutant Lung Cancer Treated with PD-1 Inhibitor Before and After EGFR TKI: Pilot Study
Hyung Soon Park, St. Vincent Hospital, Korea, Republic of Korea

P1.04-88 Microenvironment-Derived ADAM28 Impacts the Onset of Lung Cancer
Céline Hubeau, University of Liège (Uliege), Belgium

P1.04-89 The Percentage of PD-L1 Besides 50% Positivity Predicts Objective Response to Pembrolizumab in Non-Small Cell Lung Cancer
Anello Poma, University of Pisa, Italy

P1.04-90 First-Line Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer (NSCLC) – A Network Meta-Analysis by PD-L1
Gilberto Lopes, Sylvester Comprehensive Cancer Center, United States of America

P1.04-91 Liver Metastases Predicts Poorer Prognosis in Advanced NSCLC Patients Who Receiving Nivolumab Monotherapy
Guowei Zhang, The Affiliated Cancer Hospital of Zhengzhou University, China

P1.04-92 Modelling the Immunosuppressive Difference of SBRT and CRT by Simulating the Dose to Circulating Lymphocytes in Non-Small Cell Lung Cancer
Haihua Yang, Radiation Oncology Institute of Enze Medical Health Academy, Affiliated Taizhou Hospital of Wenzhou Medical University, China
P1.04-70 Application of Tumor Kinetics for Evaluation of Hyperprogression in Immune Checkpoint Inhibitor Treatment for Non-Small Cell Lung Cancer
Cheol-Kyu Park, Chonnam National University Medical School, Korea, Republic of Korea

P1.04-71 Tumor Burden Is Not Associated with Efficacy of Immune Checkpoint Inhibitors in Advanced Lung Cancer
David Gerber, UT Southwestern Medical Center, United States of America

P1.04-72 Tumor Mutational Burden as a Potential Predictive Biomarker of Response to PD-1/PD-L1 Blockade in Non-Small Cell Lung Cancer
Hyojin Kim, Seoul National University Bundang Hospital, Korea, Republic of Korea

P1.04-73 Small Cell Transformation of Non-Small Cell Lung Cancer (NSCLC) on Immune Checkpoint Inhibitors: Case Report and Literature Review
Kartik Sehgal, Beth Israel Deaconess Medical Center, United States of America

P1.04-74 Characteristics of T Cell Receptor Repertoire of Lung Cancer Patients
Naixin Liang, Peking Union Medical College, China

P1.04-75 Immune-Related Adverse Events and the Neutrophil to Lymphocyte Ratio as Predictors of Clinical Response to Immunotherapy
Luis Raez, Memorial Cancer Institute/Florida International University, United States of America

P1.04-76 Predictive Factors of Early Therapeutic Failure to Immunotherapy in Patients with Metastatic NSCLC
Victor Aurelio Ramos Sousa, AC Camargo Cancer Center, Brazil

P1.04-77 Efficacy of Anti-PD-1/L1 Therapy for Advanced Non-Small Cell Lung Cancer with Preexisting Autoimmune Markers
Takako Inoue, Osaka International Cancer Institute, Japan

P1.04-78 Efficacy of Checkpoint Inhibitors in Combination with Chemotherapy for First-Line Treatment of Advanced Non-Squamous NSCLC
Kyaw Thein, The University of Texas MD Anderson Cancer Center, United States of America

P1.04-79 CD73 Expression in Lung Adenocarcinomas and Immunological and Molecular Associations
Carmen Behrens, The University of Texas MD Anderson Cancer Center, United States of America

P1.04-80 Immunotherapy-Related Thrombosis: Considerations and Associated Factors in Non-Small Cell Lung Cancer (NSCLC) Patients
Oscar Gerardo Arrieta, Instituto Nacional de Cancerologia, Mexico

P1.04-81 Characterization of Hispanic Patients Who Experienced Hyperprogression During Treatment for Advanced NSCLC with Immunotherapy
Oscar Gerardo Arrieta, Instituto Nacional de Cancerologia, Mexico

P1.04-82 Toxicity as a Clinical Marker for Efficacy of Immunotherapy in NSCLC: A Multicentric Experience from Argentina
Maria Rizzi, Hospital Aleman de Buenos Aires, Argentina

P1.04-83 Combining Immune Gene Polymorphism and Immune Profile Predicts Brain Metastases and Death in a Brazilian Cohort of Non-Small Cell Lung Carcinoma
Vera Capelozzi, University of Sao Paulo Faculty of Medicine, Brazil

P1.04-83 MiR-195 Restrains Lung Adenocarcinoma via Regulating CD4+ T Cell Activation Through CCDC88C/Wnt Signaling Pathway
Conghua Xie, Zhongnan Hospital of Wuhan University, China

P1.06 09:45–18:00 MESOTHELIOMA

P1.06-01 Combining Immunoprofile, Immunogenic Collagen and Mismatch Repair Proteins Predicts Risk of Death and Target Therapy in Malignant Mesothelioma
Juliana Machado-Rugolo, University Hospital, Botucatu Medical School, Brazil

P1.06-02 National Trends in Outcomes in Patients with Malignant Pleural Mesothelioma
Kaushal Parikh, Mayo Clinic, United States of America

P1.06-03 Selective Depletion of Foxp3+ Regulatory T Cells After Local Radiotherapy Induces Abscopal Effects in Murine Malignant Mesothelioma
Mikihiro Kohno, Toronto General Hospital, University Health Network, Canada

P1.06-04 Deep Learning-Based Segmentation of Mesothelioma on CT Scans: Application to Patient Scans Exhibiting Pleural Effusion
Samuel Armato, University of Chicago, United States of America

P1.06-05 Clinical Features and Outcomes of Recurrence After Pleurectomy/Decortication for Malignant Pleural Mesothelioma
Akiyoshi Nakamura, Hyogo College of Medicine, Japan

P1.06-06 EORTC 1205: Randomized Study of Pleurectomy/Decortication (P/D) Preceded or Followed by Chemotherapy in Malignant Pleural Mesothelioma
Jan Van Meerbeeck, Antwerp University Hospital, Belgium

P1.06-07 Targeting Photo-Therapy for Malignant Pleural Mesothelioma; Near Infrared Photomunotherapy Targeting Podoplanin
Yuko Nishinaga, Nagoya University, Japan

P1.06-08 WDPM-Like but not Cribriform as Secondary Growth Patterns Modify Survival in Epithelioid Malignant Pleural Mesothelioma
Yu Zhi Zhang, Imperial College London, United Kingdom

P1.06-09 Prophylactic Irradiation of Tracts in Patients with Malignant Pleural Mesothelioma: A Systematic Review and Meta-Analysis
Yu Yang Soon, National University Cancer Institute, Singapore

P1.06-10 18F-FDG PET/CT in Malignant Pleural Mesothelioma: Diagnostic/Prognostic Performance and Correlation with Pathological Results
Filippo Lococo, IRCCS-Arcispedale Santa Maria Nuova, Italy

P1.06-11 Overlapping Immunophenotypes Between Mesothelioma and Angiosarcoma: Usefulness of Claudin-5 in the Differential Diagnosis
Yasuhiro Nakashima, The Cancer Institute, Japanese Foundation for Cancer Research, Japan

P1.06-12 Defects in Homologous Recombination Repair Indicates Susceptibility for Olaparib Treatment in Malignant Pleural Mesothelioma
Sabrina Borchert, University Hospital Essen, Germany
P1.06-13 Treatment Patterns and Outcomes in Advanced Malignant Pleural Mesothelioma: Surveillance, Epidemiology, and End Results Data
Melinda Daumont, Bristol-Myers Squibb, Belgium

P1.06-14 Posterior Intercostal Lymph Node Positivity as a Prognostic Indicator of Overall Survival in Resectable Malignant Pleural Mesothelioma
Aneesa Hussain, University of Maryland Medical Center, United States of America

P1.06-15 Safety of Irradiation Combined with Intracavitary Cisplatin-Fibrin After Lung-Sparing Surgery in a Rat Model of Mesothelioma
Isabelle Schmitt-Opiitz, University of Zürich, Switzerland

P1.06-16 Molecular Signature in Malignant Pleural Mesothelioma (MMP). Preliminary Data of Rames Study
Maria Pagano, AUSL-IRCCS Reggio Emilia, Italy

P1.06-17 Tumor Treating Fields (150 kHz) Combined with Cisplatin or Pemetrexed Inhibits Mesothelioma Cells in Vitro and in Vivo
Uri Weinberg, Novocure, Israel

P1.06-18 MicroRNA Expression Is Linked to Response of Malignant Pleural Mesothelioma to Cisplatin-Pemetrexed Chemotherapy
Michaela Kirscher, University Hospital Zurich, Switzerland

P1.06-19 Regional Mesothelioma Multidisciplinary Team Meetings: Perspectives from a UK Cardiothoracic Tertiary Centre
Kate Slaven, Royal Papworth Hospital, United Kingdom

P1.06-20 Malignant Pleural Mesothelioma: Survival Meta-Analysis from 15 Years of a Standard Systemic Therapy
Joseph Friedberg, University of Maryland Medical Center, United States of America

P1.06-21 Safety Meta-Analysis of Clinical Trials Delivering Tumor Treating Fields to the Upper Torso
Uri Weinberg, Novocure, Israel

P1.06-22 Pathologic and Imaging Response Correlations in Patients Treated with Neoadjuvant Chemotherapy for Mesothelioma
Muneeb Rehman, Mayo Clinic, United States of America

P1.06-23 Early Lung Cancer Team Intervention in Emergency Admissions
Joanne Dunbar, Liverpool Heart & Chest Hospital & Royal Liverpool Broadgreen University Hospital NHS Trusts., United Kingdom

P1.07-01 Lung Cancer Support Groups: Still Relevant in a Digital World?
Maureen Rigney, Go2 Foundation for Lung Cancer, United States of America

P1.07-02 Implementation of a Health and Wellbeing Programme in Conjunction with Pulmonary Rehabilitation
Josianne Roberts, The Rotherham NHS Foundation Trust, United Kingdom

P1.07-03 Improving Non-Oncology Provider Knowledge of Unique Immunotherapy Adverse Events
Enza Esposito Nguyen, St Joseph Hospital, United States of America

P1.07-04 Early Lung Cancer Team Intervention in Emergency Admissions
Joanne Dunbar, Liverpool Heart & Chest Hospital & Royal Liverpool Broadgreen University Hospital NHS Trusts., United Kingdom

P1.07-05 Developing a Nursing Triage Tool to Assess Patient Support Needs Through Treatment for Lung Cancer
Jackie Fenemore, The Christie Hospital Foundation Trust, United Kingdom

P1.07-06 Use of the Nutritional Risk Index as Screening for Malnutrition in Patients with Lung Cancer
Imanuel Goncalves, Grupo Oncoclinicas, Brazil

P1.07-07 An Interdisciplinary Collaborative Approach to Discharge Readiness on a Thoracic Surgery Specialty Unit
Sarah Levy, University of Maryland Medical Center, United States of America

P1.07-08 Screening for Fear of Cancer Recurrence in Operable Lung Cancer Patients-Scale Validation and Current Status
Year-Hur Lai, National Taiwan University, Taiwan

P1.07-09 Implementation of a Nursing Program for Cancer Patients Treated with Immunotherapy by an Immunotherapy Nurse Specialist
Jorgina Serra, Hospital de la Santa Creu i Sant Pau, Spain

P1.07-10 Investigation on Nutritional Status and Quality of Life of Patients with Lung Cancer Treated by Radiotherapy in Different Sexes
Shu-Ping Xie, Zhejiang Cancer Hospital, China

P1.07-11 An Evaluation of the Patient’s Experience and Expectations During the Implementation of NHS England, National Optimal Lung Cancer Pathway
Karen Clayton, East Cheshire NHS Trust, United Kingdom

P1.07-12 Essential Psychosocial Requirements for Quality Lung Cancer Care
Csaba Degi, Babes - Bolyai University and APSCSO, Romania

P1.07-13 The Application of Intracavitary Electrocardiogram in the Femoral Vein Catheter Tip Location in Chemotherapy Patients with Lung Cancer
Jinghui Zhang, Central South University, China

P1.07-14 Fertility and Treatment Decision Making in Older People with Lung Cancer
Angela Tod, University of Sheffield, United Kingdom

P1.07-15 Screening for Long Term Ototoxicity in Lung and Upper Aerodigestive Cancer Survivors Treated with Platinum Chemotherapy
Simranjit Kooner, Princess Margaret Cancer Centre, Canada

P1.07-16 Training Program for University Nursing Students to Reduce Lung Cancer Patient Emotional Distress
Somaya Abouabdou, Faculty of Nursing Suez Canal University, Egypt

P1.07-17 Transfer of Care: Effective Communication to Promote Improved Patient Experience
Nazanin Nouriany, University Health Network - Princess Margaret Cancer Centre, Canada

P1.07-18 The Effect of Lung Cancer on Patient Sexual Functioning: Nursing View
Somaya Abouabdou, Faculty of Nursing Suez Canal University, Egypt

P1.07-19 Palliative Care Social Workers Multi-Dimensional Roles: A Namibian Perspective
Rachel J Freeman, University of Namibia, Namibia

P1.07-20 Evaluation of the Efficacy of Continuing Nursing Education Sessions for Oncology Nurses at Princess Margaret Cancer Centre
Nazanin Nouriany, University Health Network - Princess Margaret Cancer Centre, Canada
P1.09

09:45–18:00 PATHOLOGY

Track(s): Pathology

P1.09-01 Immunoprofiling Depends on Molecular Determinants to Predict Metastases and Target Therapy in Non-Small Cell Lung Carcinomas
Juliana Rugolo-Machado, State University of Sao Paulo, Brazil

P1.09-02 Comprehensive Genomic Profiling of Non-Small Cell Lung Cancer in Brazil (GBOT 0118/LACOG 0418)
Eldsameria Mascarenhas, Nucleo de Oncologia da Bahia, Brazil

P1.09-03 Clinicopathological Characteristics for NSCLC Harboring EGFR Exon 20 Insertion
Kei Morikawa, St. Marianna University School of Medicine, Japan

P1.09-04 Comprehensive Genomic Profiling in a Brazilian Cohort of Lung Cancer Patients: Real-World Impact
Tiago Padua, Américas Oncologia, Brazil

P1.09-05 ALK Testing in Chinese Advanced NSCLC Patients: A National-Wide Multicenter Prospective Real-World Data Study (The RATICLAL Study)
Jianning Ying, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China

P1.09-06 Evaluation of Molecular Testing in a Dutch Cohort of Metastatic Non-Small Cell Lung Cancer Patients from 2017
Chantal Kuipers, University Medical Centre Utrecht, Netherlands

P1.09-07 The Clinical Utility and Performance of Whole-Exome Sequencing for NSCLC Patient Care: A Comparison to Standard-of-Care
Kenneth O’Byrne, Institute of Health and Biomedical Innovation, Queensland University of Technology Translational Research Institute, Australia

P1.09-08 Registration of Pre-Operative Lung Cancer PET/CT Scans with Post-Operative Histopathology Maps
Gabriel Reines March, NHS Greater Glasgow and Clyde, United Kingdom

P1.09-09 Model to Predict Small Lymph Nodes Metastasis in Non-Small Cell Lung Cancer
Jiancheng Li, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, China

P1.09-10 Molecular Immunocytochemistry in Various NSCLC Samples Prepared as Non-Cell Block Cytology
Silvana Smojver-Ježek, University Hospital Centre Zagreb, Croatia

P1.09-11 Influences of Sampling Method to Morphological Feature Measurement of Lung Cancer Cell
Tomoharu Kiyuna, NEC Corporation, Japan

P1.09-12 In-Situ Hybridization Visual Scoring of Epigenetic Imprinting Genes Improves Early Diagnosis and Grading of Lung Cancers
Rex Yung, Johns Hopkins University School of Medicine, United States of America

P1.09-13 Prognostic Value of TPRRS4 Expression and Its Role as Diagnostic Biomarker by Liquid Biopsy in Early Stage NSCLC
Francisco Exposito, CIBERONC, ISC-I, Spain

P1.09-14 Comparison Between Liquid Biopsy and Conventional Tissue Biopsy in EGFR Genotyping of Non-Small Cell Lung Cancer
Sang Hoon Lee, Severance Hospital, Yonsei University College of Medicine, Korea, Republic of

P1.09-15 Hybrid Organoid Reveals That Podoplanin-Positive Cancer-Associated Fibroblasts Enhance Proliferation of Lung Cancer Cell
Hiroshi Nakamura, JUntendo University, Japan

P1.09-16 Tumor Proliferation Is Associated with the Tumor Immunological Status: A Study on NSCLC Using Multiplex Immunofluorescence
Andreas Spitzmüller, Definiens AG, Germany

P1.09-17 In the Minimally Invasive Era, What Is the Role of Intra-Operative Frozen Section Prior to Lobectomy: A Single Institution Perspective
Ashok Kar, St George’s Hospital, United Kingdom

P1.09-18 Small-Sized Spread Through Air Spaces (STAS) in Resected Pulmonary Adenocarcinoma: Is It Necessary to Record It as a Prognostic Factor?
Akihiko Yoshizawa, Department of Diagnostic Pathology, Kyoto University Hospital, Japan

P1.09-19 High-Throughput Next Generation Sequencing of Treatment-Naive Non-Squamous NSCLC: The Singapore National Lung Profiling Study
Aaron Tan, National Cancer Centre Singapore, Singapore

P1.09-20 Significance of Maximal Diameter Measurement in Small-Sized Adenocarcinomas
Hironori Ninomiya, The Cancer Institute, Japanese Foundation for Cancer Research, Japan

P1.09-21 Tumor Responses Based on Tumor Growth Rate During PD-1 Inhibitor Therapy in Advanced Non-Small-Cell Lung Cancer Patients
Daan Hurkmans, Erasmus University Medical Center, Netherlands

P1.09-22 Programmed Death Ligand-1 Expression in Non-Small Cell Lung Cancer in Mexican Population and Correlation with Clinicopathologic Features
Omar Macedo-Perez, Instituto Nacional de Cancerologia, Mexico

P1.09-23 A33 and SATB2 Immunohistochemistry for Differentiating Metastatic Colorectal Carcinoma from Pulmonary Enteric Adenocarcinoma
Likun Hou, Shanghai Pulmonary Hospital, China

P1.09-24 Tumor Necrosis Correlates with PD-L1 and PD-1 Expression in Lung Adenocarcinoma
Judit Moldvay, National Koranyi Institute of Pulmonology, Hungary

P1.09-25 The Use of In-Situ RNA Analysis in the Detection of Metastatic HPV Mediated Squamous Cell Carcinoma to the Lung with p16 Correlation
Roula Katerji, University of Rochester Medical Center, United States of America

P1.09-26 Prevalence of PD-L1 Expression Rates in Different NSCLC Specimens
Wendy Cooper, Royal Prince Alfred Hospital, Australia

P1.09-27 Interobserver Variation in the Cytological Diagnosis of Pulmonary Adenocarcinoma Presenting with Ground-Glass Opacity Nodules
Hae Sung Park, Ewha Womans University Seoul Hospital, Korea, Republic of

P1.09-28 A Significant Discordance Between PANAMutyper™ and Targeted Deep Sequencing for Detecting EGFR Mutation in NSCLC
Jeonghyo Lee, Seoul National University Bundang Hospital, Korea, Republic of

P1.09-30 Molecular Characterization of Preinvasive and Invasive Lesions in Multifocal Pulmonary Adenocarcinomas
Hsiang-Ling Ho, Taipei Veterans General Hospital, Taiwan
P1.11-15 Feasibility of a Lung Health Clinic for Early Lung Cancer Identification in High-Risk Individuals in South-East London
Gillian Selman, Guy’s & St Thomas NHS Trust, United Kingdom

P1.11-16 Squamous Cell Lung Cancer Risk Is Associated with Rare, Pathogenic Germline Variants in BRCA2 and Fanconi Anemia Genes
Zeynep Gumus, Icahn School of Medicine at Mount Sinai, United States of America

P1.11-17 Osteoporosis, Coronary Artery Calcification, and COPD in a Lung Cancer Screening Cohort
James Finigan, National Jewish Health, United States of America

P1.11-18 The Results of Mandatory Smoking Cessation Intervention in a Population-Based Lung Cancer Screening Trial
Eunjee Lee, Korean National Cancer Center, Korea, Republic of

P1.11-19 Trial in Progress: Cancer Screening Study With or Without Low Dose Lung CT to Validate a Multi-Cancer Early Detection Blood Test
Sam Janes, University College London, United Kingdom

P1.11-20 Identification of a Thirteen-Gene Prognostic Signature for Lung Adenocarcinoma
Yang Wo, Affiliated Hospital of Qingdao University, China

P1.11-21 Liverpool Health Lung Project: Significant Incidental Findings in a Smoker-Predominant Cohort
Martin Ledson, Liverpool Heart and Chest Hospital, United Kingdom

P1.11-22 Lung Cancer Growth: Impact of Different Assumptions
David Yankelevitz, Icahn School of Medicine at Mt. Sinai, United States of America

P1.11-23 The Impact of the Family History of Different Cancers on Lung Cancer
Jianfu Li, Guangzhou Medical University, China

P1.11-24 Implementation of an Organized Lung Cancer Screening Program in Korea
Yeol Kim, National Cancer Control Institute, National Cancer Center, Korea, Republic of

P1.11-25 Adjustment for Lead-Time Bias and Over-Diagnosis in Lung Cancer Screening
Szu-Chun Yang, National Cheng Kung University College of Medicine and Hospital, Taiwan

P1.11-26 The Epidemiology of Ground Glass Opacity (GGO) Lung Adenocarcinoma: A Network Based Cumulative Meta-Analysis
Xiongfei Li, Tianjin Medical University General Hospital, China

P1.11-27 Computed Tomography Screening for Early Lung Cancer, COPD and Cardiovascular Disease in Shanghai: Rationale and Design of a Population-Based Comparative Study
Yihui Du, University Medical Center Groningen, Netherlands

P1.11-28 Lung Cancer: Susceptibility and Survival Differences for Women and Men
Claudia Henschke, Icahn School of Medicine at Mount Sinai, United States of America

P1.11-29 Relationship Between Lung Cancer Screening Centers in the United States and High-Risk Individuals
Candice Wilshire, Swedish Cancer Institute, United States of America

P1.11-30 Very Rapid Growth of Small Pulmonary Nodules Predicts Benignity
Joseph Barnett, Royal Brompton Hospital, United Kingdom

P1.11-31 Understanding Referral Patterns in a Lung Cancer Screening Program
Diane Haddad, Vanderbilt University Medical Center, United States of America

P1.11-32 The UKLS Nodule Risk Model (UKLS-NRM): Utilising Nodule Volumetry
Michael Marcus, The University of Liverpool, United Kingdom

P1.11-33 Prognostic Value of Symptoms at Lung Cancer Diagnosis: A Two-Year Observational Study
Dinora Polanco, Hospital Universitari Arnau de Vilanova, Spain

P1.11-34 The Liverpool Healthy Lung Project – Championing the Importance of Lung Health
Martin Ledson, Liverpool Heart and Chest Hospital, United Kingdom

P1.11-35 Comparison of Lung Cancer Screening Trials from East Asia; South Korea, Japan, and Taiwan
Sang Won Shin, Korea University Hospital, Korea, Republic of

P1.11-36 A Simple Tool to Prioritize US Ever-Smokers for CT Screening Eligibility Assessment
Hilary Robbins, International Agency for Research on Cancer, France

P1.11-37 Face Your Fear Awareness Campaign
Lorraine Dallas, Roy Castle Lung Cancer Foundation, United Kingdom

P1.11-38 Frequency and Prognostic Impact of Concomitant Mutations in KRAS and TP53 or STK11 in Brazilian Lung Adenocarcinoma Patients
Vladmir De Lima, AC Camargo Cancer Center, Brazil

P1.11-39 Low-Dose CT Lung Screening: Data Analysis of Lung Cancer Patients with Above 40 Years Old
Yuying Jin, Peking Union Medical College/Chinese Academy of Medical Sciences, Cancer Hospital, China

P1.11-40 Systematic Development and Multi-Cohort Validation of a Serum miRNA Biomarker Panel for Detection of Early Stage Non-Small Cell Lung Cancer
Lihan Zhou, Mirxes Pte Ltd, Singapore

09:45 – 18:00 SMALL CELL LUNG CANCER/NET

Track(s): Small Cell Lung Cancer/NET

P1.12-01 CDBI-HOTTIP Regulating Loop Enhances Myc-Mediated Chemoresistance in Small Cell Lung Cancer via ERK Signaling Pathway
Linlang Guo, Zhujiang Hospital, Southern Medical University, China

P1.12-02 Nationwide Assessment of the Role of Adjutant Systemic Therapy in High-Risk Lung Carcinoids
Brendon Stiles, New York Presbyterian Hospital-Weill Cornell Medical College, United States of America

P1.12-03 Antitumor Activity of Single Agent Lurbinitedcin in Patients with Relapsed SCLC Occurring ≥30 Days After Last Platinum Dose
Jose Manuel Trigo Perez, Hospital Universitario Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga-IBIMA, Spain

P1.12-04 A Phase I Study of the 177Lu-DOTATOC-Tyr3-Octreotate in Combination with Nivolumab in Patients with Extensive-Stage Small Cell Lung Cancer
Chul Kim, Georgetown University Hospital, United States of America

P1.12-05 Microenvironment Characterization of Small Cell Lung Cancer Xenografts Implanted in Hematopoietic Humanized Mice
Hui Yu, University of Colorado Anschutz Medical, United States of America

09:45 – 18:00 SMALL CELL LUNG CANCER/NET

Track(s): Small Cell Lung Cancer/NET

P1.12-01 CDBI-HOTTIP Regulating Loop Enhances Myc-Mediated Chemoresistance in Small Cell Lung Cancer via ERK Signaling Pathway
Linlang Guo, Zhujiang Hospital, Southern Medical University, China
P1.12-06 Ozone-Primed Neutrophils Promote Early Steps of Tumor Cell Metastasis to Lungs by Enhancing Their NETs Production
Alison Gillard, University of Liège (ULiège), Belgium

P1.12-07 Near Infrared Photoimmunotherapy Targeting DLL3 Against Small Cell Lung Cancer
Yoshitaka Isobe, Nagoya University, Japan

P1.12-08 The Impact of Patient Age and Socioeconomic Factors on Clinical Outcomes in Small Cell Lung Cancer (SCLC): A National Study
Ruqin Chen, Mayo Clinic Florida, United States of America

P1.12-09 RNA Sequencing in Small Cell Lung Carcinoma Reveals Change in Neuroendocrine Pattern in Primary Tumor Versus Lymph Node Metastases
Zoltán Lohanai, National Korányi Institute of Pulmonology, Hungary

P1.12-10 The Genomic Profiles of Small Cell Lung Cancer in East Asian
Rongrong Chen, Geneplus-Beijing Institute, China

P1.12-11 Exploring Sex Differences in Small Cell Lung Cancer: Is This a Hormonal Issue?
Narjust Duma, Mayo Clinic, United States of America

P1.12-12 Factors Affecting the Risk of Brain Metastasis in Limited-Stage Small Cell Lung Cancer After Prophylactic Cranial Irradiation
Mengyuan Chen, Zhejiang Cancer Hospital, China

P1.12-13 The Past, Present, and Future of SCLC and NSCLC Incidence, Mortality, and Prevalence in Denmark During 2006 Through 2030
Anders Green, Institute of Applied Economics and Health Research (ApHER), Denmark

P1.12-14 Phase II Trial of Apatinib Plus Chemotherapy for Second-Line and Above Treatment of Advanced SCLC: Focus on Efficacy and Safety
Kewei Ma, The First Hospital of Jilin University, China

P1.12-15 PET Imaging of [18F]PARP Inhibitor as a Pharmacodynamic Biomarker of Talazoparib in Small Lung Cancer PDxs
Benjamin Lok, Princess Margaret Cancer Centre, Canada

P1.12-16 LMW Heparin Adherence and Effects on Survival Within a Randomized Phase III Lung Cancer Trial (RASTEN)
Emelie Gezelius, Lund University, Sweden

P1.12-17 Association Between the Pharmacokinetics and Clinical Outcome of Amrubinib Treatment
Satoshi Fukuda, Nagoya City University Graduate School of Medical Sciences, Japan

P1.12-18 Nonclinical Safety Assessment of AMG 757, a DLL3 Bispecific T Cell Engager, in the Cynomolgus Monkey
Edward Lobenhofer, Amgen Inc., United States of America

Jialei Wang, Fudan University Shanghai Cancer Center, China

P1.12-20 Surgical Resection Versus Stereotactic Body Radiation Therapy for T1-2 NO Typical Bronchopulmonary Carcinoid Tumors
Rodney Wegner, Allegheny Health Network, United States of America

P1.12-21 Impact of Treatment Modality on Long-Term Survival of Small-Cell Lung Cancer with IA Stage: A Cohort Study of the US SEER Database
Kunshou Zhu, Fujian Cancer Hospital, China

P1.12-22 A Phase 1b/2 Study of Niraparib Plus Temozolomide Versus Standard Care as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer Patients
Amy Cummings, David Geffen School of Medicine, University of California, Los Angeles, United States of America

P1.12-23 DLL3 Is a Predictive Marker of Sensitivity to Adjuvant Chemotherapy for High-Grade Neuroendocrine Tumors
Hiroyuki Ogawa, Hyogo Cancer Center, Japan

P1.12-24 Comparison of Four Prognostic Scores for Patients with Brain Metastases from Small-Cell Lung Cancer
Lei Zhao, Shanghai Chest Hospital, China

P1.13

09:45 – 18:00 STAGING

Track(s): Staging

P1.13-01 The Importance of Staging of Lung Cancers, 30 mm or Less, Separately for Subsolid and Solid Nodules
Rowena Yip, Icahn School of Medicine at Mount Sinai, United States of America

P1.13-02 Should Aortic Lymph Nodes be Considered Hilar Lymph Nodes in Patients with Completely Resected NSCLC? A Multicenter Study
Necati Cikat, Bakirkoy Dr.Sadi Konuk Research and Education Hospital, Turkey

P1.13-03 Lung Adenocarcinomas Manifesting as Radiological Part-Solid Nodules Define a Special Clinical Subtype
Yaxing Shen, Zhongshan Hospital, China

P1.13-04 Impact of the Presence and Propagation of GGO on Survival and Pathological Characteristics in Clinical Stage I Lung Adenoacarcinoma
Shinya Katsumata, National Cancer Center Hospital East, Japan

P1.13-05 Evaluation of PET/CT Scans to Predict Pathologic Lung Cancer Staging
Mukunthan Murthi, University of Miami, United States of America

P1.13-06 Impact of Lymph Node Involvement and Tumor Location on Survival Following Resection for pN1/pN2 Non-Small Cell Lung Cancer
Andrea Bille, Guy’s Hospital NHS Foundation Trust, United Kingdom

P1.13-07 Comparison of the 7th and 8th Edition of TNM Staging for NSCLC in Patients Undergoing Pulmonary Resection After Neoadjuvant/Induction Treatment
Hüseyin Melek, Uludag University, Turkey

P1.13-08 The Maximum Standardized Uptake Values on Positron Emission Tomography Predict Pathological Characteristics of Non-Small Cell Lung Cancer
Takuto Okata, National Cancer Center Hospital East, Japan

P1.13-09 Utility of Artificial Intelligence in Estimation of the Histologic Type of Lung Cancer
Yohei Kawaguchi, Cancer Institute Hospital of JFCR, Japan

P1.13-10 Incidence of Hidden Extrathoracic Metastases and Unexpected Second Malignancies Detected by PET in Patients with Lung Cancer
Bruno Garcia Cabo, Hospital Mutua de Terrassa, Spain

P1.13-11 An Audit on IASLC Compliance of Lymph Nodes Dissection and Impact on Survival After Surgery for Non-Small Cell Lung Cancer
Eric Lim, Royal Brompton Hospital, United Kingdom
P1.14-12 The Invasion of Mediastinal Fat Tissue Should Be Considered for T4 Description in the Next TNM Classification of NSCLC
Necati Citak, Bakirkoy Dr. Sadi Konuk Research and Education Hospital, Turkey

P1.13-13 High-Risk Clinical Stage I Non-Small Cell Lung Cancer Based on High-Resolution Computed Tomography Findings
Yasuhiro Tsutani, Hiroshima University Hospital, Japan

P1.12-14 Prognosis and Clinicopathologic Characteristics of Skip N2 Metastasis in Completely Resected Non-Small Cell Lung Cancer
Takaaki Tsuboi, Kanagawa Cancer Center, Japan

P1.14
09:45 – 18:00 TARGETED THERAPY

Track(s): Targeted Therapy

P1.14-01 Are Pretreatment Inflammation-Based Prognostic Scores Useful in Predicting the Outcomes of Patients with ALK-Positive NSCLC?
Omer Fatih Olmez, Medipol University, Medical Faculty, Turkey

P1.14-02 Survey of EGFR Molecular Testing of NSCLC in the Asia-Pacific Region
Chong Kin Lam, University of Malaya, Malaysia

P1.14-03 Molecular Determinants for Lorlatinib Activity in ROS1 Positive NSCLC: Results of the Prospective PFROST Trial
Lorenza Landi, Ospedale S.Maria delle Croci, Italy

P1.14-04 Final Results of the Prospective Genomics of Young Lung Cancer (GYLC), an Addario Lung Cancer Medical Institute Study
Barbara Gitzitz, Genentech, United States of America

P1.14-05 TP53 Exon 8 Mutation and Prognosis in EGFR-Mutated NSCLC Patients Treated with First-And-Second-Generation TKIs
Paola Ulivi, IRST-IRCCS, Italy

P1.14-06 Tissue-Based Molecular and Histologic Landscape of Acquired Resistance to Osimertinib in Patients with EGFR-Mutant Lung Cancers
Adam Schoenfeld, Memorial Sloan Kettering Cancer Center, United States of America

P1.14-07 Genomic Profiling of Liquid Biopsies During 2nd/3rd Generation ALK Inhibitor Therapy to Identify Novel Mechanisms of Resistance
Erin Stewart, University Health Network, Canada

P1.14-08 Activity of Poiratinib and Other 2nd-Gen Quinazoline EGFR TKIs in Atypical Exon18 and Acquired Osimertinib Resistance Mutants
Jacqueline Robichaux, MD Anderson Cancer Center, United States of America

P1.14-09 Unveiling Hidden MET-Mediated Primary Alectinib Resistance in ALK-Positive Non-Small Cell Lung Cancer
Anh Le, University of Colorado-AMC, United States of America

P1.14-10 The Landscape of RET Genomic Alterations in Chinese Non-Small Cell Lung Cancer Patients
Yueting Qu, OrigMed, China

P1.14-11 A Prospective Multicentric Study of Target-Capture Deep Sequencing in Paired Tissue and ctDNA to Guide EGFR-Mutated Lung Cancer Treatment
Shun Lu, Shanghai Chest Hospital, China

P1.14-12 A Novel Activating MAP2K1 In-Frame Deletion Mediates Acquired Resistance to ROS1 TKIs in a Patient with ROS1 Fusion-Positive NSCLC
Hiroki Sato, Memorial Sloan Kettering Cancer Center, United States of America

P1.14-13 EGFR Amplification Mediates Resistance to Third-Generation EGFR TKIs and in vitro Validation of Combination Strategies to Overcome Resistance
Yi-Chen Zhang, Guangdong Lung Cancer Institute, China

P1.14-14 Monitoring of EGFR Mutations During Osimertinib Treatment in Advanced EGFR-Mutant T790M Positive NSCLC
Katja Mohoric, University Clinic Golnik, Slovenia

P1.14-15 Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey
Umut Demirci, Sağlık Bilimleri University Abdurrahman Yurtaslan Oncology Hospital, Turkey

P1.14-16 Resolving Resistance to Osimertinib by Combining Apatinib and Osimertinib in EGFR-Mutant NSCLC Patients
Xue Yang, Beijing Cancer Hospital, China

P1.14-17 Genomic Evolution During TKI Treatment in Non-Small Cell Lung Cancer Patients With or Without Acquired T790M Mutation
Yanjun Xu, Zhejiang Cancer Hospital, China

P1.14-18 ALK Inhibitor Sequencing and Outcomes Among ALK-Positive (ALK+) NSCLC Patients in the US Community Oncology Setting
Marc Chioda, Pfizer, United States of America

P1.14-19 Exome Analysis of Patients Treated with Apatinib Reveals Genetic Variations Discriminating Extreme Responders
Julie Niogret, Georges-François Leclerc Anticancer Center, France

P1.14-20 Tarloxotinib as a Novel Therapeutic Strategy for Oncogenic Alterations Across the ErbB Family of Receptors
Adriana Estrada-Bernal, University of Colorado, United States of America

P1.14-21 Propensity-Matched Genomic Profiling Comparison of Lung Adenocarcinomas Among 3 Races, a Multicenter Study of 4655 Patients
Ke Lan, Peking University People’s Hospital, China

P1.14-22 SASHI, a Novel Prognostic and Predictive Factor for PARP Inhibitors in Lung Cancer
Joshua Burgess, Translational Research Institute, Australia

P1.14-23 Resistance Mechanisms to Osimertinib Treatment in EGFR-Mutated Lung Cancer in a Real Life Cohort
Christi Steenamd, Erasmus MC, Netherlands

P1.14-24 Characterization of Acquired Receptor Tyrosine Kinase Fusions as Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors
Haiyuan Xu, Kunshan First People’s Hospital Affiliated to Jiangsu University, China

P1.14-25 Targeting NRG1-Fusions in Lung Adenocarcinoma: Apatinib as a Novel Potential Treatment Strategy
Michael Duruisseaux, Hôpital Louis Pradel, France

P1.14-26 ALK Fusion Variant Detection by Targeted RNA-Seq in TKIs Treated ALK-Positive Lung Adenocarcinoma
Fabrizio Tabbb, University of Turin, Italy

P1.14-27 Duration of Targeted Therapy in Advanced NSCLC (aNSCLC) with Drivers Identified by Circulating Tumor DNA (ctDNA) Analysis
Christina Baik, University of Washington, Seattle Cancer Care Alliance, United States of America
P1.14-28 Correlation Between the Qualification for the Bevacizumab Use and the Survival of NSCLC Patients with EGFR Mutations
Taiki Hakozaki, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Japan

P1.14-29 Disrupting the Paradigm: Partnering with Oncogene-Focused Patient Groups to Propel Research
Janet Freeman-Daily, The ROSIders, United States of America

P1.14-30 Phase I Study of Afinatinib Plus Bevacizumab in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations
Takaaki Tokito, Kurume University Hospital, Japan

P1.14-31 Lack of Association Between BIM Deletion Polymorphism and Clinical Efficacy of EGFR-TKIs in NSCLC Based on NGS
Si-Yang Liu, Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People’s Hospital & Guangdong Academy of Medical Sciences, China

P1.14-32 Rash and Efficacy in Anaplastic Lymphoma Kinase Positive (ALK+) Non-Small Cell Lung Cancer Patients Treated with Ensartinib
Heather Wakelee, Stanford University, United States of America

P1.14-33 Canagliflozin Inhibits Lung Cancer Survival and Enhances Its Response to Radiotherapy; Effective Blockade of mTOR Pathway, HIF1a, and Mitosis
Evangelia Tsakiridis, McMaster University, Canada

P1.14-34 The Landscape of MET Alterations in Chinese Non-Small Cell Lung Cancer Patients
Yueting Qu, OriginMed, China

P1.14-35 Epithelial-To-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status
Koji Fukuda, Cancer Research Institute Kanazawa University, Japan

P1.14-36 Phase II Trial of Afinatinib in Elderly Patients Aged Over 75 Years with EGFR Mutation Positive Non-Small Cell Lung Cancer
Ryo Ko, Juntendo University, Graduate School of Medicine, Japan

P1.14-37 Lung Cancer in Never-Smokers: A Nationwide Population Based Mapping of Targetable Alterations
Maria Planck, Division of Oncology and Pathology, Sweden

P1.14-38 Identification of FGFR1-3 Fusions in Lung Cancers Using Comprehensive Next-Generation Sequencing
Gen Lin, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, China

P1.14-39 Acquired ALK Rearrangement in EGFR-Mutant Lung Adenocarcinoma Treated with EGFR TKIs
Qian-Yu Wang, Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People’s Hospital & Guangdong Academy of Medical Sciences, China

P1.14-40 EGFR-TKIs May Sensitize Radiation Lung Damage in Stereotactic Body Radiotherapy Based on Intensity Analyzing
Xingni Tang, Radiation Oncology Institute of Enze Medical Health Academy, Affiliated Taizhou Hospital of Wenzhou Medical University, China

P1.14-41 The Combination of the PARP Inhibitor Olaparib and the ATR Inhibitor VE-821 Selectively Targets ATM-Deficient Lung Cancer Cells
Nicholas Jette, University of Calgary, Canada

P1.14-42 Apatinib Combined with EGFR - TKI in Treating Advanced Non-Small Cell Lung Cancer with EGFR - TKI Resistance (Data Updated)
Rui fen Tian, Shanxi Tumor Hospital, China

P1.14-43 A Novel Patient Derived Synchronous Cell Pair with Different Mutations in an ALK-Rearranged Lung Adenocarcinoma Underlines Tumor Heterogeneity
Paul Stockhammer, Medical University of Vienna, Austria

P1.14-44 Positive PD-L1 Expression Is Associated with Unfavorable Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with EGFR-TKIs
Boksoon Chang, Kyung Hee University Medical Center, Korea, Republic of

P1.14-45 Surgical Outcome of Non-Small Cell Lung Cancer with Clinical Single Zone N2 in Aortopulmonary Zone (LN#5 and LN#6)
Kanghoon Lee, Catholic Kwandong University International St. Mary's Hospital, Korea, Republic of

P1.14-46 Genomic Profiling of Large Cell Neuroendocrine Carcinomas of Lung: A Path Towards Individualized Treatment Options
Nhu Ngo, Foundation Medicine, Inc, United States of America

P1.14-47 cDNA NGS for Guiding Crizotinib Treatment in ALK-Rearranged Advanced NSCLC Patients (Pts)
Yong He, Daping Hospital, China

P1.14-48 Whole Exome Sequencing (WES) in Non-Small Cell Lung Carcinoma (NSCLC): Identification of Novel Biomarkers
Varsha Singh, All India Institute of Medical Sciences, India

P1.14-49 The Role of cDNA Detection (Liquid Biopsy) in Patients with NSCLC
Albina Zhabina, St. Petersburg Clinical Research Center of Specialized Types of Care (Oncology), Russian Federation

P1.14-50 A Phase 2 Trial of Cabozantinib in ROSI-Rearranged Lung Adenocarcinoma
Robin Guo, Memorial Sloan Kettering Cancer Center, United States of America

P1.14-51 LOC440416 IncRNA-Mediated Cell Cycle Arrest Regulated Crizotinib-Induced Hepatotoxicity
Xueqin Chen, Hangzhou Cancer Hospital, China

P1.14-52 Clinical Response to Osimertinib in a Patient with Metastatic NSCLC Harboring EGFR A763_Y764insFQEA Exon 20 Insertion Mutation: A Case Report
Gabriela Bravo Montenegro, Georgetown University, United States of America

P1.14-53 Co-Occurring CDKN2A/2B Alteration Is Associated with Poorer Survival in ALK-Positive Lung Cancer
Joo Young Ha, Asan Medical Center, University of Ulsan College of Medicine, Korea, Republic of

P1.14-54 Previous Therapy Strategy Impact on Efficiency of Anlotinib Hydrochloride as 3rd Line Treatment: A Subgroup Analysis of ALTER0303 Trial
Seyen Yang, The Affiliated Cancer Hospital of Zhengzhou University, China

P1.14-55 Cost-Effectiveness of Ceritinib and Alectinib vs Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced NSCLC
Bin Wu, Ren Ji Hospital, South Campus, School of Medicine, Shanghai Jiaotong University, Shanghai, China, China

P1.14-56 The Dynamic Range of Mutant Allele Fraction Detected in ctDNA from Patients with NSCLC: Clinical Experience Data and Clinical Implications
Veena Singh, Biocept, United States of America
P1.14-57 Post-Ensartinib Outcomes in Refractory Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
Sandip Patel, UC San Diego Moores Cancer Center, United States of America

P1.14-58 A Phase II Study to Evaluate Neoadjuvant Osimertinib for Surgically Resectable, EGFR-Mutant Non-Small Cell Lung Cancer
Collin Blakely, University of California, San Francisco, United States of America

P1.14-59 Clinical Implications of the Pharmacokinetics of Dacomitinib Co-Administration with H2-Receptor Antagonists in Cancer Patients
Swan Lin, Pfizer, United States of America

P1.14-60 Statins Overcome Resistance to Tyrosine Kinase Inhibitors in Patient-Derived, Oncogene-Driven NSCLC Models
Weijie Ma, UC Davis, United States of America

P1.14-61 EGFR Inhibitors Plus Bevacizumab Are Superior Compared to EGFR Inhibitor Monotherapy in Advanced EGFR+ NSCLC Patients with BIM Deletions
Oscar Gerardo Arrieta, Instituto Nacional de Cancerologia, Mexico

P1.14-62 Afinatinib in EGFR TKI-Naive Patients with EGFR Mutation-Positive NSCLC: Combined Analysis of Two Single-Arm Phase IIib Studies
BJ Srinivasa, HCG Hospital, India

P1.15-01 Prognostic Factors and Long-Term Outcomes After Pulmonary Metastasectomy from Renal Cell Carcinoma
Domenico Galetta, European Institute of Oncology, Italy

P1.15-02 Role of mTOR Inhibitor Everolimus in the Treatment of Metastatic Thymic Epithelial Tumors
Jessica Hellyer, Stanford Cancer Institute, United States of America

P1.15-03 Cabozantinib and R428 Inhibit the Growth of Esophageal Squamous Cell Carcinoma (ESCC)
Pei-Wen Yang, National Taiwan University Hospital, Taiwan

P1.15-04 Chest Wall Resection and Reconstruction for Thoracic Wall Malignancies: Induction Therapy Reduces Recurrence Rates
Milos Sarvan, University Hospital Zurich, Switzerland

P1.15-05 Genomic Variation Landscape of Thymoma and Thymic Carcinoma in Chinese Patients
Naixin Liang, Peking Union Medical College Hospital, China

P1.15-06 Resection of Thoracic Paragangliomas: A Multicenter Experience
Edward Chan, Houston Methodist, United States of America

P1.15-07 Combined Aortic Arch Resection for Thymic Cancer Using Total Rerouting of Supra-Arch Vessels
Yasushi Shintani, Osaka University Graduate School of Medicine, Japan

P1.15-08 Outcomes of T4 Esophageal Cancer Treated with Neoadjuvant Chemoradiation Followed by Surgery and Definitive Chemoradiation: A Meta-Analysis
Chia Ching Lee, National University Cancer Institute, Singapore, Singapore

P1.15-09 The Impact of Minimal Invasive Esophagectomy and Neoadjuvant Chemoradiotherapy for Esophageal Malignancy: A Nationwide Database Analysis
Cheng-Hung How, Far Easter Memorial Hospital, Taiwan

P1.15-10 Trabectedin Has Limited Clinical Activity in Pretreated Patients with Pleural Mesothelioma
Antonio Chella, Azienda Ospedaliero Universitaria Pisana, Italy

P1.15-11 Intrathoracic Neurogenic Tumors: Clinical, Pathological, and Long-Term Outcomes
Domenico Galetta, European Institute of Oncology, Italy

P1.15-12 A Different Aspect to Tumor Size Dilemma in Thymoma’s TNM Staging Classification
Ayse Yücemen, Ankara University Faculty of Medicine, Turkey

P1.15-13 Subxiphoid Uniportal Thoracoscopic Thymectomy Without Carbon Dioxide Insufflation in the Patients with Thymoma
Do Kyun Kang, Haeundae Paik Hospital, College of Medicine, Inje University, Korea, Republic of

P1.16 09:45–18:00 TREATMENT IN THE REAL WORLD - SUPPORT, SURVIVORSHIP, SYSTEMS RESEARCH

P1.16-01 Complications Associated with Lung Biopsies in Patients with Lung Cancer: A Population Based Analysis
David Gerber, UT Southwestern Medical Center, United States of America

P1.16-02 The Real-World Risk of Brain Metastases in Stage 3 Lung Cancer Patients in the Era of PET and MRI Staging
Seema Nagpal, Stanford Cancer Institute Palo Alto, United States of America

P1.16-03 Incidence and Risk Factors of Metachronous Non-Pulmonary Malignancies in Resected Lung Adenocarcinoma
Peter Kneuertz, The Ohio State University, United States of America

P1.16-04 Real World Experience of Using Comprehensive Genomic Profiling of Plasma Circulating Tumor DNA
Yan Yan, Department of Oncology, The First Affiliated Hospital of Zhengzhou University, China

P1.16-05 Incidence and Outcome of Multiple Primary Cancers (MPC) in a Series of Lung Cancer (LC) Patients
Susana Cedres, Vall d’Hebron University Hospital and Institute of Oncology (VHIO), Spain

P1.16-06 Early Changes in Pulmonary Function Are Associated with Development of Pneumonitis in NSCLC Patients Receiving Immune Checkpoint Blockade
Joshua Reuss, Johns Hopkins University, United States of America

P1.16-07 Real World Evidence of the Impact of Immunotherapy in Patients with Advanced Lung Cancer
Natasha Leighl, Princess Margaret Cancer Centre, Canada

P1.16-08 Integration of Durvalumab into the Treatment of Stage III Non-Small Cell Lung Cancer: Real-World Considerations
Sophia Gorgens, Emory University School of Medicine, United States of America
P1.16-09 Post-Progression Outcomes After Pembrolizumab in Patients with NSCLC and High PD-L1 Expression: Real-World Data from a European Cohort
Giannis Mountzios, Henry Dunant Hospital Center, Greece

P1.16-10 Real-World Efficacy of First-Line Pembrolizumab in Patients with Advanced PD-L1 High Non-Small Cell Lung Cancer in Argentina
Gonzalo Recondo, Dana-Farber Cancer Institute, United States of America

P1.16-11 A Dyad-Based Mindfulness Cancer Recovery Program for Survivors and Family Members to Reduce Lung Cancer Symptoms
Karen Mcdonnell, University of South Carolina, United States of America

P1.16-12 An Analysis of Healthcare Use and the Cost Associated to End-of-Life Care of Lung Cancer Patients in a Spanish Hospital Mariano Provenzio, Hospital Puerta de Hierro-Majadahonda, Spain

P1.16-13 Development of a Veterans Affairs Based Comprehensive Lung Cancer Survivorship Program
Scott Shofer, Duke University Medical Center, United States of America

P1.16-14 Effects of an Artificial Intelligence (AI) System on Clinical Trial Enrollment in Lung Cancer
Konstantinos Leventakos, Mayo Clinic, United States of America

P1.16-15 Rates of Systemic Anticancer Therapy (SACT) for Advanced Non-Small Cell Lung Cancer (aNSCLC) in the US, 2011–2018
Vamsidhar Velcheti, New York University, United States of America

P1.16-16 Lung Cancer Control in Sub-Saharan Africa: Experience at Amaphth Oncology in Western Kenya
Fredrick Asirwa, Amaphth_ICI Kenya, Kenya

P1.16-17 Getting to Know Our Weapons Better. Analyze from Real Life Data from León, Spain
Luis Felipe Sánchez-Cousido, Complejo Asistencial Universitario de León, Spain

P1.16-18 Pleural Malignant Effusion. Is it Possible to Predict Recurrence After Palliative Pleural Procedure?
Fernando Abrao, Hospital Alemão Oswaldo Cruz, Brazil

P1.16-19 Understanding Physician Barriers in the Management of Lung Cancer in Nepal. Can Educational Intervention Make a Difference?
Ramila Shilpakar, National Academy of Medical Sciences, Bir Hospital, Nepal

P1.16-20 Trial in Progress: Cardiac Toxicity in Patients Undergoing Curative Intent Radiotherapy for Lung Cancer
Kathryn Banfill, University of Manchester, United Kingdom

P1.16-21 Does Age Affect What Patients Value When Considering Lung Cancer Treatments? Evidence from a National Survey
Upal Basu Roy, LUNGevity Foundation, United States of America

P1.16-22 Reduced Delays in Diagnostic Pathways for Non-Small Cell Lung Cancer After Local and National Interventions
Dan Lærum, Sarlandet Hospital Kristiansand, Norway

P1.16-23 Comparison of Electronic and Traditional Thoracic Drainage Systems for Postoperative Chest Tube Management After Pulmonary Resection
Ching Feng Wu, Chang Gung Memorial Hospital, Linkou, Taiwan

P1.16-24 Detection of Plasma T790M Mutation After the First Generation EGFR-TKI Resistance of Non-Small Cell Lung Cancer in the Real World
Haiyan Li, Affiliated Taizhou Hospital at Enze of Wenzhou Medical University, China

P1.16-25 Impact of Pirfenidone on the Risk Scoring System of Postoperative Acute Exacerbation of Interstitial Pneumonia in Lung Cancer
Ryohei Matsushima, Japanese Red Cross Kumamoto Hospital, Japan

P1.16-26 Epithelial Growth Factor Receptor Mutation Pattern in Non-Small Cell Lung Cancer of Xuanwei Region in Southwestern China
Jie Lin, The Second Affiliated Hospital of Kunming Medical University, China

P1.16-27 Risk Factors Associated with a Second Primary Lung Cancer (SPLC) in Patients (Pts) with an Initial Primary Lung Cancer (IPLC)
Misako Nagasaka, Karmanos Cancer Institute, United States of America

P1.16-28 The Humanistic Burden of ALK+ NSCLC: Findings from the ALKConnect Patient Insight Network and Research Platform
Huaomao Lin, Takeda, United States of America

P1.16-29 Profiling Immune-Related Adverse Events (irAEs) in Patients with Anti-PD-1 for Advanced Non-Small Cell Lung Cancer
Yukihiro Toi, Sendai Kousei Hospital, Japan

P1.16-30 Impact of Patient TKI Copayments on Insurance Expenditure in Advanced EGFR or ALK Positive Non-Small Cell Lung Cancer (NSCLC)
Bernardo Haddock Lobo Goulart, Fred Hutchinson Cancer Research Center, United States of America

P1.16-31 Body Mass Index Relating to Patient-Reported Symptoms in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer
George Simon, UT/MD Anderson Cancer Center, United States of America

P1.16-32 Empowering Lung Cancer Survivors and Family Members to “Breathe Easier”: Adaptation and Evaluation of a M-Health Intervention
Otis Owens, University of South Carolina, United States of America

P1.16-33 From a Systematic Review to Real World Evidence: Integrating Gender as a Clinical Risk Factor in NSCLC
Gwynn Bebb, University of Calgary, Canada

P1.16-34 Association Between Skin Reactions and Clinical Benefit in Patients Treated with Anti-PD-1 Treatment for Advanced Non-Small Cell Lung Cancer
Mari Aso, Sendai Kosei Hospital, Japan

P1.16-35 The Prognostic Impact of Sarcopenia on the Clinical Outcome of Thoracic Surgery for Non-Small Cell Lung Cancer in Elderly Patients
Akishro Miura, Okayama University Hospital, Japan

P1.16-36 Treatment Patterns Among Patients with EGFRm NSCLC Treated in the US Community Oncology Setting
Melissa Pavilack, AstraZeneca, United States of America

P1.16-37 Correlation Between the Actual Measurement Value After Lung Lobectomy and the Predicted Value of Forced Expiratory Volume in 1 Second
Tatsuya Hayashi, Ehime University Hospital, Japan

P1.16-38 Racial Disparities in Long-Term Survival After Surgical Resection in the US
Meghan Taylor, University of Memphis, United States of America

P1.16-39 Oncology Emergencies in Patients with Lung Cancer: Experience of One Hospital
Marta Vilaça, Hospital Pedro Hispano, Portugal
P1.16-40 Real-World Neurocognitive Function in Lung Cancer: Initial Results of the PRO-Long Study
Lotte Van Der Weijst, Ghent University Hospital, Belgium

P1.16-41 Timing, Sites, and Correlates of Lung Cancer Recurrence: The Missing Pieces in National Datasets
David Gerber, University of Texas Southwestern Medical Center, United States of America

P1.16-42 Real-World Trends in Systemic Anticancer Therapy (SACT) for Squamous Advanced NSCLC (aNSCLC) in the US, 2011–2018
Vamsidhar Velcheti, New York University, United States of America

P1.16-43 Prevalence of Clinical and Sub-Clinical Malnutrition in Advanced Non-Small-Cell Lung Cancer Patients and Association with Outcome
Sara Piloatto, Azienda Ospedaliera Universitaria Integrata, Verona, Italy

P1.16-44 Multiple Primary Cancers (MPC) in a Cohort of Lung Cancer (LC) Patients (P): Incidence and Clinical Features
Carlos Erasun Lecuona, Catalan Institute of Oncology-Badalona; Hospital Universitari Germans Trias I Pujol; B-ARGO; IGTP, Spain

P1.16-45 Changing Attitudes Regarding Lung Cancer: Shame, Embarrassment, and Hope
Joan Schiller, University of Virginia Health System, United States of America

P1.16-46 Genetic Testing Patterns, Treatment Characteristics, and Overall Survival in ALK-Positive Metastatic NSCLC Patients Treated with Ceritinib
Julien Mazerier, CHU Toulouse, France

P1.16-47 Embedding Research (and Evidence) in Cancer Healthcare - EnRICH
Bea Brown, University of Sydney, Australia

P1.16-48 Experiences of Patients on 1st Line Care (EPIC) Study - Symptoms and Impacts of EGFR TKI Treatment on QoL in NSCLC Patients
Ivy Elkins, EGFR Registers, United States of America

P1.17 09:45–18:00 TREATMENT OF EARLY STAGE/LOCALIZED DISEASE

P1.17-01 Surgical Outcome of Early Stage Lung Cancer Related vs Unrelated to Honeycomb Lesions with Interstitial Pneumonia
Makoto Fujiwara, Hiroshima University, Japan

P1.17-02 The Investigation of Intraoperative Marking by Lobe-Specific Lymph Node Dissection for Clinical Early-Stage Non-Small Cell Lung Cancer
Keishi Ohtani, Tokyo Medical University, Japan

P1.17-03 Inter-Fraction Variability of 18-FDG PET During Lung SBRT and the Effect of Systemic and Immunotherapy: Results of a Prospective Pilot Study
Sibo Tian, Winship Cancer Institute, Emory University, United States of America

P1.17-04 Multicenter Observational Study of Node-Negative Non-Small Cell Lung Cancer Patients Who Are Excluded from a Clinical Trial
Hiroyuki Sakurai, School of Medicine, Nihon University, Japan

P1.17-05 What Is the Optimal Number of Examined Lymph Node in Stage IA Non-Small Cell Lung Cancer?
Yuan Chen, Tongji Hospital Tongji Medical College Huazhong University of Science and Tech, Wuhan, China, China

P1.17-06 Long-Term Oncological Outcome After Thoracoscopic Lobectomy for Non-Small Cell Lung Cancer Patients
Masayuki Nakao, Cancer Institute Hospital, JFCR, Japan

P1.17-07 Neoadjuvant Gefitinib in Resectable Early Stage EGFR Mutant Non-Small Cell Lung Cancer (NSCLC): A Window-of-Opportunity Study
Aaron Tan, National Cancer Centre Singapore, Singapore

P1.17-08 mRNA Expression Level of Receptor Tyrosine Kinases and Non-Receptor Tyrosine Kinases as a Recurrence Risk in Resected Adenocarcinoma of the Lung
Masaoki Ito, Hiroshima University, Japan

P1.17-09 Surgical Outcomes of Complex Versus Simple Segmentectomy for Stage I Non-Small Cell Lung Cancer
Yoshinori Handa, Hiroshima University Hospital, Japan

P1.17-10 Prediction of Visceral Pleural Invasion in c-N0 Non-Small Cell Lung Cancer
Satoru Okada, Kyoto Prefectural University of Medicine, Japan

P1.17-11 Nomogram Predicting Overall Survival Benefit of Stereotactic Ablative Radiotherapy for Early Stage Non-Small Cell Lung Cancer
Corbin Jacobs, Duke University, United States of America

P1.17-12 Osteogenic and Brain Metastases After Resection of NSCLC: Implications for the Use of FDG-PET and Brain MRI in Postoperative Surveillance
Tetsuya Mizuno, Shizuoka Cancer Center, Japan

P1.17-13 Next Generation Sequencing of the Circulating Small RNA from Serum Identifies Small RNA-Based Biomarker Panel for Stage I-II Lung Adenocarcinoma
Daisuke Ueda, Hiroshima University Hospital, Japan

P1.17-14 Prognostic Value of Immune Cell Biomarkers in Surgically Resectable Non-Small Cell Lung Cancer: A Meta-Analysis
Stephanie Tuminello, Icahn School of Medicine at Mount Sinai, United States of America

P1.17-15 Risk, Pattern and Outcome of Brain Metastases in Completely Resected Stage I (AJCC 8th Edition) Non-Squamous Non-Small Cell Lung Cancer
Jianjiao Ni, Fudan University Shanghai Cancer Center, China

P1.17-16 Neo-Adjuvant Targeted Therapy in Non-Small Cell Lung Cancer Patients: A 10-Year Experience in a Tertiary Medical Center
Hsu Ching Huang, Taipei Veterans General Hospital, Taiwan

P1.17-17 Outcomes Following Stereotactic Body Radiotherapy (SBRT) for biopsy-Confirmed vs. Radiologically-Diagnosed Primary Lung Cancer
Tze Koh, Oliva Newton John Cancer Research and Wellness Centre, Australia

P1.17-18 Surgery Alone or Plus Adjuvant Radiotherapy for Patients with NO Non-Small-Cell Lung Cancer >5 cm: A Population-Based Study
Junmiao Wen, Fudan University Shanghai Cancer Center, China

P1.17-19 Lobe-Specific Lymph Node Dissection for Clinical Early-Stage (cIA) Peripheral Non-Small Cell Lung Cancer Patients: Feasible and How?
Han-Yu Deng, West China Hospital, Sichuan University, China

P1.17-20 Evaluation of Efficacy and Safety of Uniportal Segmentectomy in the Treatment of Lung Cancer
Chenlei Zhang, Liaoning Cancer Hospital & Institute, China

P1.17-21 Safety and Effectiveness of Stereotactic Ablative Radiotherapy for Ultra-Central Lung Lesions: A Systematic Review
Hanbo Chen, London Health Sciences Centre, Canada
P1.18-08 Survival Outcomes of Salvage Therapy for Locoregionally Recurrent Non-Small Cell Lung Cancer
Sara Moore, BC Cancer, Canada

P1.18-09 Trimodal Treatment of Locally Advanced Non-Small Cell Lung Cancer: Model-Based Comparison with Chemoradiation Only
Malene Strange, Rigshospitalet University of Copenhagen, Denmark

P1.18-10 The Prognostic Impact of the Extent of Nodal Involvement in NSCLC Treated with Radical Chemoradiation
Connie Yip, National Cancer Centre Singapore, Singapore

P1.18-11 Dose Dense Paclitaxel and Carboplatin as Neoadjuvant Therapy for Resectable/Borderline Resectable NSCLC - A Phase II Trial
Abhnen Mittal, All India Institute of Medical Sciences, India

P1.18-12 PACIFIC-4/RT0G 3515: Phase III Study of Durvalumab Following SBRT for Unresected Stage I/II, Lymph-Node Negative NSCLC
Chen Hu, The Johns Hopkins University School of Medicine, United States of America

P1.18-13 Predicting Failure Patterns in Patients with Inoperable Local Advanced Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy
Xueru Zhu, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

P1.18-14 The Prognostic Significance of Significant Weight Loss in Stage III NSCLC Undergoing Definitive CRT After FDG-PET Staging
Clare Senko, Olivia Newton John Cancer Center, Australia

P1.18-15 Dosimetric and Toxicity Benefits of Adaptive IMRT in Patients with Stage III Non-Small Cell Lung Cancer
Yinnan Meng, Radiation Oncology Institute of Enze Medical Health Academy, Affiliated Taizhou Hospital of Wenzhou Medical University, China

P1.18-16 Is Tumor Shrinking During Chemoradiation for LA-NSCLC a Biomarker for Outcome?
Sara Ramella, Campus Bio-Medico University, Italy

P1.18-17 Survival After Adjuvant Chemotherapy in Completely Resected N1 Non-Small Cell Lung Cancer
Emily Wang, Institut Universitaire de Cardiologie et Pneumologie de Québec, Canada

P1.18-18 Feasibility of Hypofractionated Chemoradiation for Patients with Stage III Non-Small Cell Lung Cancer
Noelle Van Der Voort Van Zyp, Haaglanden Medisch Centrum, Netherlands

P1.18-19 Invasive Mediastinal Staging Is Mandatory for Upfront Surgery for N2 Disease
Andrew Selvaraj, St Bartholomew’s Hospital, London, United Kingdom

P1.18-20 The Relationship Between the Recurrence Timing and Inflammation-Based Prognostic Scores in Resected Non-Small-Cell Lung Cancer
Daisuke Noma, Yokohama Medical Center, Japan

P1.18-21 Short and Mid-Term Outcomes of Multimodal Treatment for Locally-Advanced Non Small Cell Lung Cancer in Elderly Patients
Francesca Mazzoni, Careggi University Hospital, Italy

P1.18-22 Impact of Using Volumetric Modulated Arc Therapy on Radiation Pneumonitis in Locally Advanced Non-Small Cell Lung Cancer
Nobuki Imano, Hiroshima University Hospital, Japan

P1.18-23 Use of Perfusion SPECT to Preserve Functional Lung in Radiotherapy for Non-Small-Cell Lung Cancer (NSCLC) Patients
Sara Ramella, Campus Bio-Medico University, Italy

P1.18-24 Neoadjuvant Therapy versus Upfront Surgery for NSCLC Patients with Clinically Suspected Subaortic or Paraaortic Lymph Nodes
Junghee Lee, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea, Republic of

P1.18-25 The Impact of Radiation Pneumonitis on Prognosis of Patients with Locally Advanced Non-Small Cell Lung Cancer Treated with Chemoradiotherapy
Takahiro Akita, Hirosaki University Graduate School of Medicine, Japan

P1.18-26 Pretreatment Risk Factors for Postoperative Pulmonary Complication After Neoadjuvant Concurrent Chemotherapy for NSCLC
Woo Sik Yu, Ajou University School of Medicine, Korea, Republic of

P1.18-27 Chemoradiotherapy of Inoperable Non-Small Cell Lung Cancer (NSCLC) with IGRT Technique Using TomoTherapy HD
Milada Zemanová, First Medical Faculty and General University Hospital in Prague, Czech Republic

P1.18-28 Salvage Surgery for Residual Lesion/Local Reprogession After Initial Medical Treatment in Advanced Non-Small Cell Lung Cancer
Keita Nakanishi, Aichi Cancer Center Hospital, Japan

P1.18-08 Survival Outcomes of Salvage Therapy for Locoregionally Recurrent Non-Small Cell Lung Cancer
Sara Moore, BC Cancer, Canada

P1.18-09 Trimodal Treatment of Locally Advanced Non-Small Cell Lung Cancer: Model-Based Comparison with Chemoradiation Only
Malene Strange, Rigshospitalet University of Copenhagen, Denmark

P1.18-10 The Prognostic Impact of the Extent of Nodal Involvement in NSCLC Treated with Radical Chemoradiation
Connie Yip, National Cancer Centre Singapore, Singapore

P1.18-11 Dose Dense Paclitaxel and Carboplatin as Neoadjuvant Therapy for Resectable/Borderline Resectable NSCLC - A Phase II Trial
Abhnen Mittal, All India Institute of Medical Sciences, India

P1.18-12 PACIFIC-4/RT0G 3515: Phase III Study of Durvalumab Following SBRT for Unresected Stage I/II, Lymph-Node Negative NSCLC
Chen Hu, The Johns Hopkins University School of Medicine, United States of America

P1.18-13 Predicting Failure Patterns in Patients with Inoperable Local Advanced Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy
Xueru Zhu, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

P1.18-14 The Prognostic Significance of Significant Weight Loss in Stage III NSCLC Undergoing Definitive CRT After FDG-PET Staging
Clare Senko, Olivia Newton John Cancer Center, Australia

P1.18-15 Dosimetric and Toxicity Benefits of Adaptive IMRT in Patients with Stage III Non-Small Cell Lung Cancer
Yinnan Meng, Radiation Oncology Institute of Enze Medical Health Academy, Affiliated Taizhou Hospital of Wenzhou Medical University, China

P1.18-16 Is Tumor Shrinking During Chemoradiation for LA-NSCLC a Biomarker for Outcome?
Sara Ramella, Campus Bio-Medico University, Italy

P1.18-17 Survival After Adjuvant Chemotherapy in Completely Resected N1 Non-Small Cell Lung Cancer
Emily Wang, Institut Universitaire de Cardiologie et Pneumologie de Québec, Canada

P1.18-18 Feasibility of Hypofractionated Chemoradiation for Patients with Stage III Non-Small Cell Lung Cancer
Noelle Van Der Voort Van Zyp, Haaglanden Medisch Centrum, Netherlands

P1.18-19 Invasive Mediastinal Staging Is Mandatory for Upfront Surgery for N2 Disease
Andrew Selvaraj, St Bartholomew’s Hospital, London, United Kingdom

P1.18-20 The Relationship Between the Recurrence Timing and Inflammation-Based Prognostic Scores in Resected Non-Small-Cell Lung Cancer
Daisuke Noma, Yokohama Medical Center, Japan

P1.18-21 Short and Mid-Term Outcomes of Multimodal Treatment for Locally-Advanced Non Small Cell Lung Cancer in Elderly Patients
Francesca Mazzoni, Careggi University Hospital, Italy

P1.18-22 Impact of Using Volumetric Modulated Arc Therapy on Radiation Pneumonitis in Locally Advanced Non-Small Cell Lung Cancer
Nobuki Imano, Hiroshima University Hospital, Japan

P1.18-23 Use of Perfusion SPECT to Preserve Functional Lung in Radiotherapy for Non-Small-Cell Lung Cancer (NSCLC) Patients
Sara Ramella, Campus Bio-Medico University, Italy

P1.18-24 Neoadjuvant Therapy versus Upfront Surgery for NSCLC Patients with Clinically Suspected Subaortic or Paraaortic Lymph Nodes
Junghee Lee, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea, Republic of

P1.18-25 The Impact of Radiation Pneumonitis on Prognosis of Patients with Locally Advanced Non-Small Cell Lung Cancer Treated with Chemoradiotherapy
Takahiro Akita, Hirosaki University Graduate School of Medicine, Japan

P1.18-26 Pretreatment Risk Factors for Postoperative Pulmonary Complication After Neoadjuvant Concurrent Chemotherapy for NSCLC
Woo Sik Yu, Ajou University School of Medicine, Korea, Republic of

P1.18-27 Chemoradiotherapy of Inoperable Non-Small Cell Lung Cancer (NSCLC) with IGRT Technique Using TomoTherapy HD
Milada Zemanová, First Medical Faculty and General University Hospital in Prague, Czech Republic

P1.18-28 Salvage Surgery for Residual Lesion/Local Reprogession After Initial Medical Treatment in Advanced Non-Small Cell Lung Cancer
Keita Nakanishi, Aichi Cancer Center Hospital, Japan

WCLC2019.IASLC.ORG

Onsite Program | IASLC 2019 World Conference on Lung Cancer

147
P2.01-01 Cemiplimab, a Human PD-1 Monoclonal Antibody, Versus Chemotherapy in First-Line Treatment of Advanced NSCLC with PD-L1 ≥50%
Sue Lee, Regeneron Pharmaceuticals, Inc., United States of America

P2.01-02 CANOPY-A: A Phase 3 Study of Canakinumab as Adjuvant Therapy in Patients with Surgically Resected NSCLC
Edward Garon, University of California Los Angeles, United States of America

P2.01-03 Tumor Treating Fields Plus Standard of Care Treatment in Stage 4 Non-Small Cell Lung Cancer (NSCLC): Phase 3 LUNAR Study
Uri Weinberg, Novocure, Israel

P2.01-04 NCI-NRG Oncology ALK PROTOCOL (NRG-LU003): A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients
Shakun Malik, National Cancer Institute NIH, United States of America

P2.01-05 MAGELLAN: Phase IB Study of Durvalumab with Novel Oncology Therapies, With/Without Chemotherapy, in Untreated Stage IV NSCLC
Sandip Patel, UC San Diego Moores Cancer Center, United States of America

P2.01-06 Phase I Study of Nivolumab and Ipilimumab Combined with Nintedanib in Advanced Non-Small Cell Lung Cancer
Jhanelle Elaine Gray, H. Lee Moffitt Cancer Center, United States of America

P2.01-07 Open-Label, Biomarker-Directed Platform Study in NSCLC Patients Who Progressed on an Anti-PD-(L)1-Containing Therapy (HUDSON)
Si-Houy Lao-Sirieix, AstraZeneca, United Kingdom

P2.01-08 Clinical Trial in Progress: CONCORDE - A Phase IB Study of Novel Agents in Combination with Conventional Radiotherapy in NSCLC
Andrew Hudson, Manchester Cancer Research Centre, United Kingdom

P2.01-09 VinMetAtezo: Phase II Trial of Metronomic Oral Vinorelbine with Atezolizumab for Recurrent Stage IV NSCLC (GFPC’04-08)
Alain Vergnenegre, CHU Dupuytren, France

P2.01-10 Real Clinical Practice Study to Evaluate 2 Line Treatment Based on Comprehensive Genomic Profiling in NSCLC: LungONE Study
Javier De Castro Carpeno, Centro Integral Oncologico Clara Campal, Hospital Universitario HM Sanchinarro, Spain

P2.01-11 ALKternate: A Proof of Concept Study in ALK-Rearranged NSCLC Alternating Lorlatinib with Crizotinib After Disease Progression
Malinda Itchins, Royal North Shore Hospital, Australia

P2.01-12 A Phase I/II Trial of IO102 and Pembrolizumab With/Without Chemotherapy as First-line Treatment of Metastatic NSCLC
Mariano Provencio, Hospital Puerta de Hierro-Majadahonda, Spain

P2.01-13 The DAIL Trial: Dietetic Assessment and Intervention in Lung Cancer
Veni Ezil, Royal Surrey County Hospital, United Kingdom

P2.01-14 Phase 3 Trial of Sitravatinib plus Nivolumab vs Docetaxel for Treatment of NSCLC After Platinum-Based Chemotherapy
Emmanuel Nidhiry, Commonwealth Cancer Center - Frankfort, United States of America

P2.01-15 Phase II Single Arm Study of CABozantinib in Non-Small Cell Lung Cancer Patients with MET Deregulation (CABinMET)
Manolo D’Arcangelo, Department AUSL Romagna-Ravenna, Italy

P2.01-16 TACTICAL: A Phase I/II Trial to Assess the Safety and Efficacy of MSCTRAIL in Metastatic Lung Adenocarcinoma
Alice Davies, University College London, United Kingdom

P2.01-17 CANOPY-1: Phase 3 Study of Canakinumab/Placebo+Pembrolizumab+Platinum-Chemotherapy in Untreated Stage IIIB-IV NSCLC Pts
Enriqueta Felip, Vall d’Hebron Institute of Oncology, Spain

P2.01-18 ORION: Durvalumab+Olaparib Versus Durvalumab Alone as Maintenance Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC)
Teresa Improta, AstraZeneca, United Kingdom

P2.01-19 Phase 2 Study of Telisotuzumab Vedotin (Teliso-V) in Previously Treated c-MET+ Non-Small Cell Lung Cancer: Trial in Progress
Christopher Ocampo, AbbVie, Inc., United States of America

P2.01-20 Anlotinib vs. Docetaxel in Advanced Non-Squamous NSCLC (EGFR Wild-Type) After Progression on Platinum-Based Chemotherapy: A Trial Protocol
Wenxiu Yao, Sichuan Cancer Hospital, China

P2.01-21 Efficacy and Safety of Combing Anlotinib and Erlotinib as a First-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Tianqing Chu, Shanghai Chest Hospital, China

P2.01-22 ORCHARD: A Phase II Platform Study in Patients with Advanced NSCLC Who Have Progressed on First-Line Osimertinib Therapy
Helena Yu, Memorial Sloan Kettering Cancer Center, United States of America

P2.01-23 DUBLIN-3, a Phase (Ph) III Trial Comparing the Plinabulin (P)/Docetaxel(D) Combination with D Alone in Stage IIib/IV NSCLC
Ramon Mohanal, BeyondSpring Pharmaceuticals, United States of America

P2.01-24 CANOPY-2: Phase 3 Study of Canakinumab Plus Docetaxel as Second/Third Line Therapy in Locally Advanced/Metastatic NSCLC
Luis Paz-Ares, 12 de Octubre University Hospital, Spain

P2.01-25 TOURIST: Thoracic Umbrella Radiotherapy Study in Stage IV NSCLC: A Phase III Randomized Trial in Development
David Woolf, Christie NHS Foundation Trust, United Kingdom
P2.01-26 EMPOWER-Lung 3: Phase 3 Study of Combinations of Cemiplimab and Chemotherapy in First-Line Treatment of Advanced NSCLC
Sue Lee, Regeneron Pharmaceuticals, Inc., United States of America

P2.01-27 Apparent Diffusion Coefficient (ADC) Change on Repeated Diffusion-Weighted MRI During Chemotherapy for Stage IV Lung NSCLC
Oscar Grundberg, Karolinska University Hospital, Sweden

P2.01-28 The Predictive Factor for Prolonged Air Leakage Over 48 Hours Using Log Data of Digital Drainage System
Hironobu Hoshino, National Cancer Center Hospital East, Japan

P2.01-29 The Correlation Between K-ras Mutant Subsets with TP53 Mutation and PD-L1 in Non-Small Cell Lung Cancer (NSCLC)
Nagla Abdel Karim, Augusta University-Georgia Cancer Center, United States of America

P2.01-30 Hepatitis B Infection or Aminotransferase Increase Associate with Poor Outcome of Anti-PD-1 Monotherapy in Patients with Advanced NSCLC
Yiwei Liu, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China

P2.01-31 Preliminary Results of Second Generation ALK Inhibitor PLB1003: A Phase La Study
Baohui Han, Shanghai Chest Hospital, China

P2.01-32 The Impact of Segmentectomy Versus Lobectomy on Pulmonary Function of Patients with Non-Small Cell Lung Cancer: A Meta-Analysis
Guoping Gao, Guangzhou Medical University, China

P2.01-33 Survival Benefit of Depleting High Serum EGF Concentration in Advanced NSCLC Patients as a Switch Maintenance Therapy
Orestes Santos Morales, Center of Molecular Immunology, Cuba

P2.01-34 Endostar Combined with Whole Brain Radiotherapy in Patients with NSCLC Brain Metastases
Xiaorong Dong, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, China

P2.01-35 Acquired MET-Aberrance Is a Mechanism of Resistance to ALK Inhibitors in ALK-Positive Advanced Non-Small-Cell Lung Cancer
Qiu-Mei Deng, Guangdong Lung Cancer Institute (GLCI), Guangdong Provincial People’s Hospital (GDPH), China

P2.01-36 A Pilot Study on Cerebrospinal Fluid Cell-free DNA Sequencing in Leptomeningeal Metastasis from Non-Small Cell Lung Cancer
Xi Wu, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China

P2.01-37 Lower Risk of Hypercoagulability in Non-Small Cell Lung Cancer Patients with EGFR Mutations
Shuta Ohara, Kindai University, Japan

P2.01-38 Gene Expression Profiling of CNS Metastases in Non-Small Cell Lung Cancer - Matched Analyses with Primary Tumors
Georgios Tsakonas, Karolinska Institute, Sweden

P2.01-39 Serial Plasma ctDNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in T790M+ NSCLC
Bin-Chi Liao, National Taiwan University Hospital, Taiwan

P2.01-40 Normalization of Carcinoembryonic Antigen Levels Is Associated with Survival Improvement in Patients with Advanced Non-Small Cell Lung Cancer
Roberto Sánchez-Reyes, Instituto Nacional de Cancerologíia, Mexico

P2.01-41 EGFR Mutation Positive Non-Small Cell Lung Cancer: Management Approach and Survival Outcomes from the Hospital of Leon
Irene Delgado Silleró, Complejo Asistencial Universitario de León, Spain

P2.01-42 ALK-Rearrangement May Promote VTE by Increasing the Expression of TF in Advanced Lung Adenocarcinoma
Sen Yang, The Affiliated Cancer Hospital of Zhengzhou University, China

P2.01-43 Pre-Therapeutic Markers and Scores Predict Response and Survival in Stage IV Lung Cancer Patients Independent of Histology
Diego Kauffmann-Guerrero, Ludwig-Maximilians-University of Munich, Germany

P2.01-44 Promoter Polymorphisms of TOP2A and ERCC1 Genes as Predictive Factors for Chemotherapy in Non-Small Cell Lung Cancer Patients
Justyna Blach, Chair and Department of Clinical Immunology, Medical University of Lublin, Poland

P2.01-45 Clinico-Molecular Characteristics and Prognostic Outcomes of TP53 Mutated Patients with Advanced Non-Small Cell Lung Cancer
Zizheng Song, Affiliated Hospital of Hebei University, China

P2.01-46 The Efficacy and Safety of 2nd-Line Nivolumab for Non-Small Cell Lung Cancer in Real-World Practice with Emphasis on Hyperprogression
Jae Cheol Lee, Asan Medical Center, Korea, Republic of

P2.01-47 Ipsilateral Lung Dose Constraints Predict Radiation Pneumonitis Better Than Conventional Ones in NSCLC Patients Treated with RCT
Deniz Yalman, Ege University Medical School & Hospital, Turkey

P2.01-48 Enhanced Expression of miR-204 Reduces Cisplatin Resistance in NSCLC
Zhuo Cao, The Sixth Affiliated Hospital of Wenzhou Medical University, China

P2.01-49 Targeting STAT3-Positive Reactive Astrocytes with Silibinin in the Therapeutic Landscape of Non-Small-Cell Lung Cancer with Brain Metastases
Joaquim Bosch-Barrera, Catalan Institute of Oncology, Hospital Universitari de Girona Doctor Josep Trueta, Spain

P2.01-50 CD 146 a Potential Therapeutic Target for Lung Cancer
Ayobami Olajuyin, Henan Provincial People Hospital, China

P2.01-51 Next-Generation Sequencing for Effective Detection of Various EGFR Exon 20 Insertions (E20ins) in Non-Small Cell Lung Cancer (NSCLC)
Inhwan Hwang, Asan Medical Center (AMC), University of Ulsan College of Medicine, Korea, Republic of

P2.01-52 Clinical Characteristics and Outcomes in NSCLC Patients Associated with Very High PD-L1 Expression
Erin McLaughlin, University of Virginia, United States of America

P2.01-53 Surgical Resection of Primary Tumor Improve the Prognosis of Lung Cancer Patients with Bone Metastasis
Dan Tian, Guangdong General Hospital, Guangdong Academy of Medical Sciences, China

P2.01-54 Real-World PD-L1 Testing Patterns for Patients with Advanced Non-Small Cell Lung Cancer in Greece
Konstantinos Syrigos, National and Kapodistrian University of Athens, Greece

P2.01-55 Immunotherapy First or After Nintedanib?: A Spanish Experience
Laura Gutiérrez Sainz, La Paz University Hospital, Spain
Highly Immunogenic Neoantigens Enhance Tumor Clinical-Pathological Features and Outcome of Systemic Inflammatory Markers as a Predictors of Serumal SERPINE2 as a Potential Biomarker for Therapy with Osimertinib in Patients with T790M Predictive Factors of Survival in Patients Treated with NSCLC Mutation Frequency in the Central American Circulating Tumor DNA Assay and Survival in Patients High NLR Is Poor Predictive Biomarker for NSCLC Radiosurgery Followed by Tumor Treating Fields Safety of Palliative Radiotherapy and Immune Bone Metastasis and Pleural Dissemination as a A Meta - Analysis and Bioinformatics Exploration of the Genomic Landscapes of DNA Copy Number PD-L1 Very High Expression Associated with Clinical Copy Number Gains (CNGs) of Clinically Relevant Afatinib in EGFR Mutation-Positive (EGFRm+) NSCLC MONDAY Temporal Changes of Radiation-Induced Lung Injury Schwann Cells Are Overexpressed and Inversely Outcome Disparities in American Indian/Alaskan Natives with Advanced Stage Lung Cancer Jessica Hellyer, Stanford Cancer Institute, United States of America P2.01-74 Clinical-Pathological Features and Outcome of Patients with Oral Metastases from Lung Cancer: A Multicenter Retrospective Study Marco Tagliamento, San Luigi Gonzaga Hospital, Italy P2.01-75 Temporal Trends in Treatment Patterns for Advanced/ Metastatic Non-Small Cell Lung Cancer (aNSCLC) in Routine Clinical Practice Victoria Stefanak, Eli Lilly and Company, United States of America P2.01-76 Bone Metastasis and Pleural Dissemination as a Potential Marker for Predicting of T790M Mutation in Advanced Non-Small Cell Lung Cancer Patients Fumiyoshi Ohyanagi, Jichi Medical University Saitama Medical Center, Japan P2.01-77 PET CT Radiogenomic Depiction with EGFR and ALK Molecular Alterations in Lung Cancer Among Indian Population Venkata Koyyala, Rajiv Gandhi Cancer Institute and Research Centre, India P2.01-78 A Meta-Analysis and Bioinformatics Exploration of the Prognostic Value of TP53 Co-Mutations in EGFR Mutated NSCLC Richeng Jiang, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, China P2.01-79 Afatinib in EGFR Mutation-Positive (EGFRm+) NSCLC Harbouring Uncommon Mutations: Experience in ‘Real-World’ Clinical Practice Yi-Long Wu, Guangdong Lung Cancer Institute (GLCI), Guangdong Provincial People’s Hospital (GDPH), China P2.01-80 Clinical Outcomes in Advanced EGFR-Mutant NSCLC Patients Treated with First-Generation EGFR TKIs Followed by Subsequent Osimertinib Yi-Hui Yao, Guangdong Lung Cancer Institute & Guangdong Provincial People’s Hospital (GPPH) & Guangdong Academy of Medical Sciences, China P2.01-81 Predictive Factors of Survival in Patients Treated with Nintedanib: A Multicenter Retrospective Spanish Study Laura Gutiérrez Sainz, La Paz University Hospital, Spain P2.01-82 Lung Cancer in Lung Transplant Recipients Shinni Otani, Okayama University Hospital, Japan P2.01-83 Role of Exosomal MicroRNAs (miRNAs) as Predictors of Response to Treatment and Prognosis in Non-Small Cell Lung Cancer (NSCLC) Mohammad Razag, Univ. of Oklahoma HSC, Stephenson Cancer Center, United States of America P2.01-84 Serumal SERPINE2 as a Potential Biomarker for Radioreistance in NSCLC Jingjing Zhang, Translational Medicine Research Center, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, China P2.01-85 Schwann Cells Are Overexpressed and Inversely Correlated with Survival of Non-Small Cell Lung Cancer Patients Yan Zhou, Shanghai Chest Hospital, China P2.01-86 Highly Immunogenic Neoantigens Enhance Tumor Response to Immune Checkpoint Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Di Wu, Cancer Center, Union Hospital, Huazhong University of Science and Technology, Wuhan, China, China
P2.01-87 β-Adrenergic Antagonists Sensitizes Chemoradiation Therapy in Locally Advanced Non-Small Cell Lung Cancer
Sherry Yan, New York University School of Medicine, United States of America

P2.01-88 Molecular Alterations in Cerebrospinal Fluid Predict Clinical Outcomes of Central Nervous System Metastases in Lung Cancer
Meimei Zheng, Guangdong Lung Cancer Institute, China

P2.01-89 Feasibility of Individualized Multidisciplinary Treatment for Locally Advanced Non-Small Cell Lung Cancer Based on the Treatment Planning
Yu Liu, Yaping Xu2; Tongji University Affiliated Lung Hospital, China, 2Shanghai Pulmonary Hospital, China

P2.01-90 Dosimetry Prediction of Locally Advanced Non-Small Cell Lung Cancer Based on the Tumor Location and the Volume Ratio of Tumor to Lung
Shuangyan Yang, Shanghai Pulmonary Hospital, China

P2.01-91 Exosomal Analysis of ALK Rearrangements by Spin Column with Porous Glass Filter
Takahiro Hatta, Nagoya University Hospital, Japan

P2.01-92 Cimavax-EGF in Combination with First-Line Chemotherapy in III Stage NSCLC
Elia Neningen, Hermanos Ameijeiras Hospital, Cuba

P2.01-93 Detection of Giant Cancer-Associated Macrophage-Like Cells After Concurrent Chemoimmunoradiation Is Associated with Poor Survival in NSCLC
Alexander Augustyn, MD Anderson Cancer Center, United States of America

P2.01-94 Advanced Age and High Modified Glasgow Prognostic Score Are Associated with Increased Complications After Pneumonectomy
Mohamed Zaatar, Ruhrlandklinik, Germany

P2.01-95 Updated Data of KRSG 1302 Study: Nedaplatin and Nab-Paclitaxel for Patients with Previously Untreated Advanced Squamous Cell Lung Cancer
Fumiyoshi Ohyanagi, Jichi Medical University Saitama Medical Center, Japan

P2.01-96 Response to Anti-HER2 Afatinib in a Case of Invasive Pulmonary Mucinous Adenocarcinoma with a SLC3A2-NRG1 Fusion
Fanny Magne, Hôpital Nord Ouest Villefranche sur Saône, France

P2.01-97 Angiotensin-Converting Enzyme Inhibitor Is Associated with Decreased Survival in NSCLC Patients Treated with PD-1 Checkpoint Blockers
Corentin Richard, Centre Georges François Leclerc, France

P2.01-98 Neutrophil-Platelet Score (NPS), a Predictive Systemic Inflammation Score for Pembrolizumab in First Line of Advanced NSCLC Patients
Xabier Mielgo Rubio, Hospital Universitario Fundación Alcorcón, Spain

P2.01-99 A Phase IIIb Open-Label Study of Afatinib in EGFR TKI-Naïve Patients with EGFR Mutation-Positive NSCLC: Final Analysis
Yi-Long Wu, Guangdong Lung Cancer Institute (GLCI), Guangdong Provincial People’s Hospital (GDPH), China

P2.01-100 Spectrum of EGFR Exon 20 Insertion Mutations and Co-Occurring Genetic Alterations in Patients with Non-Small-Cell Lung Cancer
Gabriela Bravo Montenegro, Georgetown University, United States of America

P2.01-101 Multiple Chemotherapy-Based Combination Therapy Strategies for Advanced Lung Cancer Patients: A Systematic Review and Network Meta-Analysis
Hexiao Tang, Zhongnan Hospital of Wuhan University, China

P2.01-102 Outcome of Patients with EGFR Exon 19 Mutation in a Phase III Randomized Trial Comparing Gefitinib to Gefitinib with Chemotherapy
Kumar Prabhash, Tata Memorial Center, India

P2.01-103 Real-World Treatment Patterns and Survival in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations
Sai-Hong Ou, Chao Family Comprehensive Cancer Center, University of Irvine Healthcare, United States of America

P2.02
10:15–18:15 ADVOCACY
Track(s): Advocacy

P2.02-01 ALKFusion and the Unmet Need of Patient-Centric Research
Laura Greco, ALKFusion, United States of America

P2.03
10:15–18:15 BIOLOGY
Track(s): Biology

P2.03-01 MMP1 Secreted by Cancer Cells Induces a Pro-Tumorigenic Senescent Phenotype in Fibroblasts in Large Cell Carcinoma of the Lung
Marta Gabasa, University of Barcelona, Spain

P2.03-02 A Single Sample Predictor of Transcriptional Lung Adenocarcinoma Subtypes: Predicting Biology and Prognosis
Anna Karlsson, Division of Oncology and Pathology, Sweden

P2.03-03 Landscape of Gene Fusions in Lung Adenocarcinoma Patients with Minimal Cigarette Exposure Identified on Malignant Pleural Effusions
Maria Saigi, Institut Català d’Oncologia, Spain

P2.03-04 The Prognostic Value of Serological Tumor Markers in Lung Cancer – Analysis of 13,373 Cases
Thomas Muley, Thoraxklinik at Heidelberg University Hospital, Germany

P2.03-05 PHLPP1 Expression Through AKT and ERK Dual Signaling Pathways May Slow Down the Resistance to TKI in EGFR-Mutated Lung Adenocarcinoma
Wei Wang, Radiation Oncology Institute of Enze Medical Health Academy, Affiliated Taizhou Hospital of Wenzhou Medical University, China

P2.03-06 Detection of ctDNA and Correlation with Tumor Mutation Testing in Early Stage NSCLC
Anastasios Dimou, University of Colorado Denver, United States of America

P2.03-07 Frequency of Driver Genes (EGFR, KRAS, BRAF, ALK, RET and ROS1) Alterations in Brazilian Patients with Lung Adenocarcinoma
Letícia Leal, Barretos Cancer Hospital, Brazil
P2.03-08 Analysis of Immunosuppressive Factors Produced by CSCs Revealed Galectin-3 as Immune Modulator with Prognostic Value in NSCLC Adenocarcinoma
Alejandro Herreros-Pomares, Fundación Hospital General Universitario de Valencia, Spain

P2.03-09 Arf6-Related Invasive Pathway Deteriorated Patients’ Prognosis in Mutant EGFR Lung Adenocarcinoma
Toshi Menju, Kyoto University Hospital, Japan

P2.03-10 Comprehensive Molecular Profiling and Comparison of Common and Rarer Subtypes of Lung Cancer
Ciara Domingo-Sabugo, Imperial College London, United Kingdom

P2.03-11 Impact of Ethnicity on Outcome in Never Smokers with EGFR and ALK Wildtype (EGFR/ALK-Wildtype) Lung Adenocarcinomas
Sebastiao Martins-Filho, University Health Network, Canada

P2.03-12 Epigenome-Wide Methylation Study from Blood Samples of Lung Cancer Patients and Controls
Yoonki Hong, Kangwon National University Hospital, Korea, Republic of

P2.03-13 Acquired Resistance to Aftatinib in Non-Small Cell Lung Cancer with EGFR G719X Mutation
Taishi Harada, Fukuchiyma City Hospital, Japan

P2.03-14 Developing an Immunogenic Model of Non Small Cell Lung Cancer
Sarah Laing, Institute of Cancer Sciences, University of Glasgow, United Kingdom

P2.03-15 Validation of Tumor Organoids from Lung Adenocarcinoma as a Model of Primary Tumor Genotype
Jeffrey Borgia, Rush University Medical Center, United States of America

P2.03-16 Agreement Between Different Methodologies for Non-Invasive p.T790M and EGFR Sensitizing Mutation Testing
Atchoa Romero, Hospital Puerta De Hierro Majadahonda, Spain

P2.03-17 Optimization of an Ex-Vivo Preclinical Model for Drug Testing
Elba Marin, IDIBAPS, Spain

P2.03-18 Pathogenic Germline Rare Variants and Risk of Lung Cancer
Yanhong Liu, Baylor College of Medicine, United States of America

P2.03-19 Co-Targeting PIM Kinase to Overcome MET Amplified Resistance to EGFR TKIs in NSCLC
Kathy Gately, St. James’s Hospital/Trinity College Dublin, Ireland

P2.03-20 Potent in Vitro Activity of Tarloxoxtinib for HER2 Exon 20 Mutations in Lung Cancer and Mechanism of Acquired Resistance
Takamasa Koga, Kindai University Faculty of Medicine, Japan

P2.03-21 MUC16 Germline Mutations May Associate with Inherited Lung Cancer
Tao Wang, Tianjin Medical University Cancer Institute and Hospital, China

P2.03-22 Chromate Exposure Induces DNA Hypermethylation of theMismatch Repair Gene MLH1 in Lung Cancer
Kazuya Kondo, Graduate School of Biomedical Sciences, Tokushima University, Japan

P2.03-23 UHRF1 as a Potential Therapeutic Target for KRAS Mutated Non-Small Cell Lung Cancer
Daiki Goto, Nagoya University Graduate School of Medicine, Japan

P2.03-24 Concurrent Aberrations in G2/M-Phase Transcriptional Programs and Genomic Gatekeepers Highlight Lung Cancer Predisposition in COPD Patients
Erie Marshall, BC Cancer Research Centre, Canada

P2.03-25 Assessing the Impact of Clonal Hematopoiesis in Disease Monitoring Using Targeted Cell-Free DNA (cfDNA) Sequencing Technology
Stephanie Yang, Roche, United States of America

P2.03-26 Elucidating Mechanisms of Resistance to Targeted Therapies in Mutant EGFR or KRAS Driven Lung Adenocarcinoma Harboring Dual Loss of p53 and RBL1
Yusuke Inoue, British Columbia Cancer Research Centre, Canada

P2.03-27 Discovery of WNK1-ROS1 Fusion in a Lung Adenocarcinoma Patient and the Precise Guidance for Targeted Therapies
Rui Lin, Hangzhou RepuGene Technology Co., Ltd., China

P2.03-28 A 500-Gene Panel to Detect Tumor Mutation Burden of Tissue and Plasma Samples from Lung Cancer Patients
Shanshan Xiao, Hangzhou RepuGene Technology Co., Ltd., China

P2.03-29 Circulating Levels of Ligands for Receptor Tyrosine Kinases May Contribute to an Immunosuppressive Tumor Microenvironment
Jeffrey Borgia, Rush University Medical Center, United States of America

P2.03-30 Genetic Characteristics of Lung Cancer in Patients with Idiopathic Pulmonary Fibrosis
Soo Jung Kim, Ewha Womans University, Korea, Republic of

P2.03-31 Chemokine Receptor CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC
Jeffrey Becker, University of Illinois-Chicago, United States of America

P2.03-32 Metastatic Lymph Nodes as High Immunogenicity Media for Perioperative Immunotherapy in Locally Advanced NSCLC
Chao Zhang, Guangdong Lung Cancer Institute, China

P2.03-33 ctDNA Levels Significantly Predicts Survival in NSCLC Patients with an EGFR Activating Mutation
Atchoa Romero, Hospital Puerta De Hierro Majadahonda, Spain

P2.03-34 Fractalkine Attenuate Irradiation-Induced Brain Injury Through Promoting the M2 Polarization of Microglia
Yusuke Inoue, British Columbia Cancer Research Centre, Canada

P2.03-35 Stromal TIMP-1 Drives Tumor Progression in Lung Adenocarcinoma Through CD63 Interaction
Paula Duch, University of Barcelona, Spain

P2.03-36 iTMB and bTMB in East Asian Lung Cancer Patients with No TKI-Related Driver Gene Mutations
Soo Jung Kim, Ewha Womans University, Korea, Republic of

P2.03-37 Genomic Landscape of EGFR/ALK Wild-Type Lung Adenocarcinomas in Never-Smokers and Importance of Epithelial-Mesenchymal-Transition
Stephanie Yaung, Roche, United States of America

P2.03-38 Identification of a Novel Synthetic Lethal Vulnerability in Non-Small Cell Lung Cancer by Co-Targeting TMPRSS4 and DDR1
Esther Redin, CIMA University of Navarra, Spain

P2.03-39 Systematic Evaluation of EGFR Variant Biology in Cancer
Tikvah Hayes, Dana-Farber Cancer Institute, United States of America

P2.03-40 Particle Matters Induce Carcinogenic Phenotype and Gene Expression Changes in Murine Pulmonary Progenitor Cells
Huei-Wen Chen, National Taiwan University, Taiwan

P2.03-41 Identification of Novel Blood-Brain Barrier Penetrating DNA Aptamers
Chao Zhang, Guangdong Lung Cancer Institute, China

P2.03-42 Identification of a Novel Synthetic Lethal Vulnerability in Non-Small Cell Lung Cancer by Co-Targeting TMPRSS4 and DDR1
Esther Redin, CIMA University of Navarra, Spain
P2.03-42 Highly Sensitive Sel-CapTM Lung Cancer Panel NGS for Detection of Tumor-Derived EGFR Mutations in Plasma Cell-Free DNA in Lung Cancer
Jin Hyoun Kang, Medical Oncology, Seoul St. Mary's Hospital, The Catholic University of Korea, Republic of Korea

P2.03-43 WTAP Activates Oncogenes and Accelerates Tumor Aggressiveness Through Adding m6A RNA Modification in Non-Small-Cell Lung Cancer
Katsuhiko Yoshimura, Hamamatsu University School of Medicine, Japan

P2.03-44 BLU-667 Demonstrates Robust Activity in RET Fusion-Driven Intracrinal Tumor Models
Erica Evans, Blueprint Medicines, United States of America

P2.03-45 PKCβ-PAK1 Pathway Modulates Sensitivity to Therapy in EGFR, KRAS Mutant Adenocarcinoma and Squamous Cell Carcinoma
Masaoki Ito, Hiroshima University, Japan

P2.03-46 PI3K/AKT Signal Pathway Regulates Malignant Transformation of MPLC with EGFR-Sensitive Mutation
Keweii Ma, The First Hospital of Jilin University, China

P2.03-47 Deregulation of a Novel Cis-Acting IncRNA in Non-Small Cell Lung Cancer May Control HMGAI Expression
Greg Stewart, BC Cancer Research Centre, Canada

P2.03-48 Tumor-Derived Granulocyte Chemotactic Protein 2 Cooperates with Proteases to Drive Lung Adenocarcinoma
Anne Sophie Lamort, ILBD/CPC Helmholtz Zentrum Munchen, Germany

P2.03-49 Roles of CENPU in Lung Adenocarcinoma Progression and Invasion
Yuqing Lou, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

P2.03-50 Stromal BTK Expression Predicts Poor Prognosis in NSCLC Patients
Wenhua Liang, Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University; State Key Laboratory of Respiratory Disease; National Clinical Research Center for Respiratory Disease, China

P2.03-51 Gene Variants and Expressions of Galectin-3 Is Associated with Non Small Cell Lung Cancer and Vascular Invasion of the Tumor
Akif Turna, Istanbul University, Turkey

P2.03-52 Correlation Between Inflammatory Markers and Oncological Outcomes in Surgically Resected Non-Small Cell Lung Cancer
Ryuichi Waseda, Fukuoka University, Japan

P2.03-53 Immunoproteasome as a Potential Therapeutic Target in Cisplatin-Resistant Small and Non-Small Cell Lung Cancer
Tetsuaki Shoji, Hokkaido University, Japan

P2.03-54 Imprinted Genes Predict Non-Small Cell Lung Cancer Prognosis
Chunxue Bai, Zhongshan Hospital/Fudan University, China

P2.03-55 High Integrin α3 Expression Is Associated with Poor Prognosis in Patients with NSCLC
Weijie Ma, UC Davis, United States of America

P2.03-56 Polymorphism ICAM-1 and Beta-3 Integrin Are Associated with the Development of Non-Small Cell Lung Cancer and the Prognostic Role of ICAM-1
Akif Turna, Istanbul University, Turkey

P2.03-57 The Role of Arl4c in the Carcinogenesis Process of Lung Adenocarcinoma
Kenji Kimura, Osaka University Graduate School of Medicine, Japan

P2.03-58 Double Primary Lung Cancer and Breast Cancer Is a Distinct Disease Entity
Emily Lin, Vanderbilt University Medical Center, United States of America

P2.03-59 The Role of Radiation Dose-Dependent Lipid Metabolism Reprogramming on Radiation Survival/Resistance in Lung Cancer Cells
Xiaozhong Zhu, Nanfang Hospital, Southern Medical University, China

P2.04
10:15-18:15 IMMUNO-ONCOLOGY

P2.04-01 Changes of BCR Repertoire Are Predictive Biomarker for the Efficacy of Immune Checkpoint Inhibitor in NSCLC
Koichi Azuma, Kurume University, Japan

P2.04-02 Effect of Chemotherapy, Chemoimmunotherapy, and Immunotherapy on Parameters of T Cell Exhaustion in Metastatic Non-Small Cell Lung Cancer
Joshua Bauml, Perelman School of Medicine, United States of America

P2.04-03 Nivolumab Outcomes in Octogenarian Patients with Advanced Non-Small Cell Lung Cancer in French Real-World Setting
Christos Chouaid, CHI Creteil, France

P2.04-04 CITEseq Characterization in Early Stage NSCLC: Patients Identifies Distinct Patterns of Immune Infiltrate
Thomas Marron, Icahn School of Medicine at Mount Sinai, United States Minor Outlying Islands

P2.04-05 A Retrospective Evaluation of PD-L1 Expression Heterogeneity on Primary Non-Small Cell Lung Cancer and Metastatic Lymph Nodes (REPLICA)
Andrea Bille, Guy’s Hospital NHS Trust, United Kingdom

P2.04-06 Blood-Based Multiplex Kinase Activity Profiling as a Predictive Marker for Clinical Response to Checkpoint Blockade in Advanced NSCLC
Daan Hurkmans, Erasmus University Medical Center, Netherlands

P2.04-07 Surgical Resection of Advanced Lung Cancer After a Response to EGFR-TKI and/or Immunotherapy: A Single Institution Experience
Domenico Galetta, European Institute of Oncology, Italy

P2.04-08 Preliminary External Validation of the Clinical Definitions of Resistance to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Erin Gillaspie, Vanderbilt University Medical Center, United States of America

P2.04-09 Immune-Related Adverse Events in Advanced Non-Squamous NSCLC Patients Treated with Upfront Checkpoint Inhibitors Combination
Koichi Azuma, Kurume University, Japan

P2.04-10 Biomarkers of Pathological Response on Neo-Adjuvant Chemo-Immunotherapy Treatment for Resectable Stage IIIA NSCLC Patients
Raquel Laza-Briviesca, Instituto de Investigación Sanitaria Puerta de Hierro-Majadahonda (IDIPHISA), Hospital Universitario Puerta de Hierro-Majadahonda, Spain

P2.04-11 Overcoming Resistance to Immunotherapy Using CVA21: Initial Results from a Phase II Study
Clare Senko, Olivia Newton John Cancer Center, Australia
P2.04-12 Ph I Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and SBRT to Multiple Sites in Patients with Stage IV NSCLC
Jyoti Patel, University of Chicago, United States of America

P2.04-13 Interleukin-18 and Lung Cancer: A Mendelian Randomization Study
Jiaqing Liu, Sun Yat-Sen University, China

P2.04-14 NLR, dNLR and PLR as Possible Predictive Markers in Patients with NSCLC Treated with ICI
Tiziana Vavala, SC of Oncology Ospedale Civile di Saluzzo, ASL CN1, Italy

P2.04-15 Association Between Opioids and Outcome of 1st Line Immunotherapy in Advanced NSCLC Patients: A Retrospective Evaluation
Mariella Bungaro, Medical Oncology, Ordine Mauriziano Hospital, Italy

P2.04-16 Novel CT Based Radiomic Features are Prognostic and Predictive of Benefit of Chemoimmunotherapy in Advanced Non-Squamous NSCLC
Kauat Bera, Case Western Reserve University, United States of America

P2.04-17 Immune Repertoire Is a Potential Predictive Biomarker for Evaluating the Efficacy of Mutant Neoantigen Specific T Cell Combined with PDI Antibody
Qi Song, Chinese PLA General Hospital, China

P2.04-18 Analysis of Patient Microbiome and Its Correlation to Immunotherapy Response and Toxicity in Lung Cancer
Jun Zhang, University of Iowa Hospitals and Clinics, United States of America

P2.04-19 Neoadjuvant Chemotherapy Is Associated with Immunogenic Cell Death and Increased T Cell Infiltration in Early-Stage NSCLC
Pierre-Olivier Gaudreau, The University of Texas MD Anderson Cancer Center, United States of America

P2.04-20 TP53/KMT2C Co-Mutation as a Novel Biomarker for Immunotherapy in Non-Small Cell Lung Cancer Patients
Qing Zhou, Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People’s Hospital & Guangdong Academy of Medical Sciences, China

P2.04-21 Serum CRP Decrease Has Predictive Value for Long-Term Disease Control by PD-1/PD-L1 Inhibitors in Patients with NSCLC
Reiko Matsuzawa, Nagoya University Hospital, Japan

P2.04-22 Programmed Death 1-mRNA Expression Predicts Benefit to Anti-PD1 Monotherapy in a Prospective Cohort of Advanced NSCLC
Cristina Teixido, Hospital Clinic Barcelona, Spain

P2.04-23 Tumor-Stroma Interactions Promote cGAS-STING Driven Inflammation in Lung Tumor Microenvironment
Marco Campisi, Politecnico di Torino, Italy

P2.04-24 Transcriptional Profiling of Neoantigen Specific T Cells in Resectable NSCLC Treated with Neoadjuvant Anti-PD-1
Justina Caushi, Johns Hopkins University, United States of America

P2.04-25 Gut Mycobiome and Metabolic Interactions with Bacteria in Lung Cancer Patients Reveals Potential Therapeutic Vulnerabilities
Zoltan Lohinai, National Koranyi Institute of Pulmonology, Hungary

P2.04-26 Single Cell Proteomics Profiling of Live T-Cells in KRAS+ and MET-Amp NSCLC to Predict Immune Checkpoint Inhibitor Response
Zuan-Fu Lim, West Virginia University, United States of America

P2.04-27 Clinical Implementation of Multiplex Immunofluorescence to Characterize Tumor Immune Status in Lung Cancer Patients
Lynette Sholl, Brigham and Women’s Hospital, United States of America

P2.04-28 NeoCOAST: Neoadjuvant Durvalumab Alone or with Novel Agents for Resectable, Early-Stage (I–IIIA) Non-Small Cell Lung Cancer
Rosario Garcia Campelo, Complejo Hospitalario Universitario A Coruna, Spain

P2.04-29 Association of Inflammation Related Genes with Lung Cancer Risk in Moroccan Population
Houda Kaanane, Faculty of Medicine and Pharmacy of Casablanca, Morocco

P2.04-30 Seq-ing a Better Way to Detect PD-L1 in NSCLC
Gywn Bebb, Alberta Health Services, Canada

P2.04-31 Immune Phenotypic Biomarkers in Locally Advanced Non-Small Cell Lung Cancer Treated with Definitive Chemoradiation and Atezolizumab
Steven Lin, MD Anderson, United States of America

P2.04-32 Comparison of Clinopathological and Genomic Characteristics Between NSCLCs with a PD-L1 Tumor Proportion Score of ≥90% vs <1%
Giuseppe Lamberti, Dana-Farber Cancer Institute, United States of America

P2.04-33 Single-Agent Tislelizumab, an Anti-PD1 Antibody: Results from a Phase 1 Expansion Cohort in NSCLC Patients
Andrea Pirzkall, BeiGene USA, Inc., United States of America

P2.04-34 FCGR2B Expression as a Regulator of Immunity in Non-Small Cell Lung Cancer Patients
Chung-Yu Chen, National Taiwan University Hospital Yunlin Branch, Taiwan

P2.04-35 Immune Related Adverse Events in NSCLC Patients Treated with Immune Checkpoint Therapy Who Received the Influenza Vaccination vs No Vaccination
Haritha Reddy, University of Michigan, United States of America

P2.04-36 Immune Checkpoint Inhibition for Non-Small Cell Lung Cancer (NSCLC) in Patients with Pulmonary Tuberculosis or Hepatitis B
Gloria Chan, National University Cancer Institute, Singapore, Singapore

P2.04-37 Phase I/II Trial of Durvalumab and Tremelimumab with Continuous or Intermittent MEK Inhibitor Selumetinib in Advanced NSCLC
Pierre-Olivier Gaudreau, The University of Texas MD Anderson Cancer Center, United States of America

P2.04-38 Tumor-Associated Neutrophils as a Potential Predictor for Early Recurrence in Resectable I-IIIA Lung Adenocarcinoma
Xue-Tao Li, South China University of Technology, China

P2.04-39 Clinical Characteristics of Long-Term Survivors with Nivolumab in Previously Treated Advanced NSCLC from Real World Data
Yasutaka Watanabe, Saitama Cancer Center, Japan

P2.04-40 Tumor Mutation Score Is More Powerful Than Tumor Mutation Burden in Predicting Response to Immunotherapy in Non-Small Cell Lung Cancer
Yuan Li, Renmin Hospital of Wuhan University, China
P2.04-41 Clinical and Immunological Factors Associated with Mutation Burden in Non-Small Cell Lung Cancer
Akira Ono, Shizuoka Cancer Center, Japan

P2.04-42 PD-L1-Mediated Enhancement of Hexokinase 2 Expression Is Inversely Related to T-Cell Effector Gene Expression in Non-Small-Cell Lung Cancer
Yoon Kyung Jeon, Seoul National University College of Medicine, Korea, Republic of

P2.04-43 High Occurrence of LINE-1 Retrotransposition Is Correlated with Smoking History, Local Immunosuppression and Poor Prognosis in LUSC
Jinpu Yu, Cancer Molecular Diagnostics Core, Tianjin Medical University Cancer Institute & Hospital, China

P2.04-44 Combined ImmuneCheckpoint Blockade in Mesothelioma: In Vivo Investigation of in Vitro Data
Jan Van Meerbreet, Antwerp University Hospital, Belgium

P2.04-45 A Phase Ib Dose-Escalation Study of Carotuximab in Combination with Nivolumab in Patients with Metastatic NSCLC
Francisco Robert, University of Alabama at Birmingham, United States of America

P2.04-46 Tolerability and Treatment-Related Adverse Events of Upfront Pembrolizumab Combination Regimens in Advanced NSCLC Patients
Kyaw Thein, The University of Texas MD Anderson Cancer Center, United States of America

P2.04-47 Tumor Mutational Load, CD8+ T Cells, Expression of PO-L1 and HLA Class I to Guide Immunotherapy Decisions
Daan Hurkmans, Erasmus University Medical Center, Netherlands

P2.04-48 Use of Immune Checkpoint Inhibitors in Patients with Advanced Lung Cancer and Pre-Existing Autoimmune Diseases
Samuel Cytryn, NYU Langone Health, United States of America

P2.04-49 Nivolumab Plus Ipilimumab (NI) Versus Chemotherapy Plus Nivolumab (CN) in Squamous Cell Lung Cancer (SqCLC): The SQUINT Trial
Lorenza Landi, Ospedale S.Maria delle Croci, Italy

P2.04-50 Advanced Statistical Approach Tells the Difference: Taylor-Expansion Adjustment for Survival Analyses in Immunotherapy Trials
Chih-Yuan Hsu, Vanderbilt University Medical Center, United States of America

P2.04-51A A 6-Gene Immune Genomic Signature (IGS) Predicts Resistance to Nivolumab [NIV] in Advanced Pretreated NSCLC: Results of PRINCIpe Trial
Sara Pilotto, Azienda Ospedaliera Universitaria Integrata, Verona, Italy

P2.04-52 Impact of Corticosteroids and Antibiotics on Efficacy of Immune-Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer
Mariona Riudavets, Hospital de la Santa Creu i Sant Pau, Spain

P2.04-53 Serial Ultra-Deep Sequencing of ctDNA Reveals the Clonal Evolution in Non-Small Cell Lung Cancer Patients Treated with Pembrolizumab
He Yong, Daping Hospital, Army Medical University, China

P2.04-54 Characteristic of MSI-H Lung Cancer Patients Identified with Targeted Next-Generation Sequencing
Rongrong Chen, Geneus-Beijing Institute, China

P2.04-55 Tumor Spread Through Air Spaces Is Associated with the Non-Inflamed Immune Microenvironment in Lung Squamous Cell Carcinoma
Takahiro Karasaki, university of Tokyo, Japan

P2.04-56 Improved Survival of NSCLC Filipino Patients Given Autologous Dendritic Cell Vaccine: Case Series with CTC Upgrade and IL15
Maria Teresa Barzaga, De La Salle University, Philippines

P2.04-57 Predictive and Prognostic Value of CTC Monitoring in Advanced NSCLC Patients Treated with Immune Checkpoint Inhibitors
Guanghui Gao, Shanghai Pulmonary Hospital, China

P2.04-58 The Correlation Between TMB and Clinical Factors in East Asian Lung Cancer Patients with No TKI-Related Driver Gene-Mutations
Yayi He, Shanghai Pulmonary Hospital, Tongji University, China

P2.04-59 Patient Survival in NSCLC Based on PD-L1 Expression and Tissue Origin
Sam Khan, Level 5 Robert Kilpatrick Clinical Sciences Building, United Kingdom

P2.04-60 Pembrolizumab-Based Regimens Administered at Non-Standard Frequency in Non-Small Cell Lung Cancer (NSCLC)
Kartik Sehgal, Beth Israel Deaconess Medical Center, United States of America

P2.04-61 Preliminary Report of a Multidisciplinary Task Group for the Study of Immune-Mediated Pulmonary Toxicity
Roberto Martin-Deleón, Hospital Clinic, Spain

P2.04-62 TCR Repertoire Analysis of Peripheral CD8+PD-1+ T Cells Is Effective as a Predictive Biomarker for Response to the Immune Checkpoint Inhibitor
Seiji Matsumoto, Hyogo College of Medicine, Japan

P2.04-63 Evaluation of Combined Biomarkers for Tumor Response to Immunotherapy (I/O) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Hayat Ramdani, Carl von Ossietzky University Oldenburg, Germany

P2.04-64 222 NSCLC’s Classified by PAM50: Luminal A NSCLC Is a Distinct Subtype with Low TMB and Immune Suppressive TME
Hossein Borghaei, Fox Chase Cancer Center, United States of America

P2.04-65 Peptide-Based Cancer Vaccine Shortened the Overall Survival of a Large Portion, but Not All, of Advanced Cancer Patients
Koichi Yoshiyama, Kurume University School of Medicine, Japan

P2.04-66 Immunotherapy for ALL? Representation of Minorities and the Elderly in Lung Cancer Immunotherapy Trials
Ana Velazquez, UCSF, United States of America

P2.04-67 Comparative Analysis of TMB and Mutations by Comprehensive Genomic Profiling (TSO500) in FFPE NSCLC Samples
Johan Botling, Uppsala University, Sweden

P2.04-68 Retrospective Analysis of Immune Checkpoint Inhibitors in NSCLC: Immune-Related Adverse Events and Outcomes
Alvin Lee, University College London, United Kingdom

P2.04-69 Impact of Antibiotic Usage on Survival During Checkpoint Inhibitor Treatment of Non-Small Cell Lung Cancer (NSCLC)
Mary Jo Fidler, Rush University Medical Center, United States of America

P2.04-70 PD-L1 Expression in a Population with Non-Small Cell Lung Cancer in a Reference Healthcare Center in Latin-America
Liliana Fernandez-Trujillo, Fundacion Valle del Lili Hospital Universitario, Colombia
P2.04-71 Bullous Pemphigoid: A Rare Immunomediated Event Secondary to Immunotherapy in a Patient with Metastatic Lung Cancer
Eduardo Vissotto, Hospital Santa Lucia, Brazil

P2.04-72 Clinical Feature and Management of Acquired Resistance to PD-1 Inhibitor in Advanced NSCLC
Sachi Okawa, National Cancer Center Hospital East, Japan

P2.04-73 Maintenance Treatment Using CimaVax EGF Vaccine. Experience of Single Institution
Yoanna Flores, National Institute of Oncology and Radiobiology, Cuba

P2.04-74 Radiotherapy Prior to Immunotherapy Is Associated with Durable Disease Control in Advanced NSCLC
Åsa Ojért, Oslo University Hospital - The Norwegian Radium Hospital, Norway

P2.04-75 Overall Survival by IDO1 and PD-L1 Expression in NSCLC Patients Receiving an Immune Checkpoint Inhibitor (ICI)
Richard Hall, University of Virginia, United States of America

P2.04-76 Tumor Mutational Burden by TSOS00 Next Generation Sequencing Panel and Clinical Outcome in Non-Small Cell Lung Cancer
Kristof Cuppens, Jessa Hospital, Belgium

P2.04-77 Hyperprogression with Immunotherapy in Metastatic Non-Small Cell Lung Cancer: Hôpital Charles-LeMoyne Experience
Luisa Galvis Gomez, Dr. Everett Chalmers Hospital, Canada

P2.04-78 PD-L1 Expression as a Prognostic Marker for Non-Small Cell Lung Cancer in Distinct Mutational Status
Narulom Trachu, Ramathibodi Hospital, Mahidol University, Thailand

P2.04-79 High Rate of Immune Related Pneumonitis in Lung Cancer Patients Treated with Anti PD-1 Antibodies
Andrés Aguilar Hernandez, Institute of Oncology Rosell (IOR), Quirón-Dexeus University Institute, Spain

P2.04-80 Pretreatment Nutritional Status and Response to Checkpoint Inhibitors in Lung Cancer
Nagashree Seetharamu, Northwell Health, United States of America

P2.04-81 Non-Small Cell Lung Cancer Treated with Immunotherapy: Multi-Institutional Experience from Argentina
Manglio Rizzo, Hospital Universitario Austral, Argentina

P2.04-82 Discontinuation of Anti-PD-1/PD-L1 Antibody Therapy in the Absence of Disease Progression: Clinical Outcomes in Advanced NSCLC
Nicolas Minatta, Hospital Italiano de Buenos Aires, Argentina

P2.04-83 Long-Term Follow-Up Compasionatte Use Program Nivolumab in NSCLC
Paul Baas, Netherlands Cancer Institute, Netherlands

P2.04-84 NSCLC Survival Expectancy for Patients Treated with Docetaxel/Nintedanib in the SENECA Trial and Previous Immunotherapy
Enrica Capelletto, AOU San Luigi, Orbassano, Italy

P2.04-85 Clinical Significance of the PD-L2 Expression in Patients with NSCLC Receiving Anti-PD-1 Inhibitors
Hidenobu Ishii, Kurume University School of Medicine, Japan

P2.04-86 Efficacy of Ipilimumab in Combination with Chemotherapy for First-Line Treatment of Advanced Lung Cancer
Kyaw Thein, The University of Texas MD Anderson Cancer Center, United States of America

P2.04-87 Efficacy of Immune Checkpoint Inhibitors for Locally Advanced Non-Small Cell Lung Cancer Patients Before Durvalumab Approval
Tomoya Fukui, Kitasato University, School of Medicine, Japan

P2.04-88 Surgical Outcomes of a Multicenter Phase II Trial of Neoadjuvant Atezolizumab in Resectable Stages IB-IIIB NSCLC: Update on LCMC3 Clinical Trial
Jay Lee, UCLA, United States of America

P2.04-89 Neoadjuvant Pembrolizumab in Early Stage Non-Small Cell Lung Cancer (NSCLC): Toxicity, Efficacy, and Surgical Outcomes
Neal Ready, Duke University, United States of America

P2.04-90 Nodal Immune Flare (NIF) Following Neoadjuvant Anti-PD-1 and Anti-CTLA-4 Therapy in Non-Small Cell Lung Cancer
Boris Sepesi, The University of Texas MD Anderson Cancer Center, United States of America

P2.04-91 Target Antigen Levels in NSCLC Define a Clinically Relevant Activation Threshold for NY-ESO-1c259 TCR T-Cell Therapy
Anna Domogala, Glaxosmithklein, United Kingdom

P2.04-92 Neoadjuvant Durvalumab With or Without Sub-Ablative Stereotactic Radiotherapy (SBRT) in Patients with Resectable NSCLC (NCT02904954)
Nasser Altorki, New York Presbyterian Hospital-Weill Cornell Medical College, United States of America

P2.04-93 Performance Status and Age as Predictors of Immunotherapy Outcomes in Advanced Non-Small Cell Lung Cancer
W Jeffrey Petty, Wake Forest School of Medicine, United States of America

P2.04-94 PD-L1 Expression in Uncommon EGFR-Mutant Non-Small Cell Lung Cancer and Its Response to Immunotherapy
Yun Fan, Zhejiang Cancer Hospital, China

P2.05
10:15 – 18:15 INTERVENTIONAL DIAGNOSTIC/ PULMONOLOGY

P2.05-01 Broad Genomic Profiling of Bronchoalveolar Lavage Fluid in Lung Cancer
Viswam Nair, USF/Moffitt, United States of America

P2.05-02 Added Value of Transbronchial Cryobiopsy Sampling in Navigation Bronchoscopy for Small Pulmonary Nodules
Erik Van Der Heijden, Radboud University Medical Center, Netherlands

P2.05-03 Tumor Atelectasis Gives Rise to Solid Appearance in Pulmonary Adenocarcinomas
Francesca Ambrosi, University of Bologna Medical Center, Italy

P2.05-04 Development of a New Endobronchial Treatment for Peripheral-Type Lung Cancer
Jitsuo Usuda, Nippon Medical School Hospital, Japan

P2.05-05 Availability of Four Dimensional Computed Tomography (4DCT) for Lung Cancer
Hiromasa Arai, Kanagawa Cardiovascular and Respiratory Center, Japan
P2.05-06 New Dosimetric Parameters Encompassing High Attenuation Enables More Accurate Prediction of Radiation Pneumonitis in Various Types of Cancers
Yasuki Uchida, Shiga University of Medical Science, Japan

P2.05-07 The Liverpool “Straight to CT” and “Virtual Working” Lung Cancer Pathway – 5 Years On
Martin Ledson, Liverpool Heart and Chest Hospital, United Kingdom

P2.05-08 Diagnostic Yield of EBUS-TBNA in Evaluation of PD-L1 Expression for Advanced Non-Small Cell Lung Cancer
Katsutaka Mineura, Kyoto University Hospital, Japan

P2.05-09 FDG-PET for Predicting Acute Exacerbation of Interstitial Pneumonia After Lung Cancer Surgery
Kimihiro Shimizu, Gunma University Hospital, Japan

P2.05-10 Liquid Biopsy: Association Between the Burden of Disease in Patients with EGFR-Mutated NSCLC and the Frequency of Its Detection in Blood
Mariano Provencio, Hospital Puerta de Hierro-Majadahonda, Spain

P2.05-11 3D CT Is Useful for Segmentectomy but Is Not Always True
Takeshi Mori, Japanese Red Cross Kumamoto Hospital, Japan

P2.05-12 Analysis of Biomarkers in Lung Cancer in Spain
Delvys Rodríguez-Abreu, Hospital Insular de Gran Canaria, Spain

P2.05-13 Impact of Diffusing Capacity for Postoperative Pulmonary Complications in Patients Without Obstructive Pulmonary Disease
Sumin Shin, Samsung Medical Center, Korea, Republic of

P2.05-14 Safety and Risk Factors of CT-Guided Percutaneous Transthoracic Needle Re-Biopsy for NSCLC
Meng Wang, The First Affiliated Hospital of Zhengzhou University, China

P2.05-15 Radial Endobronchial Ultrasound-Guided Transbronchial Biopsy in Peripheral Lung NSCLC. What Can Cryobiopsy Contribute?
Sonia Baaza Mena, Hospital Universitario Germans Trias i Pujol, Spain

P2.05-16 Diagnostic Value of Concomitant Use of Radial Probe Endobronchial Ultrasound with Guide Sheath and Transbronchial Biopsy in Lung Cancer
Sang Chul Lee, National Health Insurance Service Ilsan Hospital, Korea, Republic of

P2.05-17 Preoperative Identification of the Left Common Pulmonary Vein for Safe Video-Assisted Lobectomy
Shinji Kikuchi, University of Tsukuba, Japan

P2.05-18 Tissue Sampling and Prognostic Biomarkers Analysis of Peripheral Lung Tumors Using R-EBUS. Single Centre Retrospective Study
Sonja Badovinac, University Hospital Centre Zagreb, Croatia

P2.05-19 The Patency of Right Upper Lobe Bronchus After Y-Stent Placement Affect Outcome on Malignant Tracheobronchial Stenosis
Shinjiro Mizuguchi, Osaka City General Hospital, Japan

P2.06-01 STELLAR Trial: Radiological Response Patterns of TTFields Plus Chemotherapy in First-Line Treatment of Malignant Pleural Mesothelioma
Uri Weinberg, Novocure, Israel

P2.06-02 Mesothelioma Stratified Therapy (MiST): A Phase IIa Umbrella Trial for Accelerating the Development of Precision Medicines
Dean Fennell, University Hospitals of Leicester NHS Trust, United Kingdom

P2.06-03 Timing of Surgery After Induction Therapy for Malignant Pleural Mesothelioma: A National Analysis
Soraya Voigt, Duke University, United States of America

P2.06-04 Treatment Patterns and Outcomes of Advanced Malignant Pleural Mesothelioma (MPM) Patients in a Community Practice Setting
Melinda Daumont, Bristol-Myers Squibb, Belgium

P2.06-05 Multimodality Therapy Using Total Pleurectomy in Malignant Pleural Mesothelioma: Long-Term Outcomes in 150 Consecutive Cases
Loic Lang-Lazdunski, Bupa Cromwell Hospital, United Kingdom

P2.06-06 Y-box Binding Protein-1, a Potential Target in Malignant Pleural Mesothelioma, Drives Growth Through Distinct Mechanisms
Thomas Johnson, The Asbestos Diseases Research Institute, Sydney, Australia

P2.06-07 Phase I Study of CA-170: First-in-Class Small Molecule Targeting VISTA/PD-L1 in Patients with Malignant Pleural Mesothelioma
Marjorie Zauderer, Memorial Sloan Kettering Cancer Center, United States of America

P2.06-08 Nivolumab for Malignant Mesothelioma: A Real-World Experience
Maiko Niki, Hyogo College of Medicine, Japan

P2.06-09 Drop the Scalpel: Long-Term Survival in Mesothelioma Without Extrapleural Pneumonectomy or Pleurectomy Decortication
Gavitt Woodard, University of California San Francisco, United States of America

P2.06-10 ABT-806 Derived Antibody Drug Conjugates (ADCs) Inhibit Growth of Malignant Mesothelioma In-Vivo
Puey Ling Chia, Tan Tock Seng Hospital, Singapore

P2.06-11 MEDUSA: Phylogenic Analysis of Mesothelioma Tumours by Multiregional Sampling, Whole Exome Sequencing, and Copy Number Analysis
Edward Hollox, University of Leicester, United Kingdom

P2.06-12 Dysphagia in Patients with Malignant Pleural Mesothelioma (MPM)
Monica Malec, University of Chicago, United States of America

P2.06-13 Targeting RAS Signaling in Malignant Mesothelioma
Chuong Hoang, National Cancer Institute - NIH, United States of America

P2.06-14 BAP1 Mutant Malignant Pleural Mesothelioma (MPM): Outcomes with Chemotherapy, ICPI and PARPi
Elizabeth Dudnik, Davidoff Cancer Center Rabin Medical Center, Israel
P2.08-01 Outcomes Following Gamma Knife Radiosurgery for Oligometastatic Brain Metastases in Patients with NSCLC at Leeds Cancer Centre
Robert Samuel, Leeds Cancer Centre, United Kingdom

P2.08-02 Outcomes Following Stereotactic Radiosurgery for Synchronous Brain Metastases in Non-Small Cell Lung Cancer
Fiona Wilson, Christie NHS Foundation Trust, United Kingdom

P2.08-03 Clinical Outcome of Patients with Recurrent Non-Small Cell Lung Cancer After Trimodality Therapy
Ken Suzawa, Okayama University Hospital, Japan

P2.08-04 Stereotoxic Ablative Radiation Therapy to Lung Metastases Associates with Better Outcomes in Oligometastatic Lung Cancer: Prospective Study
Monika Blake-Cerda, Instituto Nacional de Cancerología, Mexico

P2.08-05 The Role of Surgical Treatment for Patients with NSCLC Demonstrating Limited Pleural Dissemination
Haruhisa Matsuguma, Tochigi Cancer Center, Japan

P2.08-06 Development and Validation of a 18F-FDG PET/CT-Based Radiomics Model for Prognosis Prediction in Synchronous Oligometastatic NSCLC
Xiaoxia Zhu, Nanfang Hospital, Southern Medical University, China

P2.08 10:15 – 18:15 OLIGOMETASTATIC NSCLC

Track(s): Oligometastatic NSCLC

P2.08-01 Outcomes Following Gamma Knife Radiosurgery for Oligometastatic Brain Metastases in Patients with NSCLC at Leeds Cancer Centre
Robert Samuel, Leeds Cancer Centre, United Kingdom

P2.08-02 Outcomes Following Stereotactic Radiosurgery for Synchronous Brain Metastases in Non-Small Cell Lung Cancer
Fiona Wilson, Christie NHS Foundation Trust, United Kingdom

P2.08-03 Clinical Outcome of Patients with Recurrent Non-Small Cell Lung Cancer After Trimodality Therapy
Ken Suzawa, Okayama University Hospital, Japan

P2.08-04 Stereotoxic Ablative Radiation Therapy to Lung Metastases Associates with Better Outcomes in Oligometastatic Lung Cancer: Prospective Study
Monika Blake-Cerda, Instituto Nacional de Cancerología, Mexico

P2.08-05 The Role of Surgical Treatment for Patients with NSCLC Demonstrating Limited Pleural Dissemination
Haruhisa Matsuguma, Tochigi Cancer Center, Japan

P2.08-06 Development and Validation of a 18F-FDG PET/CT-Based Radiomics Model for Prognosis Prediction in Synchronous Oligometastatic NSCLC
Xiaoxia Zhu, Nanfang Hospital, Southern Medical University, China
P2.09-11 Genomic Profiling of Pulmonary Lymphoepithelioma-Like Carcinoma (PLELC)
Chengzhi Zhou, The First Affiliated Hospital of Guangzhou Medical University,
P2.09-12 Next-Generation Sequencing of 7 Cases with Diffusely Coexpressed TTF-1 and p40 Reveals a New Molecular Entity in Resected NSCLC
Likun Hou, Shanghai Pulmonary Hospital, China
P2.09-13 Histological and Molecular Evaluation of Multiple Lung Carcinoma with Synchronous Presentation. Single-Center Study in Argentina
Mercedes Liliana Dalurzo, Hospital Italiano Buenos Aires, Argentina
P2.09-14 Evaluation on Inter-Assay Consistency and Inter-Reader Precision for PD-L1 Assays: Ventana SP263 and Dako 22C3 in Non-Small Cell Lung Cancer
Xin Yang, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Pathology, China
P2.09-15 PD-L1 Expression and Lymphocyte Infiltration in Resected Stage IIIAN2 NSCLC: Preliminary Data from a Lung ART Ancillary Study
Julien Adam, Gustave Roussy, France
P2.09-16 Assessment of PD-L1 and CD8 Expression in Lung Cancer Using RNA in Situ Hybridisation
Anne-Marie Baird, Trinity College Dublin, Ireland
P2.09-17 Real-World Concordance Across Pathologists for PD-L1 Scoring in Non-Small Cell Lung Cancer: Results from a Large Nationwide Initiative
Julien Adam, Gustave Roussy, France
P2.09-18 Lymphocyte Infiltration Pattern and STING Expression Identify Different Prognostic Groups in Early Stage NSCLC
Fabrizio Tabbè, Medical Oncology, Ordine Mauriziano Hospital, Italy
P2.09-19 Effect of Neoadjuvant (Radio)chemotherapy on PD-L1 Expression in Resected Non-Small Cell Lung Cancers
Philipp Zens, Institute of Pathology, University of Bern, Switzerland
P2.09-20 The Possible Clinical Significances of Infiltration of CD8+ Lymphocytes in Non-Small Cell Lung Cancers
Kazu Shiomi, Kitasato University School of Medicine, Japan
P2.09-21 A Prospective Study of the Concordance for PD-L1 Status in Core Needle Biopsy and Corresponding Resection Specimen in NSCLC
Wei Sun, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, China
P2.09-22 Molecular and Immunological Profiles of Lung Carcinoma: Are They Associated?
Andreia Cruz, Portuguese Institute of Oncology, Portugal
P2.09-23 PD-L1 Expression of Paired Primary Resected Non-Small Cell Carcinoma and Metastatic Lymph Node Fine Needle Aspirates
Rachel Bowden, Salford Royal NHS Foundation Trust, United Kingdom
P2.09-24 IASLC Global Survey for Pathologists on PD-L1 Testing for Non-Small Cell Lung Cancer
Mari Mino-Kenudson, Massachusetts General Hospital, United States of America
P2.09-25 Tumor Spread Through Air Spaces (STAS) Was Correlated with Multiple Advanced Clinicopathological Factors
Toshimasa Okazaki, Osaka Citizen Hospital, Japan
P2.09-26 Inadequate Surgical Margins at Video-Assisted Thoracoscopic Wedge Resection of Ground-Glass Opacity Lung Adenocarcinoma
Masao Naruke, AOI Hospital, Japan
P2.09-27 Correlation Between Different ROS1 Clones (SP384 & D4D6) and Consistency with ROS1 Fluorescence in Situ Hybridization (FISH) Results
Büge Öz, Istanbul Üniversitesi Cerrahpasa Tip Fakültesi, Turkey
P2.09-28 Prognostic Impact of LKB1 Expression in Advanced Non-Small-Cell Lung Cancer
Diego Armando Diaz-Garcia, Instituto Nacional de Cancerologia, Mexico
P2.09-29 Correlation of Tumor Spread Through Air Spaces and Clinicopathological Characteristics in Surgically Resected Lung Adenocarcinomas
Ming-Wei Lin, National Taiwan University Hospital, Taiwan
P2.09-30 PD-L1 Testing and Clinical Benefit in Patients Treated with CPI
Mile Kovacevic, University Clinic Golinik, Slovenia
P2.09-31 High Concordance of PD-L1 Antibody Between Clone 22C3 and Clone E1L3N in Non-Small Cell Lung Cancer Biopsy Samples
Chunyan Wu, Shanghai Pulmonary Hospital, China
P2.09-32 Higher Prevalence of EGFR Mutations Significantly Correlates with Lower PD-L1 Expression in Chinese Lung Adenocarcinoma
Shiyue Zhang, Origimed, China
P2.09-33 Prevalence of ROS1 (SP384)-Reactive Type II Pneumocyte Staining in Lung Tissue
Ina Menzl, Roche Tissue Diagnostics, United States of America
P2.09-34 Next-Generation Sequencing Implementation in Non-Small Cell Lung Cancer Molecular Diagnosis
Sergi Clavé, Hospital del Mar, Spain
P2.09-35 Proposal to Revise VENTANA ALK Scoring Interpretation Guide for Non-Small Cell Lung Carcinoma: Interpretation of ALK Heterogeneity
Li-Xu Yan, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, China

P2.10 Inadequate Surgical Margins at Video-Assisted Thoracoscopic Wedge Resection of Ground-Glass Opacity Lung Adenocarcinoma
Masao Naruke, AOI Hospital, Japan

P2.10-01 Analysis of Human Papilloma Viruses (HPV) and Human Polyoma Viruses (HPyV) in Lung Cancer from Swedish Never-Smokers
Maria Planck, Division of Oncology and Pathology, Sweden
P2.10-02 Smoking Habit in Lung Cancer in Spain
Enric Carcereny, Catalan Institut of Oncology Badalona- Hospital Universitari Germans Trias I Pujol. B-ARGO, Spain
P2.10-03 Prevalence of Tobacco Use Disorder in Patients Diagnosed with Lung Cancer and Their Tobacco Use Characteristics
Chan Kwon Park, The Cancer Research Institute, College of Medicine, The Catholic University of Korea, Korea, Republic of
P2.10-04 Predicting Non-Compliance in Routine Lung Cancer Screening for High-Risk Adults
Martin Tammemagi, Cancer Care Ontario, Canada
P2.10-05 Indoor Radon and Lung Cancer Risk. A Pooling Study on the Second Risk Factor for Lung Cancer
Alberto Ruano-Ravina, University of Santiago de Compostela, Spain

P2.10-06 Smoking Prevalence and Perceptions Among Healthcare Professionals: A Survey in an Italian Clinical Cancer Centre
Annamaria Catino, Clinical Cancer Centre, Italy

P2.10-07 Does Short-Term Cessation of Smoking Before Lung Resections Reduce the Complication Risk?
Tomoyoshi Takenaka, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Japan

P2.10-08 Association Between Smoking and Anxiety/Depression in Respiratory Tract Cancers
Zane Deliu, University of Illinois Hospital & Health Sciences System, United States of America

P2.10-09 Environmental Pollution in the City of Mexico as a Risk Factor for Lung Cancer and Its Prognostic Impact
Omar Macedo-Perez, Instituto Nacional de Cancerologia, Mexico

P2.10-10 Impact of School Based Anti-Tobacco Education for Knowledge Enhancement Among High School Children of Ernakulam City, India
Eby Aluckal, Mar Baselios Dental College, Kothamangalam, India

P2.10-11 The Relationship and Significance of Asbestos Bodies and Fibers in the Lung for the Compensation of Asbestos-Related Lung Cancer in Japan
Takumi Kishimoto, 1-10-25 Chikkomidorimachi, Japan

P2.10-12 Clinicopathological Analysis of the Lung Cancer Patients Who Have History of Asbestos Exposure
Hiroyasu Koga, Yokosuka Kyosai Hospital, Japan

P2.10-13 Effects of the Advanced Tobacco Control Training (ATCT) on Healthcare Professionals’ Smoking Cessation Knowledge and Counseling
Yeur-Hur Lai, National Taiwan University, Taiwan

P2.10-14 Prevalence, Pattern, and Intention to Quit Use of Smoked Tobacco in a Rural Community in South Eastern Nigeria
Uzochukwu Ofonakara, Federal Teaching Hospital Abakaliki, Nigeria

P2.10-15 Lung Cancer and Smoking Related Myths Among General Population: Do We Need to Make People More Aware?
Shubham Roy, Indian Society of Clinical Oncology, India

P2.10-16 Lung Cancer Occurrence Attributable to Passive Smoking Among Never Smokers in China: A Systematic Review and Meta-Analysis
Yihui Du, University Medical Center Groningen, Netherlands

P2.11-05 Novel Flexible Longitudinal Machine Learning Coupled with Patient Demographics Improves Lung Cancer Risk Prediction Using Whole Screening CTs
Kim Sandler, Vanderbilt University Medical Center, United States of America

P2.11-06 Individualized Risk-Based Lung Cancer Screening Incorporating Past Screening Findings and Changes in Smoking Behaviors
Iakovos Tournazis, Stanford University, United States of America

P2.11-07 Benefits and Harms of Contemporary Lung Cancer Screening: An Infographic to Support Public and Patient Education
Hilary Robbins, International Agency for Research on Cancer, France

P2.11-08 CT Screening of Never Smokers
Claudia Henschke, Icahn School of Medicine at Mount Sinai, United States of America

P2.11-09 Australia-Wide Cross-Sectional Survey of General Practitioners’ Knowledge and Practice of Lung Cancer Screening
Prarthana Abeyweera, Sir Charles Gardiner Hospital, Australia

P2.11-10 Discovery of Potential Biomarkers That Discriminate Early Stage NSCLC from Controls by Non-Targeted Metabolomics Profiling
Julian Kim, CancerCare Manitoba, Canada

P2.11-11 Exosomal miRNAs as Diagnosis Biomarkers for Distinguishing Benign and Malignant Nodules in Non-Small Cell Lung Cancer
Di Zheng, Shanghai Pulmonary Hospital, China

P2.11-12 Sputum Liquid Biopsy Provides a Non-Invasive Modality to Assess Driver Mutations and Tumor Heterogeneity in NSCLC
Vladimir Lima, CIPE- AC Camargo Cancer Center, Brazil

P2.11-13 What Is the Impact of Localised Data When Training Deep Neural Networks for Lung Cancer Prediction?
Anand Devaraj, Royal Brompton and Harefield NHS Foundation Trust, United Kingdom

P2.11-14 Evolutionary Action Score of TP53 Predicts the Prognosis of Patients with Stage I Lung Adenocarcinoma
Yue Zhao, Fudan University Shanghai Cancer Center, China

P2.11-15 Detection of Circulating Genetically Abnormal Cells Improves the Diagnostic Accuracy in Lung Cancer Presenting with GGNs
Bin Zhang, Tianjin Medical University Cancer Institute and Hospital, China

P2.11-16 Variability in Reading Low-Dose Chest CT: Individual Readers vs. Central Review in a Nationwide Lung Cancer Screening Project
Eui Jin Hwang, Seoul National University Hospital, Korea, Republic of

P2.11-17 Analysis of Lung Adenocarcinoma EGFR Mutation by LAMP Method: Comparison with PCR Method and Identification of a Novel Exon19 Deletion Mutation
Sho Horiuichi, Saitama Cardiovascular and Respiratory Center, Japan

P2.11-18 Circulating Serum KLK5 and LICAM Levels Potentially Predict Clinical Outcome to Anlotinib Therapy in NSCLC Patients
Jun Lu, Shanghai Chest Hospital, China
P2.11-19 Effects of Incorporating a Lung Cancer Screening Educational Intervention into Tobacco Cessation Counseling
Dan Raz, City of Hope, United States of America

P2.11-20 Risk Factors of Lung Cancer Development in IPF Patients
Hye Seon Kang, The Catholic University of Korea, Korea, Republic of

P2.11-21 Usefulness of Diffusion-Weighted Whole-Body Imaging with Background Suppression in the Postoperative Follow-up Period
Kanto Suemori, Okayama Saiseikai General Hospital, Japan

P2.11-22 Comparison of the Sensitivity of USPSTF and PLCOm2012 Lung Cancer Screening Criteria in a Racially Diverse Population
Mary Pasquinelli, University of Illinois Hospital & Health Sciences System, United States of America

P2.11-23 Performance of Lung Cancer Risk Prediction Models in I-ELCAP Smokers
Rowena Yip, Icahn School of Medicine at Mount Sinai, United States of America

P2.11-24 The First Comprehensive Primary Care Provider Training for Lung Cancer Care in the U.S. - An Innovative Online Course
Celeste Worth, University of Louisville, United States of America

P2.11-25 Pre- and Post-Surgery Metabolomic Profiles in Early-Stage NSCLC Patients
Wannisa Laosuangkoon, Mahidol University, Thailand

P2.11-26 Survival of Patients with Multiple Primaries and Single Lung Cancer - A Comparative Analysis
Anna Romaszko-Wojtowicz, University of Warmia and Mazury, Poland

P2.11-27 Early Detection of Lung Cancer: Optimal Strategies
Oleg Khivets, Roshal City Hospital, Russian Federation

P2.11-28 Late-Breaking Abstract - Clinical Potential of Sputum Ayaluronan Measurement in the Diagnosis and Prognosis of Patients with NSCLC
Vladimir De Lima, AC Camargo Cancer Center, Brazil

P2.11-29 Diagnosis and Surveillance of Solitary Pulmonary Nodules with ctDNA Methylation Sequencing: Protocol for a Prospective Multicenter Study
Wenhua Liang, Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University; State Key Laboratory of Respiratory Disease; National Clinical Research Center for Respiratory Disease, China

P2.11-30 Effects of the Size of Nodules, Reconstruction Slice Thickness and Convolution Kernel on Radiomics Model in Classifying Pulmonary Nodules
Yan Xu, Beijing Friendship Hospital, Capital Medical University, China

P2.11-31 DNA Methylation Markers for Prediction of Recurrence in Stage I Non-Small Cell Lung Cancers
Yan Wang, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China

P2.11-32 Project ACTS (Adherence to CT Screening): Developing Patient Engagement Tools to Support Lung Cancer Screening Adherence
Upal Basu Roy, LUNGevity Foundation, United States of America

P2.11-33 Organizational Readiness for Implementation of Lung Cancer Screening in a Veterans Affairs Healthcare System
Lucy Spalluto, Vanderbilt University Medical Center, United States of America

P2.11-34 Application of Next-Generation Sequencing for Screening of Sputum Samples
Yuko Minami, Department of Pathology, National Hospital Organization, Ibaraki Higashi National Hospital, Japan

P2.11-35 Lung Cancer Screening Knowledge, Perceptions and Decision-Making Among African Americans
Rafael Meza, University of Michigan, United States of America

P2.11-36 The Role of FDG-PET Scans in Pre-Invasive Endobronchial Lesions
Iliaa Smesseim, Department of Pulmonary Diseases, Amsterdam University Medical Center, Netherlands

P2.11-37 Low-Dose CT Lung Screening: Analysis of Risk Factors Related to Lung Cancer
Yujing Jin, Peking Union Medical College/Chinese Academy of Medical Sciences, Cancer Hospital, China

P2.11-38 Creating a Successful Multidisciplinary Conference for Review of Suspicious Lung Nodules
Debra Dyer, National Jewish Health, United States of America

P2.11-39 Multimodal Monitoring of Patient-Derived Early-Stage Lung Adenocarcinoma with the Chicken Chorioallantoic Membrane System
Eva Koziolek, University of California Los Angeles, United States of America

P2.11-40 Integration of Individualized Tobacco Cessation Counseling in a Lung Cancer Screening Program
Matthew Steiliga, University of Arkansas, United States of America

P2.11-41 Improving Annual Adherence in a Community Based Lung Cancer Screening Program
Karen Alisa Braithwaite, NYU Winthrop Hospital, United States of America

P2.11-42 A Prospective Multicenter Study to Assess Combined 6 Tumor Markers for Early Stage Lung Cancer in Patients with Lung Nodule
Xiuyi Zhi, Capital Medical University Xuanwu Hospital, China

P2.11-43 Management of Pulmonary Nodules Detected on CT: Multicenter Collaborative Study in Nagasaki Prefecture
Shin Tsutsui, Nagasaki University Hospital, Japan

P2.11-44 A Preliminary Study Investigating the Impact of Platelet on Circulating Tumor Cell Enumeration
Yu Chen, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China

P2.11-45 Economical Screening for Lung Cancer in a Developing Country - 5 Years Experience
Shanmugam Sankarkumar, Geeyes Diabetes and Hypertension Research Centre, India

P2.11-46 Could Malignancies Diagnosed During Round 2 of Screening Be Worked Up Sooner?
Timor Kadir, Optellum Ltd, United Kingdom

P2.12

10:15 – 18:15 SMALL CELL LUNG CANCER/NET

● Exhibit Hall

Track(s): Small Cell Lung Cancer/NET

P2.12-01 Small Cell Lung Cancer (SCLC) Treatment and Survival in the UK: A REAL-Oncology Analysis from the I-O Optimise Initiative
Melinda Daumont, Bristol-Myers Squibb, Belgium
P2.12-02 Intertumoral Heterogeneity in Small Cell Lung Carcinoma According to the Primary Tumor Versus Lymph Node Metastases Delineated by RNA Sequencing
Zsolt Megyesfalvi, National Koranyi Institute for Pulmonology, Hungary

P2.12-03 Building and Validating a Lymphocyte Nadir Based Model to Predict Survival in Patients with Limited Stage-Small Cell Lung Cancer
Feng-Ming Kong, Radiation Oncology Institute of Enze Medical Health Academy, Affiliated Taizhou Hospital of Wenzhou Medical University, China

P2.12-04 CLEPSiDRA: A Phase II Trial Combining idaademstat with Platinum-Etoposide in Platinum-Sensitive Relapsed SCLC Patients
Carlos Buesa, Oryzon Genomics SA, Spain

P2.12-05 A Phase II Trial of Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Neuroendocrine Carcinoma
Robert Ramirez, Ochsner Clinic Foundation, United States of America

P2.12-06 Factors of Importance for Survival After Platinum Re-Challenge in Platinum-Sensitive Small-Cell Lung Cancer Patients
Luigi De Petris, Karolinska Institutet, Sweden

P2.12-07 Phase I Study of Amrubcin and Cisplatin with Concurrent Thoracic Radiotherapy (TTR) in Limited-Disease Small Cell Lung Cancer (LD-SCLC)
Minoru Fukuda, Nagasaki University Hospital, Japan

P2.12-08 Surprisingly Promising Tumor Control Rate of S1 Combination with Anlotinib with Refractory Relapsed SCLC Who Failed ≥ 2 Lines Chemotherapy
Haihua Yang, Radiation Oncology Institute of Enze Medical Health Academy, Affiliated Taizhou Hospital of Wenzhou Medical University, China

P2.12-09 Phase 2 Study of Talazoparib Plus Low-Dose Temozolomide in Patients with Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer
Jonathan Goldman, David Geffen School of Medicine, University of California, Los Angeles, United States of America

P2.12-10 The Circular RNA cESRP1 Sensitizes Small Cell Lung Cancer to Chemotherapy
Linlang Guo, Zhujiang Hospital, Southern Medical University, China

P2.12-11 Quality of Life in ALTER1202 Trial of Anlotinib as Third- or Further Line Therapy for Advanced Small Cell Lung Cancer (SCLC): A Post-Hoc Analysis
Kai Li, Tianjin Cancer Hospital, China

P2.12-12 Nomograms to Predict Survival in Patients with Limited Stage Small Cell Lung Cancer Treated with Definitive Chemoradiotherapy
Junmiao Wen, Fudan University Shanghai Cancer Center, China

P2.12-13 Lurbinectedin (L) Combined with Paclitaxel (P) or Irinotecan (I) in Relapsed SCLC. Results from Two Phase Lb Trials
Santiago Ponce, Hospital Universitario 12 de Octubre, Spain

P2.12-14 A Pilot Study of Serial Plasma Metabolomics in Small Cell Lung Cancer Patients
Se-Hoon Lee, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea, Republic of

P2.12-15 The Role of Surgery in Patients with Small Cell Lung Cancer: A Period Propensity Score Matching Analysis of the SEER Database, 2010-2015
Xiaojun Du, The Affiliated Hospital of Guizhou Medical University, China

P2.12-16 Changes of Peripheral Blood sPD-L1 in Patients with Small Cell Lung Cancer During Chemotherapy and Its Clinical Significance
Hao Tian, Shanxi Medical University, China

P2.12-17 Treatment Patterns in Small Cell Lung Cancer (SCLC): An Observational Study of 2016-2018 EHR Data
Katarina Öhrling, Amgen (Europe) GmbH, Switzerland

P2.12-18 Prevalence of DLL3 Expression and Its Prognostic Role in Extensive Stage Small Cell Lung Cancer
Minhee Hong, Wonju Severance Christianity Hospital, Korea, Republic of

P2.12-19 Small Cell Lung Cancer (SCLC) Treatment and Survival in Portugal: An IPO-PORTE Study from the I-O Optimise Initiative
Marta Soares, Portuguese Institute of Oncology, Portugal

P2.12-20 NRG Oncology/Alliance LU005: A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab in LS-SCLC
Kristin Higgins, Winship Cancer Institute, Emory University, United States of America

P2.12-21 Outcomes with Immune Checkpoint Inhibitors (ICI) for Relapsed Small Cell Lung Cancer (SCLC) in a Swiss Cohort
Laetitia Mauti, Kantonsspital St. Gallen, Switzerland

P2.12-22 Risk Factors for BM Incidence in SCLC: A Predictive Model for SCLC Patients on Brain Metastasis
Jiexia Zhang, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, China

P2.12-23 Radiological Features of SCLC-Like and NSCLC-Like Large Cell Neuroendocrine Carcinoma (LCNEC)
Bregtje Hermans, Maastricht University, Netherlands

P2.12-24 Underutilization of Surgery for Localized Small Cell Lung Cancer: A Nationwide Analysis
Kaushal Parikh, Mayo Clinic, United States of America

P2.12-25 Surgical Management of Pulmonary Carcinoid ≤3cm: Extent of Resection and Lymph Nodes Examination
Yang Wo, Affiliated Hospital of Qingdao University, China

P2.12-26 The Impact of Anlotinib for Relapsed SCLC Patients with Brain Metastases: A Subgroup Analysis of ALTER 1202
Ying Cheng, Jilin Cancer Hospital, China

P2.13 10:15 – 18:15 STAGING Exhibit Hall

Track(s): Staging
P2.13-04 Molecular Nodal Restaging Based on Embryonic Markers Expression Adds No Relevant Clinical Information in Resected Lung Cancer
Ivan Macia, Hospital Universitari de Bellvitge, Spain

P2.13-05 Endobronchial Ultrasound for Mediastinal Restaging in Non-Small Cell Lung Cancer
Sonia Baeza Mena, Hospital Universitari Germans Trias i Pujol, Spain

P2.13-06 Finding a Place for Pathological Near Complete Response Patients Following Neoadjuvant/Induction Therapy in the TNM Staging
Hüseyin Melek, Uludag University, Turkey

P2.13-07 CT Staging for Suspected Lung Cancer; Should We Routinely Image the Pelvis?
Elizabeth Barclay, Manchester University NHS Foundation Trust, United Kingdom

P2.13-08 Which is the Reliable Prognosticator for Early Metastasis and Recurrence of Non-Small Cell Lung Cancer, Related with STAS?
Soo-Youn Ham, Kangbuk Samsung Hospital, Korea, Republic of

P2.13-09 The Impact of the 8th Edition of IASLC Staging in Patients Who Underwent Surgical Treatment of Lung Cancer
Mariana Soares, Instituto do Câncer do Estado de São Paulo, Brazil

P2.13-10 Lymph Node Upstaging Evaluation After Robotic Resection for NSCLC in Brazil
Ricardo Terra, Cancer Institute, University of São Paulo, Brazil

P2.13-11 Predicting Micrometastasis in Mediastinal Lymph Nodes in Patients with Non-Small Cell Lung Cancer
Suat Ersu, Koç University School of Medicine, Turkey

P2.13-12 Endobronchial Ultrasound for Diagnosis and Staging of Lung Cancer: Our Experience
Angela De Palma, Section of Thoracic Surgery, University of Bari, Italy

P2.13-13 The Utility of Three-Dimensional CT for Prediction of Tumor Invasiveness in Clinical IA Lung Adenocarcinoma
Yohei Kawaguchi, Cancer Institute Hospital of JFCR, Japan

P2.14-01 Real World Treatment Outcomes in Chinese Patients with RET-Rearranged Lung Cancer
Lu Yang, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China

P2.14-02 Interim Survival Analysis of Gefitinib Plus Vinorelbine in Advanced EGFR-Mutant Non-Small Cell Lung Cancer (Genoa Trial)
Carlo Genova, IRCCS Ospedale Policlinico San Martino, Italy

P2.14-03 Predictive Factors of Osimertinib as Salvage Treatment for Metastatic EGFR T790M Positive Lung Adenocarcinoma
Seung Hun Jang, Department of Pulmonary, Allergy and Critical Care Medicine, Hallym University Sacred Heart Hospital, Korea, Republic of

P2.14-04 Clinical Validation of Large NGS Gene Panel Using Residual Specimen
Tomohiro Sakamoto, Tottori University Hospital, Japan

P2.14-05 EGFR Mutation Status and Prognostic Impact in Patients with Surgically Resected Lung Adenocarcinoma
Yoshimasa Tokunaga, Kochi Health Sciences Center, Japan

P2.14-06 The Study of Rac3 Molecular Mechanism Through ERK Signaling Pathway in Lung Adenocarcinoma
Hongxu Liu, Liaoning Cancer Hospital & Institute, China

P2.14-07 Efficacy of Single Bevacizumab Intrapleural or Intrapercardial Injection in the Treatment of Lung Cancer-Mediated Malignant Effusion
Dongyun He, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, China

P2.14-08 Banf1 Predicts Lung Cancer Survival and Sensitivity to Platinum-Based Chemotherapy
Kenneth O’byrne, Institute of Health and Biomedical Innovation, Queensland University of Technology Translational Research Institute, Australia

P2.14-09 Concurrent TP53 Mutation Adversely Impact the Efficacy of Crizotinib in ROS1-Rearranged Lung Cancer Patients
Gen Lin, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, China

P2.14-10 Identification of Frequent, Activating HER2 Mutations and HER2 Inhibitor Response and Resistance in Canine Lung Cancer
William Hendricks, TGen, United States of America

P2.14-11 Retreatment with EGFR-TKI for S41 NSCLC Patients with EGFR Mutation
Kosuke Takahashi, Anjo Kosei Hospital, Japan

P2.14-12 Tyrosine Kinase Inhibitor Resistance Mechanisms in EGFR T790M-Positive Lung Cancer: The University of Chicago Experience
Garth Stroehbehn, University of Chicago, United States of America

P2.14-13 Elevated Expression of Eukaryotic Translation Initiation Factor 3 Subunit C Contributes to EGFR-TKI Resistance in Lung Adenocarcinoma
Takuya Shintani, Osaka University Hospital, Japan

P2.14-14 Comparison of Molecular Testing Modalities for Detection of NRG1 Rearrangements in Invasive Mucinous Adenocarcinoma
Federico Fabrizio, Fondazione IRCCS Càs Sollièvo della Sofferenza Hospital, San Giovanni Rotondo, Italy

P2.14-15 Impact of Coexisting Gene Mutations in EGFR-Mutated Non-Small Cell Lung Cancer Before Treatment on EGFR T790M Mutation Status After EGFR-TKIs
Masayuki Takeda, Kindai University Faculty of Medicine, Japan

P2.14-16 T790M or C797S Confers Acquired Resistance to Tarloxotinib and Poziotinib in EGFR Exon 20 Insertion-Driven Lung Cancer Models in Vitro
Kenichi Suda, Kindai University Faculty of Medicine, Japan

P2.14-17 Correlation Between Clinic-Pathological Data and T790M Detection in EGFR Mutated NSCLC Patients Progressing on 1st/2nd Generation TKIs
Chiara Paratore, University of Turin; San Luigi Gonzaga Hospital, Italy

P2.14-18 Upregulation of AURKA Leads to Acquired Resistance in EML4-ALK NSCLC Cell Line
Ganesh Umaphatny, Gothenburg University, Sweden

P2.14-19 Notch3 and β-Catenin Are Frequently Co-Expressed in EGFR Mutant NSCLC
Rajeswara Rao Arasada, The Ohio State University, United States of America
P2.14-20 ATORG-003: Dacomitinib With or Without Dose Titration as First-Line Therapy for Metastatic EGFR Mutant Non-Small Cell Lung Cancer (NSCLC)
Aaron Tan, National Cancer Centre Singapore, Singapore

P2.14-21 Liquid Biopsy in Lung Cancer: Comparison Between Real-Time PCR and MALDI-TOF for ctDNA Molecular Profiling
Pierre-Jean Lamy, Institut d'Analyse Genomique, France

P2.14-22 Loss of Ect2 Expression Impairs Cell-Matrix Adhesion and FAK/Src Signaling in Lung Adenocarcinoma Cells
Zeinab Kosi Baty, University of Tsukuba, Japan

P2.14-23 Initial Analysis in NSCLC Part of Randomized Trial Evaluating Topical Corticosteroid for the Facial Acneiform Rash by EGFR Inhibitors
Yutaka Fujiwara, Mitsui Memorial Hospital, Japan

P2.14-24 An Open-Label Randomized Phase II Study of Combining Osimertinib With and Without Ramucirumab in TKI-Naïve EGFR-Mutant Metastatic NSCLC
Xiuning Le, MD Anderson Cancer Center, United States of America

P2.14-25 Lorlatinib Induced Protective Autophagy via the AKT-mTOR Pathway in ALK-Rearranged Lung Cancer Cells
Conghua Lu, Daping Hospital of Army Medical University, PLA, China

P2.14-26 Outcomes in Patients with Compound Epidermal Growth Factor Receptor (EGFR) Mutations After Treatment with Tyrosine Kinase Inhibitors (TKIs)
Sean Breslin, Hospital of the University of Pennsylvania, United States of America

Guilan Dong, Tangshan People's Hospital, China

P2.14-28 Real-World Management and Outcomes of Uncommon EGFR Mutation-Positive NSCLC Patients at Two Tertiary Canadian Cancer Centres
Gwyn Bebb, Alberta Health Services, Canada

P2.14-29 Clinical Impact of Next-Generation Sequencing (NGS) in Blood Liquid Biopsies for Treatment Decisions in Advanced NSCLC
Antonio Calles Blanco, Hospital General Universitario Gregorio Marañon, Spain

P2.14-30 Predictive Value of ctDNA in Patients with EGFR Positive NSCLC Receiving 3rd Generation TKI
Mariya Stepanova, St. Petersburg Clinical Research Center of Specialized Types of Care (Oncology), Russian Federation

P2.14-31 Melatonin Inhibits Proliferation and Invasion Through Downregulating CircRNA NID1 in Non-Small Cell Lung Cancer Cells
Yang Wo, Affiliated Hospital of Qingdao University, China

P2.14-32 Epigenetic Silencing of SPARC in NSCLC
Federico Fabrizio, Fondazione IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy

P2.14-33 An Open-Label PET-MRI Study to Determine Brain Exposure of Osimertinib in Patients with EGFR Mutant NSCLC and CNS Metastases
Simon Ekman, Karolinska University Hospital, Sweden

P2.14-34 Tyrosine-Kinase Inhibitors (TKI) in First-Line Treatment of 470 Patients with Non-Small Cell Lung Cancer (NSCLC) from the Czech Republic
Jana Skřišková, Department of Respiratory Diseases and TB, Faculty of Medicine, Masaryk University, and University Hospital, Czech Republic

P2.14-35 2-Deoxy-D-Glucose Sensitizes Non-Small Cell Lung Cancer with EML4-ALK Fusion to Crizotinib via Suppression of HK2 Through AKT/mTOR Pathway
Caiyu Lin, Daping Hospital of Army Medical University, China

P2.14-36 Identification of Genomic Features in Tumor-Derived Organoids from Resectable NSCLC
Jing-Hua Chen, Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, China

P2.14-37 Anaplastic Lymphoma Kinase Inhibitor Induced Pneumonitis in Patients with NSCLC: Clinical and Radiologic Characteristics and Risk Factors
Mi Young Kim, University of Ulsan College of Medicine, Asan Medical Center, Korea, Republic of

P2.14-38 ATAD2B-ALK, a Novel Fusion in Lung Adenocarcinoma Identified Using Next-Generation Sequencing (NGS)
Hao Wu, Department of Thoracic Surgery, Peking University Shenzhen Hospital, China

P2.14-39 Effects of Renal Function on Lorlatinib Safety and Pharmacokinetics
Swan Lin, Pfizer, United States of America

P2.14-40 Tumor-Stromal Microenvironment Interactions in a PDX Model of EGFR TKI Drug Tolerance
Erin Stewart, University Health Network, Canada

P2.14-41 Risk Factors for Brain Metastasis in Patients with EGFR Mutant Non-Small Cell Lung Cancer
Takehiro Tozuka, Nippon Medical School, Japan

P2.14-42 Emergence of CCDC6-RET Fusion with Maintained EGFR T790M Mutation After Resistance to Osimertinib in NSCLC: A Case Report
Yi Guo, Shanxi Cancer Hospital, China

P2.14-43 Cost-Effectiveness of 1st-Line Treatment EGFR-TKIs for Advanced NSCLC Patients Harboring EGFR Mutation in Mexico
Laura Alejandro Ramirez Tirado, Instituto Nacional de Cancerologia (INCan), Mexico

P2.14-44 Tumor Mutation Burden and Efficacy of Molecular Targeted Therapy in Lung Cancer
Katsunori Arai, Tottori University Hospital, Japan

P2.14-45 EML4-ALK Fusion Subtype is Associated with Therapeutic Efficacy in Advanced Non-Small Cell Lung Cancer
Huijuan Wang, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, China

P2.14-46 Treatment Observations and Clinical Experience with Lorlatinib in Pretreated ALK and ROSI Rearranged NSCLC Patients
Maximilian J Hochmair, Department of Respiratory and Critical Care Medicine, and Ludwig Boltzmann Institute of COPD and Respiratory Epidemiology, Otto Wagner Hospital, Austria

P2.14-47 Real-World Multicenter Experience of First-line Apatinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer
Chong Kin Liam, University of Malaya, Malaysia

P2.14-48 Clinical Sequencing Using a NGS-Based Multiple Gene Assay in Patients with Non-Small Cell Lung Cancer
Zhengwei Dong, Amoy Diagnostics Co., Ltd., China

P2.14-49 Molecular Characteristics of HER2 Mutations in Non-Small Cell Lung Cancer
Xuewu Wei, Guangdong Lung Cancer Institute, China
P2.14-50 Low Temperature Plasma Needle Induces Cell Cycle Arrest of Epithelial Lung Cancer Cells in Vitro via a p21-Dependent Pathway
Milena Cavic, Institute for Oncology and Radiology of Serbia, Serbia

P2.14-51 Dual ALK Fusion Partners as Poor Predictive Marker in First Line Crizotinib Treated ALK Rearranged Non-Small Cell Lung Cancer
Yongchang Zhang, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, China

P2.14-52 The Results from Plasma EGFR Mutation Analysis in NEJ026 Study
Tatsuro Fukuhara, Miyagi Cancer Center, Japan

P2.14-53 High MET Overexpression Does Not Predict the Presence of MET Exon 14 Splice Mutations in NSCLC: Results from the IFCT Predict.amm Study
Simon Baldacci, Lille University Hospital, France

P2.14-54 High Incidence of CNS Metastases in Advanced or Recurrent Non-Small Cell Lung Cancer Patients with RET Fusion
Jiyn Lee, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea, Republic of

P2.14-55 Real-World Safety and Efficacy Data of Osimertinib in Patients from Japan with EGFR T790M-Positive NSCLC
Yuichiro Ohe, National Cancer Center Hospital, Japan

P2.14-56 Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of EML4-ALK Lung Cancer
Sachiko Arai, Cancer Research Institute Kanazawa University, Japan

P2.14-57 Efficacy of 3rd Generation EGFR-TKIs After Failing First or Second Generation EGFR-TKIs in EGFR Mutation-Positive NSCLC (ROOT-EGFR)
Hyun Ae Jung, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea, Republic of

P2.14-58 A Phase Illb, Open-Label Study of Aftatinib in Caucasian EGFR TKI-Naïve Patients with EGFRm+ NSCLC: An Interim Analysis
Maximilian J Hochmair, Department of Respiratory and Critical Care Medicine, and Ludwig Boltzmann Institute of COPD and Respiratory Epidemiology, Otto Wagner Hospital, Austria

P2.14-59 Osimertinib in EGFR T790M Advanced NSCLC: Analysis of Uncommon/Complex EGFR Mutations in a Real-World Study (ASTRIS)
Parneet Cheema, University of Toronto, Canada

P2.14-60 Aftatinib in EGFR Mutation-Positive NSCLC: Activity in Patients with Brain Metastases, and Impact on CNS Progression/Spread
Kenneth O’byrne, Institute of Health and Biomedical Innovation, Queensland University of Technology Translational Research Institute, Australia

P2.14-61 Acquired Resistance to Entrectinib Associated with Activation of RAS Signaling Pathway in ROS1-Rearranged Non-Small Cell Lung Cancer
Bo Mi Ku, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea, Republic of

P2.14-62 Early, Subclinical SCLC Transformation in Patients with EGFR Mutant Lung Cancer Receiving Osimertinib, Detected Through Cell-Free DNA
Erin Stewart, University Health Network, Canada

P2.14-63 Cost Analysis of the Management of CNS Metastases in Patients with Advanced ALK+ NSCLC: Alectinib vs Crizotinib
Bartomeu Massuti, Hospital General Universitario de Alicante, Spain

P2.14-64 Is ALK Inhibitor a Contraindication for Subsequent IVF Pregnancy?
Roní Gillis, Ben Gurion University of the Negev, Israel

P2.14-65 Efficacy of Dabrafenib Plus Trametinib Combination in Patients with BRAF V600E-Mutant NSCLC in Real World Setting
Jean Bernard Auliac, Centre Hospitalier Inter Communal de Créteil, France

P2.14-66 Combination ALK and MEK Inhibition in ALK-Positive Lung Cancer
John Ashton, University of Otago, New Zealand

P2.14-67 Metastatic RET-Rearranged Lung Adenocarcinomas Treated with Alectinib: Retrospective Analysis of a Single Institution
Mauricio Ribeiro, Hospital Sirio-Libanês, Brazil

P2.14-68 Dramatical Intracranial Response to Osimertinib in Patient Harbouring the Uncommon EGFR G719S/L861Q Mutation
João Victor Alessi, Hospital Sirio-Libanês, Brazil

P2.14-69 Lorlatinib Rescue Therapy for Life Threatening CNS Disease in Crizotinib-Resistant ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)
Aaron Franke, Moffitt Cancer Center, United States of America
P2.15-09 Clinical Features and Prognosis of Primary Tracheal Cancer at Our Institution’s Experience
Yoshiyuki Mishina, Kanagawa Cardiovascular and Respiratory Center, Japan

P2.15-10 Clinical Significance of Age at Diagnosis Among Patients with Thymic Epithelial Tumor
Mina Liu, Department of Radiation Oncology, China

P2.15-11 Favorable Long Term Survival After Initially Palliative Resection for a Giant Primary Rib Osteosarcoma with Severe Mediastinal Shifting
Katharina Sinn, Medical University of Vienna, Austria

P2.15-12 Epidemiology of Thymic Epithelial Tumors: 22-Year Experience from a Single-Institution
Patricia Rioja, Instituto Nacional de Enfermedades Neoplasicas, Peru

P2.15-13 The Role of Adjuvant Therapy for Atypical Bronchopulmonary Carcinoids: A Population-Based Analysis
Rodney Wegner, Allegheny Health Network, United States of America

P2.16

10:15 – 18:15 TREATMENT IN THE REAL WORLD - SUPPORT, SURVIVORSHIP, SYSTEMS RESEARCH

Track(s): Treatment in the Real World - Support, Survivorship, Systems Research

P2.16-01 Risk Factors for Short-Term Post-Operative Events Following Lung Resection
Wil Lieberman-Cribbin, Icahn School of Medicine at Mount Sinai, United States of America

P2.16-02 Randomising Patients into Trials of Thoracic Cancer Surgery: An Analysis of Patient and Cancer Team Behaviour in Practice
Michael Shackcloth, Liverpool Heart and Chest Hospital, United Kingdom

P2.16-03 IELCART Quality of Life in the First Year After Surgery for Stage IA Lung Cancer Patients: Preliminary Results
Esther Fevrier, Mount Sinai Ichac School of Medicine, United States of America

P2.16-04 Single-Port Video-Assisted Thoracoscopic Surgery Reduces Patient-Reported Symptom Burden in Patients Undergoing Lung Resection
Qiang Li, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China

P2.16-05 Population-Based ROS1 Testing in Lung Cancer: Creating Opportunity in a Publicly Funded System
Maisam Makarem, University of Toronto, Canada

P2.16-06 Molecular Features and Treatment Outcome of HER2 Mutated Advanced Non-Small Cell Lung Cancer Patients in China
Fei Xu, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China

P2.16-07 How to Manage Toxicities of EGFR-TKI for Extreme Elderly Lung Cancer Patients: Supportive Care for Patients Aged 85 and Older
Yoshitaka Seki, The Jikei Daisan Hospital, Tokyo, Japan, Japan

P2.16-08 Clinical Characteristics and Outcomes of Patients with BRAF Mutated Non-Small Cell Lung Cancer
Yuxin Mu, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China

P2.16-09 Real-World Brigatinib Use in Non-Small Cell Lung Cancer Patients with Prior Use of Crizotinib/Other ALK Therapies in the US
Huamao Lin, Takeda, United States of America

P2.16-10 Advances in Diagnosis and Treatment of Non-Small Cell Lung Cancer Are Translating into Real-World Survival Gains in the United States
Oladimeji Akinboro, Boston University Medical Center, United States of America

P2.16-11 ADVANCE-1: Development and Feasibility Testing of a Benchmarking Approach for Quality Improvement in Lung Cancer Care
Brendan Mccann, Beatson West of Scotland Cancer Centre, United Kingdom

P2.16-12 Treatment Uptake and Outcomes of Elderly Stage III NSCLC Patients: A 15-Year Retrospective Real-World Study
Amanda Gibson, University of Calgary, Canada

P2.16-13 Risk Factors of Radiation Pneumonitis in Lung Cancer Patients with Subclinical Interstitial Lung Disease After Thoracic Radiotherapy
Fangjuan Li, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China

P2.16-14 Survival Rates in Non-Small Cell Lung Cancer Patients in the Brazilian Private Health System: A Cohort Study
Carlos Gil Ferreira, Oncoclinicas, Brazil

P2.16-15 Survival and Clinical Immunotherapy Outcomes in Hispanic Patients vs Non-Hispanic White Patients with Non-Small Cell Lung Cancer
Luis Raez, Memorial Cancer Institute/Florida International University, United States of America

P2.16-16 Calf Circumference Is Associated with Postoperative Outcomes in Lung Cancer Patients Who Underwent Surgery
Akihiro Nagoya, Osaka University Graduate School of Medicine, Japan

P2.16-17 Real-World Trends in Systemic Therapy for Nonsquamous EGFR/ALK-Negative Advanced NSCLC (aNSCLC) in the US, 2011–2018
Vamsidhar Veitcheti, New York University, United States of America

P2.16-18 Opioid-Induced Constipation in Patients with Cancer Pain in Japan (OIC-J study): A Post-Hoc Analysis of Lung Cancer Patients
Hisao Imai, Gunma Prefectural Cancer Center, Japan

P2.16-19 Real World Data in Non-Small Cell Lung Cancer with Activating EGFR Mutation - A Multicenter Observational Study
Madoka Kimura, Osaka International Cancer Institute, Japan

P2.16-20 Big Data and Survival Predictors in Lung Cancer Patients
Beatriz Núñez-Garcia, Puerta de Hierro, Spain

P2.16-21 Effects of Molecular Markers on Responses, Relapses, and Survival in Lung Cancer Patients with HIV
Neha Reddy, Northwestern University Feinberg School of Medicine, United States of America

P2.16-22 Predictive Analytic of Survival Using a Neural Network in a Real World Cohort of Advanced Non Small Cell Lung Cancer Patients
Luis Pino, Fundacion Santafe, Colombia
P2.16-23 Rates of Support and Care Offerings Among Patients in an Advocacy Organization Sponsored Lung Cancer Patient Registry
Andrew Ciupek, GO2 Foundation for Lung Cancer, United States of America

P2.16-24 Prognostic Value of RDW, NLR and CYFRA 21-1 in Overall Survival of Patients with Metastatic NSCLC
Claudio J Flores, Oncosalud, Peru

P2.16-25 Epidemiology of Advanced Lung Cancer in Peru
Luis Mas, National Cancer Institute Peru, Peru

P2.16-26 Opportunity of WBRT in EGFR-Mutated Lung Adenocarcinoma Patients with Multiple Brain Metastases: A Retrospective Study Based on DS-GPA
Jindong Guo, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

P2.16-27 Longitudinal Skeletal Muscle Changes in Patients with Advanced Squamous Cell Lung Cancer
Young Saing Kim, Gachon University Gil Medical Center, Korea, Republic of

P2.16-28 Retrospective Analysis of Patients with Previous Extrathoracic Malignancies After Resection of Non-Small Cell Lung Cancer
Ami Wada, Japanese Red Cross Medical Center, Japan

P2.16-29 Lung Cancer in Lleida: An Epidemiologic Study
Joel Veas, Hospital Universitari Arnau De Vilanova, Spain

P2.16-30 Real World Data of Targeted Therapy Versus Chemotherapy Maintenance Among Patients with III-IV Clinical Stage Lung Cancer at Oncosalud - AUNA
Alfredo Aguilar, Oncosalud - AUNA, Peru

P2.16-31 Immunotherapy in the Regional Setting: Real World Experience of Outcome and Toxicity
Mike Nguyen, Austin Health, Australia

P2.16-32 Best Supportive Care for Extreme Elderly Lung Cancer Patients
Taisuke Kazuyori, The Jikei Daisan Hospital, Japan

P2.16-33 What Influences Patient Decision-Making About Lung Cancer Treatment? A Discrete Choice Experiment
Fiona Hegi-Johnson, Peter MacCallum Cancer Centre, Australia

P2.16-34 Is Prophylactic Cranial Irradiation Useful in Real World?
Beatriz Núñez-García, Puerta de Hierro, Spain

P2.16-35 Factors Associated with Prolonged Postoperative Hospital Stay in Patients Undergoing Lung Cancer Surgery
Wei Dai, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, China

P2.16-36 Patterns of Care in a Prospective Clinical Cohort of Patients with Lung Cancer - Preliminary Analyses from the EnRICH Program
Bea Brown, University of Sydney, Australia

P2.16-37 Impact of Brain Metastases on Healthcare Utilisation and Costs in Patients with NSCLC Treated with EGFR-TKIs
Deepa Subramaniam, Georgetown Lombardi Comprehensive Cancer Center, MedStar Georgetown University Medical Center, United States of America

P2.16-38 Efficacy and Safety of Target Therapy and Immunotherapy in Advanced NSCLC in Elderly: A Systematic Review of Real World Studies
Tindara Franchina, University of Messina, Italy

P2.16-39 The Association Between Dietary Protein Intake and the Risk of Lung Cancer: A Meta-Analysis
Chunwei Xu, Fujian Cancer Hospital, China

P2.16-40 Acknowledging Social and Economic Inequities Experienced by Canada’s Inuit: Implications for Diagnosis and Treatment of Lung Cancer
Chantal Bornais, The Ottawa Hospital, Canada

P2.16-41 Pembrolizumab for Previously Treated, PD-L1-Expressing Advanced NSCLC: Real-World Time on Treatment and Overall Survival
Vamsidhar Velcheti, New York University, United States of America

P2.16-42 The Use of a Smartphone Application Improves Postoperative Outcomes in Patients Undergoing Lung Cancer Resection
Carlos Fraile Oliveto, Hospital Universitari Arnau de Vilanova, Spain

P2.16-43 Immunotherapy in Elderlies. Real World Data
Luis Felipe Sánchez-Cousido, Complejo Asistencial Universitario de León, Spain

P2.16-44 Real-World Treatment Patterns and Outcomes in ALK+ NSCLC Patients Receiving Immuno-Oncology Therapy in the United States
Huamao Lin, Takeda, United States of America

P2.17
10:15 – 18:15 TREATMENT OF EARLY STAGE/LOCALIZED DISEASE

Track(s): Treatment of Early Stage/Localized Disease

P2.17-01 Analysis of Clinical Features and Prognosis of Non-Small Cell Lung Cancer Exceeding 30 mm Depending on the Ground Glass Opacity (GGO) Ratio
Atsushi Kagimoto, Hiroshima University Hospital, Japan

P2.17-02 Survival in Performance Status 3 Non-Small Cell Lung Cancer Patients Receiving Radical Radiotherapy
Roya Behrouzi, Manchester University NHS Foundation Trust, United Kingdom

P2.17-03 Surgical Outcomes of Repeated Anatomical Pulmonary Resection for the Ipsilateral Second Lung Cancers
Aritoshi Hattori, Juntendo University, Japan

P2.17-04 Role of Lymphadenectomy in Thoracoscopic Lobectomy for Non-Small Cell Lung Cancer
Samina Park, Seoul National University Hospital, Korea, Republic of

P2.17-05 Feasibility Study of Adjuvant Chemotherapy with Carboplatin and Nab-Paclitaxel for Completely Resected NSCLC
Naoko Katsurada, Kobe University Graduate School of Medicine, Japan

P2.17-06 Analysis of Left Atrial Blood Flow Using 4D Flow MRI in the Patient Who Suffered from Cerebral Infarction After Left Upper Lobectomy
Mitsuo Matsumoto, Nippon Medical School Hospital, Japan

P2.17-07 Role of Adjuvant Chemotherapy After Sublobar Resection in Stage I NSCLC
Samina Park, Seoul National University Hospital, Korea, Republic of

P2.17-08 Ethanol Release Heat-Generating Polymer for Focal Therapy of Small Lung Cancers Under Open MRI
Junichi Shimada, Kyoto Prefectural University of Medicine, Japan
P2.17-09 Preoperative Risk Factors of Potential Failure for Lobe-Specific Nodal Dissection in Clinical Early Stage (I-IIA) Non-Small Cell Lung Cancer
Jae Kwang Yun, Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, Korea, Republic of

P2.17-10 Effects of the Omega-6/Omega-3 Ratio on Postoperative Complications After Lung Resection: Preliminary Results
Carlos Deniz, Hospital Universitari de Bellvitge, Spain

P2.17-11 Evaluating PD-L1 as a Prognostic Biomarker in Surgically Resectable Non-Small Cell Lung Cancer
Stephanie Tuminello, Icahn School of Medicine at Mount Sinai, United States of America

P2.17-12 Robotic Assisted Segmentectomy - Intravenous vs Intrabronchial Fluorescence Thoracoscopy to Identify the Intersegmental Plane
Styliani Maria Kolokotroni, St Bartholomew’s Hospital, Barts Health NHS Trust, United Kingdom

P2.17-13 Thoracoscore Fails to Predict In-Hospital Mortality Following Elective Surgery in a Brazilian Lung Cancer Cohort
Eliza Ricardo, Hospital Alemão Oswaldo Cruz, Brazil

P2.17-14 Impaired Immune Defense in Tumor Micro-Environment Is Associated with Risk of Recurrence in Early Stage Lung Adenocarcinoma
Yanyan Lou, Mayo Clinic, United States of America

P2.17-15 Clinical Features and Prognosis of Lung Cancer with Cavity Lesion
Hiromichi Okuma, Hyogo Cancer Center, Japan

P2.17-16 Genomic Heterogeneity and Evolutionary Trajectory in Multifocal Synchronous Lung Cancer
Si-Yang Liu, Guangdong Provincial People’s Hospital, China

P2.17-17 Clinical Effect of Adjuvant Chemotherapy on Stage IB NSCLC with High-Risk Factors
Juwhan Choi, Korea University Guro Hospital, Korea, Republic of

P2.17-18 Acute Respiratory Distress Syndrome After Curative Surgical Resection for Lung Cancer
Deoggon Cho, St. Vincent Hospital, Korea, Republic of

P2.17-19 Quality of Life After Pulmonary Stereotactic Fractionated Radiotherapy: Longterm Results of the Phase II STRIPE Trial
Eleni Gkika, University Medical Center, Germany

P2.17-20 A Radiomic Approach to Predict Nodal and Distant Relapse in Patients Treated with Stereotactic Body Radiation Therapy for Early Stage NSCLC
Davide Franceschini, Humanitas Clinical and Research Centre, Italy

P2.17-21 A Post-Hoc Analysis of TROG 09.02 (CHISEL) Phase III Trial Investigating Pulmonary Function Changes After SABR and Conformal Radiation Therapy
Nicholas Bucknell, Peter MacCallum Cancer Centre, Australia

P2.17-22 Retrospective Analysis of Spread Through Air Spaces and Other Features in Patients with Stage IA Adenocarcinoma by the 8th TNM Classification
Keita Nakao, university of Tokyo, Japan

P2.17-23 The Role Adjuvant Chemotherapy in Resected Stage I NSCLC with High Risk Factors: A Turkish Oncology Group Study
Yesim Eraip, Istanbul University, Institute of Oncology, Turkey

P2.17-24 Minimally Invasive Surgery for Lung Cancer Improves Short Term Outcomes in Patients with History of Head and Neck Carcinoma
David Boulou, Hospital Marie Lannelongue, France

P2.17-25 Genomic Insight into Stage I Pulmonary Adenocarcinoma for Recurrence by Targeted Next-Generation Sequencing Analysis
In Ae Kim, Konkuk University Medical Center, Korea, Republic of

P2.17-26 Indocyanine Green Virtual Assisted Lung Mapping (ICG-VAL-MAP): Anyone Can Perform a Successful Preoperative Marking for a Small Lung Nodule
Toyofumi Chen-Yoshikawa, Kyoto University Hospital, Japan

P2.17-27 Evaluation of Mediastinal Lymphadenectomy Quality in Patients Operated for NSCLC from the Paulista Lung Cancer Registry(PLCR)
Leticia Lauricella, Instituto do Cancer do Estado de Sao Paulo, Brazil

P2.17-28 Examination of the Indication and Validity of Segmental Resection as Intentional and Palliative Limited Resection for Lung Cancer
Katsuo Kojima, Karatsu Red-Cross Hospital, Japan

P2.17-29 Impact of Second Predominant Pattern on Recurrence in Early Stage Resected Lung Adenocarcinoma: A Multicentric Study
Pietro Bertoglio, IRCCS Sacro Cuore Don Calabria Hospital, Italy

P2.17-30 Superior Vena Cava Resection and Prosthetic Replacement for NSCLC: Is It Worthwhile?
Josephine Chenesseau, Hospital Marie Lannelongue, France

P2.17-31 Central Lung Tumors Treated with Stereotactic Radiotherapy. Toxicity and Early Results in a Single Institution
Miriam Nuñez, Consorci Sanitari de Terrassa, Spain

P2.17-32 Using Next-Generation Sequencing to Identify Genetic Predictors of Local Failure After Lung Stereotactic Body Radiation Therapy
Victor Ng, Memorial Sloan Kettering Cancer Center, United States of America

P2.17-33 Deterioration in Health-Related Quality of Life Is Associated with Lower Lung Resection Rates in Older Adults
Andrew Blakely, City of Hope National Medical Center, United States of America

P2.17-34 Integrated Clinico-Radiomic Nomogram for Predicting Disease-Free Survival (DFS) in Stage I and II Non-Small Cell Lung Cancer
Kaustav Bera, Case Western Reserve University, United States of America

P2.17-35 Integrating CT Radiomic & Quantitative Histomorphometric Whole Slide Image Features Predicts Disease Free Survival in ES-NSCLC
Pranjal Vaidya, Case Western Reserve University, United States of America

P2.17-36 Molecular Markers, Therapeutic and Prognostic Analysis of Lung Sarcomatoid Carcinomas
Wenhua Liang, Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University; State Key Laboratory of Respiratory Disease; National Clinical Research Center for Respiratory Disease, China

P2.17-37 Prognostic Implication of Surgical Treatment for the Dominant Lung Adenocarcinoma Associated with Part-Solid Nodules
Yoowha Hwang, Seoul National Bundang Hospital, Korea, Republic of

P2.17-38 Predictive Factors for Lymph Node Metastasis in Patients with Clinical Stage I Part-Solid Lung Adenocarcinoma
So Young Lee, Seoul National University Bundang Hospital, Korea, Republic of
P2.17-39 Relationship Between EGFR Mutation and Pathological Differentiation in Patients with Clinical Stage IA Lung Adenocarcinoma
Junichiro Osawa, Tokyo Medical University, Japan

P2.17-40 Analysis of 7 Years Experiences of Uniportal Video-Assisted Thoracic Surgery for Stage I and II Lung Cancer
Do Kyun Kang, Haeundae Paik Hospital, College of Medicine, Inje University, Korea, Republic of

P2.17-41 Treatment Outcomes of Pulmonary Resection in NSCLC Patients with Autoimmune Diseases
Sheta Fukuda, Kindai University Faculty of Medicine, Japan

P2.17-42 Surgical Choice for Clinical Stage IA Non-Small Cell Lung Cancer: Novel Rationale from Intrapulmonary Lymph Node Metastasis Pattern
Han-yu Deng, West China Hospital, Sichuan University, China

P2.17-43 Complete Uniportal Thoracoscopic Anatomic Lung Resection with Systematic Mediastinal Lymphadenectomy for NSCLC
You-Jun Deng, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China

P2.18

10:15 – 18:15 TREATMENT OF LOCOREGIONAL DISEASE - NSCLC

Track(s): Treatment of Locoregional Disease - NSCLC

Exhibit Hall

P2.18-01 A Multicenter, Double-Blind, Randomized, Controlled Study of Bintrafusp Alfa (M7824) in Unresectable Stage III NSCLC
Everett Vokes, University of Chicago Medical Center, United States of America

P2.18-02 Pneumonectomy and Lung Cancer: A Treacherous Combination
Lawek Berzenji, Antwerp University Hospital, Belgium

P2.18-03 Salvage Surgery After Curative-Intent Chemo and/or Radiation for Locally Advanced Lung Cancer
Motohiro Yamashita, National Hospital Organization Shikoku Cancer Center, Japan

P2.18-04 Improved Outcome in Female Stage III NSCLC Diagnoses Is Driven by Non-Curative Intent Treatment, and Adenocarcinoma Histology
Gwyn Bebb, Alberta Health Services, Canada

P2.18-05 Patients with ypN2 NSCLC After Neoadjuvant Chemotherapy Followed by Surgery Can Benefit from PORT – A Retrospective Study of SEER Database
Yongxing Bao, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China

P2.18-06 Trends and Outcomes of Minimally Invasive Approaches for Lung Cancer Resection After Induction Therapy in the United States
Brendon Stiles, New York Presbyterian Hospital-Weill Cornell Medical College, United States of America

P2.18-07 Prognostic Factors Affecting Brain Metastasis-Free Survival in Non-Small Cell Lung Cancer Patients
Deniz Yalman, Ege University Medical School & Hospital, Turkey

P2.18-08 The Necessity and Technique of the Upper Zone Lymph Node Dissection for Non-Small-Cell Carcinoma of the Left Upper Lobe
Toshiya Yokota, Mitsui Memorial Hospital, Japan

P2.18-09 Age Does Not Affect the Benefit of Modern Chemoradiation for LA-NSCLC Patients
Sara Ramella, Campus Bio-Medico University, Italy

P2.18-10 Importance of the Multidisciplinary Tumor Board in the Treatment Strategy of Stage III Non-Small Cell Lung Cancer (NSCLC)
Justin Benet, CHU Grenoble, France

P2.18-11 Real-World Experience of Consolidation Durvalumab for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Alexander Barbaro, Department of Medical Oncology / Montefiore Medical Center, United States of America

P2.18-12 Prognostic Nutrition Index Affects Prognosis of Trimodality Therapy for Locally Advanced Lung Cancer with High T Factor
Junichi Soh, Kindai University Faculty of Medicine, Japan

P2.18-13 Endobronchial Brachytherapy: A Single Institutional Experience
Pere Trias Sabrià, Hospital Universitari de Bellvitge, Spain

P2.18-14 The Role of Surgery in High Grade Neuroendocrine Tumors of the Lung
Mehmet Bedirhan, Yedikule Chest Disease and Thoracic Surgery Hospital, Turkey

P2.18-15 Surgical Outcomes of Pneumonectomy After Induction Therapy for Non-Small-Cell Lung Cancer
Norihito Okumura, Kurashiki Central Hospital, Japan

P2.18-16 VATS Lobectomy and Chest Wall Resection for NSCLC
Hüseyin Melek, Uludag University, Turkey

P2.18-17 Outcome of Surgical Treatment for Clinical N1 Non-Small Cell Lung Cancer
Daiji Nemoto, Kanagawa Cancer Center, Japan

P2.18-18 Impact of Combined Evaluation Using Tumor Volume and Metastatic Nodal Extent in Stage III NSCLC Treated with CRT
Yutaro Tamiya, Nagoya University Hospital, Japan

P2.18-19 Radiological and Pathological Response to the Induction of Surgery in the NSCLC Stage III
Francesc Casas, Hospital Clinic de Barcelona, Spain

P2.17-39 Relationship Between EGFR Mutation and Pathological Differentiation in Patients with Clinical Stage IA Lung Adenocarcinoma
Junichiro Osawa, Tokyo Medical University, Japan

P2.17-40 Analysis of 7 Years Experiences of Uniportal Video-Assisted Thoracic Surgery for Stage I and II Lung Cancer
Do Kyun Kang, Haeundae Paik Hospital, College of Medicine, Inje University, Korea, Republic of

P2.17-41 Treatment Outcomes of Pulmonary Resection in NSCLC Patients with Autoimmune Diseases
Sheta Fukuda, Kindai University Faculty of Medicine, Japan

P2.17-42 Surgical Choice for Clinical Stage IA Non-Small Cell Lung Cancer: Novel Rationale from Intrapulmonary Lymph Node Metastasis Pattern
Han-yu Deng, West China Hospital, Sichuan University, China

P2.17-43 Complete Uniportal Thoracoscopic Anatomic Lung Resection with Systematic Mediastinal Lymphadenectomy for NSCLC
You-Jun Deng, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China

P2.18

10:15 – 18:15 TREATMENT OF LOCOREGIONAL DISEASE - NSCLC

Exhibit Hall

P2.18-01 A Multicenter, Double-Blind, Randomized, Controlled Study of Bintrafusp Alfa (M7824) in Unresectable Stage III NSCLC
Everett Vokes, University of Chicago Medical Center, United States of America

P2.18-02 Pneumonectomy and Lung Cancer: A Treacherous Combination
Lawek Berzenji, Antwerp University Hospital, Belgium

P2.18-03 Salvage Surgery After Curative-Intent Chemo and/or Radiation for Locally Advanced Lung Cancer
Motohiro Yamashita, National Hospital Organization Shikoku Cancer Center, Japan

P2.18-04 Improved Outcome in Female Stage III NSCLC Diagnoses Is Driven by Non-Curative Intent Treatment, and Adenocarcinoma Histology
Gwyn Bebb, Alberta Health Services, Canada

P2.18-05 Patients with ypN2 NSCLC After Neoadjuvant Chemotherapy Followed by Surgery Can Benefit from PORT – A Retrospective Study of SEER Database
Yongxing Bao, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China

P2.18-06 Trends and Outcomes of Minimally Invasive Approaches for Lung Cancer Resection After Induction Therapy in the United States
Brendon Stiles, New York Presbyterian Hospital-Weill Cornell Medical College, United States of America

P2.18-07 Prognostic Factors Affecting Brain Metastasis-Free Survival in Non-Small Cell Lung Cancer Patients
Deniz Yalman, Ege University Medical School & Hospital, Turkey

P2.18-08 The Necessity and Technique of the Upper Zone Lymph Node Dissection for Non-Small-Cell Carcinoma of the Left Upper Lobe
Toshiya Yokota, Mitsui Memorial Hospital, Japan

P2.18-09 Age Does Not Affect the Benefit of Modern Chemoradiation for LA-NSCLC Patients
Sara Ramella, Campus Bio-Medico University, Italy

P2.18-10 Importance of the Multidisciplinary Tumor Board in the Treatment Strategy of Stage III Non-Small Cell Lung Cancer (NSCLC)
Justin Benet, CHU Grenoble, France

P2.18-11 Real-World Experience of Consolidation Durvalumab for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Alexander Barbaro, Department of Medical Oncology / Montefiore Medical Center, United States of America

P2.18-12 Prognostic Nutrition Index Affects Prognosis of Trimodality Therapy for Locally Advanced Lung Cancer with High T Factor
Junichi Soh, Kindai University Faculty of Medicine, Japan

P2.18-13 Endobronchial Brachytherapy: A Single Institutional Experience
Pere Trias Sabrià, Hospital Universitari de Bellvitge, Spain

P2.18-14 The Role of Surgery in High Grade Neuroendocrine Tumors of the Lung
Mehmet Bedirhan, Yedikule Chest Disease and Thoracic Surgery Hospital, Turkey

P2.18-15 Surgical Outcomes of Pneumonectomy After Induction Therapy for Non-Small-Cell Lung Cancer
Norihito Okumura, Kurashiki Central Hospital, Japan

P2.18-16 VATS Lobectomy and Chest Wall Resection for NSCLC
Hüseyin Melek, Uludag University, Turkey

P2.18-17 Outcome of Surgical Treatment for Clinical N1 Non-Small Cell Lung Cancer
Daiji Nemoto, Kanagawa Cancer Center, Japan

P2.18-18 Impact of Combined Evaluation Using Tumor Volume and Metastatic Nodal Extent in Stage III NSCLC Treated with CRT
Yutaro Tamiya, Nagoya University Hospital, Japan

P2.18-19 Radiological and Pathological Response to the Induction of Surgery in the NSCLC Stage III
Francesc Casas, Hospital Clinic de Barcelona, Spain
Stop by the Member Experience Lounge, located next to the IASLC booth #300 in the Exhibit Hall, to learn about IASLC committee initiatives. Members from the following committees will be there to discuss their current projects.

**SUNDAY, SEPTEMBER 8TH**

<table>
<thead>
<tr>
<th>Time</th>
<th>Committee</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:45-10:30 am</td>
<td>Mesothelioma Committee</td>
</tr>
<tr>
<td></td>
<td>Communications Committee</td>
</tr>
<tr>
<td>4:45-6:00 pm</td>
<td>Patient Advocates Committee</td>
</tr>
<tr>
<td></td>
<td>Tobacco Control &amp; Smoking Cessation Committee</td>
</tr>
<tr>
<td></td>
<td>Screening &amp; Early Detection Committee</td>
</tr>
<tr>
<td></td>
<td>Staging &amp; Prognostic Factors Committee</td>
</tr>
</tbody>
</table>

**MONDAY, SEPTEMBER 9TH**

<table>
<thead>
<tr>
<th>Time</th>
<th>Committee</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:15-11:00am</td>
<td>Career Development &amp; Fellowship Committee</td>
</tr>
<tr>
<td></td>
<td>Education Committee</td>
</tr>
<tr>
<td>4:45-6:00pm</td>
<td>Membership Committee</td>
</tr>
<tr>
<td></td>
<td>Nurses &amp; Allied Health Professionals Committee</td>
</tr>
<tr>
<td></td>
<td>Staging &amp; Prognostic Factors Committee</td>
</tr>
<tr>
<td></td>
<td>Pathology Committee</td>
</tr>
</tbody>
</table>

FINANCIAL SUPPORT MAY BE AVAILABLE.

Sign up for future IASLC volunteer opportunities.
Sign up to volunteer for IASLC opportunities.

Stop by the Member Experience Lounge, located next to the IASLC booth #300 in the Exhibit Hall, to learn about IASLC committee initiatives. Members from the following committees will be there to discuss their current projects.

Sunday, September 8th
9:45-10:30 am
Mesothelioma Committee
Communications Committee
Patient Advocates Committee
Tobacco Control & Smoking Cessation Committee
Screening & Early Detection Committee
Staging & Prognostic Factors Committee

Monday, September 9th
10:15-11:00 am
Career Development & Fellowship Committee
Education Committee
Membership Committee
Nurses & Allied Health Professionals Committee
Staging & Prognostic Factors Committee
Pathology Committee

IASLC Committee Corner
Chat with the Staging & Prognostic Factors Committee about the IASLC 9th Edition of the Lung Cancer Staging Project.

Financial support may be available.
### EP1.01

#### 08:00 - 18:00 ADVANCED NSCLC

**Track(s):** Advanced NSCLC

#### Exhibit Hall

**EP1.01-01 Atrial Resection Without Cardiopulmonary Bypass for Lung Cancer**  
Domenico Galetta, European Institute of Oncology, Italy

**EP1.01-02 Novel Partial Tumor Irradiation Improves Treatment Outcomes for Inoperable Bulky Lung Cancer Compared with Standard of Care**  
Slavisa Tubin, KABEG Klinikum Klagenfurt, Austria

**EP1.01-03 Real World Outcome of Crizotinib for Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Patients**  
Yeon Joo Kim, Asan Medical Center, Korea, Republic of

**EP1.01-04 Phase I/II Trial of Biweekly Nab-Paclitaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer: NJLCCI402**  
Hisashi Tanaka, Hirosaki University Graduate School of Medicine, Japan

**EP1.01-05 EGFR-2013-CPHG, a Real-World Study of EGFR Mutant Advanced Non-Small-Cell Lung Cancer Patients Treated with Erlotinib**  
Didier Debieuvre, Groupe Hospitalier Régional Mulhouse Sud Alsace (GHRM), Hôpital Émile Muller, France

**EP1.01-06 Loss of Heterozygosity of Oncogene ERBB2 with an Activating Mutation Was Identified as Driver Event in Leptomeningeal Metastasis of NSCLC**  
Peng Wang, Tianjin Medical University Cancer Institute and Hospital, China

**EP1.01-07 Definitive Results of a Clinical and Molecular Multicentric Characterization of Long-Term Survivors with Advanced Non-Small Cell Lung Cancer**  
Maria Sereno, Infanta Sofia University Hospital, Spain

**EP1.01-08 Efficacy of Osimertinib in Patients of Advanced Non-Small Cell Lung Cancer with Brain Metastasis: A Retrospective Analysis**  
Jiexia Zhang, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, China

**EP1.01-09 Clinical Efficacy of Circulating Tumor DNA Test in Advanced Non-Small-Cell Lung Cancer Patients Who Might Have T970M Mutation**  
NamEun Kim, Severance Hospital, Korea, Republic of

**EP1.01-10 Pembrolizumab in Combination with Chemotherapy as First-Line Treatment of Advanced Non-Small Cell Lung Cancer**  
Kyaw Thein, The University of Texas MD Anderson Cancer Center, United States of America

**EP1.01-11 Prognosis of Lung Cancer in Patients with Interstitial Lung Disease; Comparison with NSIP and IPF**  
Sehyun Kwak, Severance Hospital, Korea, Republic of

**EP1.01-12 SNPs of Organic Cation Transporter 6 Associate with the Efficacy of Platinum Combination Chemotherapy**  
Akira Takeuchi, Nagoya City University Graduate School of Medical Sciences, Japan

**EP1.01-13 A Phase 2 Trial Assessing Osimertinib Activity Against Leptomeningeal Carcinomatosis in EGFR-Mutant Lung Cancer**  
Yuki Akazawa, National Hospital Organization Toneyama National Hospital, Japan

**EP1.01-14 The Scour Using Pretreatment NLR, Liver Metastasis, PD-L1 Status and PS as a Marker of Outcomes in Nivolumab-Treated Patients with Advanced NSCLC**  
Akihiro Tamiya, Kinki-chuho Chest Medical Center, Japan

**EP1.01-15 Systemic Hyperinflammation Is a Strong Independent Predictor of Early Mortality in Advanced NSCLC**  
Johan Isaksson, Gävle Hospital, Sweden

**EP1.01-16 Characteristics of Stage III Lung Cancer Patients in the Period 2014-2016 in Vietnam**  
Voc Dang, Vietnam National Cancer Hospital, Viet Nam

**EP1.01-17 Predictors of Survival Outcomes with Chemotherapy in Advanced NSCLC Patients with Performance Status 2 and Above and Without Driver Mutation**  
Harish Kancharla, All India Institute of Medical Sciences, India

**EP1.01-18 Clinical Features of Locally Advanced Lung Cancer Patients with Radiation Pneumonitis After Induction Chemoradiotherapy**  
Kota Araki, Okayama University Hospital, Japan

**EP1.01-19 Updated Statistics of Never-Smoker Female Lung Cancer in Korea**  
Seung Joon Kim, The Cancer Research Institute, College of Medicine, The Catholic University of Korea, Korea, Republic of

**EP1.01-20 A Single-Arm Phase II Trial of Weekly Nanoparticle Albumin-Bound Paclitaxel Monotherapy After Standard Therapy for Advanced NSCLC**  
Yasuhiro Kato, Tokyo Metropolitan Cancer and Infectious Diseases Centre, Japan

**EP1.01-21 Time on Treatment of First-Line PD-1 Inhibitor Monotherapy for Metastatic Non-Small-Cell Lung Cancer Patients: Real-World Experience Data**  
Nava Siegelmann-Danieli, Maccabi Healthcare Services, Israel

**EP1.01-22 Liquid Biopsy in the Detection of EGFR Activating and Resistance Mutations in Advanced Pulmonary Adenocarcinoma**  
Varsha Singh, All India Institute of Medical Sciences, India

**EP1.01-23 SRC Inhibition with Bosutinib as a Potential Approach for Restoring Pemetrexed Responsiveness**  
Nagla Abdel Karim, Medical College of Georgia/ Augusta University, United States of America

**EP1.01-24 Lung Adenocarcinoma: Mutational Profile in Ever Smokers and Non-Smokers Patients**  
Daniel Reis, Vila Nova de Gaia-Espinho Hospital Center, Portugal

**EP1.01-25 An Interactive Interface for Prediction of Anti-PD-1 Efficacy in Lung Cancer Patients**  
Corentin Richard, Centre Georges François Leclerc, France

**EP1.01-26 Non-Small Cellular Pulmon Cancer ALK Positive in Pediatrics**  
Alvaro Guerrero Villota, Centro Medico Imbanaco, Colombia

**EP1.01-27 Preliminary Study on Immune Checkpoint and EMT Feature of CTCs in Advanced Non-Small Cell Lung Cancer Patients**  
Lina Zhang, Beijing Chest Hospital, Capital Medical University, China
EP1.01-28 Real World Use of Atefinib in NSCLC EGFRm+ Patients Outside Clinical Trials: A FAETT Experience
Immaculada Ramos, Hospital Universitari Virgen de la Victoria, Spain

EP1.01-29 Lung Adenocarcinoma Harboring EGFR-19del/C797S/T790M Triple Mutations Responds to Brigatinib and Anti-EGFR Antibody Combination Therapy
Xiaofei Wang, Shanghai Ruijin Hospital, China

EP1.01-30 Clinico-Pathological Profile of Adenocarcinoma of the Lung – A Prospective Study in a Nepalese Population
Natasha Leight, Princess Margaret Cancer Centre, Canada

EP1.01-31 PET CT Radiogenomic Depiction in PDL1 Expression in Lung Cancer in Indian Population
Venkata Koyyala, Rajiv Gandhi Cancer Institute and Research Centre, India

EP1.01-32 Improving the Prognosis of Non-Small Cell Lung Cancer After the Approval of Immune Checkpoint Inhibitors: A Retrospective Analysis
Tepppei Yamaguchi, Aichi Cancer Center Hospital, Japan

EP1.01-33 Extracellular Medium of Senescent Lung Cancer Cells Promoted Tumor Progression Through Activation of YAP and PD-L1
Jiewei Liu, West China Hospital, Sichuan University, China

EP1.01-34 A Retrospective Study of the Pattern of Lymph Node Metastasis in Superior Sulcus Non-Small-Cell Lung Cancers
Hongxuan Li, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

EP1.01-35 Concurrent Use of Low Dose Aspirin and Vitamin D in ALK, ROS and EGFR Mutant NSCLC: A Single Institution Retrospective Analysis
Carolina Bernabe, Northwell Health Cancer Institute, Zucker School of Medicine at Hofstra/Northwell, United States of America

EP1.01-36 Quality of Life in Advanced Lung Cancer Patients in a Dutch Population
Romina Sluga, St Antonius Hospital, Netherlands

EP1.01-37 Platinum-Based Chemotherapy (CT) Rechallenge in Advanced Non Small Cell Lung Cancer (NSCLC) Patients (p): A Single Institution Experience
Enric Carcereny, Catalan Institut of Oncology Badalona- Hospital Universitari Germans Trias I Pujol. B-ARGO, Spain

EP1.01-38 Real World Experience of 1st Line Pembrolizumab in Patients with Metastatic Non-Small-Cell Lung Cancer (NSCLC)
Nicola Steele, Beatson West of Scotland Cancer Centre, United Kingdom

EP1.01-39 A Randomised Phase II Trial of Vitamin C Synergy with Hyperthermia in Patients with Advanced Non-Small-Cell Lung Cancer
Junwen Ou, Clifford Hospital, China

EP1.01-40 Outcome of EGFR-Mutated and Non-Mutated Lung Adenocarcinoma Receiving Standard Therapy - A Nepalese Cohort
Natasha Leight, Princess Margaret Cancer Centre, Canada

EP1.01-41 Feasibility of EBUS-TBNA Cytologies for an Extensive Assessment of Predictive Biomarkers in Lung Cancer
Roberto Martin-Deleon, Hospital Clinic, Spain

EP1.01-42 Is Serum Lymphocyte Count Predictive Biomarker to Identify Lung Cancer Patients Who May Benefit from an Immunotherapy?
Eun Young Heo, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Korea, Republic of

EP1.01-43 Immunotherapy and Radiotherapy - A Useful Combination?
Stephan Eisenmann, Universitätsklinikum Halle-Wittenberg, Germany

EP1.01-44 Early and Long-Term Results of Tracheal Sleeve Pneumonectomy for Lung Cancer After Induction Therapy
Domenico Galetta, European Institute of Oncology, Italy

EP1.01-45 Cisplatin Plus Gemcitabine Therapy Followed by Maintenance Gemcitabine for Advanced Squamous Cell Lung Cancer (KTORG1302)
Toshihiko Kameda, Kansai Medical University Hospital, Japan

EP1.01-46 Acute Esophageal Damage in Patients with Inoperable Non-Small Cell Lung Cancer Treated with Concurrent and Sequential Chemoradiotherapy
Simonida Crvenkova, University Clinic of Radiotherapy and Oncology, North Macedonia

EP1.01-47 Thyroid Related Adverse Events Predict Survival in NSCLC Patients Receiving Anti-PD-1/ PD-L1 Therapy
Yasar Ahmed, University Hospital Waterford, Ireland

EP1.01-48 Invasive Mucinous Adenocarcinoma of the Lung: Serial CT Findings, Clinical Features, and Treatment Outcomes
Kyongmin Beck, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Korea, Republic of

EP1.01-49 Histology-Depended Pattern of Patho-Histological Response After Induction Therapy in Locally Advanced Non-Small Cell Lung Cancer
Waldemar Schreiner, University Hospital, Friedrich-Alexander-University, Germany

EP1.01-50 Quantitative Assessment of Subsegmental Bronchi on Thin-Section CT for Pulmonary Lymphangitis Carinomatosa
daisuke Takenaka, Hyogo Cancer Center, Japan

EP1.01-51 Efficacy Impact of Serum VEGF for Elderly or Poor PS Patients Receiving Anti-PD-1 Antibody with Advanced Non-Small Cell Lung Cancer
Ryota Shibaki, Wakayama Medical University, Japan

EP1.01-52 Preferable Intracranial Chemotherapy for Lung Cancer Patients with Meningeal Metastasis Harboring CIN in CSF
Peng Wang, Tianjin Medical University Cancer Institute and Hospital, China

EP1.01-53 Update of Mutation Status in Lung Cancer. A Multicenter Local Study
Norma Piliñk, Cordoba University, Argentina

EP1.01-54 Implementation of Fine Needle Aspiration of Supraclavicular Lymph Node as a Novel Medium for Genomic Profiling in NSCLC
Zhengfei Zhu, Fudan University, China

EP1.01-55 Neoantigen Deletion Leads to Hyperprogressive Disease (HPD) in Non-Small Cell Lung Cancer (NSCLC) Treated with PD-1/PD-L1 Inhibitors
Di Wu, Cancer Center, Union Hospital, Huazhong University of Science and Technology, Wuhu,China, China

EP1.01-56 Co-Presentation of Adenocarcinoma and Squamous Cell Lung Carcinoma Harbouring ALK Rearrangement in Different Sites
Domenico Galetta, Thoracic Oncology, Clinical Cancer Centre “Giovanni Paolo II”, Italy

EP1.01-57 Clinical Profile and Treatment Outcomes of NSCLC in Elderly Subjects with Poor Performance Status from India
Digambar Behera, Postgraduate Institute of Medical Education and Research, India
EP1.01-58 Impact of Tumour Size on the Management and Outcome of Stage III Non-Small Cell Lung Cancer (NSCLC) 
Kaouthher Herbegue, Abderrahmen Mami Hospital, Tunisia

EP1.01-59 The Effectiveness of Osimertinib in a NSCLC Patient with Complex Uncommon EGFR Mutations of G719X and S768I: A Case Report 
Kewei Ma, The First Hospital of Jilin University, China

EP1.01-60 LENT Prognostic Score for Lung Cancer in the Presence of Malignant Pleural Effusion 
Giedre Cincleiviciute, Vilnius University Hospital Santaros Klinikos, Lithuania

EP1.01-61 ISEND Model as a Predictor of Efficacy in Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer: Fukushima Cohort 
Naoyuki Okabe, Fukushima Medical University, Japan

EP1.01-62 The Safety Profile and Preliminary Efficacy of Ceritinib 450mg with Food in Chinese ALK/ROS-1 Positive NSCLC Patients 
Jian Li, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, China

EP1.01-63 The Usefulness of “Serum” Samples to Detect EGFR T790M Mutation in EGFR-TKI-Resistant Non-Small-Cell Lung Cancer 
Keigo Kobayashi, Keio University School of Medicine, Japan

EP1.01-64 Effect of Amrubinib in Patients with Previously Treated Non-Small-Cell Lung Cancer 
Shin Takayama, National Hospital Organization Iwakuni Clinical Center, Japan

EP1.01-65 The Relationship Between Preliminary Efficacy and Prognosis After First-Line EGFR-TKI Treatment of Advanced NSCLC 
Yanwei Zhang, Shanghai Chest Hospital, China

EP1.01-66 Detection of Genomic Mutations in Blood and Urine ctDNA in Lung Adenocarcinoma with EGFR Mutation on Tissue – An Interim Progress Report 
Helen Brooks, Bristol Cancer Institute, United Kingdom

EP1.01-67 Molecular Profiling of K-Ras and Its Subtypes in NSCLC Patients with Liver Metastasis 
Nagla Abdel Karim, Medical College of Georgia/ Augusta University, United States of America

EP1.01-68 Impact of EGFR Genotype on the Efficacy of Osimertinib in Patients with Non-Small Cell Lung Cancer: A Prospective Observational Study 
Satoshi Igawa, Kitasato University, School of Medicine, Japan

EP1.01-69 Safety and Efficacy of Percutaneous Computed Tomography-Guided Thermal Ablation of Non-Small Cell Lung Cancer Metastases 
Ioannis Gkiozos, Oncology Center of Biomedical Research and Education, Greece

EP1.01-70 Reirradiation for Locoregionally Recurrent Lung Cancer: Outcomes in Non-Small Cell Lung Carcinoma 
Niketa Thakur, GCRI, India

EP1.01-71 Thymidylate Synthase and Folate Receptor Alpha Expression as Potential Biomarkers for Efficacy of Pemetrexed in NSCLC 
Saurav Verma, Dr. BRA Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, India

EP1.01-72 Treatment Outcome of 2nd Generation EGFR-TKI for Non-Small Cell Lung Cancer 
Tetsuro Kondo, Kanagawa Cancer Center, Japan

EP1.01-73 Trousseau’s Syndrome Associated with Pulmonary Pleomorphic Carcinoma Showing Aggressive Features: A Case Report 
Satoru Okada, Kyoto Prefectural University of Medicine, Japan

EP1.01-74 Implantation of Permanent Pleural Catheter (PPC) for Malignant Pleural Effusion (PE) in Advanced Non Small Cell Lung Cancer (NSCLC) 
Mireia Martinez-Kareaga, Txagorrirtxu Hospital, Spain

EP1.01-75 Palliative Thoracic Radiotherapy for Lung Cancer: What Is the Most Appropriate Fractionation? 
Niketa Thakur, GCRI, India

EP1.01-76 Oncomine Tumor Mutation Load Assay in NSCLC 
Gonzalo Recondo, Dana-Farber Cancer Institute, United States of America

EP1.01-77 Locally Advanced Non Small Cell Lung Cancer - Treatment Outcome in Real World Setting 
Arun Thimmagarappa, All India Institute of Medical Sciences, India

EP1.01-78 T4 Lung Cancer Invading the Descending Thoracic Aorta: A Case Successfully Treated with Surgery by a Multidisciplinary Team 
Angela De Palma, Section of Thoracic Surgery, University of Bari, Italy

EP1.01-79 Chemoradiotherapy in Advanced Non Small Cell Lung Cancer 
Mohamed Ait Erraisse, University Hospital Hassan II, Morocco

EP1.01-80 Progressive Disease with T790M Mutation vs Non-T790M Mutation in EGFR Positive Patients Treated with Tyrosine Kinase Inhibitors 
Daniel Reis, Vila Nova de Gaia-Espinho Hospital Center, Portugal

EP1.01-81 Resection of Tumors with Carinal Involvement After Induction Therapy 
Domenico Galetta, European Institute of Oncology, Italy

EP1.01-82 10 Years Single Center Experience with Resection of the Superior Vena Cava in Locally Advanced Non-Small Cell Lung Cancer 
Mir Aliareza Hoda, Medical University of Vienna, Austria

EP1.01-83 Efficacy and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced NSCLC Harboring Sensitive EGFR Mutations 
Yutaka Yamada, Ibaraki Prefectural Central Hospital & Cancer Center, Japan

EP1.01-84 Second Line Treatment with Docetaxel/Nintedanib in Patients with Metastatic Non Small Cell Lung Adenocarcinoma- Preliminary Results 
Michael Vaslamatzis, Evangelismos General Hospital, Greece

EP1.01-85 Comprehensive Next-Generation Sequencing-Guided Targeted Therapy Correlates with Survival in Non-Small-Cell Lung Cancer 
Zhenyao Chen, The Second Affiliated Hospital of Nanjing Medical University, China

EP1.01-87 Cutaneous Metastasis in Lung Cancer – A Retrospective Study in a Local Health Unit in Guarda, Portugal 
Rebecca Natal, Local Health Unit of Guarda, Portugal

EP1.01-88 Next-Generation Sequencing in Hispanic Patients with Advanced Lung Cancer and Correlation with Response to Immunotherapy 
Diana Saravia, Sylvester Cancer Center, United States of America

EP1.01-89 Retropertitoneal Metastasis with Marked Fibrosis from Lung Adenocarcinoma: An Autopsy Case Report 
Hiroki Ota, Omori Red Cross Hospital, Japan
**EP1.01-90** The Prognostic Role of Mean Platelet Volume in Patients with Advanced Non-Small Cell Lung Cancer
Ioannis Gkiolzos, Oncology Center of Biomedical Research and Education, Greece

**EP1.01-91** Outcomes with Systemic Chemotherapy with Weekly Regimen in Advanced NSCLC Patients with PS 2 and Above and Without Driver Mutation
Harish Kancharla, All India Institute of Medical Sciences, India

**EP1.01-92** Effectiveness of Second-Line Treatment with Nintedanib + Docetaxel (ND) in Patients with Metastatic Lung Adenocarcinoma
Joel Veas, Hospital Universitario Arnau De Vilanova, Spain

**EP1.01-93** Pembrolizumab in Combination with Chemotherapy as First-Line Treatment of Advanced Non-Small Cell Lung Cancer
Kyaw Thein, The University of Texas MD Anderson Cancer Center, United States of America

**EP1.01-94** The Role of Neoadjuvant Chemo-Immunotherapy in Unresectable Non-Small Cell Lung Cancer
Young Kwang Chae, Northwestern Medicine Developmental Therapeutics Institute, United States of America

**EP1.01-95** Up-Regulation of c-Met by Cox-2 Promotes Resistance of Gefitinib in NSCLC Patients
Fei Wang, Huazhong University of Science and Technology, China

**EP1.01-96** Metastatic Lymphoepithelial Lung Cancer
AbdelNasir Nourallah, AlMana General Group of Hospitals, Saudi Arabia

**EP1.01-97** Is Surgical Treatment Suitable for Stage III or IV Primary Lung Cancer?
Yoshifumi Sano, Ehime University Hospital, Japan

**EP1.01-98** Outcomes of Non-Small Cell Lung Cancer Patients with Brain Metastasis Treated by Whole Brain Radiotherapy, a Single Institution Experience
Apurna Jegannathen, University Hospitals of North Staffordshire, United Kingdom

**EP1.01-99** Effect of Immune Checkpoint Inhibitors Re-Administration in Non-Small-Cell Lung Cancer Patients
Tomoka Kawajiri, National Hospital Organization Iwakuni Clinical Center, Japan

**EP1.01-100** Evaluation of the Clinicopathological Features of Patients in Whom Residual Carcinoma in Bronchial Stump After Surgery for Lung Cancer
Yohei Kameda, Yokosuka Kyosai Hospital, Japan

**EP1.01-101** Transposition of the Pulmonary Veins for Mobilization of Rt-Middle and Lower Lobes for Safe Reconstruction After Carinal Rt-Upper Lobectomy
Takeshi Shiraishi, Fukuoka University, Japan

**EP1.01-102** Efficacy and Toxicity of Erlotinib and Gefitinib in Moroccan Patients with Advanced Non-Small Cell Lung Cancer with EGFR Mutation
Nadia Benchakroun, CHU Ibn Rochd, Morocco

**EP1.01-103** Long-Term Response to Second-Line Afinatinib for the Treatment of Advanced Lung Squamous Cell Carcinoma
Ye Guo, First Hospital of Jilin University, China

**EP1.01-104** Denosumab Experience in Lung Cancer Patients with Bone Metastases
Dilek Erdem, Bahcesehir University Medical Faculty, Turkey

**EP1.01-105** Experience in Treating Recurrent Non-Small Lung Cancer Patients After Surgery with Immune-Checkpoint Inhibitor
Masafumi Yamaguchi, National Hospital Organization Kyushu Cancer Center, Japan

**EP1.01-106** A Special Case of Synchronous Multiple Primary Lung Cancer with Mediastinal Lymph Node Metastases of Unknown Primary Origin
Kewei Ma, First Hospital of Jilin University, China

**EP1.01-107** Comparison of Outcomes in Responders and Nonresponders to Nivolumab as 2+ Line Treatment in Advanced Refractory NSCLC Pts
Konstantin Laktionov, N.N. Blokhin Russian Cancer Research Center, Russian Federation

**EP1.01-108** EGFR Exon 18 Mutations in NSCLC: Frequent Co-Occurrence of Multiple EGFR Mutations and Assessment of Cis/Trans Status
Christine Lovly, Vanderbilt University Medical Center, United States of America

---

**EP1.02**

**08:00 - 18:00** ADVOCACY

**Track(s): Advocacy**

**EP1.02-01** Prospects of Cancer Patients and Patient Association from the Viewpoint of Live Survey at Participatory Symposium
Toshiyuki Sawa, Gifu Municipal Hospital, Japan

**EP1.02-02** The Path of a Survivor
Diane Colton, Ms., Canada

---

**EP1.03**

**08:00 - 18:00** BIOLOGY

**Track(s): Biology**

**EP1.03-01** Molecular Spectrum of Patients with JAK1 Mutations in East Asian Non-Small Cell Lung Cancer
Chunwei Xu, Fujian Cancer Hospital, China

**EP1.03-02** Frequency of Microsatellite Instability in Patients with Primary Non Small Lung Cancer in a Single Institution from Colombia
Luis Pino, Fundacion Santafe, Colombia

**EP1.03-03** Association Between Molecular Spectrum of EZH2 Variants and Prognosis in Patients with Non-Small-Cell Lung Cancer in Chinese Patients
Chunwei Xu, Fujian Cancer Hospital, China

**EP1.03-04** Analysis of Post-Surgical Systemic Inflammatory Indexes After Non-Small Cell Lung Cancer Surgical Intervention
Lucia Milla Collado, Hospital Arnau Vilanova, Spain

**EP1.03-05** A Meta-Analysis of Association Between Serum Iron Levels and Lung Cancer Risk
Chunwei Xu, Fujian Cancer Hospital, China

**EP1.03-06** POLD1 Mutations Define a Unique Molecular Class of Non-Small Cell Lung Cancer in Chinese Patients
Chunwei Xu, Fujian Cancer Hospital, China

**EP1.03-07** Prevalence and Clinicopathological Characteristics of EIF1AX Mutations in Chinese Patients with Non-Small Cell Lung Cancer
Chunwei Xu, Fujian Cancer Hospital, China

**EP1.03-08** MiR-744 Facilitates Non-Small Cell Lung Cancer Progression by Transcriptional Regulation of c-FOS
Xiaoxia Zhu, Nanfang Hospital, Southern Medical University, China
**EP1.03-09** Epidemiological Study of TSC1 Mutations Among Non-Small Cell Lung Cancer Patients in China
Chunwei Xu, Fujian Cancer Hospital, China

**EP1.03-10** Expression of Anti-Aging Gene, Klotho Is a Surrogate Marker of Pemetrexed for Lung Cancer Treatment
Kyoshiko Takegahara, Nippon Medical School Hospital, Japan

**EP1.03-11** Mechanisms of Gefitinib Plus Pemetrexed on Human Non-Small Cell Lung Cancer
Yuqing Lou, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

**EP1.03-12** IL-10 Promotes Tumor Aggressiveness in Non-Small Cell Lung Cancer via Down-Regulated the Expression Level of miR-125b
Yanwei Zhang, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

**EP1.03-13** Molecular Characteristics of East Asian Patients with VHL-Mutated Non-Small-Cell Lung Cancer: A Retrospective Study
Chunwei Xu, Fujian Cancer Hospital, China

**EP1.03-14** Clinicopathologic Characteristics and Outcomes of Chinese Patients with Non-Small-Cell Lung Cancer and INPP4B Mutations
Chunwei Xu, Fujian Cancer Hospital, China

**EP1.03-15** Comparison of Plasma Expression of Drosha and Dicer mRNAs in Early and Advanced Stages of NSCLC Patients
Paweł Krawczyk, Medical University of Lublin, Poland

**EP1.03-16** Lysimachia Capilliposide C Restores Radiation Sensitivity in Radiation Resistant Lung Cancer Cells by Enhancing ERRF11 Expression
Kan Wu, Hangzhou Cancer Hospital, China

**EP1.03-17** Outcomes of Molecular Characteristics in Chinese BAP1-Mutant Non-Small Cell Lung Cancer Patients
Chunwei Xu, Fujian Cancer Hospital, China

**EP1.03-18** Analysis of IDHI Mutation Spectrum from Non-Small-Cell Lung Cancer in East Asian Patients
Chunwei Xu, Fujian Cancer Hospital, China

**EP1.03-19** The Frequency and Prognosis of MDM2 Mutations in East Asian Non-Small-Cell Lung Cancer Patients
Chunwei Xu, Fujian Cancer Hospital, China

**EP1.03-20** Diagnostic and Prognostic Utility of Differentially Expressed Circulating MicroRNAs in Indian NSCLC Patients
Sachin Kumar, All India Institute of Medical Sciences, India

**EP1.03-21** Circulating Tumor Cells Isolation Is Not a Useful Prognostic Tool for Non-Small Cell Lung Cancer Patients Candidates to Surgical Treatment
Lucia Milla Collado, Hospital Arnau Vilanova, Spain

**EP1.03-22** Prognostic Value of Serum Inflammation Biomarkers in Early Stage Lung Adenocarcinoma
Yanwei Zhang, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

**EP1.03-23** Update of the Analysis of the Status of Lymphocyte Infiltration in Patients with NSCLC
Eduardo Richardet, Instituto Oncologico de Corodoba, Argentina

**EP1.03-24** Clinicopathologic Characteristics and Survival Outcome in Chinese Patients with Non-Small Cell Lung Cancer and HGF Mutations
Chunwei Xu, Fujian Cancer Hospital, China

**EP1.03-25** Impact of Preoperative Complete Blood Cell Count-Derived Inflammation Biomarkers in Early-Staged Non-Small Cell Lung Cancer Patients
Fumihiro Shoji, NHO Kyushu Medical Center, Japan

**EP1.03-26** Analysis of Gene Expression Profiling of Lung Adenocarcinoma Brain Metastasis
Eun Su Park, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Korea, Republic of

**EP1.03-27** The Anti-Migration and Anti-Invasion Mechanisms of Capilliposide C from Lysimachia Capillipes on Lung Cancer
Yasi Xu, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, China

**EP1.03-28** Frequency and Molecular Characteristics of BRCA1 Mutations in Non-Small Cell Lung Cancer from East Asian Patients
Chunwei Xu, Fujian Cancer Hospital, China

**EP1.03-29** The Evaluation of Non-Canonical WNT/β-Catenin Ligands Expression Status in Non-Small Cell Lung Cancer
Mirosław Kozłowski, Medical University of Białystok, Poland

**EP1.03-30** FAM83A and FAM83B as Prognostic Biomarkers and Potential New Therapeutic Targets in NSCLC
Sarah Richtmann, Thoraxklinik at Heidelberg University Hospital, Germany

**EP1.03-31** Cell Migration and Epithelial Mesenchymal Transition in Lung Cancer - Different Roads and Common Themes
Karin Schelch, Medical University of Vienna, Austria

**EP1.03-32** Prevalence of EGFR and ALK Mutations in Non Small Cell Lung Cancer in Viet Nam National Cancer Hospital
Voc Dang, Vietnam National Cancer Hospital, Vietnam

**EP1.03-33** CD26/DPP4 as a Novel Prognostic Marker for Lung Adenocarcinoma
Jae-Hwi Jang, University Hospital Zürich, Switzerland

**EP1.03-34** Single Center Epidemiological Prevalence Study of Molecular Mutation in Bangladeshi Patients with Advanced Stage Non-Small Cell Lung Cancer
Qamruzzaman Chowdhury, Bangladesh Specialized Hospital Limited, Bangladesh

**EP1.03-35** Prevalence, Clinicopathologic Characteristics, and Molecular Associations of IGFR1 Mutations in East Asian Patients with NSCLC
Chunwei Xu, Fujian Cancer Hospital, China

---

**EP1.04**

**08:00 - 18:00 IMMUNO-ONCOLOGY**

Track(s): Immuno-oncology

**EP1.04-01** Association of PD-L1 Expression with Lung Adenocarcinoma Containing Solid or Micropapillary Components
Yoshiteru Kidokoro, Tottori University, Japan

**EP1.04-02** Predictors of Lung Toxicity in First Line Pembrolizumab for Advanced NSCLC: An Interim Analysis of PRELUTOX Study
Vieri Scotti, Radiation Oncology Unit- University Hospital Careggi, Italy

**EP1.04-03** Immune Cell Filtration as a Biomarker for the Diagnosis and Prognosis of Lung Adenocarcinoma
Yang Wo, Affiliated Hospital of Qingdao University, China

**EP1.04-04** Pembrolizumab-Induced Fatal Encephalopathy
Claudia Freitas, Centro Hospitalar Universitário de São João, Portugal
EPI.04-05 Outcomes of Immunotherapy in Elderly Patients. Retrospective Study of Clinical Characteristics in a Single-Center and a 4-Year Experience
Ana Laura Ortega Granados, Complejo Hospitalario de Jaén, Spain

EPI.04-06 Analysis of the Relationship Between Ratio N / L and Survival in Patients Treated with Immunotherapy in Lung Cancer
Noemi De Dios Alvarez, Complejo Hospitalario Universitario de Vigo, Spain

EPI.04-07 Influence of Radiotherapy in Second-Line Treatment with Immunotherapy in Patients with Non-Small Cell Lung Cancer
Elder Azkona, Hospital Universitario Cruces, Spain

EPI.04-08 Is Pseudoprogression Really Uncommon After Immunotherapy in Lung Cancer?
Jeong Eun Lee, Chungnam National University, Korea, Republic of

EPI.04-09 A Cross-Sectional Study of Clinical Trials on Radiotherapy Combined with Immunotherapy for Lung Cancer
Meng Yuan, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China

EPI.04-10 Nivolumab in Non-Small Cell Lung Cancer (NSCLC): A Real-Life Study
Daniel Reis, Vila Nova de Gaia-Espinho Hospital Center, Portugal

EPI.04-11 Frequency of Microsatellite Instability (MSI) in Brazilian TKI Non-Treatable Non-Small Cell Lung Cancer (NSCLC) Patients
Pedro De Marchi, Barretos Cancer Hospital, Brazil

EPI.04-12 Response to Combination of Metformin and Nivolumab in a NSCLC Patient Whose Disease Previously progressed on Nivolumab
Young Kwang Chae, Northwestern Medicine Developmental Therapeutics Institute, United States of America

EPI.04-13 Immunotherapy Versus Chemotherapy for Previously Treated Metastatic NSCLC. Results from Daily Clinical Practice
Michael Pavlakis, Evangelismos General Hospital, Greece

EPI.04-14 Effects of FoxP3-Positive Regulatory T Cell on Lymphoid Follicle Formation of Patient with Lung Squamous Cell Carcinoma
Morimichi Nishihira, Dokkyo Medical University, Japan

EPI.04-15 NSCLC Response Determinants to Chemoimmunotherapy: Deep Profiling of Tumors Following Neoadjuvant Cemiplimab and Chemotherapy
Thomas Marron, Icahn School of Medicine at Mount Sinai, United States of America

EPI.04-16 Predictive Markers for Efficacy in Malignancies Treated with Immune Checkpoint Inhibitors
Jianguo Sun, Cancer Institute of People’s Liberation Army, China

EPI.04-17 The Association of Clinicopathologic Features and Peripheral Blood Parameters with High PD-L1 Expression in Non-Small Cell Lung Cancer
Burak Bilgin, Ankara Chest Disease and Chest Surgery Hospital, Turkey

EPI.04-18 Real-World Treatment with Checkpoint Inhibitors: The Swedish Experience
Sebastian Gagatek, Uppsala Academic Hospital, Sweden

EPI.04-19 First Experience with Atezolizumab in Slovakia
Peter Berzinec, Specialised Hospital of St Zoerardus Zobor, Slovak Republic

EPI.04-20 Phase I Trial of In Situ Vaccination with Autologous CCL21-Modified Dendritic Cells (CCL21-DC) Combined with Pembrolizumab for Advanced NSCLC
Aaron Lisberg, University of California, Los Angeles, United States of America

EPI.04-21 Chronic Inflammation as Potential Predictive Factor of Nivolumab Therapy in Non-Small Cell Lung Cancer
Martin Svaton, University Hospital in Pilsen, Czech Republic

EPI.04-22 Efficacy and Safety of Immune Checkpoint Inhibitors in a Danish Real Life Non-Small Cell Lung Cancer Population
Birgitte Bjørnhart, Odense University Hospital, Denmark

EPI.04-23 Ongoing Phase II Trial of Anti-PD1 Therapy in Combination with CIMAvax-EGF in Patients with Advanced NSCLC or Squamous Cell Head and Neck Cancer
Grace Dy, Roswell Park Comprehensive Cancer Center, United States of America

EPI.04-24 Smoking History May Help Predict Immunotherapy Response in PD1+ Lung Cancer Patients
Natasha Leighl, Princess Margaret Cancer Centre, Canada

EPI.04-25 Increased PD-L1 Expression in MET Amplified (AMP) Advanced Non Small Cell Lung Cancer (NSCLC) Patients (P)
Enric Carcereny, Catalan Institut of Oncology Badalona- Hospital Universitari Germans Trias i Pujol. B-ARGO, Spain

EPI.04-26 Efficacy and Safety of Anti-PD-1 Inhibitors in Elderly Patients with Advanced Non-Small Cell Lung Cancer
Yuki Tanaka, Tokyo Medical University, Japan

EPI.04-27 Expression Analysis of Programmed Death-Ligand (PD-L1) in Large Cell Neuroendocrine Carcinoma
Tomohisa Sakaue, Ehime University Hospital, Japan

EPI.04-28 The Abscopal Effects of the Combination of Radiotherapy and GM-CSF for Patients with Metastatic Thoracic Cancers
Mina Liu, Department of Radiation Oncology, China

EPI.04-29 Khorana Score: A Potential New Biomarker for Real Life Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Immunotherapy
Birgitte Bjørnhart, Odense University Hospital, Denmark

EPI.04-30 RECIST and iRECIST Comparison in a Cohort of Patients with Advanced NSCLC Treated with Immunotherapy: Preliminary Study
Fernando Garcia Martinez, Hospital Universitario La Paz, Spain

EPI.04-31 Immunotherapy in Advanced Non-Small Cell Lung Cancer Previously Treated: Real World Data
Andreia Cruz, Portuguese Institute of Oncology, Portugal

EPI.04-32 Successful Corneal Transplantation in a Patient Treated with Nivolumab for Metastatic Non-Small Cell Lung Cancer
Carolina Dutra, CEPRON, Brazil

EPI.04-33 Pembrolizumab with High PD-L1: Who Are Non-Responders?
Fumie Shigematsu, Nagoya Medical Center, Japan

EPI.04-34 Imaging Challenges in the Immunotherapy Treatment of Non Small Cell Lung Cancer (NSCLC): Progression vs. Pseudo Progression
Carolina Dutra, CEPRON, Brazil

EPI.04-35 Immunotherapy in Non-Small Cell Lung Cancer (NSCLC) – Experiences from Clinical Practice – Sweden
Hirsh Koyi, Gavle Hospital, Sweden

EPI.04-36 Aggravation of Depigmentation for a NSCLC Patient with Pre-Existing Vitiligo Using Immune Check Point (PD-1) Inhibitor: A Case Report
Kewei Ma, The First Hospital of Jilin University, China

EPI.04-37 Response in PDL1+ Lung Cancer Patients
Martin Svaton, University Hospital in Pilsen, Czech Republic

EPI.04-38 Increased PD-L1 Expression in MET Amplified (AMP) Advanced Non Small Cell Lung Cancer (NSCLC) Patients (P)
Enric Carcereny, Catalan Institut of Oncology Badalona- Hospital Universitari Germans Trias i Pujol. B-ARGO, Spain

EPI.04-39 The Abscopal Effects of the Combination of Radiotherapy and GM-CSF for Patients with Metastatic Thoracic Cancers
Mina Liu, Department of Radiation Oncology, China

EPI.04-40 Khorana Score: A Potential New Biomarker for Real Life Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Immunotherapy
Birgitte Bjørnhart, Odense University Hospital, Denmark

EPI.04-41 Immunotherapy in Advanced Non-Small Cell Lung Cancer Previously Treated: Real World Data
Andreia Cruz, Portuguese Institute of Oncology, Portugal

EPI.04-42 Successful Corneal Transplantation in a Patient Treated with Nivolumab for Metastatic Non-Small Cell Lung Cancer
Carolina Dutra, CEPRON, Brazil

EPI.04-43 Pembrolizumab with High PD-L1: Who Are Non-Responders?
Fumie Shigematsu, Nagoya Medical Center, Japan

EPI.04-44 Imaging Challenges in the Immunotherapy Treatment of Non Small Cell Lung Cancer (NSCLC): Progression vs. Pseudo Progression
Carolina Dutra, CEPRON, Brazil

EPI.04-45 Immunotherapy in Non-Small Cell Lung Cancer (NSCLC) – Experiences from Clinical Practice – Sweden
Hirsh Koyi, Gavle Hospital, Sweden

EPI.04-46 Aggravation of Depigmentation for a NSCLC Patient with Pre-Existing Vitiligo Using Immune Check Point (PD-1) Inhibitor: A Case Report
Kewei Ma, The First Hospital of Jilin University, China

EPI.04-47 Response in PDL1+ Lung Cancer Patients
Martin Svaton, University Hospital in Pilsen, Czech Republic

EPI.04-48 Increased PD-L1 Expression in MET Amplified (AMP) Advanced Non Small Cell Lung Cancer (NSCLC) Patients (P)
Enric Carcereny, Catalan Institut of Oncology Badalona- Hospital Universitari Germans Trias i Pujol. B-ARGO, Spain

EPI.04-49 The Abscopal Effects of the Combination of Radiotherapy and GM-CSF for Patients with Metastatic Thoracic Cancers
Mina Liu, Department of Radiation Oncology, China

EPI.04-50 Khorana Score: A Potential New Biomarker for Real Life Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Immunotherapy
Birgitte Bjørnhart, Odense University Hospital, Denmark

EPI.04-51 Immunotherapy in Advanced Non-Small Cell Lung Cancer Previously Treated: Real World Data
Andreia Cruz, Portuguese Institute of Oncology, Portugal

EPI.04-52 Successful Corneal Transplantation in a Patient Treated with Nivolumab for Metastatic Non-Small Cell Lung Cancer
Carolina Dutra, CEPRON, Brazil

EPI.04-53 Pembrolizumab with High PD-L1: Who Are Non-Responders?
Fumie Shigematsu, Nagoya Medical Center, Japan

EPI.04-54 Imaging Challenges in the Immunotherapy Treatment of Non Small Cell Lung Cancer (NSCLC): Progression vs. Pseudo Progression
Carolina Dutra, CEPRON, Brazil

EPI.04-55 Immunotherapy in Non-Small Cell Lung Cancer (NSCLC) – Experiences from Clinical Practice – Sweden
Hirsh Koyi, Gavle Hospital, Sweden

EPI.04-56 Aggravation of Depigmentation for a NSCLC Patient with Pre-Existing Vitiligo Using Immune Check Point (PD-1) Inhibitor: A Case Report
Kewei Ma, The First Hospital of Jilin University, China
Liliana Fernandez-Trujillo, Fundacion Valle del Lili Hospital Universitario, Colombia

EP1.04-38 A Case of Lichenoid Reaction as Late and Uncommon Immune-Related Skin Toxicity During Nivolumab Treatment
Annamaría Catino, Clinical Cancer Centre, Italy

EP1.04-39 Is Body Mass Index a Prognostic Factor in Patients with Lung Cancer Treated with Immunotherapy?
Ines Rego, Portugal University Institute of Oncology Coimbra, Portugal

EP1.04-40 Extra-Thoracic Metastasis Indicated Worse Clinical Efficacy on Immune Checkpoint Inhibitors in Chinese Advanced NSCLC Patients
Sangtian Liu, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine, China

EP1.04-41 Efficacy of Immunotherapy in Elderly Patients with Non-Small Cell Lung Cancer: A Multicentric Experience from Argentina
Maria Rizzi, Hospital Aleman de Buenos Aires, Argentina

EP1.04-42 Using a Multiplexed Immunofluorescence Approach to Compare Immune Cell Populations in Subtypes of Non-Small Cell Lung Cancer
Anna Juncker-Jensen, NeoGenomics, United States of America

EP1.04-43 The Significance of NY-ESO 1 Seropositivity and Influence on NSCLC Patients Survival
Beáta Kútna, Faculty Hospital Motol, Czech Republic

EP1.04-44 Exploration of Factors Relating to Paradoxical Immune Response in Patients Treated with Immune Checkpoint Inhibitors for NSCLC
Oscar Gerardo Arrieta, Instituto Nacional de Cancerología, Mexico

EP1.04-45 Relevance of Antibiotic Use on Clinical Activity of Immune Checkpoint Inhibitors in Hispanic Patients with Advanced NSCLC (CLICAP-ABS)
Oscar Gerardo Arrieta, Instituto Nacional de Cancerología, Mexico

EP1.04-46 Immunotherapy at Any Line Improves Survival in Hispanic Patients with Advanced Metastatic NSCLC Compared to Chemotherapy (Quijote-CLICap)
Oscar Gerardo Arrieta, Instituto Nacional de Cancerología, Mexico

EP1.04-47 Chronic and Severe Non-Lichenoid Oral Ulcers Induced by Nivolumab: Diagnostic and Therapeutic Challenge
Oscar Gerardo Arrieta, Instituto Nacional de Cancerología, Mexico

EP1.05-01 “Liquid Withdraw” Technique in CT-Guided Cutting Needle Lung Biopsy Decrease Incidence of Complications: Prospective Study
Xue Wang, Medical School of Nanjing University, China

EP1.05-02 Endobronchial Ultrasound and Transbronchial Needle Aspiration EBUS-TBNA: In a University Hospital in Latin America
Liliana Fernandez-Trujillo, Fundacion Valle del Lili Hospital Universitario, Colombia

EP1.05-03 Therapeutic Bronchoscopy in Multimodal Therapy for the Management of Central Airway Obstruction
Liliana Fernandez-Trujillo, Fundacion Valle del Lili Hospital Universitario, Colombia

EP1.05-04 Results After Retrospective Study About Coexistence Between Bronchial Carcinoma and Active Tuberculosis in Endemic Aera
Ihsan Alloubi, CHU Med VI, Morocco

EP1.05-05 The Optimal Sequence of Bronchial Washing and Brushing for Diagnosis of Non-Visible Lung Cancer During Non-Guided Bronchoscopy
Hae-Seong Nam, Inha University Hospital, Korea, Republic of

EP1.05-06 Benefits of 18F-FDG PET/CT-Guided Core-Needle Biopsy in Necrotic or Recurrent Chest Tumors
Volodymyr Volitko, Kyiv City Clinical Hospital 17, Ukraine

EP1.05-07 Examining Endobronchial Ultrasound (EBUS) Utilisation in Lung Cancer Diagnosis and Treatment Delay. A Restrospective Observational Study
Rob Stirling, The Alfred Hospital, Australia

EP1.05-08 Obtaining Diagnostic Lung Biopsies in Suspected Lung Cancer Patients
Elizabeth Barclay, Manchester University NHS Foundation Trust, United Kingdom

EP1.05-09 Well-Differentiated Liposarcoma Causing Endobronchial Occlusion: A Case Report
Liliana Fernandez-Trujillo, Fundacion Valle del Lili Hospital Universitario, Colombia

EP1.05-10 Metastasis from a Primary Melanoma of the Sinonasal Cavity: A Case Report
Liliana Fernandez-Trujillo, Fundacion Valle del Lili Hospital Universitario, Colombia

EP1.05-11 Integrating Radiological Features to CT Guided Lung Biopsy Results; The Experience of an Argentinean University Teaching Hospital
Carolina Gabay, Instituto Angel H. Roffo, Argentina

EP1.06-01 Amrubinic Treatment as Palliative-Intended Chemotherapy for Previously Treated Malignant Pleural Mesothelioma
Shoko Kawai, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Japan

EP1.06-02 Association of Inflammatory Biomarkers with Overall Survival in Patients with Advanced Malignant Pleural Mesothelioma
Laura Gutiérrez Sainz, La Paz University Hospital, Spain

EP1.06-03 The Mesothelioma Outcomes, Research and Experience (MORE) Survey. Using Real World Research Methodology
Lorraine Creech, Mesothelioma UK, United Kingdom

EP1.06-04 Differences in Health State Preference Values for Malignant Pleural Mesothelioma and Glioblastoma Multiforme
Christina Proescholdt, Novocure, Switzerland

Cheryl Lenny, British Lung Foundation, United Kingdom

EP1.06-06 Retrospective Analysis of Clinical Features and Nonstandard Treatment of Malignant Pleural Mesothelioma in a General Hospital
Keisuke Imasaka, Saiseikai Yokohamashi Tobu Hospital, Japan
EP1.06-08 In Vivo Studies of Tumor Treating Fields to Upper Torso in Combination with Chemotherapy Show No Additional Toxicities
Uri Weinberg, Novocure, Israel

EP1.06-09 A Retrospective Analysis on Sarcomatoid Mesothelioma to Identify If Chemotherapy Provides Greater Overall Survival Compared to BSC
Rachel Thomas, Guy’s and St Thomas’ NHS Trust, United Kingdom

EP1.06-10 Malignant Pleural Mesothelioma Diagnosis: An 18-Year-Old Experience
Pablo Paglialunga, Hospital San Juan de Dios de La Plata, Argentina

EP1.06-11 Advanced Malignant Pleural Mesothelioma: A Single Institution Experience
Laura Gutiérrez Sainz, La Paz University Hospital, Spain

EP1.07
08:00 - 18:00 NURSING AND ALLIED PROFESSIONALS
Track(s): Nursing and Allied Professionals

EP1.07-01 Effectiveness of Therapeutic Massage for Treating Anxiety in Suspected Lung Cancer Patient Pre-Broncoscopic Procedures
Puji Raharja Santosa, Persahabatan Hospital, Indonesia

EP1.07-02 Role of Nurse in Patient Care During Immunotherapy Treatment Through Example of Canada and Poland
Monika Pawlik, Szpital Kliniczny Przemieniania Panskiego Uniwersytetu Medycznego w Poznaniu, Poland

EP1.07-03 Preparedness in Promoting and Self-Assessment of Nurses Ability to Promote Health Awareness in Lung Cancer Prevention
Janina Ksiazek, Medical University of Gdansk, Poland

EP1.07-04 Incomplete First Treatment Course and Related Factors of Survival Rate Analysis for Lung Cancer Patients
Chih Hsiang Hsu, Kaohsiung University Hospital, Taiwan

EP1.08
08:00 - 18:00 OLIGOMETASTATIC NSCLC
Track(s): Oligometastatic NSCLC

EP1.08-01 Whole-Brain Radiotherapy Plus Sequential or Simultaneous Integrated Boost for the Treatment of Limited Number of Brain Metastases in NSCLC
Ma Yuan, Affiliated Hospital of North Sichuan Medical College, China

EP1.08-02 Surgical Indication for Postoperative Regional Lymph Node Oligo-Recurrence in Non-Small Cell Lung Cancer
Yukio Watanabe, Juntendo University School of Medicine, Japan

EP1.08-03 Results of Definitive Treatment in Patients with Synchronous Oligometastatic Non Small Cell Lung Cancer
Serap Akyurek, Ankara University Faculty of Medicine, Turkey

EP1.08-04 Local Treatment for Patients with Pulmonary Oligo-Recurrence of Non-Small Cell Lung Cancer
Yoshitaka Kitamura, Hyogo Cancer Center, Japan

EP1.08-05 Local Non-Salvage Radiotherapy for Synchronous Oligometastatic NSCLC: A Multicenter, Randomized, Controlled, Phase 2 Study
Xiaoxia Zhu, Nanfang Hospital, Southern Medical University, China

EP1.08-06 Postoperative Oligo-Recurrence of Non-Small Cell Lung Cancer
Osamu Kawamata, Onomichi Municipal Hospital, Japan

EP1.08-07 Correlation Between Genetic Profiling and Response in Danish ALK-Positive NSCLC Patients Treated with Crizotinib
Edyta Urbanska, University of Copenhagen, Denmark

EP1.09
08:00 - 18:00 PATHOLOGY
Track(s): Pathology

EP1.09-01 Suitability of Qubit RNA IQ to Determine the RNA Quality of FFPE Samples in Cancer Genomic Medicine
Masakazu Souda, Nagasaki University Hospital, Japan

EP1.09-02 Expression of Intratumoral GFTPT2 in Lung Adenocarcinoma
Yasuto Jin, Hiratsuka Kyosai Hospital, Japan

EP1.09-03 Interobserver Variability Study of PD-L1 Immunostaining in Non-Small Cell Lung Cancer
Yu-Deok Choi, Chonnam National University Medical School, Korea, Republic of

EP1.09-04 GATA-3 Expression Is a Poor Prognostic Marker in Resected Non-Small Cell Lung Carcinoma
Naoki Yanagawa, Yamagata Prefectural Central Hospital, Japan

EP1.09-05 Correlation of ROS1 (D4D6) Immunohistochemistry with ROS1 FISH Analysis in Lung Adenocarcinoma: Is IHC a Reliable Screening Tool?
Shivani Sharma, CORE Diagnostics, India

EP1.09-06 An Unusual Diagnostic Case of Hypoglycemia: A Different Perspective of the Doege-Potter Syndrome
Nicholo Daddi, U.O.Chirurgia Toracica - Pad. 23, Italy

EP1.09-07 Detection of EGFR Mutation by Automated and Rapid qPCR Based Biocartis IdyllaTM System in Lung Cancer Patients
Shivani Sharma, CORE Diagnostics, India

EP1.09-08 Plasma Circulating Free Tumour DNA in Advanced Lung Adenocarcinoma: EGFR TKI-Naïve
Noni Soeroso, Universitas Sumatera Utara, Universitas Sumatera Utara Hospital, Indonesia

EP1.09-09 Surgical Cases of Pulmonary Pleomorphic Carcinoma at Our Institution
Haruhiko Masuda, Kanagawa Cardiovascular and Respiratory Center, Japan

EP1.09-10 A Diagnostic Pitfall in Posterior Mediastinal Tumor: Expression of CD117 in Atypical Ewing Sarcoma Masquerading as Classic Seminoma
Yen-Lin Huang, National Taiwan University Hospital, Taiwan

EP1.09-11 Lipoid Pneumonia Resembling Bilateral Lung Cancer: Be Aware of Nasal Decongestants!
Cesare Braggio, University Hospital of Parma, Italy

EP1.09-12 Lung Cancer in Kenya: Quantification of the Problem
Fredrick Asirwa, Ampath_ICI Kenya, Kenya
EP1.10 08:00 - 18:00 PREVENTION AND TOBACCO CONTROL  
Track(s): Prevention and Tobacco Control

EP1.10-01 Sociodemographic Characteristics and Perceptions of Tobacco Work and Hazards in a Rural Community of Nigeria
Uzochukwu Ofonakara, Federal Teaching Hospital Abakaliki, Nigeria

EP1.10-02 Risk for Occurrence of Lung Cancer Among Exposed to Professional Agents: A Case-Control Study
Irina Pavlovskaya, Institute of Epidemiology and Biostatistics, Medical Faculty, North Macedonia

EP1.10-03 Level of Awareness of Various Aspects of Lung Cancer Among College Students in India: Do We Need to Make Youth Awareness an Important Agenda?
Abhishek Shankar, DBRAIRCH, All India Institute of Medical Sciences, India

EP1.10-04 Characteristics of Smoker Patients with Lung Cancer in the Lung Cancer
Jair Rauseo López, Hospital Universitario de Salamanca, Spain

EP1.11 08:00 - 18:00 SCREENING AND EARLY DETECTION  
Track(s): Screening and Early Detection

EP1.11-01 Lung Cancer Screening and Canada’s Inuit: A Missed Opportunity
Chantal Bornais, The Ottawa Hospital, Canada

EP1.11-02 Implementation Planning of Lung Cancer Screening in China
Yue Cheng, Institute of Translational Medicine, United Kingdom

EP1.11-03 Diagnostic Evaluation of Patients with Solitary Pulmonary Nodules in a Tertiary Referral Center
Ioannis Gkiozos, Oncology Center of Biomedical Research and Education, Greece

EP1.11-04 Low Dose Lung CT Screening in First Responders in the Phoenix Metro Area: A Feasibility Study
Vershalee Shukla, Vincere Cancer Center, United States of America

EP1.11-05 Integration of Low Dose Computed Tomography (LDCT) for Lung Cancer Screening in the National Cancer Program in India: A Feasibility Study
Jitendra Meena, Geetanjali Medical College & Hospital, India

EP1.11-06 Design and Implementation of an Integrated Lung Cancer Prevention and Screening Program Using a Mobile CT in Brazil
Rodrigo Chiarantano, Barretos Cancer Hospital, Brazil

Yang Yang, Shanghai Pulmonary Hospital, China

EP1.11-08 Ultra-High-Resolution CT to Project the Detailed Components in Nodules; Fat Components in Pulmonary Hamartomas
Daisuke Takenaka, Hyogo Cancer Center, Japan

EP1.11-09 Evaluation of Seven-Autoantibody Panel Test in Early Detection of Lung Cancer in Routine Clinical Practice
Jian Zhang, Department of Pulmonary Medicine, Xijing Hospital, Fourth Military Medical University, China

EP1.11-10 Creating a Comprehensive Lung Cancer Screening Program to Diagnose Early Stage Lung Cancers
Karen Alisa Braithwaite, NYU Winthrop Hospital, United States of America

EP1.11-11 Familial Lung Cancer: A Call for Action
Vania Sacramento, Hospital Beiriz Ângelo, Portugal

EP1.11-12 Lung Cancer Screening: Implementation in a Multi-State, Community-Based Setting
Candice Wilshire, Swedish Cancer Institute, United States of America

EP1.11-13 Lung Cancer Screening Protocol by Using Low Dose Computerized Tomography in Combination with Digital Tomosynthesis: 4 Years Follow Up Results
Natthaya Triphuridet, Chulabhorn Royal Academy, Thailand

EP1.11-14 Knowledge and Perspectives of Indian Medical Practitioners to Lung Cancer: A Regional Sample Survey
Jitendra Meena, Geetanjali Medical College & Hospital, India

EP1.11-15 Lung Cancer Screening Program with Low-Dose CT in Greek Population
Sophia Lampaki, Aristotle University of Thessaloniki, Pulmonary Department, Greece
EP1.11-16 Comparison of Three Diagnostic Modalities for Lung Nodules
Su Kyung Hwang, Ulsan University Hospital, University of Ulsan, College of Medicine, Korea, Republic of

EP1.11-17 The Impact of Occupational Exposure on Detection of Extra-Nodular and Extrapulmonary Lesions in LDCT from a Pilot Silesian Study
Sylwia Szlubowska-Siwik, UCK im. Prof. K. Gibinskiego SUM w Katowicach, Poland

EP1.11-18 Follow-up and Recurrence After Surgery in Patients with Non-Small-Cell Lung Cancer
Margarida Felizardo, Hospital Beatriz Ângelo, Portugal

EP1.11-19 Surveillance with PET/CT and ctDNA of Lung Cancer Patients After Completion of Definitive Therapy; A Randomized Trial
Barbara Fischer, Rigshospitalet, Denmark

EP1.11-20 A Panel of Liquid Biomarkers for Early Response Capturing of NSCLC Therapies in Advanced Stages
Marc Schneider, Thoraxklinik at Heidelberg University Hospital, Germany

EP1.11-21 Lung Cancer Screening Pilot in Israel
Shani Shilo, The Israel Lung Cancer Foundation, Israel

EP1.11-22 Incorporating Genetic Counseling into the Thoracic Oncology Unit: A Pilot Project in the Real World
Guillermo Pacheco Cuellar, Centro Oncologico Estatal ISSEMyM, Mexico

EP1.11-23 Protocol for a Randomized Controlled Trial of FDG-PET-CT in Follow Up of Stage II-IIIA NSCLC Post Treatment
Rob Stirling, The Alfred Hospital, Australia

EP1.11-24 The TREAT Model 2.0: Predicting Lung Cancer in Patients Seeking Care in High-Risk Clinics
Maren Shipe, Vanderbilt University Medical Center, United States of America

EP1.12 08:00 - 18:00 SMALL CELL LUNG CANCER/NET

EP1.12-01 Does PCI Still Have a Role in Limited SCLC?
Itzhak Yehonatan, Soroka University Medical Center, Israel

EP1.12-02 SCLC Treatment Uptake and Survival Outcomes: A 2-Year Comparison Between 2 Tertiary Referral Centers in Alberta, Canada
D Bebb, Alberta Health Services, Canada

EP1.12-03 The Significance of INSM1 Expression in Small Cell Lung Cancer
Kosuke Fujino, Kumamoto University Hospital, Japan

EP1.12-04 Can Prophylactic Cranial Irradiation Reduce Neurological Symptoms in Patients with Small Cell Lung Cancer?
Taša Boskovic, Institute for Pulmonary Diseases of Vojvodina, Serbia

EP1.12-05 Is There a Role for Mediastinal Lymph Node Dissection in Pulmonary Carcinoids?
Devayanii Niyogi, Tata Memorial Hospital, India

Thanh Ton, Genentech, Inc., United States of America

EP1.12-07 High Discrepancy of Chemotherapy Outcomes Between Patients with Peripheral and Central Small Cell Lung Cancer
Shiqi Mao, Shanghai Pulmonary Hospital, China

EP1.12-08 Programmed Death-Ligand 1 and Human Leukocyte Antigen Class I Expression in Various Neuroendocrine Tumors of the Lung
Yeon Bi Han, Seoul National University Bundang Hospital, Korea, Republic of

EP1.12-09 EGFR-Mutant Adenocarcinoma Transform into Small-Cell Lung Cancer: Real or Not
Rui Li, West China Hospital of Sichuan University, China

EP1.12-10 Molecular Characterization of NSCLC-Like and SCLC-Like Subsets in Chinese Pulmonary Large-Cell Neuroendocrine Carcinoma (LCNEC)
Lin Wu, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, China

EP1.12-11 Effect of Treatment Mode on Prognosis of Resectable Limited-Stage Small Cell Lung Cancer
Fei Teng, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China

EP1.12-12 Factors Associated with Survival Outcomes Among Relapsed SCLC Diagnosed at a Canadian Cancer Centre
Gwyn Bebb, Alberta Health Services, Canada

EP1.12-13 Consolidation Radiotherapy in Extended Disease Small Cell Lung Cancer: Single Center Experience
Karmen Stanič, Institute of Oncology, Slovenia

EP1.12-14 Multiple Primary Malignant Neoplasms in Patients with Small Cell Lung Cancer. The Experience of Our Center
Michael Vaslamatzis, Evangelismos General Hospital, Greece

EP1.12-15 Oncologic Treatments and Outcomes for Small-Cell Lung Cancer Patients with Brain Metastases
Ferio L, Hospital Universitari de Girona Doctor Josep Trueta, Spain

EP1.12-16 CD47 Expression and Prognosis in Patients with Small Cell Lung CancerCD47 Expression and Prognosis in Patients with Small Cell Lung Cancer
Norma Hernandez-Pedro, Instituto Nacional de Cancerologia, Mexico

EP1.12-17 Neuroendocrine Marker Staining Pattern Categorization of Small-Sized Pulmonary Large Cell Neuroendocrine Carcinoma
Kazuhiro Minami, Kobe University Graduate School of Medicine, Japan

EP1.12-18 NET-001: A Phase II Study of ABI-009 in Metastatic Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System
Robert Ramirez, Ochsner Clinic Foundation, United States of America

Asieh Golozar, AstraZeneca, United States of America

EP1.12-20 Retrospective Study About the Impact of Metastatic Site in Small Cell Lung Cancer
Dario Sanchez Cabrero, University Hospital La Paz, Spain

EP1.12-21 Treatment Patterns and Prognostic Factors in Small-Cell Lung Cancer Patients in Israel - Real World Analysis of a Health Services Database
Nava Siegelmann-Danieli, Maccabi Healthcare Services, Israel
EP1.12-22 The Expression and Prognostic Roles of PD-L1, PAPR1 and DLL3 in Small Cell Lung Cancer
Tao Tian, The First Affiliated Hospital of Xi’an Jiaotong University, China

EP1.12-23 Surgery Is Associated with Favorable Outcome in Patients with Early Stage SCLC – Retrospective Institutional Experience
Thomas Klikovits, Medical University of Vienna, Austria

Banu Ozturk, Health Science University, Antalya Education and Research Hospital, Turkey

EP1.12-25 Comparison in Therapeutic of Operation Combined with Chemotherapy and with pd-1 and pd-11 Inhibitors for Stage 2 Small Cell Lung Cancer
Yu Zhang, The First Hospital of Lanzhou University, China

EP1.12-26 Retrospective Study About the Impact of Brain Metastases and Cranial Irradiation in Small Cell Lung Cancer
Dario Sanchez Cabrero, University Hospital La Paz, Spain

Sushmita Pathy, All India Institute of Medical Sciences, India

EP1.12-28 Anticancer Effects of Imipramine, Repositioned Drug, for Small Cell Lung Cancer
Ki Up Kim, Soon Chun Hyang University Hospital, Korea, Republic of

EP1.12-29 Retrospective Study About Small Cell Lung Cancer: Our Experience in a Spanish Hospital
Dario Sanchez Cabrero, University Hospital La Paz, Spain

EP1.12-30 Clinicopathological Features and Survival of Lung Neuroendocrine Tumors
Luis Mas, National Cancer Institute Peru, Peru

EP1.12-31 Response Rates and Overall Survival in Brazilian Patients Diagnosed with Small Cell Lung Carcinoma
Luiza Araujo, CIPE- AC Camargo Cancer Center, Brazil

EP1.12-32 Clinicopathological Features of Small Cell Lung Cancer in Albanian Patients
Daniela Xhemalaj, University Hospital “Shefket Ndroqi”, Albania

EP1.12-33 Prognostic Analysis of Surgery vs. Conservative Therapy with Chemotherapy in Stage of Limited Disease Small Cell Lung Cancer
Ayhan Berber, Mathias Spital Rheine, Germany

EP1.12-34 Small Cell Lung Cancer Revealed by Choroidal Metastasis: Case Report
Mohamed Rahli, Beni Messous Hospital, Algeria

EP1.12-35 Comparison of Long Term Results Between Matched Chemoradiotherapy and Surgery for Limited Stage Small Cell Lung Cancer
Mengyuan Chen, Zhejiang Cancer Hospital, China

EP1.12-36 Treatment Outcomes and Risk Factors of Limited-Stage Small Cell Lung Cancer Patients Treated with Chemoradiotherapy
Toyoukazu Hayakawa, Kitasato University, Japan

EP1.12-37 Higher Consistency of Mutations Between Tumor DNA and ctDNA in Small-Cell Lung Cancer Compared to Non-Small Cell Lung Cancer
Hongxia Ma, The Affiliated Traditional Medical Hospital of Xinjiang Medical University, China

EP1.12-38 Retrospective Analysis of Immunotherapy Utilization in Advanced Small Cell Carcinoma at an Academic Cancer Center
Tiffany George, The Ohio State University, United States of America

Asieh Golozar, AstraZeneca, United States of America

EP1.12-40 Neuroendocrine Tumors of the Lung: Clinicopathological Characterization and Follow-Up of Patients Treated at an Argentinean University Hospital in the Last 10 Years
A. Giorlando, Instituto Angel H. Roffo, Argentina

EP1.13 08:00 - 18:00 STAGING

Track(s): Staging

EP1.13-01 Multiple Lung Nodules: Histopathologic, Molecular and Clinic Approach Outcomes
Nicolas Minatta, Hospital Italiano de Buenos Aires, Argentina

EP1.13-02 Negative Predictive Value of EBUS-TBNA for Mediastinal Staging of Non-Small Cell Lung Cancer
Ioannis Gkiozos, Oncology Center of Biomedical Research and Education, Greece

EP1.14 08:00 - 18:00 TARGETED THERAPY

Track(s): Targeted Therapy

EP1.14-01 Major Therapeutic Response to T-DM1 in Metastatic Lung Adenocarcinoma with HER2 Mutation
Matteo Giag Levra, CHU Grenoble, France

EP1.14-02 Comparative Efficacy of First-Line Ceritinib at a Dose of 450mg with Food and Alectinib in Advanced ALK+ NSCLC
Donghao Shen, Fudan University Shanghai Cancer Center, China

EP1.14-03 Driver Genes as Predictive Indicators of Brain Metastasis in Patients with Advanced NSCLC: EGFR and ALK as Well as RET Gene Mutations
Huijuan Wang, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, China

EP1.14-04 Validation of New Targets Interfering at Phosphatidylethanolamine Production Against NSCLC
Sarah Fernandez Teixeira, Institute of Biomedical Sciences of University of Sao Paulo, Brazil

EP1.14-05 Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation
Tadaaki Yamada, Kyoto Prefectural University of Medicine, Japan

EP1.14-06 Clinical Application of an Appropriate Size NGS Panel in Advanced Non-Small Cell Lung Cancer Management: Personal Experience
Kai-Che Tung, ACT Genomics Co., Ltd., Taiwan

EP1.14-07 Efficacy and Safety of ALK Inhibitors in ALK-Rearranged Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
Daniel Breadner, London Regional Cancer Program, Canada

EP1.14-08 Irreversible Severe Cardiotoxicities Except for QTc Interval Prolongation Associated with Osimertinib
Kei Kunimasa, Osaka International Cancer Institute, Japan
EP1.14-09 Characterization of Actionable BRAFV600E and Co-Mutations in Non-Small Cell Lung Cancer (NSCLC) Patients
Pimtip Sanvarinda, Faculty of Science, Mahidol University, Thailand

Naoko Sueoka-Aragane, Saga University Hospital, Division of Respiratory Medicine, Japan

EP1.14-11 Real-Life Data of Osimertinib in Pretreated Patients with Advanced Non-Small Cell Lung Cancer harboring EGFR T790M Mutation
Cristina Alfaro Autor, Hospital Puerta De Hierro Majadahonda, Spain

EP1.14-12 KRAS Exon 2 Mutation - A Resistance Pathway to 1st and 2nd Generation EGFR TKIs
Mor Moskovitz, Rambam Health Care Campus, Israel

EP1.14-13 EGFR Mutation in Lung Adenocarcinoma: Real World Study from a Single Institute
Gebang Wang, Liaoaniong Cancer Hospital & Institute, China

EP1.14-14 MUC1 Confers Chemotherapy Resistance of Tumor-Initiating Cells Through EGFR-IL-6 Axis
Lei Huang, Shanghai Jiao Tong University School of Medicine, China

Sara Agraso Busto, Hospital Alvaro Cunqueiro, Spain

EP1.14-16 Use of Digital Droplet PCR for Detecting EGFR T790M Resistance Mutation in Plasma at Progression on TKI Therapy
Mats Jönsson, IKVL, Sweden

EP1.14-17 Acquired T790M Mutation in Patients Failing Treatment with First or Second-Generation EGFR-Tyrosine Kinase Inhibitors
Chong Kin Liam, University of Malaya, Malaysia

EP1.14-18 NGS-Molecular Characterization of Lung Adenocarcinomas from Hispanic Patients: Level of Evidence for Therapeutic Actionability
Oscar Gerardo Arrieta, Instituto Nacional de Cancerologia, Mexico

EP1.14-19 Efficacy and Safety of Afatinib for Advanced Lung Adenocarcinoma Patients with Sensitive EGFR Mutations in Chinese Population
Shouzheng Wang, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China

EP1.14-20 EGFR T790M Mutated Cells Are Not a New Emerging Sub-Clonal Population in Lung Adenocarcinoma After the Treatment of Targeted Therapy
Xiaohua Shi, Peking Union Medical College Hospital, China

EP1.14-21 Implementing Precision Medicine in a Community Cancer Center to Impact Outcomes in Lung Cancer
Elizabeth Hassen, Gibbs Cancer Center, United States of America

EP1.14-22 Amplification and Overexpression of MET in Brain Metastases of Non-Small Cell Lung Cancer
Nalan Akyurek, Gazi University Medical School, Turkey

EP1.14-23 Comparison of Molecular Testing Using Various Specimens for Non-Small Cell Lung Cancers
Tatsuo Ohira, Tokyo Medical University, Japan

EP1.14-24 Lenvatinib for Recurrent Metastatic Adenoid Cystic Carcinomas (ACC) of the Lung
Luai Al Rabadi, Oregon Health & Science University, United States of America

EP1.14-25 Development of New Lung Cancer Therapies Based on Gene-Editing Technologies
Juan Carlos Alvaréz Pérez, Universidad de Granada, Spain

EP1.14-26 Uncommon EGFR Mutations Sensitive to First-Generation EGFR-TKI, Icotinib
Dongsheng Yue, Tianjin Medical University Cancer Institute and Hospital, China

EP1.14-27 Retroperitoneal Pseudotumor Induced by Crizotinib Treatment for CMET ex14 Skip Mutation NSCLC
Roni Gillis, Ben Gurion University of the Negev, Israel

Vera Hirsh, McGill University, Canada

EP1.14-29 Mutational Landscape in Lung Cancer Patients by Targeted Next-Generation Sequencing and Differences by Gender in Spanish Population
Beatriz Jimenez Munarriz, Hm Sanchinarro, Spain

Rebeca Natal, Local Health Unit of Guarda, Portugal

EP1.14-31 Retrospective Study About EGFR Mutations in Lung Cancer: Our Experience in a Spanish Hospital
Dario Sanchez Cabrero, University Hospital La Paz, Spain

EP1.14-32 Pattern of EGFR Mutations and Response to First Generation EGFR TKIs in Patients of Metastatic Lung Cancer at a Tertiary Care Centre in India
Smita Saldanha, Kidwai Cancer Institute, India

EP1.14-33 Intestinal Metastasis from Primary ROS1-Positive Lung Adenocarcinoma Patients Responding to Crizotinib
Chunwei Xu, Fujian Cancer Hospital, China

EP1.14-34 Advanced NSCLC Treated with Gefitinib or Erlotinib for Five Years or Longer - Updated Data from the Retrospective Slovakian Study
Peter Berzinec, Specialised Hospital of St Zoerardus Zobor, Slovak Republic

EP1.14-35 Squamous Cell Carcinoma Transformation After Acquired Resistance to Osimertinib
Chii-Lu Chiang, Taipei Veterans General Hospital, Taiwan

EP1.14-36 Suicide Gene Therapy Directed by MicroRNA Activity
Alberto Arenas, Genyo - University of Granada, Spain

EP1.14-37 Anlotinib-Induced Broncho-Pericardial/Pleural Fistula in Patients Suffering from Lung Cancer (First Report)
Pengbo Deng, Xiangya Hospital of Central South University, China

EP1.14-38 Prolonged Survival in a Case of NSCLC with Recurrent Brain Metastasis - A Case Report
Subhasis Mishra, All India Institute of Medical Sciences, India

EP1.14-39 BRG1 Deficient Cells Are Sensitive to the Inhibition of Specific Lysine Demethylases (KDMs) in Lung Cancer
Octavio Romero, PEBCL-IDIBELL, Spain

Nadia Benchakroun, CHU Ibn Rochd, Morocco

EP1.14-41 Case Series: Lung Neuroendocrine Carcinoma with EGFR Mutation
Jamal Zaini, Persahabatan Hospital/ Fakultas Kedokteran Universitas Indonesia, Indonesia
EP1.15-01 A Spanish Initiative to Know the Unmet Needs of Women with Lung Cancer: “Círculos Program”
Rosario Garcia Campelo, Complejo Hospitalario Universitario A Coruna, Spain

EP1.15-02 Proactively Improving the Management of Immune-Related Adverse Events (irAEs) in a Community Cancer Program
Lavinia Dobrea, St. Joseph Hospital, St. Joseph Health, United States of America

EP1.15-03 Trial of Cost-Effectiveness Analysis of Lung Cancer Surgery-Analysis in Stage IIIA Lung Cancer
Takanori Miyoshi, Yuri Memorial Hospital, Japan

EP1.15-04 Real World Clinical Outcomes for Metastatic Non-Small Cell Lung Cancer (mNSCLC) at IRST Italy
Angelo Delmonte, IRST-IRCCS, Italy

EP1.15-05 Real World Outcomes of Advanced NSCLC Patients with Liver Metastases
Natasha Leighl, Princess Margaret Cancer Centre, Canada

EP1.15-06 Real World Diagnosis and Treatment Outcomes in Patients with EGFR-Mutant Metastatic Lung Cancer
Tianhong Li, University of California Davis Comprehensive Cancer Center, United States of America

EP1.15-07 National, Observational, Multicentric Study in Stage III Non-Small Cell Lung Cancer Patients in Turkey: Stone Trial
Ozan Guler, Başkent Universitesi, Turkey

EP1.15-08 Behobiamedipulmonary: Putting Face and Running Shoes on Patients with Lung Cancer
Jon Zabaleta, Donostia University Hospital, Spain

EP1.15-09 Delays in Care of Lung Cancer: A Moroccan Public Health Problem
Nadia Benchakroun, CHU Ibn Rochd, Morocco

EP1.15-10 Differentiation of Performance Status After Tumor Debulking in Malignant Central Airway Tumor via Rigid Bronchoscopy
Porrapat Aungkajornkul, Phramongkutkla Hospital, Thailand

EP1.15-11 Immunotherapy in NSCLC: Real World Experience in a Peruvian Population
Carlos Carracedo Gonzales, Aliada, Peru

EP1.15-12 Right vs Left Lung Cancer – Prognostic Implications
Taha Khalil, Sligo University Hospital, Ireland

EP1.15-13 Characteristics and Clinical Outcomes in Patients with Non-Small Cell Lung Carcinoma in Fundacion Santa Fe De Bogota: 42 Months Experience
Aylen Vanessa Ospina Serrano, Hospital Universitario Fundacion Santa Fe De Bogota, Colombia

EP1.15-14 Efficacy of First-Line Continuous Maintenance of Pemetrexed Therapy for Lung Adenocarcinoma When Administered at Routine or Extended Intervals
Xiaorong Dong, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, China

EP1.15-15 Subclinical Interstitial Lung Disease is a Risk Factor for Radiation Pneumonitis in Patients with Lung Cancer After Thoracic Radiation Therapy
Fangjuan Li, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China

EP1.15-16 Pembrolizumab as First Therapeutic Line in Non-Small Cell Lung Cancer – The Experience of a Portuguese Tertiary Hospital
Nuno China Pereira, Centro Hospitalar Vila Nova de Gaia/Esposinho, E.P.E., Portugal

EP1.15-17 Management of Inappropriate Use of Opioids (IUO) in Patients (P) with Lung Cancer (LC)
Teresa Moran, Catalan Institute of Oncology-Badalona; B-ARGO; IGTP, Spain

EP1.15-18 EGFR Mutation Positive Non-Small Cell Lung Cancer: Management Approach and Survival Outcomes from the Hospital of Leon
Irene Delgado Silero, Complejo Asistencial Universitario de León, Spain

EP1.15-19 Expected Years of Life Loss and Survival Outcome in Non-Small Cell Lung Cancer Patients in Rajavithi Hospital
Suntee Sa-Nguansai, College of Medicine, Rangsit University, Thailand

EP1.15-20 Pembrolizumab - Subsequent Lines in Non-Small Cell Lung Cancer: The Experience of a Tertiary Hospital
Nuno China Pereira, Centro Hospitalar Vila Nova de Gaia/Esposinho, E.P.E., Portugal
EP1.16-21 Frequencies and Prognosis of Non-Small Cell Lung Cancers Complicated with Synchronous/Metachronous Multiple Primary Cancers
Takeshi Honda, Teikyo University School of Medicine, Japan

EP1.16-22 Pemetrexed, Platinumum Combination with Bevacizumab for Chinese Patients with Advanced Lung Adenocarcinoma Cancer: A Real World Study
Xueqin Chen, Hangzhou Cancer Hospital, China

EP1.16-23 The Efficacy of S-1 in the Third or More Than Line Treatment of Advanced Non-Small Cell Lung Cancer Patients Chunwei Xu, Fujian Cancer Hospital, China

EP1.16-24 Overcoming Appointment Delay in Radiotherapy: A Single Institution Experience
Mohamed Ait Erraissi, University Hospital Hassan II, Morocco

EP1.16-25 Investigating the System Impact of Reporting Multidisciplinary Care Measures for Cancer Services in NSW
Kahren White, Cancer Institute NSW, Australia

EP1.16-26 Prehabilitation for Lung Cancer Patients Receiving Radical Radiotherapy
Pamela Rose, The Beatson West of Scotland Cancer Centre, United Kingdom

EP1.16-27 Observational Study to Investigate the Implementation Rate of Re-Biopsy in EGFR-TKI-Resistant Patients (NLCTG062)
Koichiro Nozaki, Niigata University Graduate School of Medical and Dental Sciences, Japan

EP1.16-28 ALK Translocated Patients: Survival in an Unselected Population
Beatriz Núñez-Garcia, Puerta de Hierro, Spain

EP1.16-29 Clinical Characteristics and Outcomes of Postoperative Empyema Following Lung Surgery
Kenji Kameyama, Kyoto prefectural university of medicine, Japan

EP1.16-30 Benign Emptying of the Post-Pneumonectomy Space
Filipe Leite, Instituto Português de Oncologia do Porto, Portugal

EP1.16-31 Disenfranchised Grief Tools Used in the Treatment of Bereavement, Are Used in the Therapy of Cancer Patients
Avital Kapah, Soroka Medical Center, Israel

EP1.16-32 Percentage of ALK Rearrangement as a Response Predictor in Non-Small Cell Lung Cancer Treatment
Marcos Oliveira, Unidade Local de Saúde da Guarda, Portugal

EP1.16-33 QT Prolongation in an EGFR 19 Deletion Lung Adenocarcinoma Patient from Icotinib Treatment
Chunwei Xu, Fujian Cancer Hospital, China

EP1.16-34 Survival Analysis of Icotinib for Brain Metastases in EGFR Mutated Non-Small Cell Lung Cancer
Chunwei Xu, Fujian Cancer Hospital, China

Sittthi Sukauachai, Chonburi Cancer Hospital, Thailand

EP1.16-36 A Good Intestinal Bacterial Environment Can Reduce the Side Effects of Tyrosine Kinase Inhibitors and Enhance Their Anti-Cancer Effects
Junichi Shimada, Kyoto Prefectural University of Medicine, Japan

EP1.16-37 Correlation of Serum Albumin and CRP Levels with Chemotherapy Toxicity in Patients of Metastatic Lung Cancer
Smitha Saldanha, Kidwai Cancer Institute, India

EP1.16-38 Pulmonary Infiltrates in Patients Treated with Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy
Asuka Okada, Saiseikai Suita Hospital, Japan

EP1.16-39 Prospective Epidemiological Study of Metastatic Non-Small Cell Lung Cancer (NSCLC) in Latin America – LATINO Lung (LACOG 0116)
Ana Gelatti, Hospital Mãe de Deus, Brazil

EP1.16-40 Communicating with Lung Cancer Patients in Eastern European Country: Topics of Interest
Tomi Kovacevic, Institute for Pulmonary Diseases of Vojvodina, Serbia

EP1.16-41 Lung Lobectomy for Elderly Patients Over 85 Years Old Is a Risk of a Complication and Long-Term Hospitalization Compared with Sublobar Resection
Kentaro Nakata, Okayama University Hospital, Japan

EP1.16-42 Pharmaceutical Follow-Up Program for Patients with Driver Mutation in Non-Small Cells Lung Cancer
Gisele Moreira, Grupo Oncoclinicas, Brazil

EP1.16-43 Combined Prognostic Value of CYFRA 21-1 and CEA in Overall Survival of Patients with III-IV Clinical Stage NSCLC
Claudio J Flores, Oncosaudal, Peru

EP1.16-44 Survival and Prognostic Association of Non-Small Cell Lung Cancer with Brain Metastases After WBRT: A Multicentre Study
Md Shuayb, University of British Columbia, Canada

EP1.16-45 The Use of Propensity Score Matching to Analyze the Effectiveness of Medical Procedures on the Example of Survival of Patients with Lung Tumors
Ewelina Nojszewska, Warsaw School of Economics, Poland

EP1.17 08:00 - 18:00 TREATMENT OF EARLY STAGE/LOCALIZED DISEASE
Exhibit Hall

EP1.17-01 Surgical Resection of Synchronous Quadruple Primary Lung Tumors Present as Three-Different Cancers and One Benign Mass
Yongjik Lee, Ulsan University Hospital, University of Ulsan, College of Medicine, Korea, Republic of

EP1.17-02 Artificial Intelligence in the Qualitative Study of Pulmonary Nodules by Analyzing the Genetic Map and Imaging Data of Lung Adenocarcinoma
Yu Zhang, The First Hospital of Lanzhou University, China

EP1.17-03 New Approach to Complete Video-Assisted Thoracoscopic Lobectomy in T2 and T3 Non-Small Cell Lung Cancer
Masato Kato, Hiramatsu Hospital, Japan

EP1.17-04 Pneumonectomy Should Be Avoided in Patients Who Do Not Reach the Distance of 500 Meters in 6-Minute Walking Test Due to High Early Mortality
Tomasz Marjanski, Medical University of Gdansk, Poland

EP1.17-05 Uniportal Video-Assisted Thoracoscopic Surgery Lobectomy and Segmentectomy for Early Stage Lung Cancer
Runlei Hu, Hangzhou First People’s Hospital, China

Aya Yamamoto, Kansai Rosai Hospital, Japan

EP1.17-07 Partial Anomalous Pulmonary Venous Connection Found During a Lobectomy for Lung Cancer
Fumi Yokote, Teikyo University School of Medicine, Japan
Jianye Chen, National University Hospital Singapore, Singapore

EP1.17-09 Survival Analysis of 911 Patients with Surgically Resected Lung Cancers
Jun Zhang, China Medical University Lung Cancer Center, The First Hospital of China Medical University, China

EP1.17-10 First Results of the Bronchial Cancer Registry of the Biologically Effective Dose Was Associated with Feasibility Study on the Central of Massive Lesion in Comparison of Long-Term Outcome of Wedge Skin Fluorescence Following Photodynamic Therapy
Good Survival in Females Undergoing Surgery Multimodal Aggressive Management for Askin’ Tumor: Omentopexy for Post-Pneumonectomy Association Between the Number of Resected Lymph Survival Analysis of 911 Patients with Surgically Long-Term Outcomes of Pulmonary Resection for Robotic-Assisted Thoracic Surgery for Early Stage NSCLC (ES-NSCLC) 5-Fraction Evaluation of the Influence of Removed Lymph Nodes Influence of Insurance Status on Survival of Patients Operated Stages I-II Non-Small Cell Lung Cancer with High-Dose Radiotherapy

EP1.17-11 Non-Small Cell Lung Cancer Survival: Gender Inequality After Lung Resection?
Maria Teresa Tsukazan, PUCRS Medical School, Brazil

EP1.17-12 Multimodal Aggressive Management for Askin’ Tumor: Results and Prognosis About 3 Cases
Ihsan Alloubi, CHU Med VI, Morocco

EP1.17-13 Operated Stages I-IIIB NSCLC Among Young Indian Cohorts - Clinical Profile and Outcomes
Jyoutishman Saikia, DR BRAIRCH, All India Institute of Medical Sciences, India

EP1.17-14 Less Is More: An Unusual Case of Benign Emptying of the Post - Pneumonectomy Space
Giovanni Bocchialini, University Hospital of Parma, Italy

EP1.17-15 Comparison of Long-Term Outcome of Wedge Resection, Anatomical Segmentectomy and Lobectomy in Stage I-II Non-Small Cell Lung Cancer
Katharina Sinn, Medical University of Vienna, Austria

EP1.17-16 Ultra-Small Lung Cancer (<0.5cm) Is Facing Dilemma Situation of Over-Resection
Jun Zhang, China Medical University Lung Cancer Center, The First Hospital of China Medical University, China

EP1.17-17 Feasibility Study on the Central of Massive Lesion in Non-Small Cell Lung Cancer with High-Dose Radiotherapy
Jiancheng Li, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, China

EP1.17-18 Neutrophil Count Is Non-Prognostic in Early Stage Lung Cancer Treated with SABR: Retrospective Analysis from a Single UK Centre Cohort
Tamasin Evans, The Edinburgh Cancer Centre, Western General Hospital, United Kingdom

Domenico Galetta, European Institute of Oncology, Italy

EP1.17-20 Influence of Insurance Status on Survival of Patients with Non-Small Cell Lung Cancer Underwent Surgical Treatment Yooehwa Hwang, Seoul National Bundang Hospital, Korea, Republic of

EP1.17-21 Early Stage NSCLC (ES-NSCLC) 5-Fraction Stereotactic Body Radiation Therapy (SBRT) 3-Year Patterns of Failure
Rebecca Krochmal, Georgetown University Hospital, United States of America

EP1.17-22 In Stage I Non-Small Cell Lung Cancer, Abutting Adjacent Structures Is a Possible Prognostic Factor
Jaeshin Yoon, Seoul St. Mary’s Hospital, Korea, Republic of

EP1.17-23 Omentopexy for Post-Pneumonectomy Bronchopleural Fistula in Patients with Non-Small Cell Lung Cancer After Salvage Radiotherapy
Deoggon Cho, St. Vincent Hospital, Korea, Republic of

EP1.17-24 Biologically Effective Dose Was Associated with Overall Survival in Stereotactic Body Radiotherapy for Lung Tumors
Osamu Tanaka, Asahi University Hospital, Japan

EP1.17-25 Radio-Guided Localization of Small Lung Nodules
Samuel Garcia-Reina, Hospital Universitari Germans Trias i Pujol, Spain

EP1.17-26 Spontaneous Right Contralateral Total Pneumothorax in Bullous Lung After Left Pneumonectomy for Lung Cancer Fadil Gradica, University Hospital “Shefqet Ndroqi”, Albania

EP1.17-27 Development of Titanium Alloy Vascular Mirror Forceps for Uniportal VATS
Junichi Shimada, Kyoto Prefectural University of Medicine, Japan

Po-Kuei Hsu, Taipei Veterans General Hospital, Taiwan

EP1.17-29 Evaluation of the Influence of Removed Lymph Nodes during VATS-Lobectomy in the Group of Patients with Early Stage of NSCLC on Long-Term Results
Dariusz Dziedzic, National Institute of Chest Diseases, Warsaw, Poland, Poland

Futoshi Ishiguro, Ogaki Municipal Hospital, Japan

Fatmir Caushi, University Hospital "Shefqet Ndroqi", Albania

EP1.17-32 Long-Term Outcomes of Pulmonary Resection for Lung Cancer Patients with Chronic Kidney Disease
Yoko Yamamoto, Osaka University Graduate School of Medicine, Japan

EP1.17-33 Predictors of Air-Related Complication and Re- Intervention After Pleural Drainage Tube Removal in Digital Thoracic Drainage System Use
YiYing Lee, Taipei Veterans General Hospital, Taiwan

EP1.17-34 Association Between the Number of Resected Lymph Nodes and Long-Term Survival in NO Non-Small Cell Lung Cancer: Data from a Chinese Large Cohort
Hao-Xian Yang, Sun Yat-Sen University Cancer Center, China

EP1.17-35 CBCT Radiomics May Predict Short-Term SBRT Effect in Early Stage Lung Cancer Patients
Liqiao Hou, Radiation Oncology Institute of Enze Medical Health Academy, Affiliated Taizhou Hospital of Wenzhou Medical University, China

EP1.17-36 Skin Fluorescence Following Photodynamic Therapy with Talaporfin Sodium
Sachio Maehara, Tokyo Medical University, Japan

EP1.18 08:00 - 18:00 TREATMENT OF LOCOREGIONAL DISEASE - NSCLC

EP1.18-01 Effectiveness of Video-Assisted Surgery and Pre-Operative Multi-Disciplinary Support for Preserving Respiratory Function
Masafumi Kataoka, Okayama Saiseikai General Hospital, Japan
AUTHOR INDEX

Listing in bold = Presenting author
AUTHOR INDEX

P1.01-33, P1.01-50, P1.01-69, P1.11-23, P1.12-69

P1.01-04, P1.01-22, P1.01-27, P1.01-34, P1.01-42

P2.14-07, P2.14-09, P2.14-10, P2.14-11, P2.14-12

P1.01-05, P1.01-06, P1.01-07, P1.01-08, P1.01-09, P1.01-10

P2.01-04, P2.01-05, P2.01-06, P2.01-07, P2.01-08, P2.01-09, P2.01-10

P1.01-01, P1.01-02, P1.01-03, P1.01-04, P1.01-05, P1.01-06

P1.11-23, P1.12-69, P1.13-04, P1.13-05, P1.13-06

P2.01-02, P2.01-03, P2.01-04, P2.01-05, P2.01-06

P1.01-01, P1.01-02, P1.01-03, P1.01-04, P1.01-05, P1.01-06

P2.01-01, P2.01-02, P2.01-03, P2.01-04, P2.01-05

P1.11-23, P1.12-69, P1.13-04, P1.13-05, P1.13-06

P2.01-02, P2.01-03, P2.01-04, P2.01-05, P2.01-06

P1.01-01, P1.01-02, P1.01-03, P1.01-04, P1.01-05, P1.01-06

P2.01-01, P2.01-02, P2.01-03, P2.01-04, P2.01-05
Gran Via, Fira de Barcelona

Hall 8.1 (Level 2) | Exhibit Hall
Hall 8.0 (Level 1) | Session Rooms

Hall 6 Barcelona (2005) | Plenary Sessions

MAPS & FLOOR PLANS

- Parada Taxi
- Parada Bus
- Aparcamiento
- Metro
- Ferrocarrils de la Generalitat
- Helipuerto
- Centro de Convenciones

P1, P2, P3, P4, P5, P6, P7, P8

Plenary Sessions
Exhibit Hall
Session Rooms
JOIN TODAY!

As an IASLC member, you will receive:

› Collaboration with a multidisciplinary global team of thoracic oncology experts and leaders

› Member access to the Journal of Thoracic Oncology, the premier journal in lung cancer, as well as the latest classification and staging publications

› Multidisciplinary education including the latest in groundbreaking research and treatment of thoracic malignancies

FELLOWS, RESIDENTS AND TRAINEES MAY APPLY FOR A FREE, NON-VOTING FELLOW MEMBERSHIP!

See us in the Exhibit Hall at Booth 300 or at the IASLC Membership Booth at Registration
Apply at iaslc.org
11
EXHIBIT & SPONSOR INFORMATION

wclc2019.iaslc.org
@IASLC
iaslc.lung
facebook.com/IASLC
#WCLC19
Bristol-Myers Squibb – at the intersection of DESIGN & DISCOVERY.

Visit the Bristol-Myers Squibb I-O booth 600 to learn more.
As precision oncology advances, FOCUS ON RET

RET alterations are primary oncogenic drivers across a diverse range of tumor types.\(^5\) Investigation into selective RET inhibition is actively advancing. Now is the time to consider adding RET as the next actionable biomarker that may be identified through tumor genomic testing, such as next-generation sequencing.

**Are You Ready for RET?**
Learn more at RETalteredcancers.com and visit our WCLC booth #502.

There is no guarantee that any agents under investigation will receive health authority approval or become commercially available in any country for the uses being investigated.

**RET** rearranged during transfection.

Conference Sponsors

IASLC 2019 WCLC OFFICIAL MOBILE APP

Boehringer Ingelheim

Daiichi-Sankyo

IASLC 2019 WCLC OFFICIAL MOBILE APP

Janssen Oncology

Univadis Oncology

IASLC 2019 WCLC OFFICIAL MOBILE APP

Abbvie

Janssen Oncology

AstraZeneca

AMGEN

AMGEN

IASLC 2019 WCLC OFFICIAL MOBILE APP

INTERNET CAFÉ

Delegatel Help Desk

FACULTY DINNER

PATIENT ADVOCACY LOUNGE

UNIVERSITY OF MARYLAND

NEWSPAPER

SATURDAY EDITION SUPPORTED BY

SUNDAY & MONDAY EDITIONS SUPPORTED BY

TUESDAY EDITION SUPPORTED BY

AMGEN

Bayer

Novartis
### Exhibitor Listings

#### EXHIBITORS BY NAME

<table>
<thead>
<tr>
<th>Company</th>
<th>Booth #</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Breath Of Hope Lung Foundation</td>
<td>717</td>
</tr>
<tr>
<td>AEACaP</td>
<td>627</td>
</tr>
<tr>
<td>Amgen</td>
<td>102</td>
</tr>
<tr>
<td>Amoy Diagnostics</td>
<td>611</td>
</tr>
<tr>
<td>ArcherDX, Inc.</td>
<td>402</td>
</tr>
<tr>
<td>AstraZeneca</td>
<td>100</td>
</tr>
<tr>
<td>Bayer Healthcare Pharmaceuticals, Inc.</td>
<td>305</td>
</tr>
<tr>
<td>Biodexis, Inc.</td>
<td>302</td>
</tr>
<tr>
<td>Boehringer Ingelheim</td>
<td>307</td>
</tr>
<tr>
<td>Bristol-Myers Squibb</td>
<td>600</td>
</tr>
<tr>
<td>Celgene Corporation</td>
<td>103</td>
</tr>
<tr>
<td>Daiichi Sankyo Inc.</td>
<td>314</td>
</tr>
<tr>
<td>Exelixis Inc</td>
<td>705</td>
</tr>
<tr>
<td>F. Hoffmann-La Roche</td>
<td>400</td>
</tr>
<tr>
<td>F. Hoffmann-La Roche AG - Business Suite</td>
<td>403</td>
</tr>
<tr>
<td>Genmab</td>
<td>606</td>
</tr>
<tr>
<td>Global Lung Cancer Coalition</td>
<td>208</td>
</tr>
<tr>
<td>Guardant Health</td>
<td>609</td>
</tr>
<tr>
<td>IASLC</td>
<td>300</td>
</tr>
<tr>
<td>IASLC 2020 World Conference on Lung Cancer</td>
<td>204</td>
</tr>
<tr>
<td>Illumina</td>
<td>607</td>
</tr>
<tr>
<td>Inivata</td>
<td>612</td>
</tr>
<tr>
<td>International Thoracic Oncology Nursing Forum (ITONF)</td>
<td>630</td>
</tr>
<tr>
<td>Israeli Lung Cancer Foundation</td>
<td>629</td>
</tr>
<tr>
<td>Korean Association for Lung Cancer</td>
<td>718</td>
</tr>
<tr>
<td>Lilly Oncology</td>
<td>500</td>
</tr>
<tr>
<td>Loxo Oncology</td>
<td>502</td>
</tr>
<tr>
<td>Lung Ambition Alliance</td>
<td>614</td>
</tr>
<tr>
<td>Lung Cancer Europe</td>
<td>628</td>
</tr>
<tr>
<td>MeVis Medical Solutions AG</td>
<td>209</td>
</tr>
<tr>
<td>MSD</td>
<td>700</td>
</tr>
<tr>
<td>National Lung Cancer Forum for Nurses</td>
<td>203</td>
</tr>
<tr>
<td>NeoGenomics</td>
<td>111</td>
</tr>
<tr>
<td>NIHR IDEAL &amp; Optellum</td>
<td>207</td>
</tr>
<tr>
<td>Novartis</td>
<td>409</td>
</tr>
<tr>
<td>Novocure, Inc.</td>
<td>319</td>
</tr>
<tr>
<td>Ology Medical Education</td>
<td>206</td>
</tr>
<tr>
<td>Oncimmune</td>
<td>702</td>
</tr>
<tr>
<td>Oncology Central</td>
<td>304</td>
</tr>
<tr>
<td>OSE Immunotherapeutics</td>
<td>106</td>
</tr>
<tr>
<td>PER Global, LLC</td>
<td>303</td>
</tr>
<tr>
<td>Pfizer Oncology</td>
<td>200</td>
</tr>
<tr>
<td>Polish Lung Cancer Group</td>
<td>631</td>
</tr>
<tr>
<td>Scanlan International, Inc.</td>
<td>320</td>
</tr>
<tr>
<td>Spectrum Pharmaceuticals</td>
<td>205</td>
</tr>
<tr>
<td>Springer Healthcare</td>
<td>202</td>
</tr>
<tr>
<td>Takeda</td>
<td>309</td>
</tr>
<tr>
<td>TESARO</td>
<td>313</td>
</tr>
<tr>
<td>Univadis Oncology</td>
<td>703</td>
</tr>
<tr>
<td>Wisepress Ltd.</td>
<td>719</td>
</tr>
</tbody>
</table>

#### EXHIBITORS BY BOOTH NUMBER

<table>
<thead>
<tr>
<th>Booth #</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>100</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td>102</td>
<td>Amgen</td>
</tr>
<tr>
<td>103</td>
<td>Celgene Corporation</td>
</tr>
<tr>
<td>106</td>
<td>OSE Immunotherapeutics</td>
</tr>
<tr>
<td>111</td>
<td>NeoGenomics</td>
</tr>
<tr>
<td>200</td>
<td>Pfizer Oncology</td>
</tr>
<tr>
<td>202</td>
<td>Springer Healthcare</td>
</tr>
<tr>
<td>203</td>
<td>National Lung Cancer Forum for Nurses</td>
</tr>
<tr>
<td>204</td>
<td>IASLC 2020 World Conference on Lung Cancer</td>
</tr>
<tr>
<td>205</td>
<td>Spectrum Pharmaceuticals</td>
</tr>
<tr>
<td>206</td>
<td>Ology Medical Education</td>
</tr>
<tr>
<td>207</td>
<td>NIHR IDEAL &amp; Optellum</td>
</tr>
<tr>
<td>208</td>
<td>Global Lung Cancer Coalition</td>
</tr>
<tr>
<td>209</td>
<td>MeVis Medical Solutions AG</td>
</tr>
<tr>
<td>300</td>
<td>IASLC</td>
</tr>
<tr>
<td>302</td>
<td>Biodexis, Inc.</td>
</tr>
<tr>
<td>303</td>
<td>PER Global, LLC</td>
</tr>
<tr>
<td>304</td>
<td>Oncology Central</td>
</tr>
<tr>
<td>305</td>
<td>Bayer Healthcare Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>307</td>
<td>Boehringer Ingelheim</td>
</tr>
<tr>
<td>309</td>
<td>Takeda</td>
</tr>
<tr>
<td>313</td>
<td>TESARO</td>
</tr>
<tr>
<td>314</td>
<td>Daiichi Sankyo Inc.</td>
</tr>
<tr>
<td>319</td>
<td>Novocure, Inc.</td>
</tr>
<tr>
<td>320</td>
<td>Scanlan International, Inc.</td>
</tr>
<tr>
<td>400</td>
<td>F. Hoffmann-La Roche AG - Business Suite</td>
</tr>
<tr>
<td>402</td>
<td>ArcherDX, Inc.</td>
</tr>
<tr>
<td>403</td>
<td>F. Hoffmann-La Roche</td>
</tr>
<tr>
<td>409</td>
<td>Novartis</td>
</tr>
<tr>
<td>500</td>
<td>Lilly Oncology</td>
</tr>
<tr>
<td>502</td>
<td>Loxo Oncology</td>
</tr>
<tr>
<td>600</td>
<td>Bristol-Myers Squibb</td>
</tr>
<tr>
<td>606</td>
<td>Genmab</td>
</tr>
<tr>
<td>607</td>
<td>Illumina</td>
</tr>
<tr>
<td>609</td>
<td>Guardant Health</td>
</tr>
<tr>
<td>611</td>
<td>Amoy Diagnostics</td>
</tr>
<tr>
<td>612</td>
<td>Inivata</td>
</tr>
<tr>
<td>614</td>
<td>Lung Ambition Alliance</td>
</tr>
<tr>
<td>627</td>
<td>AEACaP</td>
</tr>
<tr>
<td>628</td>
<td>Lung Cancer Europe</td>
</tr>
<tr>
<td>629</td>
<td>Israeli Lung Cancer Foundation</td>
</tr>
<tr>
<td>630</td>
<td>International Thoracic Oncology Nursing Forum (ITONF)</td>
</tr>
<tr>
<td>631</td>
<td>Polish Lung Cancer Group</td>
</tr>
<tr>
<td>700</td>
<td>MSD</td>
</tr>
<tr>
<td>702</td>
<td>Oncimmune</td>
</tr>
<tr>
<td>703</td>
<td>Univadis Oncology</td>
</tr>
<tr>
<td>705</td>
<td>Exelixis Inc</td>
</tr>
<tr>
<td>717</td>
<td>A Breath Of Hope Lung Foundation</td>
</tr>
<tr>
<td>718</td>
<td>Korean Association for Lung Cancer</td>
</tr>
<tr>
<td>719</td>
<td>Wisepress Ltd.</td>
</tr>
</tbody>
</table>
Exhibitor Descriptions

A Breath of Hope Lung Foundation

A Breath of Hope Lung Foundation, headquartered in Minnesota, works to improve lung cancer outcomes through research, public awareness, and patient education and support. ABOH has awarded $1.5 million in U.S. research funding and screening grants and provides an online animated patient guide to lung cancer in English/Spanish at youandlungcancer.com.

AEACaP Spanish Association of Lung Cancer Patients

AEACaP Spanish Association of Lung Cancer Patients is a nonprofit organization focused on:
- offering psychological support, advice and guidance to patients, affected and relatives,
- fighting to extend the lung cancer patients’ rights,
- contributing to the disease prevention,
- promoting university, scientific and medical researches

Amgen

Amgen is committed to the relentless pursuit of breakthroughs for cancer patients and their families. We are developing innovative medicines for difficult-to-treat cancers and advancing the largest pipeline of cancer therapies in our history. Our goal is to quickly advance new treatment options with the greatest potential benefit to patients.

Amoy Diagnostics

Amoy Diagnostics Co., Ltd. (AmoyDx) is an R&D based manufacturer of genetic testing products and diagnostic service provider for precision oncology. Our mission is to provide our customers with superior and innovative products and services to improve healthcare and patients’ lives.

ArcherDX

ArcherDX addresses the bottlenecks associated with using next-generation sequencing in translational research by offering a robust platform for targeted sequencing applications. By combining proprietary Anchored Multiplexed PCR (AMP) chemistry and easy-to-use, lyophilized reagents, ArcherDX technology generates highly enriched sequencing libraries to detect gene fusions, SNPs, indels and CNVs. Complemented by the Archer suite of bioinformatics software and readily accessible reports, ArcherDX technology dramatically enhances complex mutation identification and discovery.

AstraZeneca

AstraZeneca has a deep-rooted heritage in the Oncology therapeutic area. Our vision is to help patients by redefining the cancer treatment paradigm and one day eliminate cancer as a cause of death. Our broad pipeline of next-generation medicines is focused on four main disease areas - ovarian, lung, breast and haematological cancers. These are being targeted through four key platforms – immuno-oncology, genetic drivers of cancer and resistance, DNA damage repair and antibody drug conjugates.

Bayer

Bayer is committed to delivering SCIENCE FOR A BETTER LIFE by advancing a portfolio of innovative treatments. The oncology franchise includes both marketed products and clinical development compounds, which reflect the company’s approach to research; prioritizing targets and pathways with the potential to impact the way that cancer is treated.

Biodesix®

Biodesix® is a lung cancer diagnostic solutions company with three best-in-class blood tests addressing the continuum of patient care from early diagnosis of lung nodules through late stage cancer. We also enable our biopharma partners throughout the discovery, development and commercialization of personalized diagnostics to support new therapies with companion diagnostic strategies.
Boehringer Ingelheim

At Boehringer Ingelheim we are taking cancer on. We are collaborating with the oncology community to deliver scientific breakthroughs to transform the lives of patients. Our primary focus is in lung and gastrointestinal cancers, with the goal of delivering breakthrough, first-in-class treatments that can help win the fight against cancer.

Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing and delivering innovative medicines for patients with serious diseases. We are focused on helping patients in disease areas including oncology, cardiovascular, immunoscience and fibrosis. Each day, our employees work together for patients – it drives everything we do.

Celgene Corporation

Celgene Corporation (Nasdaq:CELG) is a global biopharmaceutical company that is helping healthcare providers turn incurable cancers into chronic, manageable diseases, as well as manage serious inflammatory conditions through innovative therapies. This dedication to medical progress goes hand-in-hand with our industry-leading patient support and access programs. Together, these aspects form the core of our commitment to patients worldwide. For more information, visit www.celgene.com

Daiichi Sankyo

With a legacy of more than 100 years of scientific expertise and its corporate origin in Japan, Daiichi Sankyo is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. For more information, please visit www.daiichisankyo.com

Visit us at the Lilly Booth: 500
Exhibitor Descriptions (Continued)

Exelisix

Exelisix is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers.

Genmab

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for cancer treatment. Genmab’s two marketed partnered products are DARZALEX® (daratumumab) and Arzerra® (ofatumumab). Genmab has a strong clinical and pre-clinical product pipeline of proprietary and partnered product candidates.

Global Lung Cancer Coalition

The Global Lung Cancer Coalition promotes global understanding of the burden of lung cancer and the right of patients to effective early detection, better treatment and supportive care. Serving as the international voice of lung cancer patients, the Global Lung Cancer Coalition is committed to improving disease outcomes for all.

Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally. In pursuit of its goal to manage cancer across all stages of disease, Guardant has launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its LUNAR program for recurrence and early detection.

International Association for the Study of Lung Cancer

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association’s membership includes more than 6,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit wclc2019.iaslc.org for more information.

IASLC 2020 World Conference on Lung Cancer

The IASLC 2020 World Conference on Lung Cancer will be held in the vibrant shores of Singapore, a dynamic exchange capital of the world and the gateway to Asia and beyond. Discover more on what you can look forward to at WCLC 2020 at the Singapore booth hosted by the Singapore Exhibition and Convention Bureau.

Illumina

Illumina is a leading developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. Our customers include a broad range of academic, government, pharmaceutical, biotechnology, and other leading institutions around the globe. For further details please visit www.illumina.com.

Inivata

Inivata is a leader in liquid biopsy. Our InVision® platform unlocks essential genomic information from a simple blood draw to transform the care of cancer patients. Our lead product, InVisionFirst™-Lung, is commercially available and provides molecular insights that enable clinicians to make more informed treatment decisions for NSCLC patients.
Our Commitment to Lung Cancer:
Investigating new treatment options for patients with lung cancer

INTRAPID LUNG 037

A multicenter, open-label study comparing bintrafusp alfa with pembrolizumab in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) and high PD-L1 expression levels.

INTRAPID LUNG 005

A multicenter, double-blind, randomized, controlled study evaluating bintrafusp alfa with concurrent chemoradiation (cCRT) followed by bintrafusp alfa vs placebo plus cCRT followed by durvalumab in patients with unresectable stage III NSCLC.

INTRAPID LUNG 024

An open-label study evaluating bintrafusp alfa in combination with chemotherapy in patients with stage IV NSCLC.

Merck and GSK are jointly developing and commercializing bintrafusp alfa as a global strategic alliance.

Pipeline products are under investigation and have not been proven to be safe and effective. There is no guarantee any product will be approved in the sought-after indication.

-INTRAPID is a trademark of Merck KGaA, Darmstadt, Germany. ©2019 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.
See life

break through

Advancing oncology at the speed of life™

Follow us @AmgenOncology
International Thoracic Oncology Nursing Forum

The International Thoracic Oncology Nursing Forum (ITONF) is an international organisation for those who are directly caring for people with lung cancer or mesothelioma in a nursing role. This network provides an opportunity for debate, education and knowledge transfer throughout the continuum of treatment.

Lung Ambition Alliance

The Lung Ambition Alliance is an innovative partnership committed to saving lives and dramatically improving outcomes in people with lung cancer. Visit Booth #614 to take a journey through an integrated quality care pathway, gain access to valuable quality care resources, and actively participate in our goal of survivorship.

Israeli Lung Cancer Foundation

Established in 2014 with the goal of helping Israeli lung cancer patients and their families. The Foundation provides support for patients and caregivers in areas such as up-to-date information, diagnosis and treatments, emotional support, raising awareness, promoting lung cancer screening program in Israel and more. We are the face and voice of lung cancer families in Israel.

Lung Cancer Europe

Lung Cancer Europe (LuCE) is an umbrella organisation with 23 members across 19 European country. LuCE aim to be the voice of people affected by lung cancer in Europe, advocating and networking to improve outcomes for the community.

Korean Association for Lung Cancer

The Korean Association for Lung Cancer consists of lung cancer specialists including pulmonologists, medical oncologists, thoracic surgeons, radiologists, nuclear medicine physicians, and scientists. We are pursuing multi-disciplinary approach and collaboration to make a progress in biological understanding, diagnosis, and treatment of lung cancer at the forefront in Korea.

MeVis Medical Solutions

MeVis Medical Solutions AG develops software for the analysis and processing of medical imaging data. Focus is the image-based early detection of cancer. Its state-of-the-art software solutions support the image-based early detection of lung cancer with dedicated reading software and how it can be used in lung cancer screening programs.

MSD

For more than a century, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases.

Today, MSD continues to be at the forefront of research to deliver innovative health solutions and advance the prevention and treatment of diseases around the world.

National Lung Cancer Forum For Nurses

NLCFN is a registered charity providing networking and support to nurses specialising in the care of people with lung cancer and mesothelioma. The organisation aims to support its members through innovative education programmes, professional development support, promotion of research and audit and providing a voice for lung cancer nurse specialists.

Lilly Oncology

For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. To learn more about Lilly’s commitment to people with cancer, please visit www.LillyOncology.com.

Loxo Oncology

Loxo Oncology, a wholly owned subsidiary of Eli Lilly and Company is focused on developing and commercializing highly-selective medicines for patients with genomically defined cancers. Our pipeline is comprised of purpose-built medicines designed to selectively and potently inhibit oncogenic drivers of cancer.
Programme Overview

Providing new options for patients who have exhausted currently available options represents a critical unmet need for patients with non-small cell lung cancer (NSCLC), and is also a key objective for treating physicians. As the range of treatment options for NSCLC increases, so does the need to carefully consider the evidence for selection of treatments in order to optimise clinical outcomes. Targeting the HER pathways is becoming an increasingly important focus for such patients.

At this Symposium, an international faculty of experts will discuss the evolution of treatment for NSCLC with regard to HER pathway genes and the emerging data with antibody-drug conjugates in these patients.
NeoGenomics

NeoGenomics provides clients with proven expertise, flexibility, and scalability. Additionally, we offer alternative business models and solutions that extend beyond the lab aiding in the commercialization process. Whether the need is a custom assay developed or use of a clinically validated test, we can help advance your clinical trial.

Novartis Oncology

Novartis Oncology is a global leader in improving outcomes for patients. We seek to transform cancer care through distinctive scientific and clinical strategies focused on developing targeted, immuno-oncology and combination therapies to create more effective options for patients. For more information, please visit www.novartisoncology.com.

Novocure

Novocure is a global oncology company developing a profoundly different cancer treatment utilizing a proprietary therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division.

Ology Medical Education

Ology Medical Education is a Global Provider of Independent Medical Education with a focus on oncology. We apply the latest thinking in adult learning and instructional design to develop high-impact educational experiences. We deliver these CME programs through the right channels, to ensure we reach more healthcare professionals.

Oncimmune

Oncimmune is a leader in the development, manufacture and commercialisation of cancer specific immunodiagnostics for the screening, detection and care of cancer. Oncimmune also develops precision medicine and patient stratification tools for leading pharmaceutical multinationals in both autoimmune disease and immuno-oncology. Its patented technology detects evidence of the body’s natural response to cancer, enabling detection four years or more before standard clinical diagnosis. Oncimmune’s tests facilitate clinical decision-making and are complementary to diagnostic technologies, making them valuable additions to established and new care pathways. Oncimmune partners with leading developers and distributors to make our technology available globally.

Oncology Central

Oncology Central is a free platform that unites all aspects of oncology to support a multidisciplinary approach to progression of the field. We are dedicated to advancing oncology by offering access to trusted, engaging and insightful resources – including breaking news, peer-reviewed articles, webinars and articles from key opinion leaders.

Optellum

Optellum is developing precision medicine software solutions that accelerate early diagnosis & treatment of lung cancer. We showcase NIHR IDEAL, the first prospective multi-centre trial of a lung cancer prediction digital biomarker based on imaging & Artificial Intelligence, led by Oxford University Hospitals with co-authors of BTS & NICE guidelines.

OSE Immunotherapeutics

OSE Immunotherapeutics is a French clinical-stage biotechnology company focused on developing and partnering innovative immunotherapies in immuno-oncology and autoimmune diseases.
PER Global
PER Global is a continuing education company accredited by the ACCME and approved by the CBRN. PER® is the educational resource of choice for live and online activities for healthcare professionals. We provide high-quality, evidence-based activities with a focus on practice changing advances and standards of care in treatment/disease management.

Pfizer Oncology
At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference on the lives of patients. Today, Pfizer Oncology has an industry-leading portfolio of 17 approved cancer medicines across more than 20 indications. Pfizer Oncology is striving to change the trajectory of cancer.

Polish Lung Cancer Study Group
Polish Lung Cancer Study Group (PoGRP) - multidisciplinary association from 2002. Its primary role is didactic and educational equally spreading lung cancer knowledge in Poland. In November organizes annual conference with IASLC accreditation - „Best of WCLC”. Develops Virtual Lung Cancer Units. Its Lung Cancer Registry contains above 35 000 records.

Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Scanlan
Highest quality surgical products designed and manufactured by the Scanlan family since 1921. Proudly crafting Scanlan® LEGACY Needle Holders and Forceps; featuring our new revolutionary Scan- II™ handle design. Full line Scanlan® VATS instruments including D'Amico Clamps, Suctions, Biopsy Forceps, Gonzalez-Rivas Dissector, Rocco Nodule Clamps and Khan Decortication Grasper.

Spectrum Pharmaceuticals
Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted drugs, with a focus in hematology and oncology. Spectrum has a strong track record of successfully executing across the biopharmaceutical business model. Spectrum’s pipeline has the potential to transform the company in the near future.

Springer Healthcare
Springer Healthcare education is a medical education provider that works in collaboration with a global network of scientific experts and societies to support healthcare professionals to make measurable change in their own clinical practice.

Takeda Oncology
Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology, Neuroscience and Rare Diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines.
TRK FUSION PROTEINS ARE A PRIMARY ONCOGENIC DRIVER ACROSS MULTIPLE TUMORS IN ADULTS AND CHILDREN\textsuperscript{1,2}

LOOK BELOW THE SURFACE TO FIND OUT WHAT'S DRIVING THE TUMOR

LEARN MORE ABOUT TRK FUSION CANCER AT TRKCANCER.COM

\textsuperscript{1} Okimoto RA, Bivona TG. Tracking down response and resistance to TRK inhibitors. \textit{Cancer Discov.} 2016;6(1):14-16.

Alecensa as monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).

Each hard capsule contains alectinib hydrochloride equivalent to 150 mg alectinib.

Dosage and Administration:
- A validated ALK assay is necessary for the selection of ALK-positive NSCLC patients. ALK-positive NSCLC status should be established prior to initiation of Alecensa therapy. The recommended dose of Alecensa is 600 mg, taken twice daily with food (total daily dose of 1200 mg).
- Patients with underlying severe hepatic impairment (Child-Pugh C) should receive Alecensa 600 mg, taken twice daily with food (total daily dose of 1200 mg).
- Patients with underlying severe hepatic impairment (Child-Pugh C) should receive Alecensa at a starting dose of 450 mg taken twice daily with food (total daily dose of 900 mg).

Interactions:
- Refer to Summary of Product Characteristics (SPC) prior to use of Alecensa.
- Each hard capsule contains 48 mg sodium per daily dose (1200 mg) equivalent to 2.4% of the WHO recommended maximum daily intake of 5 g sodium for an adult.

Treatment should be withheld and resumed at a reduced dose, or permanently discontinued, refer to SPC. Severe myalgia and creatine phosphokinase (CPK) elevation: Patients should be advised to report any unexplained muscle pain, tenderness, or weakness. CPK levels should be assessed every two weeks for the first month of treatment and as clinically indicated in patients reporting symptoms. Based on the severity of the CPK elevation, Alecensa should be withheld, then resumed at the same dose or dose reduced, refer to SPC. Bradycardia: Heart rate and blood pressure should be monitored as clinically indicated. Evaluate concomitant medicinal products known to cause bradycardia, as well as anti-hypertensive medicinal products if patients experience symptomatic bradycardia or life-threatening events. Symptomatic bradycardia can be managed with treatment interruption, dose reduction. If life-threatening, permanently discontinue, refer to SPC. Photosensitivity: Photosensitivity has been reported. Avoid prolonged sun exposure during treatment and for at least 7 days after discontinuation. Advice to protect against sunburn. Women of child-bearing potential: Alecensa may cause fetal harm during pregnancy. Patients of child-bearing potential receiving Alecensa must use highly effective contraceptive methods during treatment and for at least 3 months following the last dose. Lactation: Lactation: Alecensa contains lactase. Patients with rare hereditary problems of galactose intolerance, congenital lactose deficiency or glucose-galactose malabsorption should not take Alecensa. Sodium content: Alecensa contains 48 mg sodium per daily dose (1200 mg) equivalent to 2.4% of the WHO recommended maximum daily intake of 5 g sodium for an adult.

Drug interactions: Avoid grapefruit juice, grapefruit and Seville oranges.

References:

PR/ALC/1907/0016; Date of preparation: August 2019

PRESCRIBING INFORMATION

Alecensa® (alectinib) 150 mg hard capsules

Each hard capsule contains alectinib hydrochloride equivalent to 150 mg alectinib. Refer to Summary of Product Characteristics (SPC) prior to use of Alecensa.

Indications: Alecensa as monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).

Alecensa as monotherapy is indicated for the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib.

Alecensa as monotherapy is indicated for the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib. Dosage and Administration: A validated ALK assay is necessary for the selection of ALK-positive NSCLC patients. ALK-positive NSCLC status should be established prior to initiation of Alecensa therapy. The recommended dose of Alecensa is 600 mg, taken twice daily with food (total daily dose of 1200 mg). Patients with underlying severe hepatic impairment (Child-Pugh C) should receive Alecensa 600 mg, taken twice daily with food (total daily dose of 1200 mg). Patients with underlying severe hepatic impairment (Child-Pugh C) should receive Alecensa at a starting dose of 450 mg taken twice daily with food (total daily dose of 900 mg).

Monitor AST, ALT and bilirubin at baseline, and then every 2 weeks during the first 3 months following the last dose of Alecensa and should be advised of the potential harm to the fetus. Do not breast-feed while taking Alecensa. Adverse reactions:

Very common: anemia, diarrhea, vomiting, constipation, nausea, increased AST, increased ALT, increased bilirubin, rash, myalgia, increased blood creatinine, pseudohyponatremia, oedema, increased weight.

Common: Acute kidney injury, dyspnea, pneumonia, cough, dysgeusia, stomatitis, vision disorders, bradycardia, increased blood creatinine, increased blood alkaline phosphatase, photosensitivity. Serious adverse reactions:

Interstitial lung disease/pneumonitis, drug-induced liver injury. Prescribers should consult the SPC for a full list of adverse reactions. Legal Category: POM

Nearly 3 years freedom from progression

(34.8 months [95% CI: 17.7, NE])

3 years

unforgettable moments

for your ALK+ NSCLC patients

ALECENSA as monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Please report suspected adverse reactions to the National Health Authority in your country and/or Roche Safety contact in your country (www.roche.com and select your country).

Please consult the SPC for a full list of adverse reactions.

Finding out more at the Roche stand

More unforgettable moments

Years more for your ALK+ NSCLC patients

POM

Legal Category:

Settting the treatment standard in 1L ALK+ NSCLC

Risk factors for progression


PR/ALC/1907/0016; Date of preparation: August 2019

Alecensa® is a registered trade mark

Date of Preparation: May 2018

References
Exhibitor Descriptions (Continued)

TESARO

TESARO is an oncology-focused business within GSK that is devoted to providing transformative therapies to people facing cancer. We see new possibilities to responsibly develop and commercialize innovative treatments where others may not. Relationships are vital to the success of our business, and we are committed to being a trusted partner to the cancer community.

Univadis Oncology

Aptus Health dynamically connects health and life sciences companies with healthcare professionals, healthcare consumers, and other members of the healthcare ecosystem. Univadis Oncology, provided by Aptus Health, is a digital platform with a set of dedicated resources for oncologists and trainees, with the aim to continually helping them stay current with the latest national and international clinical research and breakthroughs.

Wisepress

Wisepress.com, Europe’s leading conference bookseller, has a complete range of books and journals relevant to the themes of the meeting. Books can be purchased at the stand or, if you would rather not carry them, posted to you – Wisepress will deliver worldwide. In addition to attending 200 conferences per year, Wisepress has a comprehensive medical and scientific bookshop online with great offers.

LUNG CANCER NEWS

The IASLC Lung Cancer News, the IASLC’s bi-monthly newspaper, features the latest information on lung cancer research, patient care, tobacco control, expert commentary from lung cancer thought leaders around the world and more.

Look for the IASLC Lung Cancer News in your delegate bag or pick up a copy at the IASLC Booth in the Exhibit Hall.

LungCancerNews.org
Imagine a world where every lung cancer patient is screened before the disease spreads. Where every patient gets the right drug at the right time, and the goal of any treatment plan is to cure. Where every patient, everywhere in the world, can expect to receive the highest quality care that provides the best odds in the fight against the disease. Where no patient dies from lung cancer.

Together, AstraZeneca, the International Association for the Study of Lung Cancer, the Global Lung Cancer Coalition and Guardant Health have come to form the Lung Ambition Alliance. We share one goal: to double long-term survival in lung cancer by 2025.

Through initiatives that increase early diagnosis, accelerate delivery of innovative precision medicines and improve quality care, we believe there is a way to solve the seemingly impossible and ultimately eliminate lung cancer as a cause of death.

Please visit LungAmbitionAlliance.org to know more about our first projects and help shape our priorities. Your insights will serve as an important first step on our life-changing journey toward accomplishing the impossible … together.

Join us at LungAmbitionAlliance.org.
Please note: Industry Symposia and Workshops are not part of the IASLC CME accredited scientific program.
## Industry Symposia and Workshops
### Saturday, September 7

### IWS01

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:30–11:30</td>
<td>WORKSHOP BY ROCHE: CLINICAL VALUE OF DIAGNOSTIC AGILITY IN MANAGING PATIENTS WITH LUNG CANCER</td>
</tr>
<tr>
<td>07:30–08:00</td>
<td>IWS01.01—Arrival and Breakfast</td>
</tr>
<tr>
<td>08:00–08:10</td>
<td>IWS01.02—Welcome and Opening Remarks</td>
</tr>
<tr>
<td></td>
<td>Noemi Reguart, Hospital Clinic Barcelona, Spain</td>
</tr>
<tr>
<td>08:10–08:35</td>
<td>IWS01.03—New Approaches in Lung Cancer: Biomarker Applications In Helping the Diagnosis and Early Diagnosis</td>
</tr>
<tr>
<td></td>
<td>Rafael Molina, Hospital Clinic Barcelona, Spain</td>
</tr>
<tr>
<td>08:35–09:00</td>
<td>IWS01.04—RTD–IHC Assessments for Targeted Therapy – Focus on ALK and ROS1 and Use of ROS1 IHC – Talk Followed by Question Time</td>
</tr>
<tr>
<td></td>
<td>Frédérique Penault-Llorca, Centre Jean Perrin, France</td>
</tr>
<tr>
<td>09:00–09:25</td>
<td>IWS01.05—The Challenges and Opportunities of Molecular Diagnostic Tools – Towards a Personalized Lung Cancer Healthcare</td>
</tr>
<tr>
<td></td>
<td>Noemi Reguart, Hospital Clinic Barcelona, Spain</td>
</tr>
<tr>
<td>09:25–09:40</td>
<td>IWS01.06—Break</td>
</tr>
<tr>
<td>09:40–10:05</td>
<td>IWS01.07—To Treat or Not to Treat?</td>
</tr>
<tr>
<td></td>
<td>Tuk-Kay Locke, Tunbridge Wells Hopsital, United Kingdom</td>
</tr>
<tr>
<td>10:05–11:30</td>
<td>IWS01.08—Clinical Case Reviews in a Multidisciplinary Setting</td>
</tr>
<tr>
<td>11:25–11:30</td>
<td>IWS01.09—Closing Remarks</td>
</tr>
<tr>
<td></td>
<td>Noemi Reguart, Hospital Clinic Barcelona, Spain</td>
</tr>
</tbody>
</table>

### IS01

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:45–11:15</td>
<td>SYMPOSIUM BY BAYER HEALTHCARE PHARMACEUTICALS: PRECISION MEDICINE: OPTIMIZING THE APPROACH TO LUNG CANCER THROUGH TESTING</td>
</tr>
<tr>
<td></td>
<td>Hall 8.0, Copenhagen (1980)</td>
</tr>
<tr>
<td></td>
<td>Chairs/Speakers: Silvia Novello, Italy; Anna Farago, USA; Lukas Heukamp, Germany</td>
</tr>
</tbody>
</table>

**AGENDA**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:45</td>
<td>Welcome and Introduction</td>
</tr>
<tr>
<td></td>
<td>Silvia Novello, Italy</td>
</tr>
</tbody>
</table>

**Part 1: Genomic Testing in Lung Cancer: Ask The Experts**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:55</td>
<td>The Pathologist’s Perspective</td>
</tr>
<tr>
<td></td>
<td>Lukas Heukamp, Germany</td>
</tr>
<tr>
<td>10:10</td>
<td>The Oncologist’s Perspective</td>
</tr>
<tr>
<td></td>
<td>Silvia Novello, Italy</td>
</tr>
<tr>
<td>10:25</td>
<td>Panel Discussion and Q&amp;A</td>
</tr>
<tr>
<td></td>
<td>All Speakers</td>
</tr>
</tbody>
</table>

**Part 2: The Multidisciplinary Team in Action**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:40</td>
<td>Meet the Patients</td>
</tr>
<tr>
<td></td>
<td>Anna Farago, USA</td>
</tr>
<tr>
<td>11:00</td>
<td>Panel Discussion and Q&amp;A</td>
</tr>
<tr>
<td></td>
<td>All Speakers</td>
</tr>
</tbody>
</table>

### IWS02

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00–16:00</td>
<td>HANDS-ON WORKSHOP BY FUJIFILM-SONOSITE: ENDOSCOPIC DIAGNOSIS AND STAGING OF LUNG CANCER–INTERVENTIONAL PULMONOLOGY</td>
</tr>
<tr>
<td></td>
<td>Melbourne (1991)</td>
</tr>
</tbody>
</table>

**Track(s):** Interventional Diagnostics/Pulmonology

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00–08:15</td>
<td>IWS02.01—Welcome and Introduction</td>
</tr>
<tr>
<td></td>
<td>Antoni Rosell, Spain</td>
</tr>
<tr>
<td>08:15–11:30</td>
<td>IWS02.02—Hands-On Session on 6 Stations</td>
</tr>
<tr>
<td></td>
<td>Lineal EBUS</td>
</tr>
<tr>
<td></td>
<td>Lineal EBUS Simulator</td>
</tr>
</tbody>
</table>

### IS02

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30–13:00</td>
<td>SYMPOSIUM BY OLOGY MEDICAL EDUCATION: SPOTLIGHT ON EMERGING IMMUNOTHERAPY APPROACHES AND MET INHIBITORS IN ADVANCED NSCLC</td>
</tr>
<tr>
<td></td>
<td>Hall 8.0, Hilton Head (1978)</td>
</tr>
<tr>
<td></td>
<td>Chairs/Speakers: Everett Vokes, USA; Luis Paz-Ares, Spain; Ross Camidge, USA; Martin Reck, Germany</td>
</tr>
</tbody>
</table>

**AGENDA**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30</td>
<td>Welcome and Introduction</td>
</tr>
<tr>
<td></td>
<td>Everett Vokes, USA</td>
</tr>
</tbody>
</table>
11:40 What is the Current Clinical Status of Novel Immunotherapies in Advanced NSCLC?
Luis Paz-Ares, Spain

12:05 What Does the Latest Evidence Reveal for Emerging MET Inhibitors?
Ross Camidge, USA

12:30 Are We Optimally Prepared to Provide Personalized Treatment Strategies?
Martin Reck, Germany

12:55 Summary and Adjournment

IS03
13:00–14:30 SYMPOSIUM BY TAKEDA ONCOLOGY:
CURRENT TREATMENT LANDSCAPE AND UNMET NEEDS IN ALK+ NSCLC
Hall 8.0, Copenhagen (1980)

Chairs/Speakers: Pilar Garrido, Spain; Pasi A. Jänne, USA; Sanjay Popat, United Kingdom

AGENDA
13:00 Welcome and Introductions
Pilar Garrido, Spain

13:05 Insights Into Resistance Mechanisms in ALK+ NSCLC
Pasi A. Jänne, USA

13:25 Current Treatment Landscape in ALK+ NSCLC
Sanjay Popat, United Kingdom

13:45 Long-term Safety, Tolerability, and Quality of Life with ALK Inhibitors
Pilar Garrido, Spain

14:05 Panel Discussion of a Patient Case Study and Q&A
All Faculty

14:25 Closing Remarks
Pilar Garrido, Spain

14:35Timing of I-O Treatment in Early-Stage NSCLC
Moderator: Natasha Leighl, Canada
Scott Antonia, USA vs Antonio Calles, Spain

15:00 I-O + Chemotherapy vs Non-Chemotherapy
I-O Options in 1L mNSCLC
Moderator: Scott Antonia, USA
Antonio Calles, Spain vs Natasha Leighl, Canada

15:25 2L Treatment in an Evolving Landscape:
Exploring I-O vs Non–I-O Treatment Options
Moderator: Antonio Calles, Spain
Natasha Leighl, Canada vs Scott Antonia, USA

15:50 Closing Remarks and Audience Q&A
Scott Antonia, USA

IS04
14:30–16:00 SYMPOSIUM BY BRISTOL-MYERS SQUIBB:
POINT/COUNTERPOINT: MAXIMIZING THE IMPACT OF I-O ACROSS NSCLC
Hall 8.0, Vancouver (2003)

Chairs/Speakers: Scott Antonia, USA; Natasha Leighl, Canada; Antonio Calles, Spain

AGENDA
14:30 Welcome and Introductions
Scott Antonia, USA

14:35 Timing of I-O Treatment in Early-Stage NSCLC
Moderator: Natasha Leighl, Canada
Scott Antonia, USA vs Antonio Calles, Spain

15:00 I-O + Chemotherapy vs Non-Chemotherapy
I-O Options in 1L mNSCLC
Moderator: Scott Antonia, USA
Antonio Calles, Spain vs Natasha Leighl, Canada

15:25 2L Treatment in an Evolving Landscape:
Exploring I-O vs Non–I-O Treatment Options
Moderator: Antonio Calles, Spain
Natasha Leighl, Canada vs Scott Antonia, USA

15:50 Closing Remarks and Audience Q&A
Scott Antonia, USA

IS05
16:00–17:30 SYMPOSIUM BY SPRINGER HEALTHCARE:
SIMPLIFYING THE SEQUENCING OF TREATMENT IN NSCLC PATIENTS WITH NO ACTIONABLE MUTATIONS
Hall 8.0, Copenhagen (1980)

Chairs/Speakers: Corey Langer, USA; Enriqueta Felip, Spain; David Heigener, Germany; Myung-Ju Ahn, Korea

AGENDA
16:00 Welcome and Introduction
Corey Langer, USA

16:10 Where Should We Begin?
Enriqueta Felip, Spain

16:35 Navigating the Increasingly Complex Second-line Setting
David Heigener, Germany

17:00 Special Considerations for Hyperprogressive Disease
Myung-Ju Ahn, Korea

17:15 Panel and Audience Discussion: Bridging the Gap Between Promise and Reality
All Speakers

17:25 Close
Corey Langer, USA
Industry Symposia and Workshops
Sunday, September 8

**IS06**

07:00 – 08:00 SYMPOSIUM BY F. HOFFMANN-LA ROCHE: HOW IMMUNOTHERAPY IS CONTINUING TO REVOLUTIONISE FIRST-LINE LUNG CANCER CARE

- Hall 8.0, Copenhagen (1980)

Chairs/Speakers: Ross Soo, Singapore; Thomas Newsom-Davis, United Kingdom; Fabrice Barlesi, France

**AGENDA**

07:00  Welcome and Introduction  
Ross Soo, Singapore

07:10  Non-squamous NSCLC: Continuing to Address the Unmet Need  
Thomas Newsom-Davis, United Kingdom

07:30  SCLC: Towards a New Standard of Care  
Fabrice Barlesi, France

07:45  Will the Revolution Continue?  
Audience questions: All faculty

07:55  Summary and Close  
Ross Soo, Singapore

**IS07**

07:00 – 08:00 SYMPOSIUM BY DAIICHI SANKYO: TARGETING HER PATHWAYS IN ADVANCED NSCLC: EMERGING CONCEPTS AND FUTURE OPPORTUNITIES

- Hall 8.0, Hilton Head (1978)

Chairs/Speakers: Frances Shepherd, Canada; Suresh Ramalingam, USA; Egbert Smit, Netherlands

**AGENDA**

07:00  Welcome and Introduction  
Targeting HER2 Pathways in Oncogene Driven Advanced NSCLC: The Continuing Evolution of Personalised Treatment  
Frances Shepherd, Canada

07:10  The Role of Antibody Drug Conjugates (ADCs) in Thoracic Cancer: Current State-of-the-Art  
Suresh Ramalingam, USA

07:30  Targeting HER Pathways in Advanced NSCLC: Emerging Data and Future Prospects  
Egbert Smit, Netherlands

07:50  Q&A: Audience & Wrap-Up  
All Faculty Members

**IS08**

07:00 – 08:00 SYMPOSIUM BY PFIZER: EGFR+ AND ALK+ NSCLC: MORE OPTIONS, RIGHT CHOICES

- Hall 8.0, Vienna (2016)

Chairs/Speakers: Nicolas Girard, France; Daniel Tan, Singapore; Alice Shaw, USA

**AGENDA**

07:00  Welcome and Introduction  
Nicolas Girard, France

07:05  More Options, Right Choices  
Nicolas Girard, France

07:15  EGFR: The Dilemma of Choice  
Daniel Tan, Singapore

07:35  ALK: Sequencing Our Options to Maximise Outcomes  
Alice Shaw, USA

07:50  Panel Discussion  
All faculty, facilitated by Nicolas Girard, France
Industry Symposia and Workshops are not part of the IASLC CME accredited scientific program.

**IS09**

12:00–13:30 SYMPOSIUM BY PHYSICIANS’ EDUCATION RESOURCE, LLC (PER): LEVERAGING THE LUNG CANCER TEAM IN STAGE III NSCLC WITH IMMUNO-ONCOLOGY STRATEGIES
- Hall 8.0, Hilton Head (1978)

Chairs/Speakers: Naiyer A. Rizvi, USA; Suresh Senan, Netherlands; Keith Kerr, United Kingdom; Rolf Stahel, Switzerland

**AGENDA**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00</td>
<td>Welcome, Introductions, Pre-session Survey</td>
</tr>
<tr>
<td>12:10</td>
<td>Assessing Treatment Standards for Patients with Unresectable Stage III NSCLC</td>
</tr>
<tr>
<td>12:25</td>
<td>Medical Crossfire® #1: Applying the Data to Patients with Stage III NSCLC</td>
</tr>
<tr>
<td>12:40</td>
<td>Medical Crossfire® #2: Practical Concepts and Best Practices with Novel Immunotherapies for Management of Immune-Related Adverse Events</td>
</tr>
<tr>
<td>13:00</td>
<td>Medical Crossfire® #3: Future Applications for Immunotherapy in Stage I-III NSCLC</td>
</tr>
<tr>
<td>13:15</td>
<td>Postsession Survey</td>
</tr>
<tr>
<td>13:20</td>
<td>Question-and-Answer Session/Panel Discussion</td>
</tr>
<tr>
<td>13:30</td>
<td>Adjourn</td>
</tr>
</tbody>
</table>

**IS10**

18:00–19:30 SYMPOSIUM BY BOEHRINGER INGELHEIM: TREATMENT SEQUENCING FOR ADVANCED NSCLC
- Hall 8.0, Hilton Head (1978)

Chairs/Speakers: Tetsuya Mitsudomi, Japan; Keunchil Park, South Korea; Martin Schuler, Germany; David Gandara, USA; Nick Pavlakis, Australia

**AGENDA**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>18:00</td>
<td>Meeting Welcome and Introductions</td>
</tr>
<tr>
<td>18:05</td>
<td>Maximising Time on EGFR TKI Therapy</td>
</tr>
<tr>
<td>18:20</td>
<td>Uncommon but Not Unknown: Efficacy of EGFR TKIs for Uncommon Mutations</td>
</tr>
<tr>
<td>18:35</td>
<td>Panel Discussion: First-Line Treatment Considerations for EGFR-Mutated NSCLC</td>
</tr>
<tr>
<td>18:45</td>
<td>The Role of EGFR TKIs in the Treatment of Squamous NSCLC</td>
</tr>
<tr>
<td>19:00</td>
<td>NSCLC (Adenocarcinoma): The Role of Anti-Angiogenic Therapy in Overcoming Resistance to Immunotherapy</td>
</tr>
<tr>
<td>19:15</td>
<td>Panel Discussion: Second-Line Treatment Considerations for Advanced NSCLC</td>
</tr>
<tr>
<td>19:25</td>
<td>Meeting Close</td>
</tr>
</tbody>
</table>

Tetsuya Mitsudomi, Japan
Industry Symposia and Workshops
Monday, September 9

**IS11**

07:00 – 08:00 SYMPOSIUM BY F. HOFFMANN-LA ROCHE:
WAKING UP TO PRECISION MEDICINE IN NSCLC

- Hall 8.0, Copenhagen (1980)

Chairs/Speakers: Solange Peters, Switzerland; Nir Peled, Israel; Robert Doebele, USA

**AGENDA**

07:00 Introduction
Solange Peters, Switzerland

07:05 Comprehensive Genomic Profiling: The Future is Now
Nir Peled, Israel

07:15 Leading the Way with ALK
Solange Peters, Switzerland

07:25 Advancing Patient Care with TRK and ROS1
Robert Doebele, USA

07:35 Faculty Discussion and Q&A

07:55 Close
Solange Peters, Switzerland

**IS12**

07:00 – 08:00 SYMPOSIUM BY MEDSCAPE:
EXPANDING THE THERAPEUTIC LANDSCAPE OF ADVANCED NSCLC TARGETING HER2

- Hall 8.0, Hilton Head (1978)

Chairs/Speakers: Hossein Borghaei, USA; Maurice Perol, France; Shirish Gadgeel, USA

**AGENDA**

07:00 Welcome and Introduction
Maurice Perol, France

07:05 When and How Can HER2 Be Tested in Patients with Advanced NSCLC?
Maurice Perol, France

07:20 Case Discussion: NSCLC with HER2 Alteration
Hossein Borghaei, USA

07:35 Future Therapeutic Landscape for HER2 Dysregulation
Shirish Gadgeel, USA

07:50 Panel Discussion and Audience Questions
All Faculty

08:00 Adjournment

**IS13**

07:00 – 08:00 SYMPOSIUM BY ILLUMINA:
BENEFITING LUNG CANCER PATIENTS WITH COMPREHENSIVE GENOMIC PROFILING

- Hall 8.0, Vienna (2016)

Chairs/Speakers: David Eberhard, USA; Ahmet Zehir, USA; Sandip Patel, USA

**AGENDA**

07:00 Introduction
Sandip Patel, USA

07:10 Transforming Oncology with Comprehensive Genomic Profiling
David Eberhard, USA

07:25 Diagnostic and Clinical Utility of Common to Rare Fusions in Lung Cancer
Ahmet Zehir, USA

07:50 Q&A
Please note: Industry Symposia and Workshops are not part of the IASLC CME accredited scientific program.

### IS14

12:30 – 14:00  SYMPOSIUM BY PEERVOICE: PAVING THE WAY TO BETTER OUTCOMES IN EGFR-MUTANT NSCLC: TIME TO TAKE A STEP FURTHER?  
Hall 6, Barcelona (2005)

Chairs/Speakers: Lecia V. Sequist, USA; David Planchard, France; James Chih-Hsin Yang, Taiwan

**AGENDA**

12:30  Welcome and Introduction  
Lecia V. Sequist, USA

12:35  Measuring Success of EGFR-Targeted Therapies: What's the End Goal  
David Planchard, France

12:55  Case Discussion: What Does Improved Survival Mean for Patients?  
Lecia V. Sequist, USA & Panel

13:10  Sequencing Therapies in EGFR-mutant NSCLC: Does Order Matter?  
James Chih-Hsin Yang, Taiwan

13:30  Case Discussion: Strategies for Improving Long-Term Outcomes  
Lecia V. Sequist, USA & Panel

13:45  Q&A and Conclusions  
Lecia V. Sequist, USA & Panel

### IS15

18:15 – 19:45  SYMPOSIUM BY MEDSCAPE: IMMUNE CHECKPOINT INHIBITOR TREATMENT FOR FRONTLINE METASTATIC NSCLC: THE EVOLVING ROLE OF BIOMARKERS IN GUIDING DECISIONS  
Hall 8.0, Hilton Head (1978)

Chairs/Speakers: Heather Wakelee, USA; Raffaele Califano, United Kingdom; Wilfried Eberhardt, Germany; Marina Garassino, Italy

**AGENDA**

18:15  Welcome and Introduction  
Heather Wakelee, USA

18:20  Immune Checkpoint Inhibitor Treatment Regimens in Frontline Metastatic NSCLC: Where Are We Now?  
Heather Wakelee, USA

18:30  The Role of PD-L1 Expression in Guiding Decisions: Analyzing the Current Evidence  
Raffaele Califano, United Kingdom

18:50  The Role of Tumor Mutational Burden (TMB) in Guiding Decisions: What Are We Learning From the Clinical Trial Data?  
Wilfried Eberhardt, Germany

19:10  Moving to Better Biomarker Guidance for ICI Therapies: Current and Future Outlook  
Marina Garassino, Italy

19:25  Panel Discussion  
All Faculty, Moderated by Heather Wakelee, USA

19:40  Concluding Remarks  
Heather Wakelee, USA
# Industry Symposia and Workshops

**Tuesday, September 10**

## IS16

**07:00 – 08:00 SYMPOSIUM BY NOVARTIS:**
**THE ROAD AHEAD: NEW HORIZONS IN THE TREATMENT OF NSCLC**

*Hall 8.0, Hilton Head (1978)*

**Chairs/Speakers:** Jürgen Wolf, Germany; Tony Mok, Hong Kong; David Spigel, USA

**AGENDA**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00</td>
<td>Welcome and Introduction: Recent Advances in NSCLC Treatment</td>
</tr>
<tr>
<td></td>
<td>Jürgen Wolf, Germany</td>
</tr>
<tr>
<td>07:10</td>
<td>Emerging New Targets for NSCLC</td>
</tr>
<tr>
<td></td>
<td>Tony Mok, Hong Kong</td>
</tr>
<tr>
<td>07:30</td>
<td>Shaping the Future: Targeting Inflammation Beyond Checkpoint Inhibition</td>
</tr>
<tr>
<td></td>
<td>David Spigel, USA</td>
</tr>
<tr>
<td>07:55</td>
<td>Closing</td>
</tr>
<tr>
<td></td>
<td>Jürgen Wolf, Germany</td>
</tr>
</tbody>
</table>

## IS17

**07:00 – 08:00 SYMPOSIUM BY MSD:**
**PRIORITIZING LUNG CANCER: STRENGTHENING PUBLIC POLICY RESPONSES TO UNMET NEEDS**

*Hall 6, Barcelona (2005)*

**Chairs/Speakers:** Georg Pall, Austria; Stefania Vallone, Italy; Mary Bussell, United Kingdom; Christian Sellers, USA, Corina Silvia Pop, Romania

**AGENDA**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00</td>
<td>Welcome and Introduction</td>
</tr>
<tr>
<td>07:05</td>
<td>The Global Lung Cancer Policy Landscape</td>
</tr>
<tr>
<td></td>
<td>Mary Bussell, United Kingdom</td>
</tr>
<tr>
<td>07:15</td>
<td>Case Study of National Lung Cancer Policies in Romania</td>
</tr>
<tr>
<td></td>
<td>Corina Silvia Pop, Romania</td>
</tr>
<tr>
<td>07:25</td>
<td>Moderated Panel Discussion</td>
</tr>
<tr>
<td>07:45</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>07:55</td>
<td>Closing Remarks</td>
</tr>
</tbody>
</table>

## IS18

**13:00 – 14:30 SYMPOSIUM BY MSD:**
**REDEFINING SURVIVAL EXPECTATIONS IN LUNG CANCER**

*Hall 6, Barcelona (2005)*

**Chairs/Speakers:** Johan Vansteenkiste, Belgium; Benjamin Levy, USA; Stephen Liu, USA

**AGENDA**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00</td>
<td>Welcome and Introduction</td>
</tr>
<tr>
<td></td>
<td>Johan Vansteenkistle, Belgium</td>
</tr>
<tr>
<td>13:05</td>
<td>Scientific Rationale for Combining Immune Check Point Inhibitors and Chemotherapy</td>
</tr>
<tr>
<td></td>
<td>Johan Vansteenkistle, Belgium</td>
</tr>
<tr>
<td>13:20</td>
<td>Role of IO in mNSCLC</td>
</tr>
<tr>
<td></td>
<td>Pro – Use of IO/Chemotherapy Combinations or Monotherapy in IL</td>
</tr>
<tr>
<td></td>
<td>Con – Preserve Option of IO Use for 2nd Line</td>
</tr>
<tr>
<td></td>
<td>Stephen Liu – Pro</td>
</tr>
<tr>
<td></td>
<td>Ben Levy – Con</td>
</tr>
<tr>
<td>13:50</td>
<td>Patient Cases</td>
</tr>
<tr>
<td></td>
<td>Ben Levy, USA</td>
</tr>
<tr>
<td>14:05</td>
<td>Beyond NSCLC – SCLC, Mesothelioma</td>
</tr>
<tr>
<td></td>
<td>Stephen Liu, USA</td>
</tr>
<tr>
<td>14:20</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>14:30</td>
<td>Closing Remarks</td>
</tr>
<tr>
<td></td>
<td>Johan Vansteenkistle, Belgium</td>
</tr>
</tbody>
</table>
SUNDAY, SEPTEMBER 8, 2019

12:00 – 13:15 ADDRESSING INEQUITIES IN CARE AND SUPPORT FOR LUNG CANCER PATIENTS IN THE US AND AFRICA: LESSONS AND CHALLENGES FROM THE FRONT LINES

Moderator: Christopher Lathan, MD, MS, MPH
Dana-Farber Cancer Institute (USA)

Panelists:
- Celeste Worth, MCHES
  University of Louisville, United States of America
- Scott Shofer, MD, PhD
  Duke University & Durham Veterans Affairs Health Care System, United States of America
- Chite Asirwa, MD
  International Cancer Institute, Eldoret, Kenya
- Drew Moghanaki, MD
  Atlanta Veterans Affairs Health Care System, United States of America
- Matthew Smeltzer, PhD
  University of Memphis, United States of America

12:00 – 12:10 Registration & Lunch

12:11 – 12:12 Host Opening Remarks
Catharine Grimes, Bristol-Myers Squibb Foundation

12:13 – 12:20 Moderator Opening Remarks
Christopher Lathan, MD, MS, MPH, Dana-Farber Cancer Institute

12:21 – 12:29 Lung Cancer Screening: Are we ready? Educating providers and increasing awareness about their role in lung cancer screening. Lessons from the LuCa National Training Network in the US.
Celeste Worth, MCHES, University of Louisville

12:30 – 12:38 Establishing a Pan-African collaboration to improve awareness about, data on and intervention for lung cancer. How Secure The Future is trying to rapidly build an African body of knowledge regarding lung cancer in different cultural and resource settings; health systems and within sites with varying risk-profiles and economic development
Chite Asirwa, MD International Cancer Institute (ICI), Eldoret, Kenya

12:39 – 12:47 How do we track it? The VAPALS-ELCAP Open Source Lung Screening Management System: Implications for Global Partnerships to Improve Lung Screening Access, Safety, and Efficacy
Drew Moghanaki, MD, MPH, Atlanta Veterans Affairs Health Care System

12:48 – 12:56 Planning for Survivors: Building Support Services and Survivorship Pathways for Patients Treated for Lung Cancer
Scott Shofer, MD, PhD, Duke University & Durham Veterans Affairs Health Care System

12:57 – 13:05 Putting it All Together - The Optimal Care Coordination Model (OCCM): The goal of this project is to create sustainable improvements in Medicaid patients’ access to quality lung cancer services and health outcomes by developing a comprehensive, written plan delineating a Medicaid lung cancer patient’s course of treatment and progression using an OCCM for providers, patients and their caregivers
Matthew Smeltzer, PhD, University of Memphis

13:05 – 13:15 Moderated Discussion and Q&A
Christopher Lathan, MD, MS, MPH, Dana-Farber Cancer Institute

13:15 Closing Remarks
Catharine Grimes, Bristol-Myers Squibb Foundation

Please note: Industry Symposia and Workshops are not part of the IASLC CME accredited scientific program.
IASLC 2020
Meetings Schedule

Sixth AACR-IASLC International Joint Conference: Lung Cancer
Jan. 11-14, 2020 | San Diego, CA | #Lung20

IASLC 2020 Targeted Therapies of Lung Cancer
Feb. 19-22, 2020 | Santa Monica, CA #TTLC20

European Lung Cancer Congress 2020
April 15-18, 2020 | Geneva, Switzerland #ELCC20

Lung Cancer Hot Topic: Liquid Biopsy
May 2020

IASLC 2020 World Conference on Lung Cancer
August 9-12, 2020 | Singapore | #WCLC20

IASLC 2020 North America Conference on Lung Cancer
October 15-17, 2020 | Chicago, IL #NACLCl20

Lung Cancer Hot Topic: Immunotherapy
November 2020

CONNECT WITH US
@IASLC
facebook.com/IASLC
linkedin.com
iaslc.lung
IASLC

IASLC 2020
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER
Conquering Thoracic Cancers Worldwide

IASLC 2019 World Conference on Lung Cancer | Onsite Program WCLC2019.IASLC.ORG
INDUSTRY SYMPOSIA
& WORKSHOPS
12
JOIN TODAY!

As an IASLC member, you will receive:

- Collaboration with a multidisciplinary global team of thoracic oncology experts and leaders
- Member access to the *Journal of Thoracic Oncology*, the premier journal in lung cancer, as well as the latest classification and staging publications
- Multidisciplinary education including the latest in ground-breaking research and treatment of thoracic malignancies

**SPECIAL OFFER FOR NEW MEMBERS:**

- **REGULAR,** **DEVELOPING COUNTRY AND ALLIED HEALTH** Fellow, Survivor and Caregiver Memberships *Complimentary*

Don’t forget to pick up your **Member Appreciation Gift**!

See us in the Exhibit Hall at Booth 300 or at the IASLC Membership Booth at Registration
Apply at iaslc.org
Our science turns insights into medicine

With our in-depth knowledge of antibody biology and pioneering technology, we have created innovative platforms with the promise to transform cancer treatment.

Ushering in a transformative tomorrow for patients with our pipeline of next-generation products

- 6 proprietary antibodies in clinical development
- 2 marketed partnered products
- ~20 in-house and partnered preclinical programs

Discover how we are changing the way cancer is treated at Booth 606.
VARGATEF®: Help your patients maximise their moments during 2nd-line treatment*

VARGATEF® + docetaxel: 2nd-line treatment for patients with NSCLC adenocarcinoma without actionable driver mutations who have progressed after 1st-line CT +/- IO1,2‡

CT=chemotherapy; IO=immuno-oncology; NSCLC=non-small cell lung cancer.

*vs. docetaxel alone. †After 1st-line chemotherapy, adenocarcinoma histology.


Vargatef® 100 mg/150 mg soft capsules. **Active substance:** Nintedanib. **Qualitative and quantitative composition:** Each capsule contains 100 mg/150 mg nintedanib (as esilate). Excipients with known effect: Each capsule contains 1.2 mg/1.8 mg of soya lecithin. List of excipients: Capsule content: Medium-chain triglycerides, hard fat, lecithin (soya) [E322]. Capsule shell: Gelatin, glycerol (85%), titanium dioxide [E171], iron oxide red [E172], iron oxide yellow [E172]. Printing ink: Shellac, iron oxide black [E172], propylene glycol [E1520]. **Indication:** Vargatef® is indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy. **Contraindications:** Hypersensitivity to nintedanib, peanut or soya, or to any of the excipients listed above. **Warnings and Precautions:** see SmPC. **Interactions:** If co-administered with nintedanib, potent P-gp inhibitors may increase exposure to nintedanib. Potent P-gp inducers may decrease exposure to nintedanib. The likelihood of drug-drug interactions with nintedanib based on CYP metabolism is considered to be low. **Adverse reactions:** Very common: Neutropenia (includes febrile neutropenia), decreased appetite, electrolyte imbalance, peripheral neuropathy, bleeding, diarrhoea, vomiting, nausea, abdominal pain, alanine aminotransferase (ALT) increased, aspartate aminotransferase (AST) increased, blood alkaline phosphatase (ALKP) increased, mucositis (including stomatitis), rash. Common: Febrile neutropenia, abscesses, sepsis, thrombocytopenia, dehydration, weight decreased, venous thromboembolism, hypertension, hyperbilirubinaemia, gammaglutamyltransferase (GGT) increased, pruritus. Uncommon: Myocardial infarction, perforation, pancreatitis, drug-induced liver injury, renal failure. Boehringer Ingelheim International GmbH, Binger Strasse 173, 55216 Ingelheim am Rhein, Germany. Medicinal product subject to restricted medical prescription. **Date of information:** July 2018.

▼ This medicinal product is subject to additional monitoring. Notification of suspected adverse reactions associated with this medicine is a priority. Procedure ID: PC-CRP-100752 – June 2019.